diff --git a/CVO/cvo.owl b/CVO/cvo.owl index ebf8225..59b2fe7 100644 --- a/CVO/cvo.owl +++ b/CVO/cvo.owl @@ -16,7 +16,7 @@ xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:ncbitaxon="http://purl.obolibrary.org/obo/ncbitaxon#"> - + en Chris mungall Erica Marcos @@ -33,6 +33,7 @@ Barry Smith Bjoern Peters Edison Ong + Ellen Zhang Hong Yu Jason Hu Jie Zheng @@ -49,17 +50,19 @@ Rohit Goru Ronak Sutariya Samantha G. Sayers (SGS) + Taiyu Lin Thomas Todd + Xingxian Li Yongqun "Oliver" He (YH) Yu Lin (YL) - Xingxian Li Yuanyi (Penny) Pan + Yuping Zheng Zuoshuang "Allen" Xiang A view of Vaccine Ontology (VO) with a focus on the modeling and representation of various cancer vaccines. OWL-DL Vaccine Ontology Cancer Vaccine View - 2024-06-26 + 2024-07-13 @@ -237,7 +240,6 @@ We also have the outstanding issue of how to aim different definitions to differ Consider re-defing to: An alternative name for a class or property which can mean the same thing as the preferred name (semantically equivalent, narrow, broad or related). alternative label - alternative term @@ -1129,7 +1131,7 @@ WHERE { - A shortcut relation that equals to: + A shortcut relation that is equivalent to: 'processed material' and (is_specified_output_of some 'vaccine preparation') and ('has function' some ('vaccine function' and ('is realized by' only ('vaccine immunization' and (realizes some ('vaccine host role' and (role_of some 'organism' and has_disposition some disease)))))))). The domain of this relation is a vaccine. The range of this relation is a disease. @@ -1146,16 +1148,32 @@ The range of this relation is a disease. - - A shortcut relation that equals to: -'processed material' and (is_specified_output_of some 'vaccine preparation') and ('has function' some ('vaccine function' and ('is realized by' only ('vaccine immunization' and (realizes some ('vaccine host role' and (role_of some 'organism')))))))). + + + + + + + + + + + + A shortcut relation that is equivalent to: +'processed material' and (is_specified_output_of some 'vaccine preparation') and ('has function' some ('vaccine function' and ('is realized by' only ('vaccine immunization' and (realizes some ('vaccine recipient role' and (role_of some 'organism')))))))). The domain of this relation is a vaccine. The range of this relation is a organism. + Anna Maria Masci Asiyah Yu Lin + Barry Smith + Jie Zheng Oliver He immunization for host + immunization for recipient + immunizes host vaccine immunization for host - immunizes host + vaccine immunization for recipient + immunizes recipient @@ -1175,7 +1193,7 @@ The range of this relation is a organism. - A shortcut relation that equals to: + A shortcut relation that is equivalent to: processed material and (is_specified_output_of some vaccine preparation) and (has function some (vaccine function and (is realized by only (vaccine immunization and (realizes some ('immunization target role' and (role_of some 'pathogen')))))))) The domain of this relation is a vaccine. @@ -5885,13 +5903,19 @@ https://sourceforge.net/p/obi/obi-terms/738/ - - + + + + + + + + @@ -5908,15 +5932,12 @@ https://sourceforge.net/p/obi/obi-terms/738/ - - - - - - - A vaccine is a processed material with the function that when administered, it prevents or ameliorates a disorder in a target organism by inducing or modifying adaptive immune responses specific to the antigens in the vaccine. + Material entity that is manufactured to realize the vaccine function. Many vaccines are developed to protect against infectious pathogens that causes infectious diseases. Many vaccines are also being developed against other diseases such as cancer, allergy, and autoimmune diseases. - YH, BP, BS, MC, LC, XZ, RS + Anna Maria Masci + Barry Smith + Jie Zheng + YH, BP, MC, LC, XZ, RS vaccine vaccine MeSH: D014612 @@ -6017,7 +6038,10 @@ https://sourceforge.net/p/obi/obi-terms/738/ - a process of administering substance in vivo that involves in adding a vaccine into a host (e.g., human) in vivo with the intent to invoke a protective or therapeutic adaptive immune response. + A process of administering a vaccine in vivo to a recipient (e.g., human) with the intent to invoke a protective or therapeutic adaptive immune response. + Anna Maria Masci + Barry Smith + Jie Zheng YH, BP vaccine administration process @@ -6129,7 +6153,10 @@ https://sourceforge.net/p/obi/obi-terms/738/ - A vaccine that prevents or treats cancer. It is produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced. + Vaccine that prevents or treats cancer. + Anna Maria Masci + Barry Smith + Jie Zheng Oliver He neoplasm vaccine tumor vaccine @@ -6151,12 +6178,12 @@ https://sourceforge.net/p/obi/obi-terms/738/ - vaccine function is a function that inheres in a vaccine that induces protective immune response against a disease. It is realized in the immunization process in the host. + To induce or modify protective or therapeutic immune response against a disease. PERSPN: Oliver He: There has been hot discussion about whether we use 'vaccine function' or 'vaccine role'. Vaccine role may not be the good term to use. Vaccine is designed to be 'vaccine', so it should be vaccine function. One special case is cowpox virus. The cowpox virus can be mixed with some liquid like water and used as a smallpox vaccine. In this case, people often say: the cowpox virus has a 'vaccine role'. However, the cowpox virus vaccine is a processed material of a mix of the virus with water. The virus is a virus, it is not a vaccine per se. Therefore, vaccine role may not be an accurate term. - MC - XZ - and AR - YH + Anna Maria Masci + Barry Smith + Jie Zheng + YH, MC, XZ, and AR disposition vaccine function @@ -6281,7 +6308,8 @@ https://sourceforge.net/p/obi/obi-terms/738/ - preventive vaccine function is a vaccine function realized by the process of vaccination and leading to induction of an adaptive immune response to the antigens in a vaccine, which protects against a specific disorder. + A vaccine function realized by the process of vaccination and leading to induction of an adaptive immune response to prevent a specific disorder. + Jie Zheng YH prophylactic vaccine function disposition @@ -6294,7 +6322,10 @@ https://sourceforge.net/p/obi/obi-terms/738/ - immunization is a processual entity that primes or modifies an adaptivie immune response to some antigens. + A process that results in an adaptive immune response to one or more antigens. + Anna Maria Masci + Barry Smith + Jie Zheng YH, XZ, BP WEB: http://en.wikipedia.org/wiki/Immunization process @@ -6307,8 +6338,12 @@ https://sourceforge.net/p/obi/obi-terms/738/ - Active immunization is an immunization process that entails the introduction of a foreign molecule into the body, which causes the body itself to generate adaptive immunity against the target. - YH, XZ + An immunization that involves the introduction of foreign molecules into a recipient body, in a way which causes the recipient to actively induce adaptive immunity against the immunization target. + Anna Maria Masci + Barry Smith + Jie Zheng + Oliver He + XZ WEB: http://en.wikipedia.org/wiki/Immunization process active immunization @@ -6348,7 +6383,10 @@ https://sourceforge.net/p/obi/obi-terms/738/ - artificial active immunization is an active immunization that occurs when a person or animal is vaccinated with a specific vaccine. + An immunization that is induced by a vaccine via vaccination process. + Anna Maria Masci + Barry Smith + Jie Zheng YH, XZ artificial active immunization WEB: http://en.wikipedia.org/wiki/Immunization @@ -6480,7 +6518,8 @@ https://sourceforge.net/p/obi/obi-terms/738/ - The therapeutic vaccine function is a function realized by the process of vaccination and leading to induction of an adaptive immune response to the antigens in a vaccine, which ameliorates a specific disorder. + A vaccine function realized the process of vaccination and leading to induction of an adaptive immune response to treat an existing specific disorder. + Jie Zheng YH disposition therapeutic vaccine function @@ -6509,8 +6548,7 @@ https://sourceforge.net/p/obi/obi-terms/738/ immunization objective is the specification of an objective to achieve immunization. - XZ - YH + YH, XZ WEB: http://en.wikipedia.org/wiki/Immunization information content entity immunization objective @@ -6518,6 +6556,37 @@ https://sourceforge.net/p/obi/obi-terms/738/ + + + + + + + + + + + + + + + + + + + + + + vaccine preparation is a manufacturing process to produce a vaccine. + YH, BP + vaccine generation + vaccine production + process + vaccine preparation + + + + @@ -6792,7 +6861,7 @@ However, running the reasoner takes time. As a way to reducing the time, I have - + @@ -6805,13 +6874,15 @@ However, running the reasoner takes time. As a way to reducing the time, I have - A role that inheres in an organism that is the target of a vaccination. - Jie Zheng - ZX - YH + Role that inheres in an organism that is the target of a vaccine administration (vaccination process). + Allen Xiang + Anna Maria Masci + Barry Smith + Jie Zheng + Oliver He https://github.com/vaccineontology/VO/issues/677 role - vaccine host role + vaccine recipient role @@ -6865,6 +6936,18 @@ However, running the reasoner takes time. As a way to reducing the time, I have + + + + + The objective that intends to produce vaccine via the vaccine preparation process. + YH + information content entity + vaccine target specification + + + + @@ -10010,9 +10093,8 @@ However, running the reasoner takes time. As a way to reducing the time, I have - A gene expressing a protein, either partially or entirely, serving as the antigen within a specific cancer vaccine. - Anna Maria Masci - Yongqun He + Gene expressing a protein which serves, either in whole or in part, as an antigen within a cancer vaccine. + Yongqun He|Anna Maria Masci|Barry Smith|Jie Zheng https://github.com/vaccineontology/VO/issues/677 gene canvaxgen @@ -13734,7 +13816,7 @@ However, running the reasoner takes time. As a way to reducing the time, I have - A synthetic vaccine used for cancer immunotherapy also known as Ras(val 12)-Vaccinia Vaccine,‚Äö√†√∂‚àö¬ßRASVAC-C‚Äö√†√∂‚àö¬ßis based on a mutant peptide epitope of the Ras oncoprotein at codon 12 (valine instead of glycine) that induces recognition and induction of tumor-specific, cell-mediated immune responses. Ras is an intracellular GTP-binding protein involved in signal transduction and regulation of proliferation and differentiation.‚Äö√†√∂‚àö¬ß + A synthetic vaccine used for cancer immunotherapy also known as Ras(val 12)-Vaccinia Vaccine, RASVAC-V is based on a mutant peptide epitope of the Ras oncoprotein at codon 12 (valine instead of glycine) that induces recognition and induction of tumor-specific, cell-mediated immune responses. Ras is an intracellular GTP-binding protein involved in signal transduction and regulation of proliferation and differentiation. Jie Zheng Jimmy Guo Oliver He @@ -16793,7 +16875,7 @@ However, running the reasoner takes time. As a way to reducing the time, I have - A cancer vaccine containing immunogenic, HLA-A2-specific epitopes derived from X-box‚Äö√†√∂‚àö‚Ñ¢binding protein 1-unspliced (XBP1-US), XBP1-spliced (SP), syndecan-1 (CD138), and CS1 (CD2 subset 1, CRACC, SLAMF7, CD319) with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, XBP1-US/XBP1-SP/CD138/CS1 multipeptide vaccine PVX-410 may stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens. The tumor associated antigens (TAAs) XBP1-US, XBP1-SP, CD138 and CS1, are overexpressed on the surface of multiple myeloma (MM) cells. + A cancer vaccine containing immunogenic, HLA-A2-specific epitopes derived from X-box-binding protein 1-unspliced (XBP1-US), XBP1-spliced (SP), syndecan-1 (CD138), and CS1 (CD2 subset 1, CRACC, SLAMF7, CD319) with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, XBP1-US/XBP1-SP/CD138/CS1 multipeptide vaccine PVX-410 may stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens. The tumor associated antigens (TAAs) XBP1-US, XBP1-SP, CD138 and CS1, are overexpressed on the surface of multiple myeloma (MM) cells. Jie Zheng Jimmy Guo Oliver He @@ -19511,7 +19593,7 @@ However, running the reasoner takes time. As a way to reducing the time, I have - A recombinant retroviral virus derived from SR-A strain of Rous sarcoma virus carrying a constitutively active form of the‚Äö√†√∂‚àö¬ßAKT‚Äö√†√∂‚àö¬ßGene. The viral vector‚Äö√†√∂‚àö¬ßRCAS‚Äö√†√∂‚àö¬ßharbors a Replication Competent ALV Splice acceptor. This recombinant virus was use in animal model to study gliomagenesis. + A recombinant retroviral virus derived from SR-A strain of Rous sarcoma virus carrying a constitutively active form of the AKT Gene. The viral vector RCAS harbors a Replication Competent ALV Splice acceptor. This recombinant virus was use in animal model to study gliomagenesis. Jie Zheng Jimmy Guo Oliver He @@ -19557,7 +19639,7 @@ However, running the reasoner takes time. As a way to reducing the time, I have - A recombinant retroviral virus derived from SR-A strain of Rous sarcoma virus carrying a human gene encoding the G12D mutant form of K-Ras. The viral vector,‚Äö√†√∂‚àö¬ßRCAS‚Äö√†√∂‚àö¬ßharbors a Replication Competent ALV Splice acceptor. This recombinant virus was use in animal model to study gliomagenesis. + A recombinant retroviral virus derived from SR-A strain of Rous sarcoma virus carrying a human gene encoding the G12D mutant form of K-Ras. The viral vector, RCAS harbors a Replication Competent ALV Splice acceptor. This recombinant virus was use in animal model to study gliomagenesis. Jie Zheng Jimmy Guo Oliver He @@ -19791,7 +19873,7 @@ However, running the reasoner takes time. As a way to reducing the time, I have - 2 class major histocompatibility complex‚Äö√†√∂‚àö‚Ñ¢restricted melanoma peptides + 2 class major histocompatibility complex-restricted melanoma peptides. Eliyas Asfaw Ibrahim Seleznev Jie Zheng @@ -36784,9 +36866,7 @@ Immunization Route: Intramuscular injection (i.m.) A cancer that is caused by human papillomavirus (HPV) infection. HPV infection can lead to six types of cancer including anal, cervical, oropharyngeal, penile, vaginal, and vulvar cancer. placeholder, will send new term requst to DOID - Anna Maria Masci - Xingxian Li - Jie Zheng + Jie Zheng, Xingxian Li, Anna Maria Masci https://github.com/vaccineontology/VO/issues/677 disposition HPV associated cancer @@ -36810,10 +36890,20 @@ Immunization Route: Intramuscular injection (i.m.) + + + + + + + + - An antigen expressed by the tumor cells, which may be exclusively present on tumor cells or overexpressed on them. - Anna Maria Masci + Either a tumor-specific or a tumor-associated antigen. + Anna Maria Masci + Barry Smith Jie Zheng + Oliver He https://github.com/vaccineontology/VO/issues/677 material entity tumor antigen @@ -36836,8 +36926,9 @@ Immunization Route: Intramuscular injection (i.m.) - A cancer vaccine that prevents cancer development associated with viral infections. + Cancer vaccine that prevents cancer formation and development. Anna Maria Masci + Barry Smith Jie Zheng Oliver He https://github.com/vaccineontology/VO/issues/677 @@ -36862,8 +36953,9 @@ Immunization Route: Intramuscular injection (i.m.) - A cancer vaccine that aims to eliminate or control tumor cells by recognizing the tumor cells and stimulating the immune system via tumor antigens. + Cancer vaccine that aims to eliminate or control tumor cells. Anna Maria Masci + Barry Smith Jie Zheng Oliver He https://github.com/vaccineontology/VO/issues/677 @@ -36927,6 +37019,36 @@ Immunization Route: Intramuscular injection (i.m.) + + + + + Antigen that is only expressed by tumor cells. + Anna Maria Masci + Barry Smith + Jie Zheng + Oliver He + material entity + tumor-specific antigen + + + + + + + + + Antigen that is overexpressed by tumor cells. + Anna Maria Masci + Barry Smith + Jie Zheng + Oliver He + material entity + tumor-associated antigen + + + + @@ -38074,5 +38196,5 @@ Immunization Route: Intramuscular injection (i.m.) - + diff --git a/CVX-VO/cvx-vo.owl b/CVX-VO/cvx-vo.owl index fbf9071..acf6c72 100644 --- a/CVX-VO/cvx-vo.owl +++ b/CVX-VO/cvx-vo.owl @@ -17,7 +17,7 @@ xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:ncbitaxon="http://purl.obolibrary.org/obo/ncbitaxon#"> - + en Jie Zheng Yongqun "Oliver" He (YH) @@ -25,8 +25,7 @@ The Vaccine Ontology (VO) subset for CVX codeset. OWL-DL Vaccine Ontology CVX code View - - 2024-06-26 + 2024-07-13 @@ -204,7 +203,6 @@ We also have the outstanding issue of how to aim different definitions to differ Consider re-defing to: An alternative name for a class or property which can mean the same thing as the preferred name (semantically equivalent, narrow, broad or related). alternative label - alternative term @@ -1425,7 +1423,7 @@ Some currently missing phenomena that should be considered "about" are - A shortcut relation that equals to: + A shortcut relation that is equivalent to: 'processed material' and (is_specified_output_of some 'vaccine preparation') and ('has function' some ('vaccine function' and ('is realized by' only ('vaccine immunization' and (realizes some ('vaccine host role' and (role_of some 'organism' and has_disposition some disease)))))))). The domain of this relation is a vaccine. The range of this relation is a disease. @@ -1442,16 +1440,32 @@ The range of this relation is a disease. - - A shortcut relation that equals to: -'processed material' and (is_specified_output_of some 'vaccine preparation') and ('has function' some ('vaccine function' and ('is realized by' only ('vaccine immunization' and (realizes some ('vaccine host role' and (role_of some 'organism')))))))). + + + + + + + + + + + + A shortcut relation that is equivalent to: +'processed material' and (is_specified_output_of some 'vaccine preparation') and ('has function' some ('vaccine function' and ('is realized by' only ('vaccine immunization' and (realizes some ('vaccine recipient role' and (role_of some 'organism')))))))). The domain of this relation is a vaccine. The range of this relation is a organism. + Anna Maria Masci Asiyah Yu Lin + Barry Smith + Jie Zheng Oliver He immunization for host + immunization for recipient + immunizes host vaccine immunization for host - immunizes host + vaccine immunization for recipient + immunizes recipient @@ -1471,7 +1485,7 @@ The range of this relation is a organism. - A shortcut relation that equals to: + A shortcut relation that is equivalent to: processed material and (is_specified_output_of some vaccine preparation) and (has function some (vaccine function and (is realized by only (vaccine immunization and (realizes some ('immunization target role' and (role_of some 'pathogen')))))))) The domain of this relation is a vaccine. @@ -6924,13 +6938,19 @@ https://sourceforge.net/p/obi/obi-terms/738/ - - + + + + + + + + @@ -6947,15 +6967,12 @@ https://sourceforge.net/p/obi/obi-terms/738/ - - - - - - - A vaccine is a processed material with the function that when administered, it prevents or ameliorates a disorder in a target organism by inducing or modifying adaptive immune responses specific to the antigens in the vaccine. + Material entity that is manufactured to realize the vaccine function. Many vaccines are developed to protect against infectious pathogens that causes infectious diseases. Many vaccines are also being developed against other diseases such as cancer, allergy, and autoimmune diseases. - YH, BP, BS, MC, LC, XZ, RS + Anna Maria Masci + Barry Smith + Jie Zheng + YH, BP, MC, LC, XZ, RS vaccine vaccine MeSH: D014612 @@ -7056,7 +7073,10 @@ https://sourceforge.net/p/obi/obi-terms/738/ - a process of administering substance in vivo that involves in adding a vaccine into a host (e.g., human) in vivo with the intent to invoke a protective or therapeutic adaptive immune response. + A process of administering a vaccine in vivo to a recipient (e.g., human) with the intent to invoke a protective or therapeutic adaptive immune response. + Anna Maria Masci + Barry Smith + Jie Zheng YH, BP vaccine administration process @@ -7943,7 +7963,7 @@ Reference: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=157& - A vaccine for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b. MENHIBRIX is approved for use in children 6 weeks of age through 18 months of age. + A vaccine for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b. MENHIBRIX is approved for use in children 6 weeks of age through 18 months of age. Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1437912 https://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm308566.htm @@ -9634,8 +9654,8 @@ influenzae type b (Haemophilus b, Ross strain) that is covalently bound to an ou Adenovirus types 4 and 7 vaccine Adenovirus Type 4 and Type 7 Vaccine, Live, Oral - UMLS_CUI: C0695130 SNOMEDCT: 442561000 + UMLS_CUI: C0695130 @@ -10186,8 +10206,7 @@ influenzae type b (Haemophilus b, Ross strain) that is covalently bound to an ou a vaccine component role that inheres in a recombinant vaccine vector as a vaccine component. The combination of a recombinant vaccine vector and a heterogenous protective antigen(s) inserted inside the vector for a recombinant vector vaccine. - YH - YL + YH,YL role recombinant vaccine vector role @@ -10307,7 +10326,10 @@ An adjuvant is a substance that helps and enhances the pharmacological effect of - A vaccine that prevents or treats cancer. It is produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced. + Vaccine that prevents or treats cancer. + Anna Maria Masci + Barry Smith + Jie Zheng Oliver He neoplasm vaccine tumor vaccine @@ -10464,8 +10486,7 @@ An adjuvant is a substance that helps and enhances the pharmacological effect of to be eaten. Melanie has submitted this term and its two subclasses to obo: http://sourceforge.net/tracker/?func=detail&aid=2873643&group_id=76834&atid=595654 - MC - YH + YH, MC quality edibility @@ -10497,12 +10518,12 @@ http://sourceforge.net/tracker/?func=detail&aid=2873643&group_id=76834&a - vaccine function is a function that inheres in a vaccine that induces protective immune response against a disease. It is realized in the immunization process in the host. + To induce or modify protective or therapeutic immune response against a disease. PERSPN: Oliver He: There has been hot discussion about whether we use 'vaccine function' or 'vaccine role'. Vaccine role may not be the good term to use. Vaccine is designed to be 'vaccine', so it should be vaccine function. One special case is cowpox virus. The cowpox virus can be mixed with some liquid like water and used as a smallpox vaccine. In this case, people often say: the cowpox virus has a 'vaccine role'. However, the cowpox virus vaccine is a processed material of a mix of the virus with water. The virus is a virus, it is not a vaccine per se. Therefore, vaccine role may not be an accurate term. - MC - XZ - and AR - YH + Anna Maria Masci + Barry Smith + Jie Zheng + YH, MC, XZ, and AR disposition vaccine function @@ -10581,9 +10602,9 @@ http://sourceforge.net/tracker/?func=detail&aid=2873643&group_id=76834&a a vaccine additive that stabilizes the vaccine emulsification manufacturing process and makes emulsion of the vaccine easier. YH, YL - WEB: http://www.ncbi.nlm.nih.gov/pubmed/16337664 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/16337664 vaccine component - Emulsifiers help bind ingredients together and keep them from separating, most commonly with oil and water. An emulsifier is also a surfactant that reduces the surface tension of a liquid and results in an easier, smoother spread. Reference: http://www.wisegeek.org/what-is-polysorbate-80.htm + Emulsifiers help bind ingredients together and keep them from separating, most commonly with oil and water. An emulsifier is also a surfactant that reduces the surface tension of a liquid and results in an easier, smoother spread. Reference: http://www.wisegeek.org/what-is-polysorbate-80.htm vaccine emulsifier @@ -10827,8 +10848,7 @@ http://sourceforge.net/tracker/?func=detail&aid=2873643&group_id=76834&a A role inheres in a material entity, that has been added into a vaccine's formulation by the manufacture for a specific purpose. For example: adjuvant to enhance the effect of immunogen, perservatives, stablizers and those materials added for affecting PH and isotonicity. - YH - YL + YL,YH Page 73, Chapter 6, Vaccine, 5th Edition. EXPERT CONSULT by Plotkin SA., et. al. 2008 role vaccine additive role @@ -11080,7 +11100,8 @@ http://sourceforge.net/tracker/?func=detail&aid=2873643&group_id=76834&a - preventive vaccine function is a vaccine function realized by the process of vaccination and leading to induction of an adaptive immune response to the antigens in a vaccine, which protects against a specific disorder. + A vaccine function realized by the process of vaccination and leading to induction of an adaptive immune response to prevent a specific disorder. + Jie Zheng YH prophylactic vaccine function disposition @@ -11254,7 +11275,10 @@ http://sourceforge.net/tracker/?func=detail&aid=2873643&group_id=76834&a - immunization is a processual entity that primes or modifies an adaptivie immune response to some antigens. + A process that results in an adaptive immune response to one or more antigens. + Anna Maria Masci + Barry Smith + Jie Zheng YH, XZ, BP WEB: http://en.wikipedia.org/wiki/Immunization process @@ -11267,8 +11291,12 @@ http://sourceforge.net/tracker/?func=detail&aid=2873643&group_id=76834&a - Active immunization is an immunization process that entails the introduction of a foreign molecule into the body, which causes the body itself to generate adaptive immunity against the target. - YH, XZ + An immunization that involves the introduction of foreign molecules into a recipient body, in a way which causes the recipient to actively induce adaptive immunity against the immunization target. + Anna Maria Masci + Barry Smith + Jie Zheng + Oliver He + XZ WEB: http://en.wikipedia.org/wiki/Immunization process active immunization @@ -11308,7 +11336,10 @@ http://sourceforge.net/tracker/?func=detail&aid=2873643&group_id=76834&a - artificial active immunization is an active immunization that occurs when a person or animal is vaccinated with a specific vaccine. + An immunization that is induced by a vaccine via vaccination process. + Anna Maria Masci + Barry Smith + Jie Zheng YH, XZ artificial active immunization WEB: http://en.wikipedia.org/wiki/Immunization @@ -11527,7 +11558,8 @@ http://sourceforge.net/tracker/?func=detail&aid=2873643&group_id=76834&a - The therapeutic vaccine function is a function realized by the process of vaccination and leading to induction of an adaptive immune response to the antigens in a vaccine, which ameliorates a specific disorder. + A vaccine function realized the process of vaccination and leading to induction of an adaptive immune response to treat an existing specific disorder. + Jie Zheng YH disposition therapeutic vaccine function @@ -11662,8 +11694,7 @@ http://sourceforge.net/tracker/?func=detail&aid=2873643&group_id=76834&a immunization objective is the specification of an objective to achieve immunization. - XZ - YH + YH, XZ WEB: http://en.wikipedia.org/wiki/Immunization information content entity immunization objective @@ -11701,6 +11732,37 @@ http://sourceforge.net/tracker/?func=detail&aid=2873643&group_id=76834&a + + + + + + + + + + + + + + + + + + + + + + vaccine preparation is a manufacturing process to produce a vaccine. + YH, BP + vaccine generation + vaccine production + process + vaccine preparation + + + + @@ -12466,7 +12528,7 @@ However, even this may not be comprehensive. - A live attenuated Shigella flexneri 2a vaccine that carries deletions of the plasmid-borne virulence gene icsA (mediating intra- and intercellular spread) and the chromosomal locus iuc (encoding aerobactin). + A live attenuated Shigella flexneri 2a vaccine that carries deletions of the plasmid-borne virulence gene icsA (mediating intra- and intercellular spread) and the chromosomal locus iuc (encoding aerobactin). YH PMID:10377124 vaccine @@ -13711,8 +13773,7 @@ Ref: Finn TM and Egan W, in Vaccines fifth edition, 2008. Page 73. a role inhers in a vaccine component that when added into a vccine formmulation, it can prevent the growth of bacteria or fungi that inadvertently may be introduced into the vaccine during administrating process or the manufacturing process. - YH - YL + YH,YL P73 Chapter 6, Vaccine 5th edition by Plotkin, S. et al. role The CFR requires that, with certain defined exceptions, preservatives must be added to mulitdose vials of vaccine. (P73 Chapter 6, Vaccine 5th edition by Plotkin, S. et al.) @@ -13796,8 +13857,7 @@ Ref: Finn TM and Egan W, in Vaccines fifth edition, 2008. Page 73. vaccine allergen is a material entity that is capable of stimulating a type-I hypersensitivity reaction in atopic individuals who has been vaccinated with a vaccine. - ZX - YH + YH, ZX WEB: http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf material entity vaccine allergen @@ -13812,9 +13872,7 @@ Ref: Finn TM and Egan W, in Vaccines fifth edition, 2008. Page 73.chicken egg protein allergen is a vaccine allergen that is composed of chicken egg protein. Egg protein may come from NCIS thesaurus egg - poultry, combination of minimal anatomy terminology and NCBI taxonomy... Eventually, this term chicken egg protein allergen may become a cross product of sevreal ontology terms. - MC - ZX - YH + YH, ZX, MC material entity chicken egg protein allergen @@ -13825,8 +13883,7 @@ of minimal anatomy terminology and NCBI taxonomy... Eventually, this term chicke - ZX - YH + YH, ZX material entity latex vaccine allergen @@ -13837,8 +13894,7 @@ of minimal anatomy terminology and NCBI taxonomy... Eventually, this term chicke - ZX - YH + YH, ZX material entity gelatin vaccine allergen @@ -13937,9 +13993,9 @@ of minimal anatomy terminology and NCBI taxonomy... Eventually, this term chicke a vaccine emulsifier that uses polysorbate 80, also known as polyoxyethylene sorbitan monooleate or Tween(TM) 80. YH,YL Tween 80 vaccine emulsifier - WEB: http://www.wisegeek.org/what-is-polysorbate-80.htm + WEB: http://www.wisegeek.org/what-is-polysorbate-80.htm vaccine component - Tween 80 is an amber-colored, viscous liquid with a slightly bitter taste. The product is a derivative of sorbitol and oleic acid. + Tween 80 is an amber-colored, viscous liquid with a slightly bitter taste. The product is a derivative of sorbitol and oleic acid. polysorbate 80 vaccine emulsifier @@ -14318,8 +14374,7 @@ of minimal anatomy terminology and NCBI taxonomy... Eventually, this term chicke vaccine viability is a viability of a vaccine organism. - ZX - YH + YH, ZX quality vaccine organism viability @@ -14517,8 +14572,7 @@ However, running the reasoner takes time. As a way to reducing the time, I have - ZX - YH + YH, ZX material entity protective antigen @@ -14718,7 +14772,7 @@ However, running the reasoner takes time. As a way to reducing the time, I have - SYNFLORIX is indicated for active immunization of infants and children from 6 weeks up to 5 years of age against Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and invasive disease caused by these serotypes (including sepsis, meningitis, bacteraemic pneumonia, pleural empyema and bacteraemia). + SYNFLORIX is indicated for active immunization of infants and children from 6 weeks up to 5 years of age against Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and invasive disease caused by these serotypes (including sepsis, meningitis, bacteraemic pneumonia, pleural empyema and bacteraemia). ZX WEB: http://www.gsk.ca/english/docs-pdf/product-monographs/Synflorix.pdf vaccine @@ -14793,7 +14847,7 @@ However, running the reasoner takes time. As a way to reducing the time, I have - + @@ -14806,13 +14860,15 @@ However, running the reasoner takes time. As a way to reducing the time, I have - A role that inheres in an organism that is the target of a vaccination. - Jie Zheng - ZX - YH + Role that inheres in an organism that is the target of a vaccine administration (vaccination process). + Allen Xiang + Anna Maria Masci + Barry Smith + Jie Zheng + Oliver He https://github.com/vaccineontology/VO/issues/677 role - vaccine host role + vaccine recipient role @@ -14869,6 +14925,18 @@ However, running the reasoner takes time. As a way to reducing the time, I have + + + + + The objective that intends to produce vaccine via the vaccine preparation process. + YH + information content entity + vaccine target specification + + + + @@ -17959,6 +18027,7 @@ over. Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1601236 + 1601236 Outer Membrane Vesicles (Neisseria Meningitidis Group B Nz98/254 Strain) 44012722 OMOP1131632 @@ -20861,8 +20930,7 @@ over. A vaccine role that inheres in a vaccine using virus-like particles (VLPs), multiprotein structures that mimic the organization and conformation of authentic native viruses but lack the viral genome, potentially yielding safer and cheaper vaccines. - Oliver He - Anthony Huffman + Anthony Huffman, Oliver He virus like particle vaccine role https://pubmed.ncbi.nlm.nih.gov/20923267/ role @@ -24679,8 +24747,9 @@ administered prior to exposure or within two weeks after exposure. - A cancer vaccine that prevents cancer development associated with viral infections. + Cancer vaccine that prevents cancer formation and development. Anna Maria Masci + Barry Smith Jie Zheng Oliver He https://github.com/vaccineontology/VO/issues/677 @@ -24705,8 +24774,9 @@ administered prior to exposure or within two weeks after exposure. - A cancer vaccine that aims to eliminate or control tumor cells by recognizing the tumor cells and stimulating the immune system via tumor antigens. + Cancer vaccine that aims to eliminate or control tumor cells. Anna Maria Masci + Barry Smith Jie Zheng Oliver He https://github.com/vaccineontology/VO/issues/677 @@ -30735,5 +30805,5 @@ immunogen: ROT - + diff --git a/robot_report.tsv b/robot_report.tsv index e186f7c..ed8abf2 100644 --- a/robot_report.tsv +++ b/robot_report.tsv @@ -95,7 +95,6 @@ WARN annotation_whitespace OPL:0000359 IAO:0000116 "Tachyzoites can be found in WARN annotation_whitespace RO:0002093 rdfs:comment X ends_during Y iff: ((start(Y) before_or_simultaneous_with end(X)) AND end(X) before_or_simultaneous_with end(Y). @en WARN annotation_whitespace RO:0002161 IAO:0000425 Class: ?X DisjointWith: RO_0002162 some ?Y WARN annotation_whitespace VO:0000018 IAO:0000115 A Brucella abortus vaccine that expresses Cu/Zn SOD with DNA plasmid pcDNA. -WARN annotation_whitespace VO:0000031 IAO:0000115 A vaccine for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b. MENHIBRIX is approved for use in children 6 weeks of age through 18 months of age. WARN annotation_whitespace VO:0000035 IAO:0000115 "a vaccinia virus vaccine that is a freeze-dried calf lymph smallpox vaccine, specifically, Dryvax is a live-virus preparation of vaccinia prepared from calf lymph. " WARN annotation_whitespace VO:0000048 IAO:0000117 YL WARN annotation_whitespace VO:0000048 IAO:0000117 ZX @@ -103,64 +102,42 @@ WARN annotation_whitespace VO:0000069 IAO:0000115 "A Measles-Mumps-Rubella vacci WARN annotation_whitespace VO:0000070 IAO:0000115 A Measles-Mumps vaccine that is manufactured by Merck and used for human. WARN annotation_whitespace VO:0000079 IAO:0000115 an influenza vaccine that is similar to Fluzone but has high dose. WARN annotation_whitespace VO:0000091 IAO:0000115 "A Measles-Mumps-Rubella-Vericella vaccine that is live and manufactured by Merck & Co, Inc. " -WARN annotation_whitespace VO:0000096 rdfs:seeAlso UMLS_CUI: C0695130 WARN annotation_whitespace VO:0000137 IAO:0000115 A vaccine role that indicates the vaccine being a combination vaccine. WARN annotation_whitespace VO:0000145 IAO:0000115 a vaccine component role that inheres in a recombinant vaccine vector as a vaccine component. The combination of a recombinant vaccine vector and a heterogenous protective antigen(s) inserted inside the vector for a recombinant vector vaccine. WARN annotation_whitespace VO:0000147 IAO:0000115 an adjuvant role that inheres in a vaccine component which is added as part of a vaccine and induces enhanced adaptive immune response to the vaccine antigen. -WARN annotation_whitespace VO:0000151 IAO:0000117 YL WARN annotation_whitespace VO:0000154 IAO:0000115 A Brucella abortus gene that has the name sodC and comes from strain 2308. WARN annotation_whitespace VO:0000166 IAO:0000115 a vaccine vector that uses a live bacterium as the vector WARN annotation_whitespace VO:0000194 IAO:0000115 a USA licensed vaccine role that inheres ina vaccine approven to be by the US FDA to be used for humans in the USA. WARN annotation_whitespace VO:0000207 IAO:0000115 A vaccine contraindication is a contraindication that increases the risks of a vaccination. WARN annotation_whitespace VO:0000208 IAO:0000115 "A vaccine role that is not licensed or in clinical trial; instead, it has been experimently approved to induce protection or treatment effect in vivo in at least an experimental animal model. " WARN annotation_whitespace VO:0000211 IAO:0000115 an organismal quality of a whole organism vaccine where the whole organism is inactivated/killed and lacks the capability of replication. -WARN annotation_whitespace VO:0000245 IAO:0000117 MC -WARN annotation_whitespace VO:0000278 IAO:0000117 MC -WARN annotation_whitespace VO:0000278 IAO:0000117 XZ -WARN annotation_whitespace VO:0000278 IAO:0000117 and AR WARN annotation_whitespace VO:0000310 IAO:0000115 a vaccine additive that stabilizes the vaccine emulsification manufacturing process and makes emulsion of the vaccine easier. -WARN annotation_whitespace VO:0000310 IAO:0000119 WEB: http://www.ncbi.nlm.nih.gov/pubmed/16337664 -WARN annotation_whitespace VO:0000310 rdfs:comment "Emulsifiers help bind ingredients together and keep them from separating, most commonly with oil and water. An emulsifier is also a surfactant that reduces the surface tension of a liquid and results in an easier, smoother spread. Reference: http://www.wisegeek.org/what-is-polysorbate-80.htm " -WARN annotation_whitespace VO:0000330 IAO:0000117 MC WARN annotation_whitespace VO:0000335 IAO:0000115 A vaccination site that is used for injection of a vaccine. WARN annotation_whitespace VO:0000369 IAO:0000115 A 'has vaccine component' relation that specifies the plasmid used for development of a particular DNA vaccine. WARN annotation_whitespace VO:0000375 IAO:0000112 'Mycobacterium avium relA mutant vaccine' includes a gene mutation of relA from virulent Mycobacterium avium. WARN annotation_whitespace VO:0000384 IAO:0000119 "PMID:18472194 " -WARN annotation_whitespace VO:0000395 IAO:0000117 YL -WARN annotation_whitespace VO:0000395 IAO:0000117 ZX WARN annotation_whitespace VO:0000400 IAO:0000115 A vaccine that contains one vaccine for priming and at least one other vaccine for boosting. WARN annotation_whitespace VO:0000401 IAO:0000115 A prime-boost vaccine that contains one DNA vaccine for priming and at least one other vaccine for boosting. -WARN annotation_whitespace VO:0000426 IAO:0000117 MC WARN annotation_whitespace VO:0000435 IAO:0000115 a vaccine component that is composed of a plasmid and used in the generation of a DNA vaccine. WARN annotation_whitespace VO:0000441 IAO:0000115 "vaccine candidate role is the role of a material entity in an investigation, which has not been experimentally or clinically verified to induce a protection or treatment in vivo in a host organism. " -WARN annotation_whitespace VO:0000441 IAO:0000117 YH WARN annotation_whitespace VO:0000465 IAO:0000115 a S. aureus vaccine that uses bacterin as the protective antigen. WARN annotation_whitespace VO:0000467 IAO:0000115 a S. aureus vaccine that uses the bacterial phage lysate as the protective antigen. WARN annotation_whitespace VO:0000469 IAO:0000115 a bacterial vaccine that uses bacterin from a bacterial strain isolated from a herd with a purpose to generate hard-specific vaccine. WARN annotation_whitespace VO:0000470 IAO:0000115 an autogenous bacterin vaccine that is prepared for poultry use. WARN annotation_whitespace VO:0000476 IAO:0000115 "A 'has vaccine component' relation that specifies a gene inserted to DNA vaccine plasmid for development of a particular DNA vaccine, and this gene encodes for a protein antigen. " WARN annotation_whitespace VO:0000483 IAO:0000115 A subunit vaccine that is made using a part of whole organism as subunit for vaccine development. -WARN annotation_whitespace VO:0000499 IAO:0000117 XZ WARN annotation_whitespace VO:0000504 IAO:0000115 a vaccine role that indicates the vaccine being a whole organism vaccine. WARN annotation_whitespace VO:0000512 IAO:0000115 a viral vaccine against a disease caused by a virus belong to Poxviridae. -WARN annotation_whitespace VO:0000519 rdfs:seeAlso GenBank: AC020633; Protein RefSeq: NP_001090 WARN annotation_whitespace VO:0000524 IAO:0000116 "This relation only works for those vaccine antigen that is physically part of a vaccine preparation. It does not include those antigens that are not part of vaccine. For example, a protein antigen expressed in a DNA vaccine is not a part of vaccine pe ser. In this case, the vaccine expresses the protein, but the gene is part of the vaccine, not the protein. For the case, we can use the relation 'DNA vaccine expresses protein antigen' under the relation 'expresses'. " WARN annotation_whitespace VO:0000532 IAO:0000115 A route of administration that is loacted in the hypodermis (subcutaneous tissue) region. -WARN annotation_whitespace VO:0000540 IAO:0000117 MC WARN annotation_whitespace VO:0000560 IAO:0000115 A toxin is a poisonous substance produced within living cells or organisms; man-made substances created by artificial processes are thus excluded. WARN annotation_whitespace VO:0000560 rdfs:comment "The term was first used by organic chemist Ludwig Brieger (1849-1919).[3] For a toxic substance not produced within living organisms, \""toxicant\"" and \""toxics\"" are also sometimes used.[citation needed]. Toxins can be small molecules, peptides, or proteins that are capable of causing disease on contact with or absorption by body tissues interacting with biological macromolecules such as enzymes or cellular receptors. Toxins vary greatly in their severity, ranging from usually minor and acute (as in a bee sting) to almost immediately deadly (as in botulinum toxin).-- from Wikipedia. " WARN annotation_whitespace VO:0000574 IAO:0000115 "A path that is located in gross anatomical part of an organism (e.g., human) and is used for administering a vaccine, a drug, fluid, poison, or other substance into the body. " -WARN annotation_whitespace VO:0000575 IAO:0000117 AR -WARN annotation_whitespace VO:0000575 IAO:0000117 BP -WARN annotation_whitespace VO:0000575 IAO:0000117 LC -WARN annotation_whitespace VO:0000575 IAO:0000117 MC -WARN annotation_whitespace VO:0000575 IAO:0000117 and ZX WARN annotation_whitespace VO:0000577 IAO:0000115 A subunit vaccine that uses small peptide(s) as immunoepitopes. -WARN annotation_whitespace VO:0000585 IAO:0000117 XZ WARN annotation_whitespace VO:0000599 IAO:0000116 "a vaccine component that uses a microbe (e.g., bacterium, virus, and parasitic organism) as a vector that is inserted with the DNA(s) of a heterologous protective antigen(s) to generate a \""recombinant vector vaccine\"". The microorganism used as a vector generally has a stable non or low pathogenic phenotype for the species the vaccine is intended for. " WARN annotation_whitespace VO:0000608 IAO:0000115 An 'expresses' relation that specifies a relation between a DNA vaccine and a protein antigen to be expressed by the DNA vaccine. WARN annotation_whitespace VO:0000615 IAO:0000115 A role that inheres in a prepared material entity that is designed to induce protection or treatment for a disease or infection. @@ -173,7 +150,6 @@ WARN annotation_whitespace VO:0000636 IAO:0000115 A vaccine role that indicates WARN annotation_whitespace VO:0000642 rdfs:comment "There is no single 'influenza virus' in NCBI_Taxon. We usually use: ('unidentified influenza virus' or 'Influenzavirus A' or 'Influenzavirus B' or 'Influenzavirus C') However, even this may not be comprehensive. " -WARN annotation_whitespace VO:0000663 IAO:0000115 A live attenuated Shigella flexneri 2a vaccine that carries deletions of the plasmid-borne virulence gene icsA (mediating intra- and intercellular spread) and the chromosomal locus iuc (encoding aerobactin). WARN annotation_whitespace VO:0000671 IAO:0000115 "A Salmonella vaccine against typhoid fever (or called typoid), caused by Salmonella enterica enterica, serovar Typhi. " WARN annotation_whitespace VO:0000675 IAO:0000115 "a Streptococcal vaccine that is used against S. pneumoniae infection, which causes pneumococcal diseases. " WARN annotation_whitespace VO:0000685 IAO:0000115 a recombinant vector vaccine role that inheres in a bacterium that carries a vaccine antigen for development of a particular vaccine @@ -186,55 +162,22 @@ WARN annotation_whitespace VO:0000794 IAO:0000115 A Brucella abortus gene that h WARN annotation_whitespace VO:0000799 IAO:0000115 "An object property that represents a mutational relation between a vaccine organism and another material (e.g., gene or protein). the mutated material initially exists in the original wildtype organism. " WARN annotation_whitespace VO:0000807 IAO:0000115 A vaccine role that indicates the vaccine being a toxoid vaccine. WARN annotation_whitespace VO:0000818 IAO:0000115 An object property that specifies a relation between a vaccine and a vaccine virmugen. -WARN annotation_whitespace VO:0000910 IAO:0000117 ZX -WARN annotation_whitespace VO:0000912 IAO:0000117 MC -WARN annotation_whitespace VO:0000912 IAO:0000117 ZX -WARN annotation_whitespace VO:0000913 IAO:0000117 ZX -WARN annotation_whitespace VO:0000915 IAO:0000117 ZX -WARN annotation_whitespace VO:0000916 IAO:0000117 ZX -WARN annotation_whitespace VO:0000917 IAO:0000117 ZX WARN annotation_whitespace VO:0000922 IAO:0000115 a vaccine stablizer that is based on monosodium glutamate. WARN annotation_whitespace VO:0000929 rdfs:comment "Potential Acute Health Effects: Slightly hazardous in case of skin contact (irritant), of eye contact (irritant), of ingestion, of inhalation. Reference: http://www.sciencelab.com/msds.php?msdsId=9926640 " -WARN annotation_whitespace VO:0000930 IAO:0000119 WEB: http://www.wisegeek.org/what-is-polysorbate-80.htm -WARN annotation_whitespace VO:0000930 rdfs:comment "Tween 80 is an amber-colored, viscous liquid with a slightly bitter taste. The product is a derivative of sorbitol and oleic acid. " WARN annotation_whitespace VO:0000931 IAO:0000115 a cell culture residual in vaccine that is residual protein from cell culture. WARN annotation_whitespace VO:0000957 IAO:0000115 a B. abortus vaccine that uses a recombinant vector. -WARN annotation_whitespace VO:0001002 IAO:0000115 "A DNA vaccine plasmid vector that has the plasmid label phCMV1. This plasmid is 4200 base pairs long, has a CMV promoter, contains kanamycin and neomycin antibiotics resistance genes, and is manufactured by Genlantis. " WARN annotation_whitespace VO:0001014 IAO:0000115 a live attenuated quality of a bacterial vaccine strain. WARN annotation_whitespace VO:0001015 IAO:0000115 a live attenuated quality of a virus vaccine strain. WARN annotation_whitespace VO:0001019 IAO:0000115 an avian reovirus vaccine that using live attenauted reovirus. WARN annotation_whitespace VO:0001021 IAO:0000115 a feline panleukopenia virus vaccine where the virus used is live attenuated. WARN annotation_whitespace VO:0001028 IAO:0000115 a parasite vaccine vector using a live attenuated Leishmania tarentolae strain. -WARN annotation_whitespace VO:0001031 IAO:0000115 a bacterial vaccine vector using a live attenuated Salmonella enterica strain SL3261. -WARN annotation_whitespace VO:0001038 IAO:0000115 "a bacterial vaccine vector using the HS93Tox- mutant of the serovar 7 strain of Actinobacillus pleuropneumoniae. This mutant lacks the genes encoding the toxin ApxA and the post-translational activating protein ApxC, but still has genes required for secretion, making it a good vector. " -WARN annotation_whitespace VO:0001041 IAO:0000115 "A Listeria monocytogenes vaccine vector that uses the highly attenuated LM1-2 strain -" -WARN annotation_whitespace VO:0001041 IAO:0000119 PMID: 23027427 WARN annotation_whitespace VO:0001050 IAO:0000118 PrV vaccine vector WARN annotation_whitespace VO:0001060 IAO:0000118 NDV vaccine vector -WARN annotation_whitespace VO:0001068 IAO:0000115 A Herpes simplex virus vaccine vector that uses a virus type 1 strain -WARN annotation_whitespace VO:0001082 IAO:0000115 "an adenovirus vaccine vector that contains a deletion of the gp64 gene. As a result of the deletion, this vector is unable to propagate infection from cell to cell, and this defect results from both a severe reduction in the production of budded virions and the absence of GP64 on virions. " WARN annotation_whitespace VO:0001084 IAO:0000115 a viral vaccine vector that uses a baculovirus as the vector -WARN annotation_whitespace VO:0001089 IAO:0000117 XZ -WARN annotation_whitespace VO:0001090 IAO:0000117 XZ -WARN annotation_whitespace VO:0001094 IAO:0000117 XZ -WARN annotation_whitespace VO:0001098 IAO:0000117 XZ -WARN annotation_whitespace VO:0001099 IAO:0000117 XZ -WARN annotation_whitespace VO:0001100 IAO:0000117 XZ -WARN annotation_whitespace VO:0001101 IAO:0000117 XZ WARN annotation_whitespace VO:0001107 IAO:0000115 a vaccinia virus vector that uses the Modified Vaccinia Ankara (MVA) virus. WARN annotation_whitespace VO:0001109 IAO:0000115 a vaccinia virus vector that uses the MVTT vaccine strain as the vector. MVTT is an attenuated vaccine strain. WARN annotation_whitespace VO:0001111 IAO:0000115 A poxvirus vaccine vector that uses an attenuated lumpy skin disease virus as the vector. WARN annotation_whitespace VO:0001128 IAO:0000115 a canarypox vaccine vector that uses an attenuated canarypox virus strain ALVAC. The ALVAC vector is a canarypox virus clone obtained after four rounds of plaque purification of a strain from a vaccine for canaries. -WARN annotation_whitespace VO:0001139 IAO:0000117 ZX -WARN annotation_whitespace VO:0001145 IAO:0000117 ZX -WARN annotation_whitespace VO:0001148 IAO:0000117 ZX -WARN annotation_whitespace VO:0001149 IAO:0000117 ZX -WARN annotation_whitespace VO:0001150 IAO:0000117 ZX -WARN annotation_whitespace VO:0001160 IAO:0000117 ZX -WARN annotation_whitespace VO:0001161 IAO:0000117 ZX -WARN annotation_whitespace VO:0001162 IAO:0000117 ZX -WARN annotation_whitespace VO:0001163 IAO:0000117 ZX WARN annotation_whitespace VO:0001186 IAO:0000119 "Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026. " WARN annotation_whitespace VO:0001188 IAO:0000115 A measurement datum that represents a vaccine strain. Different strains can be represented using distinct digital numbers. WARN annotation_whitespace VO:0001188 IAO:0000119 "Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026. " @@ -272,23 +215,7 @@ WARN annotation_whitespace VO:0001220 rdfs:comment "This term has an equivalent However, running the reasoner takes time. As a way to reducing the time, I have tentatively made tern two subclasses instead of equivalent class. If needed, the equivalent class can be used in SPARQL or converted back in VO. --Oliver " -WARN annotation_whitespace VO:0001232 IAO:0000117 ZX -WARN annotation_whitespace VO:0001245 IAO:0000115 "SYNFLORIX is indicated for active immunization of infants and children from 6 weeks up to 5 years of age against Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and invasive disease caused by these serotypes (including sepsis, meningitis, bacteraemic pneumonia, pleural empyema and bacteraemia). " -WARN annotation_whitespace VO:0001274 IAO:0000117 Jie Zheng -WARN annotation_whitespace VO:0001274 IAO:0000117 ZX -WARN annotation_whitespace VO:0001275 IAO:0000117 ZX -WARN annotation_whitespace VO:0001281 IAO:0000117 ZX -WARN annotation_whitespace VO:0001282 IAO:0000117 ZX -WARN annotation_whitespace VO:0001283 IAO:0000117 ZX -WARN annotation_whitespace VO:0001284 IAO:0000117 ZX -WARN annotation_whitespace VO:0001361 IAO:0000117 YL -WARN annotation_whitespace VO:0001374 IAO:0000117 MC -WARN annotation_whitespace VO:0001374 IAO:0000117 YL WARN annotation_whitespace VO:0001380 IAO:0000117 Oliver He -WARN annotation_whitespace VO:0001381 IAO:0000117 MC -WARN annotation_whitespace VO:0001381 IAO:0000117 YL -WARN annotation_whitespace VO:0001383 IAO:0000117 MC -WARN annotation_whitespace VO:0001383 IAO:0000117 YL WARN annotation_whitespace VO:0001384 IAO:0000117 RR WARN annotation_whitespace VO:0001395 IAO:0000115 a vaccine that contains two or more individual vaccines. WARN annotation_whitespace VO:0001400 IAO:0000117 RR @@ -579,8 +506,6 @@ WARN annotation_whitespace VO:0003024 IAO:0000115 a vaccine powder that is freez WARN annotation_whitespace VO:0003033 IAO:0000115 a protein vaccine stablizer that is specifically bovine serum albumin. WARN annotation_whitespace VO:0003035 IAO:0000115 a vaccine stabilizer that is generated based on amino acids. WARN annotation_whitespace VO:0003036 IAO:0000115 a vaccine stabilizer that is specifically made by a sucrose. -WARN annotation_whitespace VO:0003039 IAO:0000115 a polysorbate 20 vaccine stabilizer that is Alkest TW20. -WARN annotation_whitespace VO:0003040 IAO:0000115 a polysorbate 20 vaccine stabilizer that is Tween 20. WARN annotation_whitespace VO:0003041 IAO:0000115 an antibiotics vaccine residual that has the antibiotics of neomycin. WARN annotation_whitespace VO:0003042 IAO:0000115 the vaccine antiegn that induces protective immune response. WARN annotation_whitespace VO:0003048 IAO:0000115 "when the vaccination of a significant portion of a population (or herd), in contagious diseases that are transmitted from individual to individual, chains of infection are likely to be disrupted, so the large numbers of a population are immue or less susceptible to the disease. " @@ -601,23 +526,7 @@ WARN annotation_whitespace VO:0004429 IAO:0000117 Oliver He WARN annotation_whitespace VO:0004430 IAO:0000117 Oliver He WARN annotation_whitespace VO:0004604 IAO:0000117 Oliver He WARN annotation_whitespace VO:0004739 IAO:0000117 Oliver He -WARN annotation_whitespace VO:0004913 IAO:0000117 Oliver He -WARN annotation_whitespace VO:0004921 IAO:0000117 Anthony Huffman -WARN annotation_whitespace VO:0004921 IAO:0000117 Oliver He -WARN annotation_whitespace VO:0004922 IAO:0000117 Anthony Huffman -WARN annotation_whitespace VO:0004922 IAO:0000117 Oliver He -WARN annotation_whitespace VO:0004923 IAO:0000117 Anthony Huffman -WARN annotation_whitespace VO:0004923 IAO:0000117 Oliver He -WARN annotation_whitespace VO:0004924 IAO:0000117 Anthony Huffman -WARN annotation_whitespace VO:0004924 IAO:0000117 Oliver He -WARN annotation_whitespace VO:0004925 IAO:0000117 Anthony Huffman -WARN annotation_whitespace VO:0004925 IAO:0000117 Oliver He WARN annotation_whitespace VO:0005278 IAO:0000117 Oliver He -WARN annotation_whitespace VO:0005304 IAO:0000117 Amogh Madireddi -WARN annotation_whitespace VO:0005305 IAO:0000117 Amogh Madireddi -WARN annotation_whitespace VO:0005306 IAO:0000117 Amogh Madireddi -WARN annotation_whitespace VO:0005307 IAO:0000117 Amogh Madireddi -WARN annotation_whitespace VO:0005506 IAO:0000117 Anna Maria Masci WARN annotation_whitespace VO:0006094 IAO:0000116 "Chemical Nature: Nucleic acid Mechanism of Action: TLR9 agonist Immune profile induced: Mixed Th1/Th2 @@ -768,6 +677,9 @@ WARN annotation_whitespace VO:0007331 IAO:0000117 Oliver He WARN annotation_whitespace VO:0007332 IAO:0000117 Oliver He WARN annotation_whitespace VO:0007333 IAO:0000117 Oliver He WARN annotation_whitespace VO:0007334 IAO:0000117 Oliver He +WARN annotation_whitespace VO:0007336 IAO:0000115 A cancer vaccine that consists of of irradiated autologous tumor cells admixed with GM-CSF-secreting bystander cells. The CD8+ T cells can react against CLL-associated antigens. Autologous tumor cell vaccination is an effective strategy to advance long-term leukemia control following allogeneic hematopoietic stem cell transplantation (allo-HSCT). +WARN annotation_whitespace VO:0007342 IAO:0000115 "A cancer vaccine that is composed of oxidized ovarian tumor cell lysate, with potential immunostimulatory and antineoplastic activities. The autologous oxidized ovarian tumor cell lysate vaccine exposes the immune system to an undefined amount of tumor-associated antigens (TAAs), which may result in the induction of both anti-tumor cytotoxic T-lymphocytes (CTLs) and antibody-dependent responses against TAA-expressing cells, leading to tumor cell lysis. Compared to non-oxidized tumor cell lysate vaccines, oxidized tumor cell lysate vaccines induce necrotic cell death, increase the immunogenicity of the TAAs and may enhance the anti-tumor immune response. Cyclophosphamide/Fludarabine Lymphodepletion and an immunomodulatory combination of Interferon-alpha Bevacizumab and Aspirin followed by adoptive transfer of vaccine-primed ex vivo CD3/CD28-costimulated peripheral blood autologous T cells and vaccination with whole tumor vaccine administered intradermally in combination with Bevacizumab in patients with recurrent ovarian cancer fallopian tube or primary peritoneal cancer may help treat their tumors. Patients will receive 5-10 million cells intradermally. " +WARN annotation_whitespace VO:0007348 IAO:0000115 "A cancer vaccine made up of Bcl-xl_42 and the adjuvant CAF09b for patients with hormone-sensitive Prostate Cancer (PC) and lymph node metastases. B-cell lymphoma extra large protein (Bcl-xl) protein plays a vital role in the cancer cell's ability to avoid programmed cell death (apoptosis) and is upregulated in a variety of cancerous diseases, Bcl-xl_42 is a peptide fragment of the full protein and can lead to the death of cancer cells. CAF09b improves the activation of the immune system. " WARN annotation_whitespace VO:0007349 IAO:0000117 Oliver He WARN annotation_whitespace VO:0007350 IAO:0000117 Oliver He WARN annotation_whitespace VO:0007351 IAO:0000117 Oliver He @@ -783,6 +695,7 @@ WARN annotation_whitespace VO:0007360 IAO:0000117 Oliver He WARN annotation_whitespace VO:0007361 IAO:0000117 Oliver He WARN annotation_whitespace VO:0007362 IAO:0000117 Oliver He WARN annotation_whitespace VO:0007363 IAO:0000117 Oliver He +WARN annotation_whitespace VO:0007364 IAO:0000115 "A cancer vaccine consisting of the bcr-abl b2a2 fusion oncoprotein, frequently expressed in chronic myelogenous leukemia (CML), with potential antineoplastic activity. Vaccination with the bcr-abl (b2a2)-derived peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl b2a2 fusion protein. The vaccine is made from made from the proteins that cause leukemia cells in CML to behave abnormally. Imatinib mesylate is the standard therapy for CML and blocks the function of this protein. In combination, these may decrease or eliminate all evidence of disease in patients who have CML that is in remission after treatment with imatinib mesylate, but who still have small amounts of detectable disease. " WARN annotation_whitespace VO:0007365 IAO:0000117 Oliver He WARN annotation_whitespace VO:0007366 IAO:0000117 Oliver He WARN annotation_whitespace VO:0007367 IAO:0000117 Oliver He @@ -805,6 +718,9 @@ WARN annotation_whitespace VO:0007410 IAO:0000115 "A cell-based cancer vaccine c WARN annotation_whitespace VO:0007475 OGG:0000000006 " 4582" WARN annotation_whitespace VO:0007477 IAO:0000115 An autologous dendritic cell (DC) cancer vaccine with GITRL RNA-transfected that has potential immunostimulatory activity. WARN annotation_whitespace VO:0007497 IAO:0000115 "A cancer vaccine containing dendritic cells (DCs) that are transfected with messenger RNA (mRNA) encoding human telomerase reverse transcriptase (hTERT) and survivin in addition to patient-specific melanoma-derived mRNA with potential immunostimulatory and antineoplastic activities. Upon administration, hTERT/survivin/melanoma tumor cell-derived mRNA-transfected dendritic cell vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against melanoma cells expressing hTERT, survivin, and patient-specific melanoma-associated antigens. hTERT, the catalytic subunit of human telomerase, and survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types, playing key roles in tumor cell growth and survival. " +WARN annotation_whitespace VO:0007511 IAO:0000115 "A cancer vaccine prepared as tumor cells are isolated from the lesion site of patients with recurrent or metastatic bladder cancer, and dendritic cells or macrophages are isolated from peripheral blood. The vaccine activates an immune response and the microenvironment of bladder cancer lesions, and improves the anti-recurrence treatment effect of bladder cancer. " +WARN annotation_whitespace VO:0007513 IAO:0000115 "A cancer vaccine for patients with Locally Advanced, Triple-Negative Breast Cancer or ER-Positive, Her2-Negative Breast Cancer to receive ex vivo-generated tumor antigen-loaded dendritic cells (DCs), which can prime lymphocytes and regulate and maintain immune responses. The vaccine may boost T cell immunity targeted against breast cancer, enhance chemotherapy effectiveness and decrease tumor metastagenicity, and decrease the recurrence rates of LA TNBC and ER+/HER2- BC. " +WARN annotation_whitespace VO:0007526 IAO:0000115 "A cancer vaccine comprised of estrogen receptor alpha (ERa; estrogen receptor 1; ESR1) mutant peptides, combined with the immunoadjuvants granulocyte-macrophage colony-stimulating factor (GM-CSF) and montanide ISA, with potential immunomodulating and antineoplastic activities. ESR1 mutant peptides in the ESR1 peptides/GM-CSF/montanide ISA vaccine may activate the immune system to induce an immune response against tumor cells expressing these ESR1 mutations. Cancer peptides used in this vaccine are derived from the estrogen receptor and are combined with the adjuvant Montanide ISA and GM-CSF to enhance their immune response. The vaccine may improve outcomes of patients with endocrine resistant breast cancer. " WARN annotation_whitespace VO:0007532 IAO:0000115 A cancer vaccine containing dendritic cells (DCs) that are transfected with messenger RNA (mRNA) encoding human telomerase reverse transcriptase (hTERT) and LAMP. WARN annotation_whitespace VO:0007537 IAO:0000115 "A conjugate consisting of fluorescein isothiocyanate (FITC) conjugated with folate with potential antineoplastic activity. Folate-FITC binds to folate receptors, which are overexpressed on the surfaces of many cancer cells including kidney and ovarian cancer cells. Once bound to the cancer cell through the folate moiety of the conjugate, circulating anti-fluorescein antibodies may recognize and bind to the FITC moiety, resulting in antibody-dependent cellular cytotoxicity. " WARN annotation_whitespace VO:0007557 OGG:0000000006 " 4582" @@ -890,9 +806,28 @@ WARN annotation_whitespace VO:0007649 IAO:0000117 Oliver He WARN annotation_whitespace VO:0007650 IAO:0000117 Oliver He WARN annotation_whitespace VO:0007651 IAO:0000117 Oliver He WARN annotation_whitespace VO:0007652 IAO:0000117 Oliver He -WARN annotation_whitespace VO:0007653 IAO:0000117 Anna Maria Masci -WARN annotation_whitespace VO:0007653 IAO:0000117 Xingxian Li -WARN annotation_whitespace VO:0007655 IAO:0000117 Anna Maria Masci +WARN annotation_whitespace VO:0007664 IAO:0000115 "A cancer vaccine comprised of K562 cells transfected with the granulocyte macrophage-colony stimulating factor (GM-CSF) gene with potential immunopotentiating properties. This vaccine may stimulate the host immune system to produce an antitumoral T-lymphocyte response, thereby inhibiting tumor growth. A cultured cell line is genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from a patient. Vaccines made from gene-modified cancer cells may help the body build an effective immune response to kill cancer cells. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving vaccine therapy together with imatinib mesylate may be an effective treatment for chronic myelogenous leukemia. The vaccine can also be combined with stem cell transplantation. The vaccine may induce an immune response to common myeloid antigens (e.g., Wilms' tumor-1 [WT-1], survivin, or proteinase-3) in patients with Myelodysplastic Syndrome. " +WARN annotation_whitespace VO:0007665 IAO:0000119 NCT: https://clinicaltrials.gov/study/NCT00840931 +WARN annotation_whitespace VO:0007667 IAO:0000115 "A cancer vaccine that uses irradiated, adenovirus transduced autologous myeloblasts to secrete granulocyte-macrophage colony-stimulating factor (GVAX) early after allogeneic hematopoietic stem cell transplantation (HSCT) to induce potent immune responses. The vaccine may prevent advanced myelodysplastic syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), or acute myeloid leukemia (AML) from relapsing after stem cell transplant. The patients own cancer cells are engineered to produce a protein called GM-CSF, which can be effective in stimulating a powerful immune response specific to that cancer. " +WARN annotation_whitespace VO:0007672 IAO:0000115 "A cancer vaccine made from a person's white blood cells mixed with tumor proteins (HLA-A1- and HLA-A2.1-restricted peptides derived from melanoma-associated tumor antigens) and CD40-ligand, and may make the body build an immune response to kill tumor cells. This is combined with denileukin diftitox, which " +WARN annotation_whitespace VO:0007678 IAO:0000115 "A cancer vaccine derived from the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) with potential immunomodulating and antineoplastic activities. It may activate the immune system to induce an immune response against IDO-expressing tumor cells, which may restore the proliferation and activation of various immune cells including cytotoxic T-lymphocytes (CTLs), natural killer cells (NKs), and dendritic cells (DCs), and may eradicate IDO-expressing tumor cells through a CTL-mediated response. This vaccine, using a small fragment of IDO, can be used in combination with either Ipilimumab or Vemurafenib to treat malignant melanoma that has metastasized. " +WARN annotation_whitespace VO:0007693 IAO:0000115 "A cancer vaccine containing a mixture of killed bacteria with potential immunostimulatory and antineoplastic activities. Mixed bacteria vaccine (MBV or Coley's toxins) consists of a pyrogenic bacterial lysate derived from Serratia marcescens and Streptococcus pyogenes; the active components in the lysate may be lipopolysaccharide (LPS), a component of the Gram-negative bacterial cell wall of Serratia, and streptokinase, an enzyme produced by Streptococcus pyogenes. LPS has been shown to stimulate the host humoral immune response and induce the release of various antitumor cytokines such as tumor necrosis factor (TNF) and interleukin-12 (IL-12). The mixed bacteria vaccine (MBV) is administered at a starting dose of 250 EU (1 µL) and escalated in each patient to a dose inducing the desired pyrogenic effect, defined as a body temperature of 38°C to 39.5°C. It is given to patients with malignant tumors that expressed the NY-ESO-1 antigen. It is designed to induce immunological effects and tumor response following vaccination. " +WARN annotation_whitespace VO:0007695 IAO:0000115 A cancer vaccine made with dendritic cells (DCs) pulsed with mRNA encoded tumor antigens. These personalized cell vaccines may lead to antitumor specific T cell responses. +WARN annotation_whitespace VO:0007702 IAO:0000115 "A cancer vaccine adjuvant and synthetic Toll-like receptor (TLR) type 1 and 2 ligand composed of a lipopeptide containing a water-soluble derivative of Pam3-Cys, the biologically active component of the mycobacterial 19 kDa lipoprotein of mycobacteria, that is covalently linked to a synthetic peptide (GDPKHPKSF), with potential immunostimulating activity. TLR1/2 agonist Pam3Cys-GDPKHPKSF targets, binds to and activates TLR1/2, which induces CD8- and T-helper 1 CD4-positive T-cell responses. This may enhance T-cell-mediated immune responses when administered together with peptide vaccine. A multi-peptide vaccine can be used in combination with the TLR1/2 ligand XS15 in CLL patients undergoing ibrutinib-based regimes. Applying several CLL-associated antigens simultaneously increases the likelihood that a multi-clonal, broad and at the same time highly specific T-cell response is mounted, thereby preventing potential tumor escape mechanisms. The novel TLR1/2 ligand (XS15, developed in Tübingen) that (i) is water-soluble and (ii) GMP-amenable, (iii) non-toxic and (iv) effective in inducing T cells specific for peptides in vivo. A personalized multi-peptide vaccination can also be used in combination with the TLR1/2 ligand XS15 for individual patients with advanced solid and hematological malignancies without any approved treatment options. " +WARN annotation_whitespace VO:0007711 IAO:0000115 "A cancer vaccine consisting of autologous DCs loaded with immunogenic peptides derived from autologous cancer cells, with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-loaded autologous DC vaccine stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. Neoantigens arising from the mutations of the tumor genome expressed specifically on the tumor cell instead of normal cells, suggesting that vaccines targeting neoantigens should generate a highly tumor-specific response with minimal off-target effects. Neoantigens are identified from tumor tissues from a gastric cancer, hepatocellular carcinoma, lung cancer or colorectal cancer patient. Dendritic cells are then primed with synthesized peptides. The vaccine can be combined with microwave ablation ti treat patients with Hepatocellular Carcinoma (HCC). It can also be combined with Anti-PD1 (Nivolumab) as for patients with resected Hepatocellular Carcinoma (HCC) and Liver Metastases From Colorectal Cancer (CRLM). " +WARN annotation_whitespace VO:0007711 IAO:0000119 NCT: https://clinicaltrials.gov/study/NCT03871205 +WARN annotation_whitespace VO:0007711 IAO:0000119 NCT: https://clinicaltrials.gov/study/NCT04147078 +WARN annotation_whitespace VO:0007711 IAO:0000119 NCT: https://clinicaltrials.gov/study/NCT04912765] +WARN annotation_whitespace VO:0007713 IAO:0000115 "A cancer vaccine comprised of synthetic peptides derived from the cancer-testis antigen NY-ESO-1, preferentially expressed antigen in melanoma (PRAME), human melanoma antigen A3 (MAGE-A3) and the human Wilms tumor protein-1 (WT-1), with potential immunostimulating and antineoplastic activities. NY-ESO-1/PRAME/MAGE-A3/WT-1 peptide vaccine may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing NY-ESO-1, PRAME, MAGE-A3 and WT-1, resulting in tumor cell lysis. As proteins are degraded in cells, peptides are presented on the surface of these cells as a complex with tissue type molecules (HLA molecules). T-cells may then recognize the peptide-HLA complexes, via its T-cell receptor, potentially resulting in tumor-cell killing, if sufficient priming takes place. Cancer testis antigens (CTA's) are known to be immunogenic and are only expressed at immunoprivileged sites, thus out of reach of immune responses, and on cancer cells, making them ideal targets for therapeutic cancer vaccination. The CTA's chosen were NY-ESO-1, MAGE-A3 and PRAME. WT-1 is additionally included as this protein has proven to be an important antigen in hematological malignancies. It is combined with azacitidine for treatment of patients with high-risk myelodysplastic syndrome or acute myeloid leukemia. " +WARN annotation_whitespace VO:0007715 IAO:0000115 "A cancer vaccine composed of autologous ovarian cancer antigens obtained from hydrolyzed, inactivated blood and tumor tissue of patients with ovarian cancer, with potential immunostimulatory and antineoplastic activities. The ovarian cancer antigens stimulate the immune system and activate a cytotoxic T-lymphocyte (CTL) immune response against ovarian cancer cells. Ovarian cancer patients can be given one pill a day for three months. " +WARN annotation_whitespace VO:0007718 IAO:0000115 "A cancer vaccine made up of CPC-P501 protein formulated with the adjuvant AS15. Patients with hormone-sensitive prostate cancer and rising PSA, after primary tumor treatment, can be treated with the P501-AS15 vaccine. " +WARN annotation_whitespace VO:0007725 IAO:0000115 "A cancer vaccine for melanoma. Melanomas have mutations (changes in genetic material) that are specific to an individual patient and tumor. These mutations can cause the tumor cells to produce proteins that appear very different from the body's own cells. These proteins used in a vaccine may induce strong immune responses, which may help the participant's body fight any tumor cells that could cause the melanoma to come back in the future. NeoVax is a long-peptide vaccine targeting up to 20 personal neoantigens per patient for patients with surgically resected stage IIIB/C or IVM1a/b melanoma. There was long-term persistence of neoantigen-specific T cell responses following vaccination, with ex vivo detection of neoantigen-specific T cells exhibiting a memory phenotype, as well as diversification of neoantigen-specific T cell clones over time, with emergence of multiple T cell receptor clonotypes exhibiting distinct functional avidities. There was also tumor infiltration by neoantigen-specific T cell clones after vaccination and epitope spreading, suggesting on-target vaccine-induced tumor cell killing. Personal neoantigen peptide vaccines thus induce T cell responses that persist over years and broaden the spectrum of tumor-specific cytotoxicity in patients with melanoma. " +WARN annotation_whitespace VO:0007726 IAO:0000115 "A cancer vaccine that contains 6 synthetic peptides mixed with the adjuvant Montanide™. The peptides were selected to induce T cell responses against 12 dominant epitopes from 7 cancer testis antigens (CTAs), which are the most frequently expressed CTAs in colorectal cancer. The 6 peptides were optimized to induce long lasting CRC specific T cell responses. Colorectal cancer peptide vaccine PolyPEPI1018 potentially elicits a cytotoxic T-lymphocyte response against colorectal tumors expressing the CTAs associated with the vaccine, which may result in a reduction in tumor cell proliferation. " +WARN annotation_whitespace VO:0007727 IAO:0000115 "A cancer vaccine consisting of whole irradiated heterologous melanoma cells which express multiple melanoma-related antigens. Polyvalent melanoma vaccine may stimulate an antitumoral cytotoxic T-cell immune response in the host, resulting in inhibition of tumor cell proliferation and tumor cell death. Vaccines may make the body build an immune response and kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Interferon alfa-2b may interfere with the growth of tumor cells. Treatment with this combination may help treat melanoma. " +WARN annotation_whitespace VO:0007730 IAO:0000115 "A cancer vaccine containing seven 17 amino acids long synthetic RAS oncogene-encoded peptides representing the most common codon 12 and 13 oncogenic mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS), with potential immunomodulating and antineoplastic activities. The vaccine may stimulate a specific CD4-positive helper T-lymphocyte- and cytotoxic T-lymphocyte (CTL)-mediated immune response against RAS mutant-specific-expressing cancer cells, resulting in an inhibition of tumor cell proliferation and tumor cell death. The vaccine can be given in combination with Balstilimab and QS-21 for patients with pancreatic cancer to increase efficacy. " +WARN annotation_whitespace VO:0007733 IAO:0000115 "A cancer vaccine that consists of the oligosaccharide antigen sialyl Lewis (CA19-9) conjugated to the nonspecific immunomodulator keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. The sialyl Lewis-keyhole limpet hemocyanin conjugate vaccine may induce production of IgG and IgM antibodies as well as trigger an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing the sialyl Lewis antigen. The vaccine therapy together with QS21 may cause a stronger immune response and kill more tumor cells. " +WARN annotation_whitespace VO:0007735 IAO:0000115 "A cancer vaccine made with GMCSF transgene that directly stimulates increased expression of tumor antigen(s) and enhances dendritic cell migration to the vaccination site. TGFβ2 blockade following intracellular TGFβ2 antisense gene expression reduces production of immune inhibiting activity at the vaccine site. This vaccine integrates enhancement of an anticancer immune response concurrently with a reduction in cancer-induced immune suppression. Autologous cancer cells are harvested from patients with advanced refractory cancer, and a TGFβ2 antisense / GMCSF expression vector plasmid is constructed. The autologous cancer tissue is irradiated and electrocorporated with the vector. " +WARN annotation_whitespace VO:0007740 IAO:0000115 "A cancer vaccine that is composed of dendritic cells pulsed with tumor cells lysates that stimulate a potent and specific cell mediated anti-tumor immune response. It can be used in combination with high-dose chemotherapy and hematopoietic stem cell transplantation (HSCT). The combination may increase overall survival and progression-free survival for patients with high-risk pediatric and young adult tumors (localized solid tumors such as, sarcoma, neuroblastoma, and Wilms' tumor). " WARN annotation_whitespace VO:0010252 IAO:0000115 A variable representing dose representing the vaccination WARN annotation_whitespace VO:0010259 IAO:0000115 A variable representing the vaccine preservative WARN annotation_whitespace VO:0010272 IAO:0000115 A measurment datum that records the method of sacrifice (i.e. killing). @@ -5644,6 +5579,47 @@ WARN missing_definition VO:0010230 IAO:0000115 WARN missing_definition VO:0010231 IAO:0000115 WARN missing_definition VO:0010232 IAO:0000115 WARN missing_definition VO:0010233 IAO:0000115 +WARN missing_definition VO:0010289 IAO:0000115 +WARN missing_definition VO:0010290 IAO:0000115 +WARN missing_definition VO:0010291 IAO:0000115 +WARN missing_definition VO:0010292 IAO:0000115 +WARN missing_definition VO:0010293 IAO:0000115 +WARN missing_definition VO:0010294 IAO:0000115 +WARN missing_definition VO:0010295 IAO:0000115 +WARN missing_definition VO:0010296 IAO:0000115 +WARN missing_definition VO:0010297 IAO:0000115 +WARN missing_definition VO:0010298 IAO:0000115 +WARN missing_definition VO:0010299 IAO:0000115 +WARN missing_definition VO:0010300 IAO:0000115 +WARN missing_definition VO:0010301 IAO:0000115 +WARN missing_definition VO:0010302 IAO:0000115 +WARN missing_definition VO:0010303 IAO:0000115 +WARN missing_definition VO:0010304 IAO:0000115 +WARN missing_definition VO:0010305 IAO:0000115 +WARN missing_definition VO:0010306 IAO:0000115 +WARN missing_definition VO:0010307 IAO:0000115 +WARN missing_definition VO:0010308 IAO:0000115 +WARN missing_definition VO:0010309 IAO:0000115 +WARN missing_definition VO:0010310 IAO:0000115 +WARN missing_definition VO:0010311 IAO:0000115 +WARN missing_definition VO:0010312 IAO:0000115 +WARN missing_definition VO:0010313 IAO:0000115 +WARN missing_definition VO:0010314 IAO:0000115 +WARN missing_definition VO:0010315 IAO:0000115 +WARN missing_definition VO:0010316 IAO:0000115 +WARN missing_definition VO:0010317 IAO:0000115 +WARN missing_definition VO:0010318 IAO:0000115 +WARN missing_definition VO:0010319 IAO:0000115 +WARN missing_definition VO:0010320 IAO:0000115 +WARN missing_definition VO:0010321 IAO:0000115 +WARN missing_definition VO:0010322 IAO:0000115 +WARN missing_definition VO:0010323 IAO:0000115 +WARN missing_definition VO:0010324 IAO:0000115 +WARN missing_definition VO:0010325 IAO:0000115 +WARN missing_definition VO:0010326 IAO:0000115 +WARN missing_definition VO:0010327 IAO:0000115 +WARN missing_definition VO:0010328 IAO:0000115 +WARN missing_definition VO:0010329 IAO:0000115 WARN missing_definition VO:0010632 IAO:0000115 WARN missing_definition VO:0010705 IAO:0000115 WARN missing_definition VO:0010706 IAO:0000115 @@ -12490,7 +12466,6 @@ INFO lowercase_definition RO:0002511 IAO:0000115 inverse of transcribed from INFO lowercase_definition RO:0002512 IAO:0000115 x is the ribosomal translation of y if and only if a ribosome reads x through a series of triplet codon-amino acid adaptor activities (GO:0030533) and produces y INFO lowercase_definition RO:0002513 IAO:0000115 inverse of ribosomal translation of INFO lowercase_definition RO:0002604 IAO:0000115 "x is the opposite of y if there exists some distance metric M, and there exists no z such as M(x,z) <= M(x,y) or M(y,z) <= M(y,x)." -INFO lowercase_definition VO:0000002 IAO:0000115 "a process of administering substance in vivo that involves in adding a vaccine into a host (e.g., human) in vivo with the intent to invoke a protective or therapeutic adaptive immune response." INFO lowercase_definition VO:0000017 IAO:0000115 whole organism vaccine that uses killed pathogen organism as its component. INFO lowercase_definition VO:0000035 IAO:0000115 "a vaccinia virus vaccine that is a freeze-dried calf lymph smallpox vaccine, specifically, Dryvax is a live-virus preparation of vaccinia prepared from calf lymph. " INFO lowercase_definition VO:0000050 IAO:0000115 a lentivirus vaccine vector that uses a HIV strain as the vector @@ -12518,7 +12493,6 @@ INFO lowercase_definition VO:0000219 IAO:0000115 a vaccine component that is use INFO lowercase_definition VO:0000228 IAO:0000115 a vaccine component that contains the solid form of all vaccine components. A vaccine can be reconstituted by mixing vaccine powder with vaccine solvent. INFO lowercase_definition VO:0000243 IAO:0000115 assay of CFU reduction in spleen is a CFU reduction assay that is measured using the extracted spleen as the tissue for isolation of infected pathogens. INFO lowercase_definition VO:0000263 IAO:0000115 sodBFt is a live vaccine strain mutant of Francisella tularensis with reduced Fe-superoxide dismutase gene expression. Ref: PMID:18692537. -INFO lowercase_definition VO:0000278 IAO:0000115 vaccine function is a function that inheres in a vaccine that induces protective immune response against a disease. It is realized in the immunization process in the host. INFO lowercase_definition VO:0000283 IAO:0000115 a viral vaccine vector that uses a herpesvirus as the vector. INFO lowercase_definition VO:0000288 IAO:0000115 a processual entity that specifies host response to a vaccine. INFO lowercase_definition VO:0000289 IAO:0000115 a process that specifies host response to a vaccine adjuvant. @@ -12552,7 +12526,6 @@ INFO lowercase_definition VO:0000441 IAO:0000115 "vaccine candidate role is the INFO lowercase_definition VO:0000444 IAO:0000115 vaccine licensing is a vaccine approval process that involves in licensing a vaccine. INFO lowercase_definition VO:0000447 IAO:0000115 a viral vaccine vector that uses an poxvirus as the vector. INFO lowercase_definition VO:0000448 IAO:0000115 "a Salmonella vaccine against infection with S. paratyphi, which causes paratyphoid fevers. Paratyphoid fevers are a group of enteric illnesses caused by serotypic strains of the Salmonella genus of bacteria, S. Paratyphi." -INFO lowercase_definition VO:0000452 IAO:0000115 "preventive vaccine function is a vaccine function realized by the process of vaccination and leading to induction of an adaptive immune response to the antigens in a vaccine, which protects against a specific disorder." INFO lowercase_definition VO:0000455 IAO:0000115 a vaccine that is used for prevention against a disease. INFO lowercase_definition VO:0000460 IAO:0000115 an influenza virus vaccine against equine influenza viral infection INFO lowercase_definition VO:0000463 IAO:0000115 a bacterial vaccine against infection with Coxiella burnetii which causes Q fever @@ -12565,9 +12538,7 @@ INFO lowercase_definition VO:0000475 IAO:0000115 a Rabies virus vaccine against INFO lowercase_definition VO:0000477 IAO:0000115 a Rabies virus vaccine against Rabies in human INFO lowercase_definition VO:0000487 IAO:0000115 a S. typhi vaccine that is live and orally administerred INFO lowercase_definition VO:0000489 IAO:0000115 a licensed vaccine role that is bears in a licensed human vaccine. -INFO lowercase_definition VO:0000490 IAO:0000115 immunization is a processual entity that primes or modifies an adaptivie immune response to some antigens. INFO lowercase_definition VO:0000493 IAO:0000115 natural active immunization is an active immunization that occur naturally when a person or animal comes in contact with antigens includeing microbes. -INFO lowercase_definition VO:0000494 IAO:0000115 artificial active immunization is an active immunization that occurs when a person or animal is vaccinated with a specific vaccine. INFO lowercase_definition VO:0000495 IAO:0000115 "induction of adaptive immune response to antigen is an active immunization process that results in induction of adaptive immune response to some antigens, for example, in a vaccine." INFO lowercase_definition VO:0000496 IAO:0000115 disorder prevention is a processual entity that prevents a disorder that is the physical basis of a disease. INFO lowercase_definition VO:0000497 IAO:0000115 disorder treatment is a processual entity that leads to treat a disorder that is the physical basis of a disease. @@ -12669,13 +12640,13 @@ INFO lowercase_definition VO:0001023 IAO:0000115 a bacterial vaccine vector that INFO lowercase_definition VO:0001024 IAO:0000115 an avian influenza vaccine that uses inactivated viral organism INFO lowercase_definition VO:0001025 IAO:0000115 a viral vaccine vector that uses a vesicular stomatitis virus (VSV) as the vector. INFO lowercase_definition VO:0001028 IAO:0000115 a parasite vaccine vector using a live attenuated Leishmania tarentolae strain. -INFO lowercase_definition VO:0001031 IAO:0000115 a bacterial vaccine vector using a live attenuated Salmonella enterica strain SL3261. +INFO lowercase_definition VO:0001031 IAO:0000115 a bacterial vaccine vector using a live attenuated Salmonella enterica strain SL3261. INFO lowercase_definition VO:0001032 IAO:0000115 a bacterial vaccine vector using a live attenuated Edwardsiella tarda strain EIB202 INFO lowercase_definition VO:0001034 IAO:0000115 a vaccine vector that uses a parasite as the vector. INFO lowercase_definition VO:0001035 IAO:0000115 a bacterial vaccine against Yersinia ruckeri infection INFO lowercase_definition VO:0001036 IAO:0000115 a bacterial vaccine vector using a live attenuated Streptococcus gordonii vaccine vector. INFO lowercase_definition VO:0001037 IAO:0000115 a bacterial vaccine vector using a live attenuated Bordetella pertussis BPZE as a vaccine vector. -INFO lowercase_definition VO:0001038 IAO:0000115 "a bacterial vaccine vector using the HS93Tox- mutant of the serovar 7 strain of Actinobacillus pleuropneumoniae. This mutant lacks the genes encoding the toxin ApxA and the post-translational activating protein ApxC, but still has genes required for secretion, making it a good vector. " +INFO lowercase_definition VO:0001038 IAO:0000115 "a bacterial vaccine vector using the HS93Tox- mutant of the serovar 7 strain of Actinobacillus pleuropneumoniae. This mutant lacks the genes encoding the toxin ApxA and the post-translational activating protein ApxC, but still has genes required for secretion, making it a good vector." INFO lowercase_definition VO:0001040 IAO:0000115 an Avipox virus vaccine vector that uses a fowlpox virus as the vector INFO lowercase_definition VO:0001043 IAO:0000115 an Avipox virus vaccine vector that uses an attenuated canarypox virus strain INFO lowercase_definition VO:0001044 IAO:0000115 a bacterial vaccine vector that uses an attenuated Vibrio cholerae strain @@ -12702,7 +12673,7 @@ INFO lowercase_definition VO:0001076 IAO:0000115 "a recombinant vector vaccine t INFO lowercase_definition VO:0001077 IAO:0000115 a bacterial vaccine against Mycoplasma synoviae infection INFO lowercase_definition VO:0001078 IAO:0000115 "a recombinant vector vaccine that uses a homologous vector, i.e., when the target species of the vaccine is not one of the natural hosts for the vector." INFO lowercase_definition VO:0001081 IAO:0000115 an adenovirus vaccine vector that uses an Adenovirus serotype 5 strain. -INFO lowercase_definition VO:0001082 IAO:0000115 "an adenovirus vaccine vector that contains a deletion of the gp64 gene. As a result of the deletion, this vector is unable to propagate infection from cell to cell, and this defect results from both a severe reduction in the production of budded virions and the absence of GP64 on virions. " +INFO lowercase_definition VO:0001082 IAO:0000115 "an adenovirus vaccine vector that contains a deletion of the gp64 gene. As a result of the deletion, this vector is unable to propagate infection from cell to cell, and this defect results from both a severe reduction in the production of budded virions and the absence of GP64 on virions." INFO lowercase_definition VO:0001083 IAO:0000115 protozoan vaccine that is used to protect against Giardia intestinalis infection INFO lowercase_definition VO:0001084 IAO:0000115 a viral vaccine vector that uses a baculovirus as the vector INFO lowercase_definition VO:0001085 IAO:0000115 a Chlamydia bacterial vaccine against C. abortus infection @@ -12866,8 +12837,8 @@ INFO lowercase_definition VO:0003035 IAO:0000115 a vaccine stabilizer that is ge INFO lowercase_definition VO:0003036 IAO:0000115 a vaccine stabilizer that is specifically made by a sucrose. INFO lowercase_definition VO:0003037 IAO:0000115 a vaccine stabilizer that is specifically made by a lactose. INFO lowercase_definition VO:0003038 IAO:0000115 a vaccine stabilizer that is a protein. -INFO lowercase_definition VO:0003039 IAO:0000115 a polysorbate 20 vaccine stabilizer that is Alkest TW20. -INFO lowercase_definition VO:0003040 IAO:0000115 a polysorbate 20 vaccine stabilizer that is Tween 20. +INFO lowercase_definition VO:0003039 IAO:0000115 a polysorbate 20 vaccine stabilizer that is Alkest TW20. +INFO lowercase_definition VO:0003040 IAO:0000115 a polysorbate 20 vaccine stabilizer that is Tween 20. INFO lowercase_definition VO:0003041 IAO:0000115 an antibiotics vaccine residual that has the antibiotics of neomycin. INFO lowercase_definition VO:0003042 IAO:0000115 the vaccine antiegn that induces protective immune response. INFO lowercase_definition VO:0003048 IAO:0000115 "when the vaccination of a significant portion of a population (or herd), in contagious diseases that are transmitted from individual to individual, chains of infection are likely to be disrupted, so the large numbers of a population are immue or less susceptible to the disease. " diff --git a/src/VO.owl b/src/VO.owl index 93f2265..5b21539 100644 --- a/src/VO.owl +++ b/src/VO.owl @@ -92,6 +92,10 @@ Yu Lin (YL) Yuanyi (Penny) Pan Zuoshuang "Allen" Xiang + Xingxian Li + Ellen Zhang + Taiyu Lin + Yuping Zheng The Vaccine Ontology (VO) is a community-based biomedical ontology in the domain of vaccine and vaccination. VO aims to standardize vaccine types and annotations, integrate various vaccine data, and support computer-assisted reasoning. The VO supports basic vaccine R&D and clincal vaccine usage. VO is being developed as a community-based ontology with support and collaborations from the vaccine and bio-ontology communities. OWL-DL An ontology in the domain of vaccine and vaccination diff --git a/src/modules/cancer_vaccine.owl b/src/modules/cancer_vaccine.owl index 4da67a9..a2a6adf 100644 --- a/src/modules/cancer_vaccine.owl +++ b/src/modules/cancer_vaccine.owl @@ -13062,7 +13062,7 @@ - + @@ -15915,7 +15915,7 @@ - + @@ -17004,7 +17004,7 @@ - + @@ -18944,7 +18944,7 @@ - + @@ -19214,7 +19214,7 @@ - + @@ -19254,7 +19254,7 @@ - + @@ -19296,7 +19296,7 @@ - + @@ -19333,7 +19333,7 @@ - + @@ -19715,7 +19715,7 @@ - + @@ -19755,7 +19755,7 @@ - + @@ -19789,7 +19789,7 @@ - + @@ -19827,7 +19827,7 @@ - + @@ -19870,7 +19870,7 @@ - + @@ -19910,7 +19910,7 @@ - + @@ -19957,7 +19957,7 @@ - + @@ -19999,7 +19999,7 @@ - + @@ -20046,7 +20046,7 @@ - + @@ -20096,7 +20096,7 @@ - + @@ -20136,7 +20136,7 @@ - + @@ -20176,7 +20176,7 @@ - + @@ -20212,7 +20212,7 @@ - + @@ -20259,7 +20259,7 @@ - + @@ -20569,7 +20569,7 @@ - + @@ -20972,7 +20972,7 @@ - + @@ -22535,7 +22535,7 @@ - + @@ -25018,7 +25018,7 @@ - + @@ -25787,7 +25787,7 @@ - + @@ -26629,7 +26629,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -26974,7 +26974,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -27017,7 +27017,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -27057,7 +27057,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -27097,7 +27097,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -27141,7 +27141,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -27177,7 +27177,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -27221,7 +27221,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -27262,7 +27262,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -27337,7 +27337,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -27371,7 +27371,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -27411,7 +27411,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -27451,7 +27451,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -27589,7 +27589,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -27734,7 +27734,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -28307,7 +28307,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -31715,7 +31715,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -31750,7 +31750,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -31796,7 +31796,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -31833,7 +31833,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -31879,7 +31879,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -31924,7 +31924,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -31966,7 +31966,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -32021,7 +32021,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -32068,7 +32068,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -32112,7 +32112,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -32160,7 +32160,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -32202,7 +32202,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -32245,7 +32245,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -32280,7 +32280,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -32330,7 +32330,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -32378,7 +32378,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -32426,7 +32426,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -32474,7 +32474,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -32517,7 +32517,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -32569,7 +32569,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -32651,7 +32651,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -32691,7 +32691,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -32737,7 +32737,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -32777,7 +32777,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -32826,7 +32826,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -32869,7 +32869,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -32920,7 +32920,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -32964,7 +32964,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -32999,7 +32999,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -33047,7 +33047,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -33091,7 +33091,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -33144,7 +33144,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -33197,7 +33197,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -33245,7 +33245,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -33279,7 +33279,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -33326,7 +33326,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -33367,7 +33367,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -33417,7 +33417,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -33466,7 +33466,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -33519,7 +33519,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -33559,7 +33559,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -33598,7 +33598,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -33638,7 +33638,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -33680,7 +33680,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -33733,7 +33733,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -33776,7 +33776,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -33817,7 +33817,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -33863,7 +33863,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -33910,7 +33910,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -33958,7 +33958,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -34002,7 +34002,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -34046,7 +34046,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -34092,7 +34092,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -34132,7 +34132,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -34173,7 +34173,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -34214,7 +34214,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -34258,7 +34258,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -34298,7 +34298,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -34344,7 +34344,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -34393,7 +34393,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -34437,7 +34437,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -34477,7 +34477,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -34517,7 +34517,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -34551,7 +34551,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -34592,7 +34592,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -34641,7 +34641,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -34682,7 +34682,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -34723,7 +34723,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -34774,7 +34774,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -34821,7 +34821,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -34870,7 +34870,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -34912,7 +34912,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -34959,7 +34959,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -35012,7 +35012,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -35052,7 +35052,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -35093,7 +35093,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -35131,7 +35131,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -35184,7 +35184,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -35225,7 +35225,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -35260,7 +35260,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -35300,7 +35300,7 @@ Immunization Route: Intramuscular injection (i.m.) - + @@ -35335,7 +35335,7 @@ Immunization Route: Intramuscular injection (i.m.) - + diff --git a/src/templates/cancer_vaccine.csv b/src/templates/cancer_vaccine.csv index 624913d..9b348cb 100644 --- a/src/templates/cancer_vaccine.csv +++ b/src/templates/cancer_vaccine.csv @@ -708,129 +708,129 @@ Immunization Route: Intramuscular injection (i.m.)",,,4078,VIOLIN: https://violi 705,VO:0007656,preventive cancer vaccine,,cancer vaccine,VO:0000177,('cancer vaccine' and 'has function' some 'preventive vaccine function'),,,,,,,,,,,,Cancer vaccine that prevents cancer formation and development.,,,,,,,,Oliver He|Jie Zheng|Anna Maria Masci|Barry Smith,,,https://github.com/vaccineontology/VO/issues/677, 706,VO:0007657,therapeutic cancer vaccine,,cancer vaccine,VO:0000177,('cancer vaccine' and 'has function' some 'therapeutic vaccine function'),,,,,,,,,,,,Cancer vaccine that aims to eliminate or control tumor cells.,,,,,,,,Oliver He|Jie Zheng|Anna Maria Masci|Barry Smith,,,https://github.com/vaccineontology/VO/issues/677, 707,VO:0007660,DNA cancer vaccine,,cancer vaccine,VO:0000177,('cancer vaccine' and 'has role' some 'DNA vaccine role'),,,,DNA vaccine role,,,,,,,,A cancer vaccine that is composed of a plasmid vaccine vector (a circular double stranded DNA molecule) containing the whole of parts of genes encoding one or more vaccine antigen proteins.,,,,,,,,Jie Zheng,,,, -708,VO:0007185,4-peptide melanoma vaccine,,melanoma vaccine,VO:0000422,,Gene name: Melan-A|Gene name: gp100|Gene name: MAGE-3|Gene name: NA17,2315|6490|4102,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,melanoma,Homo sapiens,,subcutaneous route|intradermal route,"A cancer vaccine that may stimulate an immune response against 4 different melanoma associated antigens. This may lead to a reduction in tumor cell proliferation of cancer cells expressing these antigens. The vaccine may contain 4 class I MHC-restricted synthetic melanoma peptides (1 each restricted by HLA-A1, -A3, and two restricted by HLA-A2) and a helper tetanus peptide. The peptides may include Melan-A, gp100, MAGE-3, and NA17. The vaccine can be used in combination Ontak, which may produce an immune response in patients with metastatic melanoma, and the Ontak may improve these immune responses and lead to tumor shrinkage.",,,6370,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6370,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C91722,NCT: https://clinicaltrials.gov/study/NCT00515528,Hayleigh Kahn|Jie Zheng,,,, -709,VO:0007248,a2/4-1bbl melanoma vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: 4-1BBL,8744,Clinical trial,,,,therapeutic cancer vaccine,melanoma,Homo sapiens,,intravenous route,"A cancer vaccine used to treat patients with malignant melanoma. It is made of a compatible melanoma cell line that has been engineered to express a molecule termed 4-1BBL, which enhances the chances of the cell line to be recognized by the patient's immune system, and to induce its stimulation, with an immune response to residual tumor in the body. It will be used in combination with intravenous low dose cyclophosphamide, 300 mg/m2.",,,6260,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6260,,,NCT: https://clinicaltrials.gov/study/NCT01898039,Hayleigh Kahn|Jie Zheng,,,, -710,VO:0007273,adenovirus-transfected autologous dc vaccine plus cik cells,,lung cancer vacine,VO:0005486,,Gene name: MUC1|Gene name: Survivin,4582|332,Clinical trial,recombinant vector vaccine role,,adenoviral vector vaccine role,therapeutic cancer vaccine,lung cancer,Homo sapiens,,,A cancer vaccine that uses adenovirus MUC1 and Survivin transfected autologous dendritic cells combined with cytokine-induced killer cells in cancer patients with Extensive-Stage Small- Cell Lung Cancer.,,,6261,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6261,,,NCT: https://clinicaltrials.gov/study/NCT01174082,Hayleigh Kahn|Jie Zheng,,,, -711,VO:0007317,ags-003-bld vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: CD40LG,959,Clinical trial,,,,therapeutic cancer vaccine,urinary bladder cancer,Homo sapiens,,intradermal route,"A cancer vaccine composed of autologous, mature dendritic cells (DCs) are electroporated with in vitro transcribed (IVT) RNAs encoding for a synthetic form of T-cell protein CD40 ligand (CD40L) and IVT RNA encoding for autologous tumor-associated antigens (TAAs) derived from patient-specific bladder cell carcinoma (BCC) cells, with potential immunostimulatory and antineoplastic activities. The RNA is translated and processed, and BCC-specific antigenic peptides are subsequently presented via major histocompatibility complex (MHC) Class I molecules on the DCs surface. The MHC-presented peptides interact with and activate CD8-positive T-cells, which elicits a highly specific cytotoxic T-cell (CTL) response against tumor cells expressing the patient-specific BCC TAAs. The signal cascade initiated by expression of the co-stimulatory molecule CD40L results in the secretion of the inflammatory cytokine IL-12, which further stimulates CTLs. The vaccine can be used in combination with gemcitabine hydrochloride and cisplatin which stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading, while the vaccine helps the body build an effective immune response to kill tumor cells. In combination, they may make the tumor smaller and reduce the amount of tissue that needs to be removed by surgery in patients with bladder cancer.",,,6363,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6363,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C129522,NCT: https://clinicaltrials.gov/study/NCT02944357,Hayleigh Kahn|Jie Zheng,,,, -712,VO:0007323,alk peptide vaccine,,non-small cell lung cancer vaccine,VO:0003140,,,,Research,subunit vaccine role,,,therapeutic cancer vaccine,lung non-small cell carcinoma,Homo sapiens,,,"A cancer vaccine that restored priming of Anaplastic lymphoma kinase (ALK)-specific CD8+ T cells, eradicated lung tumors in combination with ALK tyrosine kinase inhibitors (TKIs) and prevented metastatic dissemination of tumors to the brain. Human ALK peptides are displayed by HLA-A*02:01 and HLA-B*07:02 molecules. The peptides are immunogenic and recognized by CD8+ T cells from individuals with non-small cell lung cancer (NSCLC).",PubMed:37430060,,6382,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6382,,,,Hayleigh Kahn|Jie Zheng,,,, -713,VO:0007324,allogeneic GM-CSF-secreting lethally irradiated pancreatic tumor cell vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: GM-CSF,12981,Clinical trial,,,,therapeutic cancer vaccine,pancreatic cancer,Homo sapiens,,intradermal route,"A cancer vaccine made of allogeneic pancreatic tumor cells are transfected with a GM-CSF gene to treat ocally advanced, unresectable or metastatic pancreatic adenocarcinoma. It may be in combination with Ipilimumab (an antibody that blocks negative signals to T cells).",,,6336,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6336,,,NCT: https://clinicaltrials.gov/study/NCT00836407,Hayleigh Kahn|Jie Zheng,,,, -714,VO:0007325,allogeneic HLA-A2/4-1BB ligand-expressing melanoma vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: HLA-A|Gene name: 4-1BBL,3105|8744,Clinical trial,,,,therapeutic cancer vaccine,melanoma,Homo sapiens,,,"A cancer vaccine that consists of an allogeneic cell line that has a high expression level of melanoma molecules (HLA A2/4-1BB Ligand), and has been genetically modified to induce a strong immune response. Stimulation of the immune response against the tumor can help destroy residual tumor in melanoma patients with very high risk for disease recurrence and in patients with relatively low tumor burden who already got first line treatment for their disease.",,,6313,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6313,,,NCT: https://clinicaltrials.gov/study/NCT01861938,Hayleigh Kahn|Jie Zheng,,,, -715,VO:0007326,anti-HER2/HER3 dendritic cell vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: HER2|Gene name:HER3,2064|2065,Clinical trial,,,,therapeutic cancer vaccine,breast cancer,Homo sapiens,,intradermal route,"A cancer vaccine that uses anti-HER2/HER3 dendritic cells in combination with Pembrolizumab in patients with Asymptomatic Brain Metastasis From Triple Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC). The dendritic cells boost the immune system, and the Pembrolizumab enhances cancer immune responses, in combination they may shrink the cancer.",,,6263,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6263,,,NCT: https://clinicaltrials.gov/study/NCT04348747,Hayleigh Kahn|Jie Zheng,,,, -716,VO:0007335,autolgous DC vaccine pulsed with autologous tumor homogenate for metastatic rcc,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,kidney cancer,Homo sapiens,,intradermal route,A cancer vaccine that uses dendritic cells pulsed with autologous tumor homogenate in combination With High Dose-IL2 and immunomodulating radiotherapy for patients with Metastatic RCC.,,,6266,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6266,,,NCT: https://clinicaltrials.gov/study/NCT03226236,Hayleigh Kahn|Jie Zheng,,,, -717,VO:0007336,autologous CLL tumor cell vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,leukemia,Homo sapiens,,,A cancer vaccine that consists of of irradiated autologous tumor cells admixed with GM-CSF-secreting bystander cells. The CD8+ T cells can react against CLL-associated antigens. Autologous tumor cell vaccination is an effective strategy to advance long-term leukemia control following allogeneic hematopoietic stem cell transplantation (allo-HSCT). ,PubMed:23912587,,6379,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6379,,,,Hayleigh Kahn|Jie Zheng,,,, -718,VO:0007337,autologous cancer testis antigen specific dendritic cell vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: NY-ESO-1|Gene name: MAGE-A1|Gene name: MAGE-A3,1485|4100|4102,Clinical trial,,,,therapeutic cancer vaccine,sarcoma,Homo sapiens,,,"A cancer vaccine that uses autologous cancer testis (CT) antigen specific dendritic cell (DC) preceded by decitabine as a demethylating chemotherapy for patients with high-risk neuroblastoma, Ewings sarcoma, osteogenic sarcoma, rhabdomyosarcoma or synovial sarcoma. The mature DC is pulsed with overlapping peptides mixes derived from full-length NY-ESO-1, MAGE-A1, and MAGE-A3.",,,6268,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6268,,,NCT: https://clinicaltrials.gov/study/NCT01241162,Hayleigh Kahn|Jie Zheng,,,, -719,VO:0007338,autologous CMV-pp65-flLAMP mRNA loaded dendritic cell vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: LAMP,27074,Clinical trial,,,,therapeutic cancer vaccine,brain cancer,Homo sapiens,,intradermal route,"A cancer vaccine consisting of autologous dendritic cells (DCs) loaded with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) as a fusion protein with the full-length lysosome-associated membrane protein (flLAMP), with potential immunostimulatory and antineoplastic activities. The vaccine exposes the immune system to the CMV pp65 peptide, which may elicit a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells. The incorporation of flLAMP may route CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC class II antigen presentation, thereby promoting CD4-positive T-cell responses. Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) is a powerful adjuvant capable of stimulating macrophage function, inducing proliferation and maturation of DCs, and is able to enhance T-lymphocyte stimulatory function. The vaccine can be used in combination with monoclonal antibodies, such as basiliximab, that can block tumor growth in different ways, as well as temozolomide, and radiation therpay. The combination of treatments may kill more tumor cells.",,,6347,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6347,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C156067,NCT: https://clinicaltrials.gov/study/NCT00626483,Hayleigh Kahn|Jie Zheng,,,, -720,VO:0007339,autologous dendritic cell vaccine loaded with personalized peptide vaccine (pep-dc vaccine),,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,lung non-small cell carcinoma,Homo sapiens,,subcutaneous route,A cancer vaccine made of dendritic cells (DCs) loaded with personalized peptides (PEP) given in combination with low-dose cyclophosphamide for patients with advanced or recurrent metastatic NSCLC.,,,6267,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6267,,,NCT: https://clinicaltrials.gov/study/NCT05195619,Hayleigh Kahn|Jie Zheng,,,, -721,VO:0007340,autologous lymphoma immunoglobulin-derived scFv-chemokine DNA vaccine,,lymphoma vaccine,VO:0005427,,Gene name: MIP3a,6364,Clinical trial,DNA vaccine role,,,therapeutic cancer vaccine,lymphoma,Homo sapiens,,intradermal route,A cancer vaccine that encodes macrophage inflammatory protein 3 alpha (MIP3a)-fused lymphoma idiotype in single chain format for patients with atients with Asymptomatic Phase Lymphoplasmacytic Lymphoma.,,,6264,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6264,,,,Hayleigh Kahn|Jie Zheng,,,, -722,VO:0007341,autologous neuroblastoma cell vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: IL-2,3558,Clinical trial,,,,therapeutic cancer vaccine,neuroblastoma,Homo sapiens,,subcutaneous route,"A cancer vaccine that uses autologous neuroblastoma cells, irradiated and genetically modified by adenoviral vectors to secrete interleukin-2 (IL-2) for patients with high-risk neuroblastoma. The adenoviral vector are used to transduce the cells ex-vivo, patients are not treated with the viral vector.",,,6269,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6269,,,NCT: https://clinicaltrials.gov/study/NCT00048386,Hayleigh Kahn|Jie Zheng,,,, -723,VO:0007342,autologous oxidized ovarian tumor cell lysate vaccine,,ovarian cancer vaccine,VO:0005493,,,,Clinical trial,subunit vaccine role,,,therapeutic cancer vaccine,ovarian cancer,Homo sapiens,,intradermal route,"A cancer vaccine that is composed of oxidized ovarian tumor cell lysate, with potential immunostimulatory and antineoplastic activities. The autologous oxidized ovarian tumor cell lysate vaccine exposes the immune system to an undefined amount of tumor-associated antigens (TAAs), which may result in the induction of both anti-tumor cytotoxic T-lymphocytes (CTLs) and antibody-dependent responses against TAA-expressing cells, leading to tumor cell lysis. Compared to non-oxidized tumor cell lysate vaccines, oxidized tumor cell lysate vaccines induce necrotic cell death, increase the immunogenicity of the TAAs and may enhance the anti-tumor immune response. Cyclophosphamide/Fludarabine Lymphodepletion and an immunomodulatory combination of Interferon-alpha Bevacizumab and Aspirin followed by adoptive transfer of vaccine-primed ex vivo CD3/CD28-costimulated peripheral blood autologous T cells and vaccination with whole tumor vaccine administered intradermally in combination with Bevacizumab in patients with recurrent ovarian cancer fallopian tube or primary peritoneal cancer may help treat their tumors. Patients will receive 5-10 million cells intradermally. ",,,6330,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6330,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C122402,NCT: [https://clinicaltrials.gov/study/NCT01312376,Hayleigh Kahn|Jie Zheng,,,, -724,VO:0007343,autologous total tumor mrna and CMV-pp65-flLAMP mRNA loaded liposome vaccine,,brain cancer vaccine,VO:0005428,,Gene name: LAMP,27074,Clinical trial,RNA vaccine role,,,therapeutic cancer vaccine,brain cancer,Homo sapiens,,intravenous route,"A cancer vaccine consisting of total tumor RNA (TTRNA) derived and amplified from autologous tumor cells and mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) as a fusion protein with the full-length lysosome-associated membrane protein (flLAMP), formulated in DOTAP lipid particles, with potential immunostimulatory and antineoplastic activities. he autologous total tumor mRNA and CMV-pp65-flLAMP mRNA loaded liposome vaccine, the mRNA is taken up, translated and presented by antigen presenting cells (APCs). This leads to an induction of both cytotoxic T-lymphocyte and memory T-cell dependent immune responses that specifically target and destroy the patient's cancer cells that express these tumor antigens. The incorporation of flLAMP may route CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC class II antigen presentation, thereby promoting CD4-positive T-cell responses. Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine is used to treat patients with Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM). The vaccine is also used for for the treatment of early melanoma recurrence following adjuvant Anti-PD-1 antibody therapy.",,,6270,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6270,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C178432,NCT: https://clinicaltrials.gov/study/NCT04573140|NCT: https://clinicaltrials.gov/study/NCT05264974,Hayleigh Kahn|Jie Zheng,,,, -725,VO:0007344,autologous tumor cell lysate vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine made from the patient's cancer cells that may make the body build an immune response and kill their tumor cells. The autologous tumor cell vaccine will be given together with adjuvant interferon gamma or sargramostim (GM-CSF) in patients with advanced cancer (breast, lung, prostate, colorectal, sarcoma, renal, melanoma). The vaccine uses irradiated autologous tumor cells and tumor lysate.",,,6364,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6364,,,NCT: https://clinicaltrials.gov/study/NCT00002505,Hayleigh Kahn|Jie Zheng,,,, -726,VO:0007345,"autologous, dnp-modified ovarian cancer vaccine",,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,ovarian cancer,Homo sapiens,,intradermal route,"A cancer vaccine made from the patient's own tumor tissue may stimulate an immune response against the patient's tumor cells. O-Vax nay induce a DTH response to autologous, DNP-modified ovarian cancer cells. The vaccine includes DNP-modified autologous ovarian tumor cells followed by cyclophosphamide then weekly doses of DNP-modified autologous ovarian tumor cells mixed with Bacillus of Calmette and Guérin (BCG).",,,6334,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6334,,,NCT: https://clinicaltrials.gov/study/NCT00660101,Hayleigh Kahn|Jie Zheng,,,, -727,VO:0007346,B7.1/​IL-2 leukaemia cell vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: B7.1,941,Clinical trial,,,,therapeutic cancer vaccine,leukemia,Homo sapiens,,,A cancer vaccine containing human acute myeloid leukemic (AML) blasts that have been genetically engineered to express a B7.1/IIL-2 fusion protein. It uses B7.1 (CD80)/IL-2 immune gene therapy for high risk MDS RAEB-2 and acute myeloid leukaemia (AML) patients who are unsuitable for an allogeneic haematological stem cell transplant.,,,6265,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6265,,,NCT: https://clinicaltrials.gov/study/NCT02493829,Hayleigh Kahn|Jie Zheng,,,, -728,VO:0007347,BC-819 vaccine,,pancreatic cancer vaccine,VO:0005430,,,,Clinical trial,DNA vaccine role,,,therapeutic cancer vaccine,pancreatic cancer,Homo sapiens,,intratumoral route,"A cancer vaccine made with BC-819 (also known as DTA-H19), which is a double-stranded DNA plasmid, 4,560 base pairs (bp) in length, carrying the gene for the Diphtheria toxin A (DT-A) chain under the regulation of the H19 promoter. The DT-A chain expression is triggered by the presence of H19 transcription factors that are only up-regulated in tumor cells. The selective initiation of toxin expression results in selective tumor cell destruction via inhibition of protein synthesis selectively in the tumor cell, enabling highly targeted cancer treatment. It is used in combination with intravenously administered gemcitabine for patients with Locally Advanced Pancreatic Adenocarcinoma. The activation of the H19 gene promoter-containing plasmids and DTA expression are limited to tumor cells, as high levels of H19 expression are only found in tumor cells. DTA disrupts protein synthesis. Tumor-cell selective expression of this toxin leads to the selective destruction of the tumor while sparing healthy, normal cells.",,,6273,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6273,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C107685,NCT: https://clinicaltrials.gov/study/NCT01413087,Hayleigh Kahn|Jie Zheng,,,, -729,VO:0007348,Bcl-Xl_42-CAF09b vaccine,,prostate cancer vaccine,VO:0005425,,,,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,prostate cancer,Homo sapiens,,intramuscular route,"A cancer vaccine made up of Bcl-xl_42 and the adjuvant CAF09b for patients with hormone-sensitive Prostate Cancer (PC) and lymph node metastases. B-cell lymphoma extra large protein (Bcl-xl) protein plays a vital role in the cancer cell's ability to avoid programmed cell death (apoptosis) and is upregulated in a variety of cancerous diseases, Bcl-xl_42 is a peptide fragment of the full protein and can lead to the death of cancer cells. CAF09b improves the activation of the immune system. ",,,6272,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6272,,,NCT: https://clinicaltrials.gov/study/NCT03412786,Hayleigh Kahn|Jie Zheng,,,, -730,VO:0007355,Bcr-Abl (b2a2)-derived peptide vaccine,,leukemia cancer vaccine,VO:0005487,,Gene name: bcr-abl,25,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,leukemia,Homo sapiens,,subcutaneous route,"A cancer vaccine consisting of the bcr-abl b2a2 fusion oncoprotein, frequently expressed in chronic myelogenous leukemia (CML), with potential antineoplastic activity. Vaccination with the bcr-abl (b2a2)-derived peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl b2a2 fusion protein. (NCIT_C61309) The vaccine is made from made from the proteins that cause leukemia cells in CML to behave abnormally. Imatinib mesylate is the standard therapy for CML and blocks the function of this protein. In combination, these may decrease or eliminate all evidence of disease in patients who have CML that is in remission after treatment with imatinib mesylate, but who still have small amounts of detectable disease.",,,6354,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6353,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C61309,NCT: https://clinicaltrials.gov/study/NCT00267085,Hayleigh Kahn|Jie Zheng,,,, -731,VO:0007364,Bcr-Abl (b3a2)-derived peptide vaccine,,leukemia cancer vaccine,VO:0005487,,Gene name: bcr-abl,25,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,leukemia,Homo sapiens,,subcutaneous route,"A cancer vaccine consisting of the bcr-abl b2a2 fusion oncoprotein, frequently expressed in chronic myelogenous leukemia (CML), with potential antineoplastic activity. Vaccination with the bcr-abl (b2a2)-derived peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl b2a2 fusion protein. The vaccine is made from made from the proteins that cause leukemia cells in CML to behave abnormally. Imatinib mesylate is the standard therapy for CML and blocks the function of this protein. In combination, these may decrease or eliminate all evidence of disease in patients who have CML that is in remission after treatment with imatinib mesylate, but who still have small amounts of detectable disease. ",,,6274,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6274,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C61310,NCT: https://clinicaltrials.gov/study/NCT00466726,Hayleigh Kahn|Jie Zheng,,,, -732,VO:0007400,Bcr-Abl peptide vaccine,,leukemia cancer vaccine,VO:0005487,,Gene name: bcr-abl,25,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,leukemia,Homo sapiens,,subcutaneous route,"A cancer vaccine consisting of the bcr-abl b3a2 fusion oncoprotein, frequently expressed in chronic myelogenous leukemia (CML), with potential antineoplastic activity. Vaccination with the bcr-abl (b3a2)-derived peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl b3a2 fusion protein. The bcr-abl p210-b3a2 breakpoint-derived pentapeptide vaccine is used in combination with GM-CSF. The peptides may help the body build an effective immune response to kill cancer cells, and the GM-CSF may increase the number of immune cells found in bone marrow or peripheral blood. This combination is used to treat patients with Philadelphia chromosome-positive chronic myelogenous leukemia. It can also be used in combination with imatinib mesylate to decrease or eliminate all evidence of disease in patients who have CML that is in remission after treatment with imatinib mesylate, but who still have small amounts of detectable disease",,,6372,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6372,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C2205,NCT: https://clinicaltrials.gov/study/NCT00004052|NCT: https://clinicaltrials.gov/study/NCT00455221,Hayleigh Kahn|Jie Zheng,,,, -733,VO:0007462,bivalent neuroblastoma vaccine with adjuvant OPT-821,,cancer vaccine,VO:0000177,,,,Clinical trial,conjugate vaccine role,,,therapeutic cancer vaccine,neuroblastoma,Homo sapiens,,subcutaneous route,"A cancer vaccine that is a bivalent vaccine with the antigens GD2L and GD3L for patients with High-Risk Neuroblastoma. The antigens are linked to KLH and mixed with OPT-821. It is given in combination with oral β-glucan, which can help white blood cells kill cancer.",,,6262,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6262,,,NCT: https://clinicaltrials.gov/study/NCT00911560,Hayleigh Kahn|Jie Zheng,,,, -734,VO:0007480,cancer stem cell-loaded dc vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,pancreatic cancer,Homo sapiens,,subcutaneous route,A cancer vaccine made of peripheral blood and tumor specimen harvested from patients with metastatic adenocarcinoma of the pancreas to generate cancer stem cell (CSC)-loaded denritic cell (DC) vaccines. CSC-primed antibodies and T cells are capable of selective targeting CSCs and conferring antitumor immunity.,,,6276,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6276,,,NCT: https://clinicaltrials.gov/study/NCT02074046,Hayleigh Kahn|Jie Zheng,,,, -735,VO:0007500,CAR G36-PDL1 vaccine,,renal cancer vaccine,VO:0005494,,Gene name: HLA,3105,Research,,,,therapeutic cancer vaccine,kidney cancer,Homo sapiens,,,"A cancer vaccine made with chimeric antigen receptor (CAR) T cells that can be used to treat solid tumors. These CAR-T cells are engineered to target carbonic anhydrase IX (CAIX) to secrete anti-PD-L1 monoclonal antibody (mAb), termed immune-restoring (IR) CAR G36-PDL1. The T cells can be used to treat clear cell renal cell carcinoma (ccRCC) with reconstituted human leukocyte antigen (HLA) partially matched human leukocytes derived from fetal CD34+ hematopoietic stem cells (HSCs) and bearing human ccRCC skrc-59 cells under the kidney capsule. The cells can restore active antitumor immunity by promoting tumor-killing cytotoxicity, reducing immunosuppressive cell components such as M2 macrophages and exhausted CD8+ T cells, and enhancing T follicular helper (Tfh)-B cell crosstalk.",PubMed:38327771,,6380,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6380,,,,Hayleigh Kahn|Jie Zheng,,,, -736,VO:0007510,CDX-1307 vaccine,,bladder cancer vaccine,VO:0005485,,Gene name: hCG-β,1082,Clinical trial,subunit vaccine role,,,therapeutic cancer vaccine,urinary bladder cancer,Homo sapiens,,,"A cancer vaccine for bladder cancer designed to generate an immune response against a protein called human chorionic gonadotropin-beta (hCG-β). hCG-β is made by several types of cancers, including bladder cancer, and has been shown to be associated with shorter times to development of metastases and reduced survival in bladder cancer. Administering the CDX-1307 vaccine will cause the body's immune system to attack bladder cancer cells in order to kill them or otherwise keep them from spreading or coming back. The human monoclonal antibody (B11) directed against the mannose receptor and linked to the beta-subunit of human chorionic gonadotropin (hCG beta) with potential immunostimulating and antineoplastic activities. The monoclonal antibody moiety of human monoclonal antibody B11-hCG beta fusion protein CDX-1307 binds to mannose receptors on antigen presenting cells (APCs), including human dendritic cells (DCs) and macrophages. APCs present the processed hCG beta antigen on their cell surfaces, which may initiate an antibody-dependent cell-mediated cytotoxicity (ADCC) response against hCG beta-expressing tumor cells.",,,6277,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6277,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C77858,NCT: https://clinicaltrials.gov/study/NCT01094496,Hayleigh Kahn|Jie Zheng,,,, -737,VO:0007511,chimeric exosomal tumor vaccine,,bladder cancer vaccine,VO:0005485,,,,Clinical trial,subunit vaccine role,,,therapeutic cancer vaccine,urinary bladder cancer,Homo sapiens,,,"A cancer vaccine prepared as tumor cells are isolated from the lesion site of patients with recurrent or metastatic bladder cancer, and dendritic cells or macrophages are isolated from peripheral blood. The vaccine activates an immune response and the microenvironment of bladder cancer lesions, and improves the anti-recurrence treatment effect of bladder cancer. ",,,6278,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6278,,,NCT: https://clinicaltrials.gov/study/NCT05559177,Hayleigh Kahn|Jie Zheng,,,, -738,VO:0007512,CLL idiotypic DNA vaccine,,leukemia cancer vaccine,VO:0005487,,,,Clinical trial,DNA vaccine role,,,therapeutic cancer vaccine,leukemia,Homo sapiens,,,A cancer vaccine that treats patients with Binet Stage A Chronic Lymphocytic Leukemia (CLL) by using a fragment of Deoxyribonucleic acid (DNA) containing the sequence of their own immunoglobulin gene. The vaccine is designed to generate an immune response and shrink or slow the CLL.,,,6279,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6279,,,NCT: https://clinicaltrials.gov/study/NCT00038415,Hayleigh Kahn|Jie Zheng,,,, -739,VO:0007513,cyclin B1/WT-1/CEF-loaded DC vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: cyclin B1|Gene name: WT-1|Gene name: CEF,931|7490|2064,Clinical trial,,,,therapeutic cancer vaccine,breast cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine for patients with Locally Advanced, Triple-Negative Breast Cancer or ER-Positive, Her2-Negative Breast Cancer to receive ex vivo-generated tumor antigen-loaded dendritic cells (DCs), which can prime lymphocytes and regulate and maintain immune responses. The vaccine may boost T cell immunity targeted against breast cancer, enhance chemotherapy effectiveness and decrease tumor metastagenicity, and decrease the recurrence rates of LA TNBC and ER+/HER2- BC. ",,,6288,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6288,,,NCT: https://clinicaltrials.gov/study/NCT02018458,Hayleigh Kahn|Jie Zheng,,,, -740,VO:0007514,DC/AML fusion vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,leukemia,Homo sapiens,,,"A cancer vaccine consisting of autologous dendritic cells (DCs) fused with autologous acute myeloid leukemia (AML) cells, with potential immunostimulatory and antineoplastic activities. It is generated in vitro by mixing DCs and irradiated AML cells harvested from individual patients, in the presence of polyethylene glycol (PEG), to produce hybrid DC-leukemia fusion cells. The vaccine may elicit a cytotoxic T-lymphocyte (CTL)-mediated antitumor immune response against a broad array of AML-associated antigens, which may lead to AML cell lysis. When dendritic cells and tumor cells are brought together, the dendritic cells can stimulate immune responses against the tumor and, in some cases, cause the tumor to shrink. GM-CSF is a drug that stimulates white blood cells and is given with the DC AML Vaccine in an effort to enhance the effect of the vaccine.",,,6374,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6374,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148214,NCT: https://clinicaltrials.gov/study/NCT01096602|NCT: https://clinicaltrials.gov/study/NCT03059485,Hayleigh Kahn|Jie Zheng,,,, -741,VO:0007515,dendritic cell survivin vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: survivin|Gene name: CD11|Gene name: HLA-DR,332|3684|3123,Clinical trial,,,,therapeutic cancer vaccine,multiple myeloma,Homo sapiens,,intramuscular route,"A cancer vaccine made using the participant's own blood cells. The vaccine will contain a virus called an adenovirus, similar the virus that causes the common cold. The dendritic cells contain survivin+, CD11c+, Human Leukocyte Antigen - antigen D Related (HLA-DR)+ by flow-cytometry. The vaccine is given in combination with G-CSF, T cells, and the CD34 progenitor cells.",,,6351,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6351,,,NCT: https://clinicaltrials.gov/study/NCT02851056,Hayleigh Kahn|Jie Zheng,,,, -742,VO:0007516,dendritic cell tumor peptide vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,brain cancer,Homo sapiens,,intradermal route,"A cancer vaccine composed of dendritic cells pulsed with peptide epitopes that stimulate cytotoxic T lymphocyte anti-tumor activity. This vaccine is used to treat diffuse hemispheric glioma with a H3 G34 mutation that has come back (recurrent) and/or is growing, spreading, or getting worse (progressive). It is made with the patient's own white blood cells and peptide-pulsed dendritic cells, which may help the body build an effective immune response to kill tumor cells. It is combined with immunotherapy monoclonal antibodies, such as nivolumab and ipilimumab, which also may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.",,,6282,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6282,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1987,NCT: https://clinicaltrials.gov/study/NCT05457959,Hayleigh Kahn|Jie Zheng,,,, -743,VO:0007517,dendritic cell/​myeloma fusion vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,multiple myeloma,Homo sapiens,,subcutaneous route,A cancer vaccine onsisting of autologous dendritic cells (DCs) fused with patient-derived plasma cell (multiple) myeloma cells with potential immunostimulatory and antineoplastic activities. Autologous DC/multiple myeloma fusions stimulate both helper and cytotoxic T-lymphocyte (CTL) responses through the presentation of internalized and newly synthesized tumor associated antigens (TAAs). This may promote cellular and humoral antitumor immune responses in patients with plasma cell myeloma. This vaccine uses Dendritic cell/myeloma fusions with granulocyte macrophage colony-stimulating factor (GM-CSF) adjuvant plus lenalidomide maintenance therapy. The dendritic cell myeloma vaccine may improve response in patients with multiple myeloma after autologous Hematopoietic Cell Transplant (HCT).,,,6323,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6323,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C158480,NCT: https://clinicaltrials.gov/study/NCT02728102,Hayleigh Kahn|Jie Zheng,,,, -744,VO:0007519,"dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes",,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,brain cancer,Homo sapiens,,,"A cancer vaccine made of tumor cells and tumor stem cells that are isolated from a sample from a patient with glioblastoma multiforme. Dendritic cells are isolated from peripheral blood mononuclear cells and cultured. The tumor sample provides tumor specific antigens to prepare the dendritic vaccine. Cytotoxic lymphocytes are obtained from peripheral blood after dendritic vaccine administrations. Hematopoietic stem cells are harvested from closely related donor after granulocyte-colony-stimulating factor (G-CSF) administration. Allogeneic haploidentical hematopoietic stem cells are administered intrathecally, dendritic cells are administered subcutaneously, and cytotoxic lymphocytes are adminstered intrathecally. The combination of these treatments may control tumor cell quantity and target regulation of effector functions of tumor stem cells.",,,6285,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6285,,,NCT: https://clinicaltrials.gov/study/NCT01759810,Hayleigh Kahn|Jie Zheng,,,, -745,VO:0007520,"dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes",,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,brain cancer,Homo sapiens,,intramuscular route,"A cancer vaccine from tumor cells and tumor stem cells that are isolated from a sample from a patient with glioblastoma multiforme. Dendritic cells are isolated from peripheral blood mononuclear cells and cultured. The tumor sample provides tumor specific antigens to prepare the dendritic vaccine. Cytotoxic lymphocytes are obtained from peripheral blood after dendritic vaccine administrations. Hematopoietic stem cells are harvested from closely related donor after granulocyte-colony-stimulating factor (G-CSF) administration. Autologous haploidentical hematopoietic stem cells are administered intrathecally, dendritic cells are administered subcutaneously, and cytotoxic lymphocytes are adminstered intrathecally. The combination of these treatments may control tumor cell quantity and target regulation of effector functions of tumor stem cells.",,,6286,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6286,,,NCT: https://clinicaltrials.gov/study/NCT01759810,Hayleigh Kahn|Jie Zheng,,,, -746,VO:0007521,DIPG and GMB Immunomodulatory DC vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,brain cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine based on ex vivo genetic modifications in combination with known tumor-specific antigens may substantially enhance the activation potential of tumor-specific T cells with improved benefit to patients. This DC vaccine is based on autologous DCs pulsed with genetically modified tumor cells or related antigens such as neoantigens to induce a strong anti-tumor immunity. The patient will receive intravenous cyclophosphamide (200 mg/m2) or oral (cytoxan) before the vaccine, followed by DC vaccine and intravenous bevacizumab (15 mg/kg).",,,6301,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6301,,,NCT: https://clinicaltrials.gov/study/NCT03914768,Hayleigh Kahn|Jie Zheng,,,, -747,VO:0007522,electrofusion DC vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,kidney cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine made with PEG fusions generated from allogeneic dendritic cells and autologous tumor-derived cells with GM-CSF and Il-4. The vaccine is irradiated, frozen, and thawed before being administered to patients with AJCC Stage IV Renal Cell Carcinoma. The vaccine could have and effect on the immune system and cancer.",,,6287,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6287,,,NCT: https://clinicaltrials.gov/study/NCT00625755,Hayleigh Kahn|Jie Zheng,,,, -748,VO:0007526,ESR1 peptide vaccine,,breast cancer vaccine,VO:0005484,,Gene name: ESR1,2099,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,breast cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine comprised of estrogen receptor alpha (ERa; estrogen receptor 1; ESR1) mutant peptides, combined with the immunoadjuvants granulocyte-macrophage colony-stimulating factor (GM-CSF) and montanide ISA, with potential immunomodulating and antineoplastic activities. ESR1 mutant peptides in the ESR1 peptides/GM-CSF/montanide ISA vaccine may activate the immune system to induce an immune response against tumor cells expressing these ESR1 mutations. Cancer peptides used in this vaccine are derived from the estrogen receptor and are combined with the adjuvant Montanide ISA and GM-CSF to enhance their immune response. The vaccine may improve outcomes of patients with endocrine resistant breast cancer. ",,,6289,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6289,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C175590,NCT: https://clinicaltrials.gov/study/NCT04270149,Hayleigh Kahn|Jie Zheng,,,, -749,VO:0007530,"follicular lymphoma, patient-specific, soluble protein idiotype vaccine",,lymphoma vaccine,VO:0005427,,,,Clinical trial,conjugate vaccine role,,,therapeutic cancer vaccine,lymphoma,Homo sapiens,,,"A cancer vaccine directed against the soluble protein idiotype of an individual follicular lymphoma with potential antineoplastic activity. The vaccine may induce an idiotype-specific cytotoxic T-lymphocyte (CTL) response against follicular lymphoma cells expressing the idiotype, resulting in tumor cell lysis. Idiotypic vaccinations have the capacity of inducing an idiotype- and tumor-specific immune response, inducing specific immune responses able to kill in vivo follicular lymphoma cells, and prolonging survival of responding patients. This vaccine may contribute to preventing relapse indefinitely in responding patients.",,,6290,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6290,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C71036,NCT: https://clinicaltrials.gov/study/NCT00530140,Hayleigh Kahn|Jie Zheng,,,, -750,VO:0007543,FRAME-001 personalized vaccine,,non-small cell lung cancer vaccine,VO:0003140,,,,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,lung non-small cell carcinoma,Homo sapiens,,subcutaneous route,"A cancer vaccine made from tumor-specific neopeptides resulting from frameshift mutations in tumor cells, so-called Frames, present potentially potent targets for the immune system and can be utilized in therapeutic anti-cancer vaccination with the intention to synergize in their effect with immune checkpoint inhibitors. The personalized vaccine FRAME-001 based on a patient's Framome and selection of Frame peptides in advanced NSCLC cancer patients after standard first line treatment consisting of immune checkpoint inhibitor pembrolizumab as monotherapy or combined with chemotherapy (carboplatin/cisplatin and pemetrexed/paclitaxel) could help treat patients with non-small cell lung cancer.",,,6291,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6291,,,NCT: https://clinicaltrials.gov/study/NCT04998474,Hayleigh Kahn|Jie Zheng,,,, -751,VO:0007661,GD2-CAR vaccine,,cancer vaccine,VO:0000177,,,,Clinical trial,,,,therapeutic cancer vaccine,cancer,Homo sapiens,,,"A cancer vaccine made with T cells genetically engineered to express anti-GD2 Chimeric Antigen Receptor to treat patients with children and young adults with GD2+ solid tumors, including neuroblastoma. The T cells may have an antitumor effect. They can be used in combination with AP1903 and Cyclophosphamide. (NCT02107963) There are increased CXCR3- classical monocytes in patients as CAR-T numbers waned.",pubmed:38134936,,6381,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6381,,,NCT: https://clinicaltrials.gov/study/NCT02107963,Hayleigh Kahn|Jie Zheng,,,, -752,VO:0007662,"GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid KLH conjugate vaccine",,lung cancer vaccine,VO:0005486,,Gene name: GD 2|Gene name: GD3|Gene name: Globo H|Gene name: fucosyl GM1,2583|6489|2524|8705,Clinical trial,conjugate vaccine role,,,therapeutic cancer vaccine,lung cancer,Homo sapiens,,,"A cancer vaccine used to treat patients with small cell lung cancer by using several components (small cell lung cancer targets) that have been tested individually in patients with small cell lung cancer or other cancers (GD2, GD3, Globo H, Fucosyl GM1 and N-propionylated polysialic acid) so that the body will make antibodies to the vaccine which will also react against the cancer. Two other substances (KLH and OPT-821) are added which boost the immune system. Vaccination with the pentavalent KLH conjugate vaccine may induce production of IgG and IgM antibodies as well as an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumors expressing any of these antigens.",,,6275,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6275,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C97034,NCT: https://clinicaltrials.gov/study/NCT01349647,Hayleigh Kahn|Jie Zheng,,,, -753,VO:0007663,genetically engineered allogeneic prostate carinoma cells secreting interleukin-2 and interferon gamma,,whole cell cancer vaccine,VO:0007658,,Gene name: IL2|Gene name: Interferon gamma,3558|3458,Clinical trial,,,,therapeutic cancer vaccine,prostate cancer,Homo sapiens,,,A cancer vaccine made with HLA class I-matched allogeneic human prostate carcinoma cells that are genetically engineered to secrete interleukin-2 and interferon gamma for patients with prostate carcinoma. Interleukin-2 may stimulate a person's white blood cells including natural killer cells to kill prostate cancer cells. Interferon gamma may interfere with the growth of the cancer cells. Combining interferon gamma with interleukin-2 may be a more effective treatment for prostate cancer.,,,6292,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6292,,,NCT: https://clinicaltrials.gov/study/NCT00002637,Hayleigh Kahn|Jie Zheng,,,, -754,VO:0007664,GM-K562 cell vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: GM-CSF,1437,Clinical trial,,,,therapeutic cancer vaccine,leukemia,Homo sapiens,,subcutaneous route,"A cancer vaccine comprised of K562 cells transfected with the granulocyte macrophage-colony stimulating factor (GM-CSF) gene with potential immunopotentiating properties. This vaccine may stimulate the host immune system to produce an antitumoral T-lymphocyte response, thereby inhibiting tumor growth. A cultured cell line is genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from a patient. Vaccines made from gene-modified cancer cells may help the body build an effective immune response to kill cancer cells. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving vaccine therapy together with imatinib mesylate may be an effective treatment for chronic myelogenous leukemia. The vaccine can also be combined with stem cell transplantation. The vaccine may induce an immune response to common myeloid antigens (e.g., Wilms' tumor-1 [WT-1], survivin, or proteinase-3) in patients with Myelodysplastic Syndrome. ",,,6293,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6293,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C52190,NCT: https://clinicaltrials.gov/study/NCT00301093|NCT: https://clinicaltrials.gov/study/NCT00361296|NCT: https://clinicaltrials.gov/study/NCT00442130|NCT: https://clinicaltrials.gov/study/NCT00809250,Hayleigh Kahn|Jie Zheng,,,, -755,VO:0007665,GM.CD40L cell vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: CD40LG,959,Clinical trial,,,,therapeutic cancer vaccine,cancer,Homo sapiens,,intradermal route,"A cancer vaccine composed of irradiated tumor cells transduced with granulocyte-macrophage colony-stimulating factor (GM-CSF) and CD40-ligand (CD40L) genes. The vaccine may stimulate an anti-tumoral dendritic cell-mediated host immune response. Universal GM-CSF-producing and CD40L-expressing bystander cell line is used to form an autologous tumor cell-based vaccine for patients with mantle cell lymphoma in order to make the body build an effective immune response to kill cancer cells. It can be used in combination with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Dexamethasone, and IL-2. The vaccine can be done with bystander and autologous tumor cells for patients with malignant melanoma. It can also be combined with lenalidomide for patients with myelodysplastic syndrome (MDS).",,,6271,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6271,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C48391,NCT: https://clinicaltrials.gov/study/NCT00101101|NCT: https://clinicaltrials.gov/study/NCT00101166| NCT: https://clinicaltrials.gov/study/NCT00840931,Hayleigh Kahn|Jie Zheng,,,, -756,VO:0007666,gp100 mature dendritic cell vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: gp100,6490,Clinical trial,,,,therapeutic cancer vaccine,cancer,Homo sapiens,,intravenous route,A cancer vaccine using dendritic cells (a kind of white blood cell) as a vaccine could stimulate your own immune system to react to your melanoma cells. Autologous dendritic cells are pulsed with 2 gp100 melanoma peptides (G209-2M and G280-9V) plus up to an additional 10 unique melanoma tumor-specific peptides. Patients also receive cyclophosphamide 300mg/m2 IV in order to deplete regulatory T cells.,,,6308,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6308,,,NCT: https://clinicaltrials.gov/study/NCT00683670,Hayleigh Kahn|Jie Zheng,,,, -757,VO:0007667,GVAX leukemia vaccine,,leukemia cancer vaccine,VO:0005487,,Gene name: GM-CSF,1437,Clinical trial,recombinant vector vaccine role,,,therapeutic cancer vaccine,leukemia,Homo sapiens,,subcutaneous route|intradermal route,"A cancer vaccine that uses irradiated, adenovirus transduced autologous myeloblasts to secrete granulocyte-macrophage colony-stimulating factor (GVAX) early after allogeneic hematopoietic stem cell transplantation (HSCT) to induce potent immune responses. The vaccine may prevent advanced myelodysplastic syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), or acute myeloid leukemia (AML) from relapsing after stem cell transplant. The patients own cancer cells are engineered to produce a protein called GM-CSF, which can be effective in stimulating a powerful immune response specific to that cancer. ",PubMed:34807983,,6385,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6385,,,NCT: https://clinicaltrials.gov/study/NCT01773395,Hayleigh Kahn|Jie Zheng,,,, -758,VO:0007668,H3.3K27M-specific peptide vaccine,,brain cancer vaccine,VO:0005428,,,,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,brain cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine composed of a peptide derived from histone H3.3 containing the amino acid substitution mutation lysine (Lys) 27-to-methionine (H3.3K27M), with potential immunoactivating and antineoplastic activities. Following the administration of the vaccine, the immune system may exert a cytotoxic T-lymphocyte (CTL)-mediated immune response against H3.3K27M-expressing tumor cells. A lysine 27-to-methionine (K27M) somatic mutation at histone H3 variant (H3.3) is a feature mutation in diffuse intrinsic pontine gliomas (DIPGs). This vaccine contains an H3.3-K27M targeted neoantigen peptide that can be taken up by antigen-presenting cells (APCs). APCs can present the peptide with the major histocompatibility complex (MHC) molecules on cell surface, thereby activating neoantigen-specific T cells and triggering corresponding cytotoxic T cell immune responses to eliminate H3.3-K27M-expressing DIPG cells.",,,6295,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6295,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C132684,NCT: https://clinicaltrials.gov/study/NCT04749641,Hayleigh Kahn|Jie Zheng,,,, -759,VO:0007669,"HER-2-neu, CEA peptides, GM-CSF, montanide ISA-51 vaccine",,colorectal cancer vaccine,VO:0005426,,Gene name: carcinoembryonic antigen|Gene name: HER-2-neu,1048|2064,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,colorectal cancer,Homo sapiens,,,"A cancer vaccine comprised of HER-2-neu and carcinoembryonic antigen synthetic (CEA) peptides, combined with the adjuvants granulocyte-macrophage colony stimulating factor (GM-CSF), and Montanide ISA-51 with potential antineoplastic activity. The vaccine may stimulate a cytotoxic T-cell response against HER-2-neu- and CEA-expressing tumor cells. Vaccines made from peptides may make the body build an immune response to kill tumor cells. This vaccine is compromised of HER-2-neu and carcinoembryonic antigen synthetic peptides, sargramostim (GM-CSF), and Montanide ISA-51, and aims to cause an immune response in patients with stage IIB, III, or IV colorectal cancer.",,,6294,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6294,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C48392,NCT: https://clinicaltrials.gov/study/NCT00091286,Hayleigh Kahn|Jie Zheng,,,, -760,VO:0007670,HER2 ICD peptide vaccine,,breast cancer vaccine,VO:0005484,,Gene name: HER-2/neu,2064,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,breast cancer,Homo sapiens,,intradermal route,A cancer vaccine made from peptides that may help the body build an effective immune response to kill tumor cells. Patients with HER2 positive locally advanced breast cancer can be vaccinated with a HER2 Intracellular Domain (ICD) peptide-based vaccine administered concurrently with trastuzumab. The vaccine may lead to an immune response (HER2 specific T cell immunity and/or the development of intramolecular epitope spreading).,,,6352,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6352,,,NCT: https://clinicaltrials.gov/study/NCT00343109,Hayleigh Kahn|Jie Zheng,,,, -761,VO:0007671,HLA neoantigen vaccine,,cancer vaccine,VO:0000177,,Gene name: HLA,3123,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,cancer,Homo sapiens,,,"A cancer vaccine for vaccination with neoantigens that can both expand pre-existing neoantigen-specific T-cell populations and induce a broader repertoire of new T-cell specificities in cancer patients, tipping the intra-tumoural balance in favour of enhanced tumour control. The vaccine targets up to 20 predicted personal tumour neoantigens. The vaccine induced CD4+ and CD8+ T cells responses. These T cells discriminated mutated from wild-type antigens, and in some cases directly recognized autologous tumour.",PubMed:28678778,,6377,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6377,,,,Hayleigh Kahn|Jie Zheng,,,, -762,VO:0007672,"HLA-A1, HLA-A2, and CD40-ligand pulsed dendritic cell vaccine",,whole cell cancer vaccine,VO:0007658,,Gene name: HLA-A|Gene name: CD40L,3105|959,Clinical trial,,,,therapeutic cancer vaccine,cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine made from a person's white blood cells mixed with tumor proteins (HLA-A1- and HLA-A2.1-restricted peptides derived from melanoma-associated tumor antigens) and CD40-ligand, and may make the body build an immune response to kill tumor cells. This is combined with denileukin diftitox, which ",,,6283,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6283,,,NCT: https://clinicaltrials.gov/study/NCT00056134,Hayleigh Kahn|Jie Zheng,,,, -763,VO:0007673,hodgkin's antigens-GM-CSF-expressing cell vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,lymphoma,Homo sapiens,,,"A cancer vaccine consisting of Hodgkin lymphoma cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene with potential antineoplastic activity. Hodgkin antigens-GM-CSF-expressing cell vaccine may stimulate a cytotoxic T-lymphocyte (CTL) immune response against Hodgkin lymphoma-associated antigens, which may result in the lysis of tumor cells expressing these antigens. Also, transfected Hodgkin lymphoma cells secrete GM-CSF, which may potentiate the CTL response against Hodgkin lymphoma-associated antigens. Vaccines made from a tumor antigen may help the body build an effective immune response to kill tumor cells. This vaccine contains cells expressing Hodgkin's antigens and GM-CSF, and could cause an immunological response in Hodgkin's lymphoma patients.",,,6296,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6296,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C61592,NCT: https://clinicaltrials.gov/study/NCT00478062,Hayleigh Kahn|Jie Zheng,,,, -764,VO:0007674,HPV E6/E7-encoding semliki forest virus vaccine Vvax001,,cancer vaccine,VO:0000177,,Gene name: E6|Gene name: E7,1489078|1489079,Clinical trial,recombinant vector vaccine role,,,therapeutic cancer vaccine,cancer,Homo sapiens,,intramuscular route,"A cancer vaccine consisting of a recombinant, attenuated, replication-incompetent form of the Semliki Forest Virus (SFV) vector encoding the viral oncoproteins E6 and E7 derived from the human papillomavirus (HPV), with potential immunomodulating and antineoplastic activities. The vaccine induces expression of the E6/E7 proteins and stimulates both the innate and the adaptive immune system, resulting in a potent cytotoxic T-lymphocyte (CTL) response against and lysis of tumor cells expressing HPV E6 and E7. The vaccine may help to treat patients with a history of (pre) malignant cervical lesions.",,,6369,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6369,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148539,NCT: https://clinicaltrials.gov/study/NCT03141463,Hayleigh Kahn|Jie Zheng,,,, -765,VO:0007675,hyperacute - breast cancer vaccine,,breast cancer vaccine,VO:0005484,,Gene name: Ggta1,14594,Clinical trial,recombinant vector vaccine role,,,therapeutic cancer vaccine,breast cancer,Homo sapiens,,intradermal route,"A cancer vaccine composed of irradiated allogeneic breast cancer cell lines (HAB-1 and HAB-2) that have been transduced with a recombinant Moloney murine leukemia virus (MoMLV)-based retroviral vector expressing the murine alpha (1,3) GT gene. The immune response to the foreign substance could stimulate the immune system to attack the patient's own cancer cells that have similar proteins without this sugar pattern, causing the tumor to remain stable or shrink.",,,6297,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6297,,,NCT: https://clinicaltrials.gov/study/NCT00090480,Hayleigh Kahn|Jie Zheng,,,, -766,VO:0007676,hyperacute-melanoma vaccine,,melanoma vaccine,VO:0000422,,Gene name: Ggta1,14594,Clinical trial,recombinant vector vaccine role,,,therapeutic cancer vaccine,melanoma,Homo sapiens,,intradermal route,"A cancer vaccine composed of irradiated allogeneic melanoma cell lines (HAM-1, HAM-2 and HAM-3). These cell lines have been transduced with a recombinant Moloney murine leukemia virus (MoMLV)-based retroviral vector expressing the murine alpha(1,3)GT gene, a mouse gene that causes the production of a foreign pattern of protein-sugars on the cell surface. The immune response to the foreign substance could stimulate the immune system to attack the patient's own cancer cells that have similar proteins without this sugar pattern, causing the tumor to remain stable or shrink.",,,6298,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6298,,,NCT: https://clinicaltrials.gov/study/NCT00300612,Hayleigh Kahn|Jie Zheng,,,, -767,VO:0007677,hyperacute-prostate cancer vaccine,,prostate cancer vaccine,VO:0005425,,Gene name: Ggta1,14594,Clinical trial,recombinant vector vaccine role,,,therapeutic cancer vaccine,prostate cancer,Homo sapiens,,intradermal route,"A cancer vaccine composed of irradiated allogeneic prostate cancer cell lines (HAP-1 and HAP-2) that have been transduced with a recombinant Moloney murine leukemia virus (MoMLV)-based retroviral vector expressing the murine alpha (1,3) GT gene, a mouse gene that causes the production of a foreign pattern of protein-sugars on the cell surface. It is hoped that the immune response to the foreign substance will stimulate the immune system to attack the patient's own cancer cells that have similar proteins without this sugar pattern, causing the tumor to remain stable or shrink.. The expression of the murine alpha (1,3) galactosyltransferase [alpha (1,3) GT] gene results in the cell surface expression of alpha (1,3) galactosyl-epitopes (alpha-gal) on membrane glycoproteins and glycolipids.",,,6299,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6299,,,NCT: https://clinicaltrials.gov/study/NCT00105053,Hayleigh Kahn|Jie Zheng,,,, -768,VO:0007678,IDO peptide vaccine,,melanoma vaccine,VO:0000422,,Gene name: IDO,3620,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,melanoma,Homo sapiens,,,"A cancer vaccine derived from the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) with potential immunomodulating and antineoplastic activities. It may activate the immune system to induce an immune response against IDO-expressing tumor cells, which may restore the proliferation and activation of various immune cells including cytotoxic T-lymphocytes (CTLs), natural killer cells (NKs), and dendritic cells (DCs), and may eradicate IDO-expressing tumor cells through a CTL-mediated response. This vaccine, using a small fragment of IDO, can be used in combination with either Ipilimumab or Vemurafenib to treat malignant melanoma that has metastasized. ",,,6368,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6368,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C159498,NCT: https://clinicaltrials.gov/study/NCT02077114,Hayleigh Kahn|Jie Zheng,,,, -769,VO:0007679,IL-2 peptide and GM-CSF-in-adjuvant melanoma vaccine,,melanoma vaccine,VO:0000422,,,,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,melanoma,Homo sapiens,,subcutaneous route|intradermal route,"A cancer vaccine compromised of melanoma peptides plus GM-CSF-in-adjuvant. It is combined with low-dose IL-2 therapy, which could significantly enhance the immunologic efficacy.",,,6312,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6312,,,NCT: https://clinicaltrials.gov/study/NCT00928902,Hayleigh Kahn|Jie Zheng,,,, -770,VO:0007680,IL15-DC vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: IL15,3600,Clinical trial,,,,therapeutic cancer vaccine,melanoma,Homo sapiens,,subcutaneous route,"A cancer vaccine made with autologous dendritic cells that are manufactured with GM-CSF, IL15 and loaded with melanoma/HIV peptides and KLH; then activated with LPS and CD40 Ligand.IL15 is a T cell growth factor that could have a very important role in cancer immunotherapy. IL15 DCs are particularly efficient at priming functional melanoma specific CD8+ T cells. The use of IL15 in the manufacture of the DC vaccine could result in an improved immunotherapy product for melanoma patients.",,,6300,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6300,,,NCT: https://clinicaltrials.gov/study/NCT01189383,Hayleigh Kahn|Jie Zheng,,,, +708,VO:0007185,4-peptide melanoma vaccine,,melanoma vaccine,VO:0000422,,Gene name: Melan-A|Gene name: gp100|Gene name: MAGE-3|Gene name: NA17,2315|6490|4102,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,melanoma,Homo sapiens,,subcutaneous route|intradermal route,"A cancer vaccine that may stimulate an immune response against 4 different melanoma associated antigens. This may lead to a reduction in tumor cell proliferation of cancer cells expressing these antigens. The vaccine may contain 4 class I MHC-restricted synthetic melanoma peptides (1 each restricted by HLA-A1, -A3, and two restricted by HLA-A2) and a helper tetanus peptide. The peptides may include Melan-A, gp100, MAGE-3, and NA17. The vaccine can be used in combination Ontak, which may produce an immune response in patients with metastatic melanoma, and the Ontak may improve these immune responses and lead to tumor shrinkage.",,,6370,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6370,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C91722,NCT: https://clinicaltrials.gov/study/NCT00515528,Hayleigh Kahn|Jie Zheng,,,, +709,VO:0007248,a2/4-1bbl melanoma vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: 4-1BBL,8744,Clinical trial,,,,therapeutic vaccine function,melanoma,Homo sapiens,,intravenous route,"A cancer vaccine used to treat patients with malignant melanoma. It is made of a compatible melanoma cell line that has been engineered to express a molecule termed 4-1BBL, which enhances the chances of the cell line to be recognized by the patient's immune system, and to induce its stimulation, with an immune response to residual tumor in the body. It will be used in combination with intravenous low dose cyclophosphamide, 300 mg/m2.",,,6260,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6260,,,NCT: https://clinicaltrials.gov/study/NCT01898039,Hayleigh Kahn|Jie Zheng,,,, +710,VO:0007273,adenovirus-transfected autologous dc vaccine plus cik cells,,lung cancer vacine,VO:0005486,,Gene name: MUC1|Gene name: Survivin,4582|332,Clinical trial,recombinant vector vaccine role,,adenoviral vector vaccine role,therapeutic vaccine function,lung cancer,Homo sapiens,,,A cancer vaccine that uses adenovirus MUC1 and Survivin transfected autologous dendritic cells combined with cytokine-induced killer cells in cancer patients with Extensive-Stage Small- Cell Lung Cancer.,,,6261,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6261,,,NCT: https://clinicaltrials.gov/study/NCT01174082,Hayleigh Kahn|Jie Zheng,,,, +711,VO:0007317,ags-003-bld vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: CD40LG,959,Clinical trial,,,,therapeutic vaccine function,urinary bladder cancer,Homo sapiens,,intradermal route,"A cancer vaccine composed of autologous, mature dendritic cells (DCs) are electroporated with in vitro transcribed (IVT) RNAs encoding for a synthetic form of T-cell protein CD40 ligand (CD40L) and IVT RNA encoding for autologous tumor-associated antigens (TAAs) derived from patient-specific bladder cell carcinoma (BCC) cells, with potential immunostimulatory and antineoplastic activities. The RNA is translated and processed, and BCC-specific antigenic peptides are subsequently presented via major histocompatibility complex (MHC) Class I molecules on the DCs surface. The MHC-presented peptides interact with and activate CD8-positive T-cells, which elicits a highly specific cytotoxic T-cell (CTL) response against tumor cells expressing the patient-specific BCC TAAs. The signal cascade initiated by expression of the co-stimulatory molecule CD40L results in the secretion of the inflammatory cytokine IL-12, which further stimulates CTLs. The vaccine can be used in combination with gemcitabine hydrochloride and cisplatin which stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading, while the vaccine helps the body build an effective immune response to kill tumor cells. In combination, they may make the tumor smaller and reduce the amount of tissue that needs to be removed by surgery in patients with bladder cancer.",,,6363,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6363,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C129522,NCT: https://clinicaltrials.gov/study/NCT02944357,Hayleigh Kahn|Jie Zheng,,,, +712,VO:0007323,alk peptide vaccine,,non-small cell lung cancer vaccine,VO:0003140,,,,Research,subunit vaccine role,,,therapeutic vaccine function,lung non-small cell carcinoma,Homo sapiens,,,"A cancer vaccine that restored priming of Anaplastic lymphoma kinase (ALK)-specific CD8+ T cells, eradicated lung tumors in combination with ALK tyrosine kinase inhibitors (TKIs) and prevented metastatic dissemination of tumors to the brain. Human ALK peptides are displayed by HLA-A*02:01 and HLA-B*07:02 molecules. The peptides are immunogenic and recognized by CD8+ T cells from individuals with non-small cell lung cancer (NSCLC).",PubMed:37430060,,6382,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6382,,,,Hayleigh Kahn|Jie Zheng,,,, +713,VO:0007324,allogeneic GM-CSF-secreting lethally irradiated pancreatic tumor cell vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: GM-CSF,12981,Clinical trial,,,,therapeutic vaccine function,pancreatic cancer,Homo sapiens,,intradermal route,"A cancer vaccine made of allogeneic pancreatic tumor cells are transfected with a GM-CSF gene to treat ocally advanced, unresectable or metastatic pancreatic adenocarcinoma. It may be in combination with Ipilimumab (an antibody that blocks negative signals to T cells).",,,6336,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6336,,,NCT: https://clinicaltrials.gov/study/NCT00836407,Hayleigh Kahn|Jie Zheng,,,, +714,VO:0007325,allogeneic HLA-A2/4-1BB ligand-expressing melanoma vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: HLA-A|Gene name: 4-1BBL,3105|8744,Clinical trial,,,,therapeutic vaccine function,melanoma,Homo sapiens,,,"A cancer vaccine that consists of an allogeneic cell line that has a high expression level of melanoma molecules (HLA A2/4-1BB Ligand), and has been genetically modified to induce a strong immune response. Stimulation of the immune response against the tumor can help destroy residual tumor in melanoma patients with very high risk for disease recurrence and in patients with relatively low tumor burden who already got first line treatment for their disease.",,,6313,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6313,,,NCT: https://clinicaltrials.gov/study/NCT01861938,Hayleigh Kahn|Jie Zheng,,,, +715,VO:0007326,anti-HER2/HER3 dendritic cell vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: HER2|Gene name:HER3,2064|2065,Clinical trial,,,,therapeutic vaccine function,breast cancer,Homo sapiens,,intradermal route,"A cancer vaccine that uses anti-HER2/HER3 dendritic cells in combination with Pembrolizumab in patients with Asymptomatic Brain Metastasis From Triple Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC). The dendritic cells boost the immune system, and the Pembrolizumab enhances cancer immune responses, in combination they may shrink the cancer.",,,6263,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6263,,,NCT: https://clinicaltrials.gov/study/NCT04348747,Hayleigh Kahn|Jie Zheng,,,, +716,VO:0007335,autolgous DC vaccine pulsed with autologous tumor homogenate for metastatic rcc,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,kidney cancer,Homo sapiens,,intradermal route,A cancer vaccine that uses dendritic cells pulsed with autologous tumor homogenate in combination With High Dose-IL2 and immunomodulating radiotherapy for patients with Metastatic RCC.,,,6266,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6266,,,NCT: https://clinicaltrials.gov/study/NCT03226236,Hayleigh Kahn|Jie Zheng,,,, +717,VO:0007336,autologous CLL tumor cell vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,leukemia,Homo sapiens,,,A cancer vaccine that consists of of irradiated autologous tumor cells admixed with GM-CSF-secreting bystander cells. The CD8+ T cells can react against CLL-associated antigens. Autologous tumor cell vaccination is an effective strategy to advance long-term leukemia control following allogeneic hematopoietic stem cell transplantation (allo-HSCT). ,PubMed:23912587,,6379,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6379,,,,Hayleigh Kahn|Jie Zheng,,,, +718,VO:0007337,autologous cancer testis antigen specific dendritic cell vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: NY-ESO-1|Gene name: MAGE-A1|Gene name: MAGE-A3,1485|4100|4102,Clinical trial,,,,therapeutic vaccine function,sarcoma,Homo sapiens,,,"A cancer vaccine that uses autologous cancer testis (CT) antigen specific dendritic cell (DC) preceded by decitabine as a demethylating chemotherapy for patients with high-risk neuroblastoma, Ewings sarcoma, osteogenic sarcoma, rhabdomyosarcoma or synovial sarcoma. The mature DC is pulsed with overlapping peptides mixes derived from full-length NY-ESO-1, MAGE-A1, and MAGE-A3.",,,6268,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6268,,,NCT: https://clinicaltrials.gov/study/NCT01241162,Hayleigh Kahn|Jie Zheng,,,, +719,VO:0007338,autologous CMV-pp65-flLAMP mRNA loaded dendritic cell vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: LAMP,27074,Clinical trial,,,,therapeutic vaccine function,brain cancer,Homo sapiens,,intradermal route,"A cancer vaccine consisting of autologous dendritic cells (DCs) loaded with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) as a fusion protein with the full-length lysosome-associated membrane protein (flLAMP), with potential immunostimulatory and antineoplastic activities. The vaccine exposes the immune system to the CMV pp65 peptide, which may elicit a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells. The incorporation of flLAMP may route CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC class II antigen presentation, thereby promoting CD4-positive T-cell responses. Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) is a powerful adjuvant capable of stimulating macrophage function, inducing proliferation and maturation of DCs, and is able to enhance T-lymphocyte stimulatory function. The vaccine can be used in combination with monoclonal antibodies, such as basiliximab, that can block tumor growth in different ways, as well as temozolomide, and radiation therpay. The combination of treatments may kill more tumor cells.",,,6347,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6347,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C156067,NCT: https://clinicaltrials.gov/study/NCT00626483,Hayleigh Kahn|Jie Zheng,,,, +720,VO:0007339,autologous dendritic cell vaccine loaded with personalized peptide vaccine (pep-dc vaccine),,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,lung non-small cell carcinoma,Homo sapiens,,subcutaneous route,A cancer vaccine made of dendritic cells (DCs) loaded with personalized peptides (PEP) given in combination with low-dose cyclophosphamide for patients with advanced or recurrent metastatic NSCLC.,,,6267,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6267,,,NCT: https://clinicaltrials.gov/study/NCT05195619,Hayleigh Kahn|Jie Zheng,,,, +721,VO:0007340,autologous lymphoma immunoglobulin-derived scFv-chemokine DNA vaccine,,lymphoma vaccine,VO:0005427,,Gene name: MIP3a,6364,Clinical trial,DNA vaccine role,,,therapeutic vaccine function,lymphoma,Homo sapiens,,intradermal route,A cancer vaccine that encodes macrophage inflammatory protein 3 alpha (MIP3a)-fused lymphoma idiotype in single chain format for patients with atients with Asymptomatic Phase Lymphoplasmacytic Lymphoma.,,,6264,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6264,,,,Hayleigh Kahn|Jie Zheng,,,, +722,VO:0007341,autologous neuroblastoma cell vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: IL-2,3558,Clinical trial,,,,therapeutic vaccine function,neuroblastoma,Homo sapiens,,subcutaneous route,"A cancer vaccine that uses autologous neuroblastoma cells, irradiated and genetically modified by adenoviral vectors to secrete interleukin-2 (IL-2) for patients with high-risk neuroblastoma. The adenoviral vector are used to transduce the cells ex-vivo, patients are not treated with the viral vector.",,,6269,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6269,,,NCT: https://clinicaltrials.gov/study/NCT00048386,Hayleigh Kahn|Jie Zheng,,,, +723,VO:0007342,autologous oxidized ovarian tumor cell lysate vaccine,,ovarian cancer vaccine,VO:0005493,,,,Clinical trial,subunit vaccine role,,,therapeutic vaccine function,ovarian cancer,Homo sapiens,,intradermal route,"A cancer vaccine that is composed of oxidized ovarian tumor cell lysate, with potential immunostimulatory and antineoplastic activities. The autologous oxidized ovarian tumor cell lysate vaccine exposes the immune system to an undefined amount of tumor-associated antigens (TAAs), which may result in the induction of both anti-tumor cytotoxic T-lymphocytes (CTLs) and antibody-dependent responses against TAA-expressing cells, leading to tumor cell lysis. Compared to non-oxidized tumor cell lysate vaccines, oxidized tumor cell lysate vaccines induce necrotic cell death, increase the immunogenicity of the TAAs and may enhance the anti-tumor immune response. Cyclophosphamide/Fludarabine Lymphodepletion and an immunomodulatory combination of Interferon-alpha Bevacizumab and Aspirin followed by adoptive transfer of vaccine-primed ex vivo CD3/CD28-costimulated peripheral blood autologous T cells and vaccination with whole tumor vaccine administered intradermally in combination with Bevacizumab in patients with recurrent ovarian cancer fallopian tube or primary peritoneal cancer may help treat their tumors. Patients will receive 5-10 million cells intradermally. ",,,6330,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6330,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C122402,NCT: [https://clinicaltrials.gov/study/NCT01312376,Hayleigh Kahn|Jie Zheng,,,, +724,VO:0007343,autologous total tumor mrna and CMV-pp65-flLAMP mRNA loaded liposome vaccine,,brain cancer vaccine,VO:0005428,,Gene name: LAMP,27074,Clinical trial,RNA vaccine role,,,therapeutic vaccine function,brain cancer,Homo sapiens,,intravenous route,"A cancer vaccine consisting of total tumor RNA (TTRNA) derived and amplified from autologous tumor cells and mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) as a fusion protein with the full-length lysosome-associated membrane protein (flLAMP), formulated in DOTAP lipid particles, with potential immunostimulatory and antineoplastic activities. he autologous total tumor mRNA and CMV-pp65-flLAMP mRNA loaded liposome vaccine, the mRNA is taken up, translated and presented by antigen presenting cells (APCs). This leads to an induction of both cytotoxic T-lymphocyte and memory T-cell dependent immune responses that specifically target and destroy the patient's cancer cells that express these tumor antigens. The incorporation of flLAMP may route CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC class II antigen presentation, thereby promoting CD4-positive T-cell responses. Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine is used to treat patients with Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM). The vaccine is also used for for the treatment of early melanoma recurrence following adjuvant Anti-PD-1 antibody therapy.",,,6270,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6270,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C178432,NCT: https://clinicaltrials.gov/study/NCT04573140|NCT: https://clinicaltrials.gov/study/NCT05264974,Hayleigh Kahn|Jie Zheng,,,, +725,VO:0007344,autologous tumor cell lysate vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine made from the patient's cancer cells that may make the body build an immune response and kill their tumor cells. The autologous tumor cell vaccine will be given together with adjuvant interferon gamma or sargramostim (GM-CSF) in patients with advanced cancer (breast, lung, prostate, colorectal, sarcoma, renal, melanoma). The vaccine uses irradiated autologous tumor cells and tumor lysate.",,,6364,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6364,,,NCT: https://clinicaltrials.gov/study/NCT00002505,Hayleigh Kahn|Jie Zheng,,,, +726,VO:0007345,"autologous, dnp-modified ovarian cancer vaccine",,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,ovarian cancer,Homo sapiens,,intradermal route,"A cancer vaccine made from the patient's own tumor tissue may stimulate an immune response against the patient's tumor cells. O-Vax nay induce a DTH response to autologous, DNP-modified ovarian cancer cells. The vaccine includes DNP-modified autologous ovarian tumor cells followed by cyclophosphamide then weekly doses of DNP-modified autologous ovarian tumor cells mixed with Bacillus of Calmette and Guérin (BCG).",,,6334,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6334,,,NCT: https://clinicaltrials.gov/study/NCT00660101,Hayleigh Kahn|Jie Zheng,,,, +727,VO:0007346,B7.1/​IL-2 leukaemia cell vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: B7.1,941,Clinical trial,,,,therapeutic vaccine function,leukemia,Homo sapiens,,,A cancer vaccine containing human acute myeloid leukemic (AML) blasts that have been genetically engineered to express a B7.1/IIL-2 fusion protein. It uses B7.1 (CD80)/IL-2 immune gene therapy for high risk MDS RAEB-2 and acute myeloid leukaemia (AML) patients who are unsuitable for an allogeneic haematological stem cell transplant.,,,6265,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6265,,,NCT: https://clinicaltrials.gov/study/NCT02493829,Hayleigh Kahn|Jie Zheng,,,, +728,VO:0007347,BC-819 vaccine,,pancreatic cancer vaccine,VO:0005430,,,,Clinical trial,DNA vaccine role,,,therapeutic vaccine function,pancreatic cancer,Homo sapiens,,intratumoral route,"A cancer vaccine made with BC-819 (also known as DTA-H19), which is a double-stranded DNA plasmid, 4,560 base pairs (bp) in length, carrying the gene for the Diphtheria toxin A (DT-A) chain under the regulation of the H19 promoter. The DT-A chain expression is triggered by the presence of H19 transcription factors that are only up-regulated in tumor cells. The selective initiation of toxin expression results in selective tumor cell destruction via inhibition of protein synthesis selectively in the tumor cell, enabling highly targeted cancer treatment. It is used in combination with intravenously administered gemcitabine for patients with Locally Advanced Pancreatic Adenocarcinoma. The activation of the H19 gene promoter-containing plasmids and DTA expression are limited to tumor cells, as high levels of H19 expression are only found in tumor cells. DTA disrupts protein synthesis. Tumor-cell selective expression of this toxin leads to the selective destruction of the tumor while sparing healthy, normal cells.",,,6273,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6273,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C107685,NCT: https://clinicaltrials.gov/study/NCT01413087,Hayleigh Kahn|Jie Zheng,,,, +729,VO:0007348,Bcl-Xl_42-CAF09b vaccine,,prostate cancer vaccine,VO:0005425,,,,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,prostate cancer,Homo sapiens,,intramuscular route,"A cancer vaccine made up of Bcl-xl_42 and the adjuvant CAF09b for patients with hormone-sensitive Prostate Cancer (PC) and lymph node metastases. B-cell lymphoma extra large protein (Bcl-xl) protein plays a vital role in the cancer cell's ability to avoid programmed cell death (apoptosis) and is upregulated in a variety of cancerous diseases, Bcl-xl_42 is a peptide fragment of the full protein and can lead to the death of cancer cells. CAF09b improves the activation of the immune system. ",,,6272,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6272,,,NCT: https://clinicaltrials.gov/study/NCT03412786,Hayleigh Kahn|Jie Zheng,,,, +730,VO:0007355,Bcr-Abl (b2a2)-derived peptide vaccine,,leukemia cancer vaccine,VO:0005487,,Gene name: bcr-abl,25,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,leukemia,Homo sapiens,,subcutaneous route,"A cancer vaccine consisting of the bcr-abl b2a2 fusion oncoprotein, frequently expressed in chronic myelogenous leukemia (CML), with potential antineoplastic activity. Vaccination with the bcr-abl (b2a2)-derived peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl b2a2 fusion protein. (NCIT_C61309) The vaccine is made from made from the proteins that cause leukemia cells in CML to behave abnormally. Imatinib mesylate is the standard therapy for CML and blocks the function of this protein. In combination, these may decrease or eliminate all evidence of disease in patients who have CML that is in remission after treatment with imatinib mesylate, but who still have small amounts of detectable disease.",,,6354,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6353,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C61309,NCT: https://clinicaltrials.gov/study/NCT00267085,Hayleigh Kahn|Jie Zheng,,,, +731,VO:0007364,Bcr-Abl (b3a2)-derived peptide vaccine,,leukemia cancer vaccine,VO:0005487,,Gene name: bcr-abl,25,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,leukemia,Homo sapiens,,subcutaneous route,"A cancer vaccine consisting of the bcr-abl b2a2 fusion oncoprotein, frequently expressed in chronic myelogenous leukemia (CML), with potential antineoplastic activity. Vaccination with the bcr-abl (b2a2)-derived peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl b2a2 fusion protein. The vaccine is made from made from the proteins that cause leukemia cells in CML to behave abnormally. Imatinib mesylate is the standard therapy for CML and blocks the function of this protein. In combination, these may decrease or eliminate all evidence of disease in patients who have CML that is in remission after treatment with imatinib mesylate, but who still have small amounts of detectable disease. ",,,6274,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6274,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C61310,NCT: https://clinicaltrials.gov/study/NCT00466726,Hayleigh Kahn|Jie Zheng,,,, +732,VO:0007400,Bcr-Abl peptide vaccine,,leukemia cancer vaccine,VO:0005487,,Gene name: bcr-abl,25,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,leukemia,Homo sapiens,,subcutaneous route,"A cancer vaccine consisting of the bcr-abl b3a2 fusion oncoprotein, frequently expressed in chronic myelogenous leukemia (CML), with potential antineoplastic activity. Vaccination with the bcr-abl (b3a2)-derived peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl b3a2 fusion protein. The bcr-abl p210-b3a2 breakpoint-derived pentapeptide vaccine is used in combination with GM-CSF. The peptides may help the body build an effective immune response to kill cancer cells, and the GM-CSF may increase the number of immune cells found in bone marrow or peripheral blood. This combination is used to treat patients with Philadelphia chromosome-positive chronic myelogenous leukemia. It can also be used in combination with imatinib mesylate to decrease or eliminate all evidence of disease in patients who have CML that is in remission after treatment with imatinib mesylate, but who still have small amounts of detectable disease",,,6372,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6372,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C2205,NCT: https://clinicaltrials.gov/study/NCT00004052|NCT: https://clinicaltrials.gov/study/NCT00455221,Hayleigh Kahn|Jie Zheng,,,, +733,VO:0007462,bivalent neuroblastoma vaccine with adjuvant OPT-821,,cancer vaccine,VO:0000177,,,,Clinical trial,conjugate vaccine role,,,therapeutic vaccine function,neuroblastoma,Homo sapiens,,subcutaneous route,"A cancer vaccine that is a bivalent vaccine with the antigens GD2L and GD3L for patients with High-Risk Neuroblastoma. The antigens are linked to KLH and mixed with OPT-821. It is given in combination with oral β-glucan, which can help white blood cells kill cancer.",,,6262,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6262,,,NCT: https://clinicaltrials.gov/study/NCT00911560,Hayleigh Kahn|Jie Zheng,,,, +734,VO:0007480,cancer stem cell-loaded dc vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,pancreatic cancer,Homo sapiens,,subcutaneous route,A cancer vaccine made of peripheral blood and tumor specimen harvested from patients with metastatic adenocarcinoma of the pancreas to generate cancer stem cell (CSC)-loaded denritic cell (DC) vaccines. CSC-primed antibodies and T cells are capable of selective targeting CSCs and conferring antitumor immunity.,,,6276,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6276,,,NCT: https://clinicaltrials.gov/study/NCT02074046,Hayleigh Kahn|Jie Zheng,,,, +735,VO:0007500,CAR G36-PDL1 vaccine,,renal cancer vaccine,VO:0005494,,Gene name: HLA,3105,Research,,,,therapeutic vaccine function,kidney cancer,Homo sapiens,,,"A cancer vaccine made with chimeric antigen receptor (CAR) T cells that can be used to treat solid tumors. These CAR-T cells are engineered to target carbonic anhydrase IX (CAIX) to secrete anti-PD-L1 monoclonal antibody (mAb), termed immune-restoring (IR) CAR G36-PDL1. The T cells can be used to treat clear cell renal cell carcinoma (ccRCC) with reconstituted human leukocyte antigen (HLA) partially matched human leukocytes derived from fetal CD34+ hematopoietic stem cells (HSCs) and bearing human ccRCC skrc-59 cells under the kidney capsule. The cells can restore active antitumor immunity by promoting tumor-killing cytotoxicity, reducing immunosuppressive cell components such as M2 macrophages and exhausted CD8+ T cells, and enhancing T follicular helper (Tfh)-B cell crosstalk.",PubMed:38327771,,6380,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6380,,,,Hayleigh Kahn|Jie Zheng,,,, +736,VO:0007510,CDX-1307 vaccine,,bladder cancer vaccine,VO:0005485,,Gene name: hCG-β,1082,Clinical trial,subunit vaccine role,,,therapeutic vaccine function,urinary bladder cancer,Homo sapiens,,,"A cancer vaccine for bladder cancer designed to generate an immune response against a protein called human chorionic gonadotropin-beta (hCG-β). hCG-β is made by several types of cancers, including bladder cancer, and has been shown to be associated with shorter times to development of metastases and reduced survival in bladder cancer. Administering the CDX-1307 vaccine will cause the body's immune system to attack bladder cancer cells in order to kill them or otherwise keep them from spreading or coming back. The human monoclonal antibody (B11) directed against the mannose receptor and linked to the beta-subunit of human chorionic gonadotropin (hCG beta) with potential immunostimulating and antineoplastic activities. The monoclonal antibody moiety of human monoclonal antibody B11-hCG beta fusion protein CDX-1307 binds to mannose receptors on antigen presenting cells (APCs), including human dendritic cells (DCs) and macrophages. APCs present the processed hCG beta antigen on their cell surfaces, which may initiate an antibody-dependent cell-mediated cytotoxicity (ADCC) response against hCG beta-expressing tumor cells.",,,6277,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6277,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C77858,NCT: https://clinicaltrials.gov/study/NCT01094496,Hayleigh Kahn|Jie Zheng,,,, +737,VO:0007511,chimeric exosomal tumor vaccine,,bladder cancer vaccine,VO:0005485,,,,Clinical trial,subunit vaccine role,,,therapeutic vaccine function,urinary bladder cancer,Homo sapiens,,,"A cancer vaccine prepared as tumor cells are isolated from the lesion site of patients with recurrent or metastatic bladder cancer, and dendritic cells or macrophages are isolated from peripheral blood. The vaccine activates an immune response and the microenvironment of bladder cancer lesions, and improves the anti-recurrence treatment effect of bladder cancer. ",,,6278,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6278,,,NCT: https://clinicaltrials.gov/study/NCT05559177,Hayleigh Kahn|Jie Zheng,,,, +738,VO:0007512,CLL idiotypic DNA vaccine,,leukemia cancer vaccine,VO:0005487,,,,Clinical trial,DNA vaccine role,,,therapeutic vaccine function,leukemia,Homo sapiens,,,A cancer vaccine that treats patients with Binet Stage A Chronic Lymphocytic Leukemia (CLL) by using a fragment of Deoxyribonucleic acid (DNA) containing the sequence of their own immunoglobulin gene. The vaccine is designed to generate an immune response and shrink or slow the CLL.,,,6279,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6279,,,NCT: https://clinicaltrials.gov/study/NCT00038415,Hayleigh Kahn|Jie Zheng,,,, +739,VO:0007513,cyclin B1/WT-1/CEF-loaded DC vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: cyclin B1|Gene name: WT-1|Gene name: CEF,931|7490|2064,Clinical trial,,,,therapeutic vaccine function,breast cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine for patients with Locally Advanced, Triple-Negative Breast Cancer or ER-Positive, Her2-Negative Breast Cancer to receive ex vivo-generated tumor antigen-loaded dendritic cells (DCs), which can prime lymphocytes and regulate and maintain immune responses. The vaccine may boost T cell immunity targeted against breast cancer, enhance chemotherapy effectiveness and decrease tumor metastagenicity, and decrease the recurrence rates of LA TNBC and ER+/HER2- BC. ",,,6288,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6288,,,NCT: https://clinicaltrials.gov/study/NCT02018458,Hayleigh Kahn|Jie Zheng,,,, +740,VO:0007514,DC/AML fusion vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,leukemia,Homo sapiens,,,"A cancer vaccine consisting of autologous dendritic cells (DCs) fused with autologous acute myeloid leukemia (AML) cells, with potential immunostimulatory and antineoplastic activities. It is generated in vitro by mixing DCs and irradiated AML cells harvested from individual patients, in the presence of polyethylene glycol (PEG), to produce hybrid DC-leukemia fusion cells. The vaccine may elicit a cytotoxic T-lymphocyte (CTL)-mediated antitumor immune response against a broad array of AML-associated antigens, which may lead to AML cell lysis. When dendritic cells and tumor cells are brought together, the dendritic cells can stimulate immune responses against the tumor and, in some cases, cause the tumor to shrink. GM-CSF is a drug that stimulates white blood cells and is given with the DC AML Vaccine in an effort to enhance the effect of the vaccine.",,,6374,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6374,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148214,NCT: https://clinicaltrials.gov/study/NCT01096602|NCT: https://clinicaltrials.gov/study/NCT03059485,Hayleigh Kahn|Jie Zheng,,,, +741,VO:0007515,dendritic cell survivin vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: survivin|Gene name: CD11|Gene name: HLA-DR,332|3684|3123,Clinical trial,,,,therapeutic vaccine function,multiple myeloma,Homo sapiens,,intramuscular route,"A cancer vaccine made using the participant's own blood cells. The vaccine will contain a virus called an adenovirus, similar the virus that causes the common cold. The dendritic cells contain survivin+, CD11c+, Human Leukocyte Antigen - antigen D Related (HLA-DR)+ by flow-cytometry. The vaccine is given in combination with G-CSF, T cells, and the CD34 progenitor cells.",,,6351,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6351,,,NCT: https://clinicaltrials.gov/study/NCT02851056,Hayleigh Kahn|Jie Zheng,,,, +742,VO:0007516,dendritic cell tumor peptide vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,brain cancer,Homo sapiens,,intradermal route,"A cancer vaccine composed of dendritic cells pulsed with peptide epitopes that stimulate cytotoxic T lymphocyte anti-tumor activity. This vaccine is used to treat diffuse hemispheric glioma with a H3 G34 mutation that has come back (recurrent) and/or is growing, spreading, or getting worse (progressive). It is made with the patient's own white blood cells and peptide-pulsed dendritic cells, which may help the body build an effective immune response to kill tumor cells. It is combined with immunotherapy monoclonal antibodies, such as nivolumab and ipilimumab, which also may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.",,,6282,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6282,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1987,NCT: https://clinicaltrials.gov/study/NCT05457959,Hayleigh Kahn|Jie Zheng,,,, +743,VO:0007517,dendritic cell/​myeloma fusion vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,multiple myeloma,Homo sapiens,,subcutaneous route,A cancer vaccine onsisting of autologous dendritic cells (DCs) fused with patient-derived plasma cell (multiple) myeloma cells with potential immunostimulatory and antineoplastic activities. Autologous DC/multiple myeloma fusions stimulate both helper and cytotoxic T-lymphocyte (CTL) responses through the presentation of internalized and newly synthesized tumor associated antigens (TAAs). This may promote cellular and humoral antitumor immune responses in patients with plasma cell myeloma. This vaccine uses Dendritic cell/myeloma fusions with granulocyte macrophage colony-stimulating factor (GM-CSF) adjuvant plus lenalidomide maintenance therapy. The dendritic cell myeloma vaccine may improve response in patients with multiple myeloma after autologous Hematopoietic Cell Transplant (HCT).,,,6323,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6323,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C158480,NCT: https://clinicaltrials.gov/study/NCT02728102,Hayleigh Kahn|Jie Zheng,,,, +744,VO:0007519,"dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes",,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,brain cancer,Homo sapiens,,,"A cancer vaccine made of tumor cells and tumor stem cells that are isolated from a sample from a patient with glioblastoma multiforme. Dendritic cells are isolated from peripheral blood mononuclear cells and cultured. The tumor sample provides tumor specific antigens to prepare the dendritic vaccine. Cytotoxic lymphocytes are obtained from peripheral blood after dendritic vaccine administrations. Hematopoietic stem cells are harvested from closely related donor after granulocyte-colony-stimulating factor (G-CSF) administration. Allogeneic haploidentical hematopoietic stem cells are administered intrathecally, dendritic cells are administered subcutaneously, and cytotoxic lymphocytes are adminstered intrathecally. The combination of these treatments may control tumor cell quantity and target regulation of effector functions of tumor stem cells.",,,6285,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6285,,,NCT: https://clinicaltrials.gov/study/NCT01759810,Hayleigh Kahn|Jie Zheng,,,, +745,VO:0007520,"dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes",,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,brain cancer,Homo sapiens,,intramuscular route,"A cancer vaccine from tumor cells and tumor stem cells that are isolated from a sample from a patient with glioblastoma multiforme. Dendritic cells are isolated from peripheral blood mononuclear cells and cultured. The tumor sample provides tumor specific antigens to prepare the dendritic vaccine. Cytotoxic lymphocytes are obtained from peripheral blood after dendritic vaccine administrations. Hematopoietic stem cells are harvested from closely related donor after granulocyte-colony-stimulating factor (G-CSF) administration. Autologous haploidentical hematopoietic stem cells are administered intrathecally, dendritic cells are administered subcutaneously, and cytotoxic lymphocytes are adminstered intrathecally. The combination of these treatments may control tumor cell quantity and target regulation of effector functions of tumor stem cells.",,,6286,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6286,,,NCT: https://clinicaltrials.gov/study/NCT01759810,Hayleigh Kahn|Jie Zheng,,,, +746,VO:0007521,DIPG and GMB Immunomodulatory DC vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,brain cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine based on ex vivo genetic modifications in combination with known tumor-specific antigens may substantially enhance the activation potential of tumor-specific T cells with improved benefit to patients. This DC vaccine is based on autologous DCs pulsed with genetically modified tumor cells or related antigens such as neoantigens to induce a strong anti-tumor immunity. The patient will receive intravenous cyclophosphamide (200 mg/m2) or oral (cytoxan) before the vaccine, followed by DC vaccine and intravenous bevacizumab (15 mg/kg).",,,6301,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6301,,,NCT: https://clinicaltrials.gov/study/NCT03914768,Hayleigh Kahn|Jie Zheng,,,, +747,VO:0007522,electrofusion DC vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,kidney cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine made with PEG fusions generated from allogeneic dendritic cells and autologous tumor-derived cells with GM-CSF and Il-4. The vaccine is irradiated, frozen, and thawed before being administered to patients with AJCC Stage IV Renal Cell Carcinoma. The vaccine could have and effect on the immune system and cancer.",,,6287,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6287,,,NCT: https://clinicaltrials.gov/study/NCT00625755,Hayleigh Kahn|Jie Zheng,,,, +748,VO:0007526,ESR1 peptide vaccine,,breast cancer vaccine,VO:0005484,,Gene name: ESR1,2099,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,breast cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine comprised of estrogen receptor alpha (ERa; estrogen receptor 1; ESR1) mutant peptides, combined with the immunoadjuvants granulocyte-macrophage colony-stimulating factor (GM-CSF) and montanide ISA, with potential immunomodulating and antineoplastic activities. ESR1 mutant peptides in the ESR1 peptides/GM-CSF/montanide ISA vaccine may activate the immune system to induce an immune response against tumor cells expressing these ESR1 mutations. Cancer peptides used in this vaccine are derived from the estrogen receptor and are combined with the adjuvant Montanide ISA and GM-CSF to enhance their immune response. The vaccine may improve outcomes of patients with endocrine resistant breast cancer. ",,,6289,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6289,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C175590,NCT: https://clinicaltrials.gov/study/NCT04270149,Hayleigh Kahn|Jie Zheng,,,, +749,VO:0007530,"follicular lymphoma, patient-specific, soluble protein idiotype vaccine",,lymphoma vaccine,VO:0005427,,,,Clinical trial,conjugate vaccine role,,,therapeutic vaccine function,lymphoma,Homo sapiens,,,"A cancer vaccine directed against the soluble protein idiotype of an individual follicular lymphoma with potential antineoplastic activity. The vaccine may induce an idiotype-specific cytotoxic T-lymphocyte (CTL) response against follicular lymphoma cells expressing the idiotype, resulting in tumor cell lysis. Idiotypic vaccinations have the capacity of inducing an idiotype- and tumor-specific immune response, inducing specific immune responses able to kill in vivo follicular lymphoma cells, and prolonging survival of responding patients. This vaccine may contribute to preventing relapse indefinitely in responding patients.",,,6290,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6290,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C71036,NCT: https://clinicaltrials.gov/study/NCT00530140,Hayleigh Kahn|Jie Zheng,,,, +750,VO:0007543,FRAME-001 personalized vaccine,,non-small cell lung cancer vaccine,VO:0003140,,,,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,lung non-small cell carcinoma,Homo sapiens,,subcutaneous route,"A cancer vaccine made from tumor-specific neopeptides resulting from frameshift mutations in tumor cells, so-called Frames, present potentially potent targets for the immune system and can be utilized in therapeutic anti-cancer vaccination with the intention to synergize in their effect with immune checkpoint inhibitors. The personalized vaccine FRAME-001 based on a patient's Framome and selection of Frame peptides in advanced NSCLC cancer patients after standard first line treatment consisting of immune checkpoint inhibitor pembrolizumab as monotherapy or combined with chemotherapy (carboplatin/cisplatin and pemetrexed/paclitaxel) could help treat patients with non-small cell lung cancer.",,,6291,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6291,,,NCT: https://clinicaltrials.gov/study/NCT04998474,Hayleigh Kahn|Jie Zheng,,,, +751,VO:0007661,GD2-CAR vaccine,,cancer vaccine,VO:0000177,,,,Clinical trial,,,,therapeutic vaccine function,cancer,Homo sapiens,,,"A cancer vaccine made with T cells genetically engineered to express anti-GD2 Chimeric Antigen Receptor to treat patients with children and young adults with GD2+ solid tumors, including neuroblastoma. The T cells may have an antitumor effect. They can be used in combination with AP1903 and Cyclophosphamide. (NCT02107963) There are increased CXCR3- classical monocytes in patients as CAR-T numbers waned.",pubmed:38134936,,6381,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6381,,,NCT: https://clinicaltrials.gov/study/NCT02107963,Hayleigh Kahn|Jie Zheng,,,, +752,VO:0007662,"GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid KLH conjugate vaccine",,lung cancer vaccine,VO:0005486,,Gene name: GD 2|Gene name: GD3|Gene name: Globo H|Gene name: fucosyl GM1,2583|6489|2524|8705,Clinical trial,conjugate vaccine role,,,therapeutic vaccine function,lung cancer,Homo sapiens,,,"A cancer vaccine used to treat patients with small cell lung cancer by using several components (small cell lung cancer targets) that have been tested individually in patients with small cell lung cancer or other cancers (GD2, GD3, Globo H, Fucosyl GM1 and N-propionylated polysialic acid) so that the body will make antibodies to the vaccine which will also react against the cancer. Two other substances (KLH and OPT-821) are added which boost the immune system. Vaccination with the pentavalent KLH conjugate vaccine may induce production of IgG and IgM antibodies as well as an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumors expressing any of these antigens.",,,6275,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6275,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C97034,NCT: https://clinicaltrials.gov/study/NCT01349647,Hayleigh Kahn|Jie Zheng,,,, +753,VO:0007663,genetically engineered allogeneic prostate carinoma cells secreting interleukin-2 and interferon gamma,,whole cell cancer vaccine,VO:0007658,,Gene name: IL2|Gene name: Interferon gamma,3558|3458,Clinical trial,,,,therapeutic vaccine function,prostate cancer,Homo sapiens,,,A cancer vaccine made with HLA class I-matched allogeneic human prostate carcinoma cells that are genetically engineered to secrete interleukin-2 and interferon gamma for patients with prostate carcinoma. Interleukin-2 may stimulate a person's white blood cells including natural killer cells to kill prostate cancer cells. Interferon gamma may interfere with the growth of the cancer cells. Combining interferon gamma with interleukin-2 may be a more effective treatment for prostate cancer.,,,6292,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6292,,,NCT: https://clinicaltrials.gov/study/NCT00002637,Hayleigh Kahn|Jie Zheng,,,, +754,VO:0007664,GM-K562 cell vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: GM-CSF,1437,Clinical trial,,,,therapeutic vaccine function,leukemia,Homo sapiens,,subcutaneous route,"A cancer vaccine comprised of K562 cells transfected with the granulocyte macrophage-colony stimulating factor (GM-CSF) gene with potential immunopotentiating properties. This vaccine may stimulate the host immune system to produce an antitumoral T-lymphocyte response, thereby inhibiting tumor growth. A cultured cell line is genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from a patient. Vaccines made from gene-modified cancer cells may help the body build an effective immune response to kill cancer cells. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving vaccine therapy together with imatinib mesylate may be an effective treatment for chronic myelogenous leukemia. The vaccine can also be combined with stem cell transplantation. The vaccine may induce an immune response to common myeloid antigens (e.g., Wilms' tumor-1 [WT-1], survivin, or proteinase-3) in patients with Myelodysplastic Syndrome. ",,,6293,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6293,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C52190,NCT: https://clinicaltrials.gov/study/NCT00301093|NCT: https://clinicaltrials.gov/study/NCT00361296|NCT: https://clinicaltrials.gov/study/NCT00442130|NCT: https://clinicaltrials.gov/study/NCT00809250,Hayleigh Kahn|Jie Zheng,,,, +755,VO:0007665,GM.CD40L cell vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: CD40LG,959,Clinical trial,,,,therapeutic vaccine function,cancer,Homo sapiens,,intradermal route,"A cancer vaccine composed of irradiated tumor cells transduced with granulocyte-macrophage colony-stimulating factor (GM-CSF) and CD40-ligand (CD40L) genes. The vaccine may stimulate an anti-tumoral dendritic cell-mediated host immune response. Universal GM-CSF-producing and CD40L-expressing bystander cell line is used to form an autologous tumor cell-based vaccine for patients with mantle cell lymphoma in order to make the body build an effective immune response to kill cancer cells. It can be used in combination with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Dexamethasone, and IL-2. The vaccine can be done with bystander and autologous tumor cells for patients with malignant melanoma. It can also be combined with lenalidomide for patients with myelodysplastic syndrome (MDS).",,,6271,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6271,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C48391,NCT: https://clinicaltrials.gov/study/NCT00101101|NCT: https://clinicaltrials.gov/study/NCT00101166| NCT: https://clinicaltrials.gov/study/NCT00840931,Hayleigh Kahn|Jie Zheng,,,, +756,VO:0007666,gp100 mature dendritic cell vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: gp100,6490,Clinical trial,,,,therapeutic vaccine function,cancer,Homo sapiens,,intravenous route,A cancer vaccine using dendritic cells (a kind of white blood cell) as a vaccine could stimulate your own immune system to react to your melanoma cells. Autologous dendritic cells are pulsed with 2 gp100 melanoma peptides (G209-2M and G280-9V) plus up to an additional 10 unique melanoma tumor-specific peptides. Patients also receive cyclophosphamide 300mg/m2 IV in order to deplete regulatory T cells.,,,6308,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6308,,,NCT: https://clinicaltrials.gov/study/NCT00683670,Hayleigh Kahn|Jie Zheng,,,, +757,VO:0007667,GVAX leukemia vaccine,,leukemia cancer vaccine,VO:0005487,,Gene name: GM-CSF,1437,Clinical trial,recombinant vector vaccine role,,,therapeutic vaccine function,leukemia,Homo sapiens,,subcutaneous route|intradermal route,"A cancer vaccine that uses irradiated, adenovirus transduced autologous myeloblasts to secrete granulocyte-macrophage colony-stimulating factor (GVAX) early after allogeneic hematopoietic stem cell transplantation (HSCT) to induce potent immune responses. The vaccine may prevent advanced myelodysplastic syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), or acute myeloid leukemia (AML) from relapsing after stem cell transplant. The patients own cancer cells are engineered to produce a protein called GM-CSF, which can be effective in stimulating a powerful immune response specific to that cancer. ",PubMed:34807983,,6385,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6385,,,NCT: https://clinicaltrials.gov/study/NCT01773395,Hayleigh Kahn|Jie Zheng,,,, +758,VO:0007668,H3.3K27M-specific peptide vaccine,,brain cancer vaccine,VO:0005428,,,,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,brain cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine composed of a peptide derived from histone H3.3 containing the amino acid substitution mutation lysine (Lys) 27-to-methionine (H3.3K27M), with potential immunoactivating and antineoplastic activities. Following the administration of the vaccine, the immune system may exert a cytotoxic T-lymphocyte (CTL)-mediated immune response against H3.3K27M-expressing tumor cells. A lysine 27-to-methionine (K27M) somatic mutation at histone H3 variant (H3.3) is a feature mutation in diffuse intrinsic pontine gliomas (DIPGs). This vaccine contains an H3.3-K27M targeted neoantigen peptide that can be taken up by antigen-presenting cells (APCs). APCs can present the peptide with the major histocompatibility complex (MHC) molecules on cell surface, thereby activating neoantigen-specific T cells and triggering corresponding cytotoxic T cell immune responses to eliminate H3.3-K27M-expressing DIPG cells.",,,6295,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6295,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C132684,NCT: https://clinicaltrials.gov/study/NCT04749641,Hayleigh Kahn|Jie Zheng,,,, +759,VO:0007669,"HER-2-neu, CEA peptides, GM-CSF, montanide ISA-51 vaccine",,colorectal cancer vaccine,VO:0005426,,Gene name: carcinoembryonic antigen|Gene name: HER-2-neu,1048|2064,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,colorectal cancer,Homo sapiens,,,"A cancer vaccine comprised of HER-2-neu and carcinoembryonic antigen synthetic (CEA) peptides, combined with the adjuvants granulocyte-macrophage colony stimulating factor (GM-CSF), and Montanide ISA-51 with potential antineoplastic activity. The vaccine may stimulate a cytotoxic T-cell response against HER-2-neu- and CEA-expressing tumor cells. Vaccines made from peptides may make the body build an immune response to kill tumor cells. This vaccine is compromised of HER-2-neu and carcinoembryonic antigen synthetic peptides, sargramostim (GM-CSF), and Montanide ISA-51, and aims to cause an immune response in patients with stage IIB, III, or IV colorectal cancer.",,,6294,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6294,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C48392,NCT: https://clinicaltrials.gov/study/NCT00091286,Hayleigh Kahn|Jie Zheng,,,, +760,VO:0007670,HER2 ICD peptide vaccine,,breast cancer vaccine,VO:0005484,,Gene name: HER-2/neu,2064,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,breast cancer,Homo sapiens,,intradermal route,A cancer vaccine made from peptides that may help the body build an effective immune response to kill tumor cells. Patients with HER2 positive locally advanced breast cancer can be vaccinated with a HER2 Intracellular Domain (ICD) peptide-based vaccine administered concurrently with trastuzumab. The vaccine may lead to an immune response (HER2 specific T cell immunity and/or the development of intramolecular epitope spreading).,,,6352,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6352,,,NCT: https://clinicaltrials.gov/study/NCT00343109,Hayleigh Kahn|Jie Zheng,,,, +761,VO:0007671,HLA neoantigen vaccine,,cancer vaccine,VO:0000177,,Gene name: HLA,3123,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,cancer,Homo sapiens,,,"A cancer vaccine for vaccination with neoantigens that can both expand pre-existing neoantigen-specific T-cell populations and induce a broader repertoire of new T-cell specificities in cancer patients, tipping the intra-tumoural balance in favour of enhanced tumour control. The vaccine targets up to 20 predicted personal tumour neoantigens. The vaccine induced CD4+ and CD8+ T cells responses. These T cells discriminated mutated from wild-type antigens, and in some cases directly recognized autologous tumour.",PubMed:28678778,,6377,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6377,,,,Hayleigh Kahn|Jie Zheng,,,, +762,VO:0007672,"HLA-A1, HLA-A2, and CD40-ligand pulsed dendritic cell vaccine",,whole cell cancer vaccine,VO:0007658,,Gene name: HLA-A|Gene name: CD40L,3105|959,Clinical trial,,,,therapeutic vaccine function,cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine made from a person's white blood cells mixed with tumor proteins (HLA-A1- and HLA-A2.1-restricted peptides derived from melanoma-associated tumor antigens) and CD40-ligand, and may make the body build an immune response to kill tumor cells. This is combined with denileukin diftitox, which ",,,6283,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6283,,,NCT: https://clinicaltrials.gov/study/NCT00056134,Hayleigh Kahn|Jie Zheng,,,, +763,VO:0007673,hodgkin's antigens-GM-CSF-expressing cell vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,lymphoma,Homo sapiens,,,"A cancer vaccine consisting of Hodgkin lymphoma cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene with potential antineoplastic activity. Hodgkin antigens-GM-CSF-expressing cell vaccine may stimulate a cytotoxic T-lymphocyte (CTL) immune response against Hodgkin lymphoma-associated antigens, which may result in the lysis of tumor cells expressing these antigens. Also, transfected Hodgkin lymphoma cells secrete GM-CSF, which may potentiate the CTL response against Hodgkin lymphoma-associated antigens. Vaccines made from a tumor antigen may help the body build an effective immune response to kill tumor cells. This vaccine contains cells expressing Hodgkin's antigens and GM-CSF, and could cause an immunological response in Hodgkin's lymphoma patients.",,,6296,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6296,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C61592,NCT: https://clinicaltrials.gov/study/NCT00478062,Hayleigh Kahn|Jie Zheng,,,, +764,VO:0007674,HPV E6/E7-encoding semliki forest virus vaccine Vvax001,,cancer vaccine,VO:0000177,,Gene name: E6|Gene name: E7,1489078|1489079,Clinical trial,recombinant vector vaccine role,,,therapeutic vaccine function,cancer,Homo sapiens,,intramuscular route,"A cancer vaccine consisting of a recombinant, attenuated, replication-incompetent form of the Semliki Forest Virus (SFV) vector encoding the viral oncoproteins E6 and E7 derived from the human papillomavirus (HPV), with potential immunomodulating and antineoplastic activities. The vaccine induces expression of the E6/E7 proteins and stimulates both the innate and the adaptive immune system, resulting in a potent cytotoxic T-lymphocyte (CTL) response against and lysis of tumor cells expressing HPV E6 and E7. The vaccine may help to treat patients with a history of (pre) malignant cervical lesions.",,,6369,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6369,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148539,NCT: https://clinicaltrials.gov/study/NCT03141463,Hayleigh Kahn|Jie Zheng,,,, +765,VO:0007675,hyperacute - breast cancer vaccine,,breast cancer vaccine,VO:0005484,,Gene name: Ggta1,14594,Clinical trial,recombinant vector vaccine role,,,therapeutic vaccine function,breast cancer,Homo sapiens,,intradermal route,"A cancer vaccine composed of irradiated allogeneic breast cancer cell lines (HAB-1 and HAB-2) that have been transduced with a recombinant Moloney murine leukemia virus (MoMLV)-based retroviral vector expressing the murine alpha (1,3) GT gene. The immune response to the foreign substance could stimulate the immune system to attack the patient's own cancer cells that have similar proteins without this sugar pattern, causing the tumor to remain stable or shrink.",,,6297,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6297,,,NCT: https://clinicaltrials.gov/study/NCT00090480,Hayleigh Kahn|Jie Zheng,,,, +766,VO:0007676,hyperacute-melanoma vaccine,,melanoma vaccine,VO:0000422,,Gene name: Ggta1,14594,Clinical trial,recombinant vector vaccine role,,,therapeutic vaccine function,melanoma,Homo sapiens,,intradermal route,"A cancer vaccine composed of irradiated allogeneic melanoma cell lines (HAM-1, HAM-2 and HAM-3). These cell lines have been transduced with a recombinant Moloney murine leukemia virus (MoMLV)-based retroviral vector expressing the murine alpha(1,3)GT gene, a mouse gene that causes the production of a foreign pattern of protein-sugars on the cell surface. The immune response to the foreign substance could stimulate the immune system to attack the patient's own cancer cells that have similar proteins without this sugar pattern, causing the tumor to remain stable or shrink.",,,6298,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6298,,,NCT: https://clinicaltrials.gov/study/NCT00300612,Hayleigh Kahn|Jie Zheng,,,, +767,VO:0007677,hyperacute-prostate cancer vaccine,,prostate cancer vaccine,VO:0005425,,Gene name: Ggta1,14594,Clinical trial,recombinant vector vaccine role,,,therapeutic vaccine function,prostate cancer,Homo sapiens,,intradermal route,"A cancer vaccine composed of irradiated allogeneic prostate cancer cell lines (HAP-1 and HAP-2) that have been transduced with a recombinant Moloney murine leukemia virus (MoMLV)-based retroviral vector expressing the murine alpha (1,3) GT gene, a mouse gene that causes the production of a foreign pattern of protein-sugars on the cell surface. It is hoped that the immune response to the foreign substance will stimulate the immune system to attack the patient's own cancer cells that have similar proteins without this sugar pattern, causing the tumor to remain stable or shrink.. The expression of the murine alpha (1,3) galactosyltransferase [alpha (1,3) GT] gene results in the cell surface expression of alpha (1,3) galactosyl-epitopes (alpha-gal) on membrane glycoproteins and glycolipids.",,,6299,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6299,,,NCT: https://clinicaltrials.gov/study/NCT00105053,Hayleigh Kahn|Jie Zheng,,,, +768,VO:0007678,IDO peptide vaccine,,melanoma vaccine,VO:0000422,,Gene name: IDO,3620,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,melanoma,Homo sapiens,,,"A cancer vaccine derived from the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) with potential immunomodulating and antineoplastic activities. It may activate the immune system to induce an immune response against IDO-expressing tumor cells, which may restore the proliferation and activation of various immune cells including cytotoxic T-lymphocytes (CTLs), natural killer cells (NKs), and dendritic cells (DCs), and may eradicate IDO-expressing tumor cells through a CTL-mediated response. This vaccine, using a small fragment of IDO, can be used in combination with either Ipilimumab or Vemurafenib to treat malignant melanoma that has metastasized. ",,,6368,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6368,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C159498,NCT: https://clinicaltrials.gov/study/NCT02077114,Hayleigh Kahn|Jie Zheng,,,, +769,VO:0007679,IL-2 peptide and GM-CSF-in-adjuvant melanoma vaccine,,melanoma vaccine,VO:0000422,,,,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,melanoma,Homo sapiens,,subcutaneous route|intradermal route,"A cancer vaccine compromised of melanoma peptides plus GM-CSF-in-adjuvant. It is combined with low-dose IL-2 therapy, which could significantly enhance the immunologic efficacy.",,,6312,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6312,,,NCT: https://clinicaltrials.gov/study/NCT00928902,Hayleigh Kahn|Jie Zheng,,,, +770,VO:0007680,IL15-DC vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: IL15,3600,Clinical trial,,,,therapeutic vaccine function,melanoma,Homo sapiens,,subcutaneous route,"A cancer vaccine made with autologous dendritic cells that are manufactured with GM-CSF, IL15 and loaded with melanoma/HIV peptides and KLH; then activated with LPS and CD40 Ligand.IL15 is a T cell growth factor that could have a very important role in cancer immunotherapy. IL15 DCs are particularly efficient at priming functional melanoma specific CD8+ T cells. The use of IL15 in the manufacture of the DC vaccine could result in an improved immunotherapy product for melanoma patients.",,,6300,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6300,,,NCT: https://clinicaltrials.gov/study/NCT01189383,Hayleigh Kahn|Jie Zheng,,,, 771,VO:0007681,intracel KLH vaccine,,cancer vaccine,VO:0000177,,,,Clinical trial,peptide vaccine role,,,,cancer,Homo sapiens,,subcutaneous route,A cancer vaccine that could teach T-cells to detect and kill cancer cells better. Intracel KLH is given without adjuvant subcutaneously and with Tetanus Toxoid 0.5 ml intramuscularly.,,,6302,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6302,,,NCT: https://clinicaltrials.gov/study/NCT00000105,Hayleigh Kahn|Jie Zheng,,,, -772,VO:0007682,KLH and tumor lysate pulsed DC vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,cancer,Homo sapiens,,intradermal route,A cancer vaccine made with dendritic cells pulsed with KLH and tumor lysate for patients with neuroblastoma.,,,6303,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6303,,,NCT: https://clinicaltrials.gov/study/NCT02745756,Hayleigh Kahn|Jie Zheng,,,, -773,VO:0007683,KLH-id vaccine,,cancer vaccine,VO:0000177,,,,Clinical trial,subunit vaccine role,,,therapeutic cancer vaccine,cancer,Homo sapiens,,intramuscular route,A cancer vaccine made of tumor protein taken from a cancer patient's plasma (liquid part of the blood) and KLH (a protein designed to increase the immune response of the vaccine).,,,6259,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6259,,,NCT: https://clinicaltrials.gov/study/NCT01174082,Hayleigh Kahn|Jie Zheng,,,, -774,VO:0007684,KLH-pulsed autologous dendritic cell vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,cancer,Homo sapiens,,intratumoral route,"A cancer vaccine made with autologous dendritic cells pulsed with KLH for this vaccination, combined with radiation or a gene therapy agent, TNFerade. TNFerade or radiation serves to generate cell death stimulating the immune response. The dendritic cell vaccine may direct a distant and lasting effective anti-tumor immune response to achieve a local and systemic clinical benefit.",,,6304,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6304,,,NCT: https://clinicaltrials.gov/study/NCT00868114,Hayleigh Kahn|Jie Zheng,,,, -775,VO:0007685,KRAS-targeted mRNA vaccine,,cancer vaccine,VO:0000177,,Gene name: KRAS,3845,Clinical trial,RNA vaccine role,,,therapeutic cancer vaccine,cancer,Homo sapiens,,intramuscular route,"A cancer vaccine used alone or in combination with PD-1 inhibitor in patients with advanced solid tumors with KRAS mutation (G12C, G12D, or G12V) and HLA type HLA-A11:01 or HLA C08:02. The vaccine is a lipid nanoparticle (LNP)-formulated mRNA-based cancer vaccine that targets the most commonly occurring KRAS mutations (G12D, G12V, and G12C). The mRNA-derived KRAS-targeted vaccine V941 (mRNA-5671) is taken up and translated by antigen presenting cells (APCs). Following translation, the epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy tumor cells harboring these specific KRAS mutations.",,,6348,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6348,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C162186,NCT: https://clinicaltrials.gov/study/NCT05202561,Hayleigh Kahn|Jie Zheng,,,, -776,VO:0007686,LMP2A-loaded conventional DC vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: EBV|Gene name: LMP2,10376|5698,Clinical trial,,,,therapeutic cancer vaccine,lymphoma,Homo sapiens,,intravenous route,"A cancer vaccine made with Epstein Barr Virus (EBV)-derived tumor antigen, Latent Membrane Protein-2 (LMP2)-loaded dendritic cell (DC) vaccines are administered alone or co-administered with the TLR9 ligand, DUK-CPG-001, in patients with EBV+ lymphoma in the setting of autologous stem cell transplant with infusion of mature T cells. It may induce EBV derived tumor antigen specific CD8+ T cell response in patients with EBV+ lymphoma in the setting of autologous stem cell transplant.",,,6305,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6305,,,NCT: https://clinicaltrials.gov/study/NCT02115126,Hayleigh Kahn|Jie Zheng,,,, -777,VO:0007687,"MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine",,ovarian cancer vaccine,VO:0005493,,Gene name: MAGE-A1|Gene name: HER2-neu|Gene name: FBP,4100|2064|2348,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,ovarian cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine comprised of multiple peptides derived from MAGE-1A, Her-2/neu, and folate binding protein (FBP), with potential immunostimulating and antineoplastic properties. The MAGE-A1, Her-2/neu, FBP peptides cancer vaccine includes the peptides MAGE-A1:161-169, FBP:191-199, Her-2/neu:369-377, MAGE-A1:96-104, and Her-2/neu:754-762. Vaccination with this cancer vaccine may activate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing the corresponding antigens, resulting in tumor cell lysis. The vaccine compromises synthetic ovarian cancer-associated peptides administered with a synthetic tetanus toxoid helper peptide emulsified in Montanide ISA-51 before or after paclitaxel and carboplatin in patients with stage III-IV ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer undergoing optimal cytoreductive surgery. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving vaccine therapy and chemotherapy after surgery may kill any tumor cells that remain after surgery.",,,6306,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6306,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C62775,NCT: https://clinicaltrials.gov/study/NCT00373217,Hayleigh Kahn|Jie Zheng,,,, -778,VO:0007688,"MART-1, tyrosinase and MAGE-A6 autologous DC vaccine",,whole cell cancer vaccine,VO:0007658,,Gene name: MART-1|Gene name: tyrosinase|Gene name: MAGE-A6,2315|7299|4105,Clinical trial,,,,therapeutic cancer vaccine,melanoma,Homo sapiens,,intradermal route,"A cancer vaccine made with autologous dendritic cells (DC) are transduced with the MART-1, tyrosinase and MAGE-A6 (melanoma associated antigens, MAA) genes for melanoma patients. Some patients also receive interferon-alfa 2b (IFN) intravenously.",,,6280,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6280,,,NCT: https://clinicaltrials.gov/study/NCT01622933,Hayleigh Kahn|Jie Zheng,,,, -779,VO:0007689,mature dendritic cell melanoma vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,melanoma,Homo sapiens,,,A cancer vaccine that may elicit a cytotoxic T-cell (CTL) response against cancer cells. Autologous dendritic cells are pulsed with melanoma tumor-specific peptides. The mature dendritic cell (mDC3/8) vaccine (primer and booster) in patients with stage III and stage IV melanoma is followed by treatment with pembrolizumab (anti-PD-1 therapy). Using dendritic cells (a kind of white blood cell) as a vaccine could stimulate your own immune system to react to your melanoma cells.,,,6307,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6307,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C162250,NCT: https://clinicaltrials.gov/study/NCT03092453,Hayleigh Kahn|Jie Zheng,,,, -780,VO:0007690,MDX-1379 (gp100) melanoma peptide vaccine,,melanoma vaccine,VO:0000422,,Gene name: gp100,6490,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,melanoma,Homo sapiens,,subcutaneous route,"A cancer vaccine made up of two peptides that are pieces of a bigger melanoma protein (gp100). These peptides bind to HLA-A2 which is then recognized by T cells. It could be given in combination with MDX-010 (ipilimumab, BMS-734016). MDX-010 (anti-CTLA4) antibodies are designed to keep the immune system running by blocking CTLA-4 from down-regulating T cell activation.",,,6309,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6309,,,NCT: https://clinicaltrials.gov/study/NCT00094653,Hayleigh Kahn|Jie Zheng,,,, -781,VO:0007691,MDX-CTLA4 antibody/tyrosinase/gp100/MART-1 melanoma vaccine,,melanoma vaccine,VO:0000422,,Gene name: tyrosinase|Gene name: gp100|Gene name: MART-1,7299|6490|2315,Clinical trial,,,cocktail vaccine role,therapeutic cancer vaccine,melanoma,Homo sapiens,,intravenous route,"A cancer vaccine composed of CTLA-4 antibody; tyrosinase, gp100, and MART-1 peptides; and incomplete Freund's adjuvant (IFA) with or without interleukin-12 in patients with resected stage III or IV melanoma.",,,6310,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6310,,,NCT: https://clinicaltrials.gov/study/NCT00028431,Hayleigh Kahn|Jie Zheng,,,, -782,VO:0007692,melanoma helper peptide vaccine,,melanoma vaccine,VO:0000422,,,,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,melanoma,Homo sapiens,,subcutaneous route|intradermal route,"A cancer vaccine consisting of peptides derived from melanoma-associated antigens and an adjuvant peptide derived from tetanus toxoid. Vaccination with this agent may stimulate a host cytotoxic T-cell response against tumor cells expressing melanoma-associated antigens, resulting in tumor cell lysis. Vaccines made from peptides may make the body build an immune response to kill tumor cells. Vaccines using melanoma peptides from cytotoxic T cells and helper T cells could work in treating patients with metastatic melanoma. This vaccine contains 12 melanoma peptides restricted by Human Leukocyte Antigen (HLA)-A1, -A2, or -A3 and 6 melanoma helper peptides restricted by HLA-DR molecules emulsified with sargramostim (Granulocyte-macrophage colony-stimulating factor, GM-CSF) and Montanide ISA-51 or Montanide ISA-51 VG (ISA-51).",,,6311,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6311,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C38700,NCT: https://clinicaltrials.gov/ct2/show/NCT00071981,Hayleigh Kahn|Jie Zheng,,,, -783,VO:0007693,mixed bacterial cancer vaccine,,cancer vaccine,VO:0000177,,,,Clinical trial,,vaccine organism inactivated,,therapeutic cancer vaccine,cancer,Homo sapiens,,subcutaneous route|intralesional route,"A cancer vaccine containing a mixture of killed bacteria with potential immunostimulatory and antineoplastic activities. Mixed bacteria vaccine (MBV or Coley's toxins) consists of a pyrogenic bacterial lysate derived from Serratia marcescens and Streptococcus pyogenes; the active components in the lysate may be lipopolysaccharide (LPS), a component of the Gram-negative bacterial cell wall of Serratia, and streptokinase, an enzyme produced by Streptococcus pyogenes. LPS has been shown to stimulate the host humoral immune response and induce the release of various antitumor cytokines such as tumor necrosis factor (TNF) and interleukin-12 (IL-12). The mixed bacteria vaccine (MBV) is administered at a starting dose of 250 EU (1 µL) and escalated in each patient to a dose inducing the desired pyrogenic effect, defined as a body temperature of 38°C to 39.5°C. It is given to patients with malignant tumors that expressed the NY-ESO-1 antigen. It is designed to induce immunological effects and tumor response following vaccination. ",,,6314,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6314,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C74063,NCT: https://clinicaltrials.gov/study/NCT00623831,Hayleigh Kahn|Jie Zheng,,,, -784,VO:0007694,mRNA neoantigen tumor vaccine,,cancer vaccine,VO:0000177,,,,Clinical trial,RNA vaccine role,,,therapeutic cancer vaccine,cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine with or without PD-1/L1 may help treat patients with advanced gastric cancer. A personalized mRNA tumor vaccine encoding neoantigen may also help treat patients with advanced esophageal squamous carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma and colorectal adenocarcinoma. The vaccine can also be used in combination with PD-1 for the treatment of advanced solid tumors.",,,6328,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6328,,,NCT: https://clinicaltrials.gov/study/NCT05359354|NCT: https://clinicaltrials.gov/study/NCT05227378|NCT: https://clinicaltrials.gov/study/NCT03468244,Hayleigh Kahn|Jie Zheng,,,, -785,VO:0007695,mRNA tumor antigen DC vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,brain cancer,Homo sapiens,,,A cancer vaccine made with dendritic cells (DCs) pulsed with mRNA encoded tumor antigens. These personalized cell vaccines may lead to antitumor specific T cell responses. ,,,6339,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6339,,,NCT: https://clinicaltrials.gov/study/NCT02808416,Hayleigh Kahn|Jie Zheng,,,, -786,VO:0007696,mRNA-based personalized cancer vaccine NCI-4650,,cancer vaccine,VO:0000177,,,,Clinical trial,RNA vaccine role,,,therapeutic cancer vaccine,cancer,Homo sapiens,,intramuscular route,"A cancer vaccine targeting up to fifteen tumor-associated antigens (TAAs) that are specifically expressed by a patient's cancer cells, with potential immunostimulatory and antineoplastic activities. Up to fifteen neoantigen epitopes are incorporated in a proprietary formulation designed to maximize mRNA delivery and minimize mRNA-triggered immune responses. The mRNA-based PCV NCI-4650 is taken up and the mRNAs are translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This induces both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy the patient's cancer cells that express these neoantigens. Exome sequencing can identify certain gene mutations in a person's tumor. This can then be used to create cancer treatments. This mRNA vaccine might cause certain tumors to shrink. Immunogenic neoantigens and can predict for neoantigens binding the patient human leukocyte antigen (HLA) molecules from melanoma or epithelial cancer patients and use these epitopes for a personalized therapeutic messenger ribonucleic acid (mRNA) vaccine.",,,6324,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6324,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148239,NCT: https://clinicaltrials.gov/study/NCT03480152,Hayleigh Kahn|Jie Zheng,,,, -787,VO:0007697,MT-201-GBM monocyte vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,cancer,Homo sapiens,,intravenous route,"A cancer vaccine consisting of autologous monocytes loaded with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) as a fusion protein with the lysosome-associated membrane protein (LAMP), with potential immunostimulatory and antineoplastic activities. The autologous CMV-pp65-LAMP mRNA loaded monocyte vaccine MT-201-GBM exposes the immune system to the CMV pp65 peptide, which may elicit a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells. The incorporation of LAMP may route CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC class II antigen presentation, thereby promoting CD4-positive T-cell responses. MT-201-GBM (pp65CMV antigen monocytes) are administered to patients newly diagnosed with a type of brain tumor called glioblastoma (GBM) that has an unmethylated MGMT (O[6]-methylguanine-DNA methyltransferase) (MGMT) gene promoter. The vaccine is made from a type of immune cell called monocytes, which have been engineered to express a cytomegalovirus (CMV) protein. Patients also receive standard radiation therapy combined with temozolomide.",,,6315,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6315,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C179670,NCT: https://clinicaltrials.gov/study/NCT04741984,Hayleigh Kahn|Jie Zheng,,,, -788,VO:0007698,MUC1 peptide-poly-ICLC vaccine,,cancer vaccine,VO:0000177,,Gene name: MUC-1,4582,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine containing mucus 1 (MUC1) peptide and the adjuvant poly-ICLC with potential immunostimulatory and antineoplastic activities. MUC1 peptide-poly-ICLC adjuvant vaccine may induce the host immune system to mount a cytotoxic T cell response against MUC1-expressing tumor cells. MUC1 peptide-poly-ICLC adjuvant vaccine in boosting systemic immunity to MUC1 in women with stage I-III 'triple-negative' [i.e., ER(-) PR(-) HER2/neu(-)] breast cancer. MUC1 peptide-Poly-ICLC vaccine could also work in preventing lung cancer in current and former smokers at high risk for lung cancer. Vaccines made from peptides may help the body build an effective immune response to kill cells. MUC1 peptide-Poly-ICLC vaccine may stimulate the body's immune system and slow or stop the changes from normal to pre-cancer to cancer.",,,6316,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6316,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C82417,NCT: https://clinicaltrials.gov/study/NCT00986609|NCT: https://clinicaltrials.gov/study/NCT03300817,Hayleigh Kahn|Jie Zheng,,,, -789,VO:0007699,multi-epitope HER2 peptide vaccine TPIV100,,breast cancer vaccine,VO:0005484,,Gene name: HER2,2064,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,breast cancer,Homo sapiens,,intradermal route,"A cancer vaccine comprised of four peptides derived from the tumor-associated antigen (TAA) HER-2/neu (ErbB-2), with potential immunomodulating and antineoplastic activities. The four peptides may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing the HER-2/neu antigen, which may result in the inhibition of proliferation in Her-2/neu-expressing tumor cells. TPIV100 is a type of vaccine made from HER2 peptide that may help the body build an effective immune response to kill tumor cells that express HER2. Sargramostim increases the number of white blood cells in the body following chemotherapy for certain types of cancer and is used to alert the immune system. TPIV100 and sargramostim could work in treating patients with HER2 positive, stage II-III breast cancer.",,,6317,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6317,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C173525,NCT: https://clinicaltrials.gov/study/NCT04197687,Hayleigh Kahn|Jie Zheng,,,, -790,VO:0007700,multi-epitope melanoma peptide vaccine,,melanoma vaccine,VO:0000422,,Gene name: tyrosinase|Gene name: gp100|Gene name: MAGE-A3|Gene name: HLA-A|Gene name: HLA-B,7299|6490|4102|3105|3106,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,melanoma,Homo sapiens,,subcutaneous route,"A cancer vaccine consisting of a combination of peptides derived form several melanoma epitopes. Vaccination with multi-epitope melanoma peptide vaccine stimulates the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the corresponding antigens, resulting in tumor cell lysis. This vaccine may stimulate a broader CTL response compared to single-antigen vaccines. Vaccines made from melanoma peptides or antigens may help the body build an effective immune response to kill tumor cells in patients with stage IIC-IV melanoma. This vaccine is a tyrosinase/gp100/MAGE-3 class I peptide vaccine combined with Montanide ISA 51 or ISA 51 VG with CpG adjuvant 7909 in human leukocyte antigen (HLA) class I A1, A3 or A11 and B44 matched patients with surgically resected stages IIC, III and IV melanoma.",,,6318,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6318,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C38695,NCT: https://clinicaltrials.gov/study/NCT00085189,Hayleigh Kahn|Jie Zheng,,,, -791,VO:0007701,multiantigen liposome loaded dendritic cell vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,kidney cancer,Homo sapiens,,intradermal route,A cancer vaccine for which Advanced Renal Cell Carcinoma patients undergo total nephrectomy to harvest primary tumor for vaccine preparation. Dendritic cells are then pulsed with multiantigens or tumor cells. Some patients also receive vaccination with irradiated autologous tumor lysate. The vaccine may make the body build an immune response to kill tumor cells.,,,6284,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6284,,,NCT: https://clinicaltrials.gov/study/NCT00004880,Hayleigh Kahn|Jie Zheng,,,, -792,VO:0007702,multipeptide XS15 vaccine,,leukemia cancer vaccine,VO:0005487,,Gene name: TLR1|Gene name: TLR2,7096|7097,Clinical trial,,,cocktail vaccine role,therapeutic cancer vaccine,leukemia,Homo sapiens,,,"A cancer vaccine adjuvant and synthetic Toll-like receptor (TLR) type 1 and 2 ligand composed of a lipopeptide containing a water-soluble derivative of Pam3-Cys, the biologically active component of the mycobacterial 19 kDa lipoprotein of mycobacteria, that is covalently linked to a synthetic peptide (GDPKHPKSF), with potential immunostimulating activity. TLR1/2 agonist Pam3Cys-GDPKHPKSF targets, binds to and activates TLR1/2, which induces CD8- and T-helper 1 CD4-positive T-cell responses. This may enhance T-cell-mediated immune responses when administered together with peptide vaccine. A multi-peptide vaccine can be used in combination with the TLR1/2 ligand XS15 in CLL patients undergoing ibrutinib-based regimes. Applying several CLL-associated antigens simultaneously increases the likelihood that a multi-clonal, broad and at the same time highly specific T-cell response is mounted, thereby preventing potential tumor escape mechanisms. The novel TLR1/2 ligand (XS15, developed in Tübingen) that (i) is water-soluble and (ii) GMP-amenable, (iii) non-toxic and (iv) effective in inducing T cells specific for peptides in vivo. A personalized multi-peptide vaccination can also be used in combination with the TLR1/2 ligand XS15 for individual patients with advanced solid and hematological malignancies without any approved treatment options. ",,,6319,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6319,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C179595,NCT: https://clinicaltrials.gov/study/NCT04688385|NCT: https://clinicaltrials.gov/study/NCT05014607,Hayleigh Kahn|Jie Zheng,,,, -793,VO:0007703,multiple signals loaded dendritic cells vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,hepatocellular carcinoma,Homo sapiens,,intravenous route,A cancer vaccine that can efficiently present T cells with antigens of HCC sensitize their antitumor properties meanwhile low dose cyclophosphamide (CY) can effectively improve the microenvironment of immunity. Multiple signals loaded dendritic cells vaccine combined low dose of cyclophosphamide combining with radical surgery or TACE or targeted agents for patients with hepatocellular carcinoma coul prolong their survival time.,,,6320,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6320,,,NCT: https://clinicaltrials.gov/study/NCT04317248,Hayleigh Kahn|Jie Zheng,,,, -794,VO:0007704,mutated neopeptide vaccine,,brain cancer vaccine,VO:0005428,,Gene name: HLA,3123,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,brain cancer,Homo sapiens,,,"A cancer vaccine with neopeptides designed with single amino acid mutations to enhance their immunogenicity and bind to HLA class I and II molecules. Exome and RNA sequencing as well as in silico HLA-binding predictions to autologous HLA molecules were used to identify candidate neopeptides. Subsequently, in silico HLA-anchor placements were used to deduce putative T-cell receptor (TCR) contacts of peptides. Single amino acids of TCR contacting residues were then mutated by amino acid replacements. TIL-derived CD4+ T-cell clones showed strong responses and tumor cell lysis not only against the designed neopeptide but also against the unmutated natural peptides of the tumor. Turning tumor self-peptides into foreign antigens by introduction of designed mutations is a promising strategy to induce strong intratumoral CD4+ T-cell responses in a cold tumor like glioblastoma.",PubMed:36228153,,6383,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6383,,,,Hayleigh Kahn|Jie Zheng,,,, -795,VO:0007705,MVA-BN-CV301 vaccine,,cancer vaccine,VO:0000177,,Gene name: MUC1|Gene name: CEA|Gene name: B7.1|Gene name: ICAM-1|Gene name: LFA-3,4582|1048|941|3383|965,Clinical trial,recombinant vector vaccine role,,,therapeutic cancer vaccine,cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine consisting of a proprietary version of the recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding both the two human tumor-associated antigens (TAAs) carcinoembryonic antigen (CEA) and mucin-1 (MUC-1), and TRICOM, which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. MVA-BN-CV301, followed by multiple boosting doses of the fowlpox virus (FPV) vaccine CV301 may lead to a cytotoxic T-lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells is activated. In addition, the CV301-dependent anti-tumor CTL response upregulates the expression of programmed cell death ligand 1 (PD-L1); therefore, when CV301 is combined with a programmed cell death 1 (PD-1) immune checkpoint inhibitor, the antitumor effect may be increased. CV301 is a poxviral-based vaccine comprised of recombinant Modified vaccinia Ankara (MVA-BN-CV301, prime) and recombinant fowlpox (FPV-CV301, boost). CV301 contains transgenes encoding two (2) tumor-associated antigens (TAA), mucin 1 (MUC1) and carcinoembryonic antigen (CEA), as well as three costimulatory molecules (B7.1, intercellular adhesion molecule 1 (ICAM-1) and lymphocyte function-associated antigen 3 (LFA-3), designated TRICOM). It is given in combination with SX-682 and M7824 for patients with Triple Negative Breast Cancer (TNBC) and Human papilloma virus (HPV) negative head and neck squamous cell carcinoma (HNSCC).",,,6321,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6321,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C143059,NCT: https://clinicaltrials.gov/study/NCT04574583,Hayleigh Kahn|Jie Zheng,,,, -796,VO:0007706,MVF-HER-2(628-647)-CRL 1005 vaccine,,cancer vaccine,VO:0000177,,Gene name: HER2,2064,Clinical trial,,,,therapeutic cancer vaccine,cancer,Homo sapiens,,intramuscular route,"A cancer vaccine of a chimeric peptide immunogen of human epidermal growth factor-2 (HER-2) with antineoplastic property. MVF-HER-2(628-647)-CRL 1005 vaccine, coated with poloxamer CRL-1005 to form microparticles, consists of a mutated HER-2 B-cell epitope, HER-2(628-647), and a promiscuous T cell epitope (amino acid sequence 288-302) of the measles virus fusion protein (MVF). The vaccine may stimulate the host immune response to mount a cytotoxic T-lymphocyte response against tumor cells that overexpress the HER2 protein, resulting in tumor cell lysis. MVF-HER-2(628-647)-CRL 1005 vaccine may induce anti-HER-2 antibody in patients with metastatic or recurrent cancer (Breast, Ovarian, Non-small cell lung cancer, Gastric adenocarcinoma).",,,6322,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6322,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C2637,NCT: https://clinicaltrials.gov/study/NCT00017537,Hayleigh Kahn|Jie Zheng,,,, -797,VO:0007707,NEO-PV-01 vaccine,,lung cancer vaccine,VO:0005486,,,,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,lung cancer,Homo sapiens,,,"A cancer vaccine consisting of patient-specific mutated peptide epitopes, which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. The neoantigen-based anti-cancer vaccine NEO-PV-01 stimulates the host immune system to mount a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. Both metastatic squamous non-small cell lung cancer (NSCLC) and extensive stage small cell lung cancer (SCLC) are incurable with current therapies, but due to mutations induced by cigarette smoke, typically express a large number of altered proteins that can be recognized as foreign by the immune system. Targeting the immune system against tumor specific antigens using a peptide vaccine could lead to improved response rate and prolonged overall survival with no additional toxicity when combined with Pembrolizumab (monoclonal antibodies that block PD-1/PD-L1 interactions) and standard of care chemotherapy.",,,6325,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6325,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C129935,NCT: https://clinicaltrials.gov/study/NCT03166254,Hayleigh Kahn|Jie Zheng,,,, -798,VO:0007708,neoantigen DNA vaccine,,renal cancer vaccine,VO:0005494,,,,Clinical trial,DNA vaccine role,,,therapeutic cancer vaccine,kidney cancer,Homo sapiens,,intramuscular route,A cancer vaccine that may enhance anti-tumor immune response in Renal Cell Carcinoma in combination with checkpoint inhibitors ipilimumab (anti-CTLA-4 antibody) and nivolumab (anti-PD-1 antibody).,,,6326,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6326,,,NCT: https://clinicaltrials.gov/study/NCT03598816,Hayleigh Kahn|Jie Zheng,,,, -799,VO:0007709,neoantigen peptide vaccine,,cancer vaccine,VO:0000177,,,,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,cancer,Homo sapiens,,intramuscular route,"A cancer vaccine consisting of patient-specific antigens, which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. The neoantigen peptide vaccine, the peptides stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. Personalized neo-antigen peptide vaccine is a product combines multiple patient specific neo-antigens. Given personalized neo-antigen peptide vaccine together with Th1 polarizing adjuvant poly ICLC may induce a polyclonal, poly-epitope, cytolytic T cell immunity against the patient's tumor. Patients also receive nivolumab.",,,6327,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6327,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C165508,NCT: https://clinicaltrials.gov/study/NCT05098210,Hayleigh Kahn|Jie Zheng,,,, -800,VO:0007710,neoantigen synthetic long peptide vaccine,,cancer vaccine,VO:0000177,,,,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,cancer,Homo sapiens,,intramuscular route,"A cancer vaccine consisting of synthetic long peptides (SLPs), ranging from 20-35 amino acids in size, that are derived from two or more of the patient's tumor-specific mutant antigens (TSMAs), with potential immunostimulatory and antitumor activities. SLP vaccine may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL)-mediated immune response against the TSMAs expressed by the tumor cells. This vaccine is a optimized neoantigen synthetic long peptide (SLP) vaccines for pancreatic cancer patients following neoadjuvant chemotherapy. The neoantigen SLP vaccines will incorporate prioritized neoantigens and will be co-administered with poly-ICLC. It can be used in combination with chemoradiation with temozolomide for patients with newly diagnosed glioblastoma.",,,6332,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6332,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C150471,NCT: https://clinicaltrials.gov/study/NCT02510950|NCT: https://clinicaltrials.gov/study/NCT05111353,Hayleigh Kahn|Jie Zheng,,,, -801,VO:0007711,neoantigen-loaded autologous dendritic cell vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine consisting of autologous DCs loaded with immunogenic peptides derived from autologous cancer cells, with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-loaded autologous DC vaccine stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. Neoantigens arising from the mutations of the tumor genome expressed specifically on the tumor cell instead of normal cells, suggesting that vaccines targeting neoantigens should generate a highly tumor-specific response with minimal off-target effects. Neoantigens are identified from tumor tissues from a gastric cancer, hepatocellular carcinoma, lung cancer or colorectal cancer patient. Dendritic cells are then primed with synthesized peptides. The vaccine can be combined with microwave ablation ti treat patients with Hepatocellular Carcinoma (HCC). It can also be combined with Anti-PD1 (Nivolumab) as for patients with resected Hepatocellular Carcinoma (HCC) and Liver Metastases From Colorectal Cancer (CRLM). ",,,6281,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6281,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C141422,NCT: https://clinicaltrials.gov/study/NCT03674073| NCT: https://clinicaltrials.gov/study/NCT03871205| NCT: https://clinicaltrials.gov/study/NCT04147078| NCT: https://clinicaltrials.gov/study/NCT04912765],Hayleigh Kahn|Jie Zheng,,,, -802,VO:0007712,"NY-ESO-1, MAGE-A1, and MAGE-A3 dendritic cell vaccine",,whole cell cancer vaccine,VO:0007658,,Gene name: NY-ESO-1|Gene name: MAGE-A1|Gene name: MAGE-A3,1485|4100|4102,Clinical trial,,,,therapeutic cancer vaccine,cancer,Homo sapiens,,intramuscular route,"A cancer vaccine that is made from the subject's blood cells and is designed to interact in the patient's body with cells that are programmed to fight specific tumor proteins NY-ESO-1, Melanoma Antigen Gene-A1 (MAGE-A1) and Melanoma Antigen Gene-A3 (MAGE-A3). The vaccine can be given in combination with decitabine which may increase the amount and activity of these cancer proteins on the surface of tumor cells to increase the possibility that the vaccine will stimulate cells to act against the tumor cells. The dendritic cells may stimulate CD4 and CD8 antigen specific T cells in patients with relapsed or refractory pediatric high grade gliomas, medulloblastomas, and central nervous system primitive neuroectodermal tumors (CNS PNETs).",,,6367,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6367,,,NCT: https://clinicaltrials.gov/study/NCT02332889,Hayleigh Kahn|Jie Zheng,,,, -803,VO:0007713,NY-ESO-1/PRAME/MAGE-A3/WT-1 peptide vaccine,,leukemia cancer vaccine,VO:0005487,,Gene name: NY-ESO-1|Gene name: PRAME|Gene name: MAGE-A3|Gene name: WT-1,1485|23532|4102|7490,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,leukemia,Homo sapiens,,,"A cancer vaccine comprised of synthetic peptides derived from the cancer-testis antigen NY-ESO-1, preferentially expressed antigen in melanoma (PRAME), human melanoma antigen A3 (MAGE-A3) and the human Wilms tumor protein-1 (WT-1), with potential immunostimulating and antineoplastic activities. NY-ESO-1/PRAME/MAGE-A3/WT-1 peptide vaccine may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing NY-ESO-1, PRAME, MAGE-A3 and WT-1, resulting in tumor cell lysis. As proteins are degraded in cells, peptides are presented on the surface of these cells as a complex with tissue type molecules (HLA molecules). T-cells may then recognize the peptide-HLA complexes, via its T-cell receptor, potentially resulting in tumor-cell killing, if sufficient priming takes place. Cancer testis antigens (CTA's) are known to be immunogenic and are only expressed at immunoprivileged sites, thus out of reach of immune responses, and on cancer cells, making them ideal targets for therapeutic cancer vaccination. The CTA's chosen were NY-ESO-1, MAGE-A3 and PRAME. WT-1 is additionally included as this protein has proven to be an important antigen in hematological malignancies. It is combined with azacitidine for treatment of patients with high-risk myelodysplastic syndrome or acute myeloid leukemia. ",,,6329,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6329,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C127125,NCT: https://clinicaltrials.gov/study/NCT02750995,Hayleigh Kahn|Jie Zheng,,,, -804,VO:0007714,OCDC and NeoDC vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,esophageal cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine made with autologous DCs that are pulsed with HOCl-oxidized autologous tumor lysate (OCDC) and administered in prime phase, along with a personal neoantigen-sensitized DC(NeoDC) vaccine administered in the boost phase for Esophageal Squamous Cell Carcinoma.",,,6331,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6331,,,NCT: https://clinicaltrials.gov/study/NCT05317325,Hayleigh Kahn|Jie Zheng,,,, -805,VO:0007715,oral cancer vaccine V3-OVA,,ovarian cancer vaccine,VO:0005493,,,,Clinical trial,,,,therapeutic cancer vaccine,ovarian cancer,Homo sapiens,,oral route,"A cancer vaccine composed of autologous ovarian cancer antigens obtained from hydrolyzed, inactivated blood and tumor tissue of patients with ovarian cancer, with potential immunostimulatory and antineoplastic activities. The ovarian cancer antigens stimulate the immune system and activate a cytotoxic T-lymphocyte (CTL) immune response against ovarian cancer cells. Ovarian cancer patients can be given one pill a day for three months. ",,,6354,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6354,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C159540,NCT: https://clinicaltrials.gov/study/NCT03556566,Hayleigh Kahn|Jie Zheng,,,, -806,VO:0007716,oral therapeutic vaccine V3-X,,cancer vaccine,VO:0000177,,,,Clinical trial,,,,therapeutic cancer vaccine,cancer,Homo sapiens,,oral route,"A cancer vaccine consisting of the tumor-associated antigen (TAA) oligosaccharide antigen sialyl Lewis A (CA19-9; sialylated Lewis A antigen; carbohydrate antigen 19-9; cancer antigen 19-9), with potential immunostimulating and antineoplastic activities. Oral therapeutic vaccine V3-X induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing CA19-9. Cholangiocarcinoma (CCA) is a malignant neoplasm originating from the epithelial cells lining the intra- or extrahepatic biliary ducts. This immunotherapeutic formulation is made from pooled heat- and chemically-inactivated blood from donors with CCA for a pill for cholangiocarcinoma patients.",,,6333,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6333,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148144,NCT: https://clinicaltrials.gov/study/NCT03042182,Hayleigh Kahn|Jie Zheng,,,, -807,VO:0007717,P30-linked EphA2/CMV pp65/survivin peptide vaccine P30-EPS,,brain cancer vaccine,VO:0005428,,Gene name: EphA2|Gene name: survivin,1969|332,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,brain cancer,Homo sapiens,,,"A cancer vaccine comprised of three immunogenic tetanus toxoid epitope P30-linked tumor-associated antigen (TAA) peptides, P30-linked Ephrin receptor A2 (EphA2), P30-linked cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) and P30-linked survivin, with potential immunostimulating and antineoplastic activities. The vaccine may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing EphA2, CMV pp65 and survivin. Hiltonol is used as an adjuvant to stimulate or enhance the activation of your immune system. The vaccine and adjuvant may help treat HLA-A*0201 positive patients with a newly diagnosed, unmethylated, and untreated World Health Organization (WHO) grade IV malignant glioma.",,,6362,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6362,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C187131,NCT: https://clinicaltrials.gov/study/NCT05283109,Hayleigh Kahn|Jie Zheng,,,, -808,VO:0007718,P501-AS15 vaccine,,prostate cancer vaccine,VO:0005425,,,,Clinical trial,subunit vaccine role,,,therapeutic cancer vaccine,prostate cancer,Homo sapiens,,,"A cancer vaccine made up of CPC-P501 protein formulated with the adjuvant AS15. Patients with hormone-sensitive prostate cancer and rising PSA, after primary tumor treatment, can be treated with the P501-AS15 vaccine. ",,,6335,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6335,,,NCT: https://clinicaltrials.gov/study/NCT00148928,Hayleigh Kahn|Jie Zheng,,,, -809,VO:0007719,pancreatic tumor personalized neoantigen vaccine,,pancreatic cancer vaccine,VO:0005430,,,,Clinical trial,subunit vaccine role,,,therapeutic cancer vaccine,pancreatic cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine based on next-generation sequencing and major histocompatibility complex affinity prediction algorithm, which may help treat patients with pancreatic ductal adenocarcinoma. This vaccine may elicit measurable neoantigen-specific immunologic responses in patients.",,,6341,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6341,,,NCT: https://clinicaltrials.gov/study/NCT03558945,Hayleigh Kahn|Jie Zheng,,,, -810,VO:0007720,PD-L1 peptide vaccine,,melanoma vaccine,VO:0000422,,Gene name: PD-L1,29126,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,melanoma,Homo sapiens,,subcutaneous route,"A cancer vaccine composed of a peptide derived from the tumor-associated antigen (TAA) and immune checkpoint molecule programmed cell death-1 ligand 1 (PD-L1) combined with the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Vaccination with PD-L1 peptide vaccine may activate the immune system to induce an immune response against PD-L1-expressing cells. This may increase and restore the proliferation and activation of various immune cells, including cytotoxic T-lymphocytes (CTLs), and may eradicate PD-L1-expressing tumor cells. The vaccines aims to stimulate PD-L1 specific T-cells, hence eliminating both PD-L1 positive tumor cells as well as PD-L1 positive immunosuppressive and antigen presenting cells in the tumor microenvironment. It has been used in clinical trials for patients with multiple melanoma.",,,6338,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6338,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148146,NCT: https://clinicaltrials.gov/study/NCT03042793,Hayleigh Kahn|Jie Zheng,,,, -811,VO:0007721,PD-L1/IDO peptide vaccine IO102-103,,melanoma vaccine,VO:0000422,,Gene name: PD-L1|Gene name: IDO,29126|3620,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,melanoma,Homo sapiens,,,"A cancer vaccine composed of IO103, a peptide derived from the tumor-associated antigen (TAA) programmed cell death-1 ligand 1 (PD-L1), IO102, the 21-mer peptide vaccine derived from the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO), and the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Both IDO and PD-L1 reactive CD8 T cells are cytotoxic and can kill cancer cells and immune regulatory cells in vitro. Thus boosting specific T cells that recognize immune regulatory proteins such as IDO and PD-L1 may directly modulate immune regulation. The the programmed death 1 (PD-1) regulatory antibody Nivolumab may further help treat patients with metastatic melanoma.",,,6337,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6337,,NCI: ttps://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148154,NCT: https://clinicaltrials.gov/study/NCT03047928,Hayleigh Kahn|Jie Zheng,,,, -812,VO:0007722,personal neoantigen cancer vaccine,,cancer vaccine,VO:0000177,,,,Research,subunit vaccine role,,,therapeutic cancer vaccine,cancer,Homo sapiens,,,"A cancer vaccine designed to target the unique immunogenic mutations arising in each patient's tumor. Peptide binding to MHC is a critical gateway to both the initiation of a T-cell immune response by the antigen presenting cell (APC), and to the detection and elimination of tumor cells presenting the particular peptide by the stimulated cytotoxic T lymphocyte (CTL). The attraction of neoantigens as cancer targets for the immune system results from the structural and geographical features of the mutation. Neoantigen peptides are only found in tumor cells, so CTLs should show exquisite specificity, reducing the opportunity for autoimmune disease.",PubMed:25101225,,6387,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6387,,,,Hayleigh Kahn|Jie Zheng,,,, -813,VO:0007723,personalized follicular lymphoma vaccine,,lymphoma vaccine,VO:0005427,,,,Clinical trial,subunit vaccine role,,,therapeutic cancer vaccine,lymphoma,Homo sapiens,,,"A cancer vaccine co-administered with poly-ICLC, nivolumab, and rituximab (or another monoclonal antibody against CD20) to treat Follicular Lymphoma. The peptides comprising the vaccine are reconstituted in up to 4 pools with 5 peptides per pool (A, B, C, and D).",,,6342,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6342,,,NCT: https://clinicaltrials.gov/study/NCT03121677,Hayleigh Kahn|Jie Zheng,,,, -814,VO:0007724,personalized mature dendritic cell vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,lung cancer,Homo sapiens,,,"A cancer vaccine that may stimulate the immune system to react to lung cancer cells, in combination with Cyclophosphamide.",,,6340,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6340,,,NCT: https://clinicaltrials.gov/study/NCT02419170,Hayleigh Kahn|Jie Zheng,,,, -815,VO:0007725,personalized neoantigen melanoma vaccine,,melanoma vaccine,VO:0000422,,,,Clinical trial,subunit vaccine role,,,therapeutic cancer vaccine,melanoma,Homo sapiens,,,"A cancer vaccine for melanoma. Melanomas have mutations (changes in genetic material) that are specific to an individual patient and tumor. These mutations can cause the tumor cells to produce proteins that appear very different from the body's own cells. These proteins used in a vaccine may induce strong immune responses, which may help the participant's body fight any tumor cells that could cause the melanoma to come back in the future. NeoVax is a long-peptide vaccine targeting up to 20 personal neoantigens per patient for patients with surgically resected stage IIIB/C or IVM1a/b melanoma. There was long-term persistence of neoantigen-specific T cell responses following vaccination, with ex vivo detection of neoantigen-specific T cells exhibiting a memory phenotype, as well as diversification of neoantigen-specific T cell clones over time, with emergence of multiple T cell receptor clonotypes exhibiting distinct functional avidities. There was also tumor infiltration by neoantigen-specific T cell clones after vaccination and epitope spreading, suggesting on-target vaccine-induced tumor cell killing. Personal neoantigen peptide vaccines thus induce T cell responses that persist over years and broaden the spectrum of tumor-specific cytotoxicity in patients with melanoma. ",PubMed:33479501,,6375,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6375,,,NCT: https://clinicaltrials.gov/study/NCT01970358,Hayleigh Kahn|Jie Zheng,,,, -816,VO:0007726,PolyPEPI1018 CRC vaccine,,colorectal cancer vaccine,VO:0005426,,Gene name: CTAG1B,1485,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,colorectal cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine that contains 6 synthetic peptides mixed with the adjuvant Montanide™. The peptides were selected to induce T cell responses against 12 dominant epitopes from 7 cancer testis antigens (CTAs), which are the most frequently expressed CTAs in colorectal cancer. The 6 peptides were optimized to induce long lasting CRC specific T cell responses. Colorectal cancer peptide vaccine PolyPEPI1018 potentially elicits a cytotoxic T-lymphocyte response against colorectal tumors expressing the CTAs associated with the vaccine, which may result in a reduction in tumor cell proliferation. ",,,6343,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6343,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C154278,NCT: https://clinicaltrials.gov/study/NCT03391232,Hayleigh Kahn|Jie Zheng,,,, -817,VO:0007727,polyvalent melanoma vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,melanoma,Homo sapiens,,intradermal route,"A cancer vaccine consisting of whole irradiated heterologous melanoma cells which express multiple melanoma-related antigens. Polyvalent melanoma vaccine may stimulate an antitumoral cytotoxic T-cell immune response in the host, resulting in inhibition of tumor cell proliferation and tumor cell death. Vaccines may make the body build an immune response and kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Interferon alfa-2b may interfere with the growth of tumor cells. Treatment with this combination may help treat melanoma. ",,,6344,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6344,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1633,NCT: https://clinicaltrials.gov/study/NCT00004104,Hayleigh Kahn|Jie Zheng,,,, -818,VO:0007728,prodencel,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,prostate cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine made with autologous dendritic cells targeting prostate cancer (PC)-specific antigen(s), with potential immunostimulatory and antineoplastic activities. Upon administration of prodencel, the DCs stimulate a specific cytotoxic T-lymphocyte (CTL)-mediated immune response against PC cells expressing the antigen(s), resulting in tumor cell lysis. (NCIT_C192174) The vaccine could help treat patients with metastatic castration-resistant prostate cancer (mCRPC) after novel androgen-deprived therapy and docetaxel chemotherapy failure.",,,6345,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6345,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C192174,NCT: https://clinicaltrials.gov/study/NCT05533203,Hayleigh Kahn|Jie Zheng,,,, -819,VO:0007729,pUMVC3-IGFBP2-HER2-IGF1R plasmid DNA vaccine,,breast cancer vaccine,VO:0005484,,Gene name: IGFBP2|Gene name: HER2|Gene name: IGF1R,3485|2064|3480,Clinical trial,DNA vaccine role,,,therapeutic cancer vaccine,breast cancer,Homo sapiens,,intradermal route,"A cancer vaccine containing the mammalian expression vector pUMVC3 encoding epitopes derived from three tumor-associated antigens (TAAs): human insulin-like growth factor-binding protein 2 (IGFBP2), human epidermal growth factor receptor 2 (HER2; ERBB2) and insulin-like growth factor 1 receptor (IGF1R), with potential immunostimulating and antineoplastic activities. The vaccine This activates the immune system to mount a combined response from specific T helper type 1 (Th1) cells, memory T-cells and cytotoxic T-lymphocytes (CTL) against IGFBP2-, HER2-, and IGF1R-expressing tumor cells. This vaccine may prevent cancer from coming back in patients with non-metastatic, node positive, human epidermal growth factor receptor (HER)2 negative breast cancer in which all signs and symptoms have disappeared. Vaccines made from deoxyribonucleic acid (DNA) may help the body build an effective immune response to kill tumor cells. It is given in combination with sargramostim.",,,6346,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6346,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C127910,NCT: https://clinicaltrials.gov/study/NCT02780401,Hayleigh Kahn|Jie Zheng,,,, -820,VO:0007730,RAS peptide cancer vaccine TG01,,pancreatic cancer vaccine,VO:0005430,,,,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,pancreatic cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine containing seven 17 amino acids long synthetic RAS oncogene-encoded peptides representing the most common codon 12 and 13 oncogenic mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS), with potential immunomodulating and antineoplastic activities. The vaccine may stimulate a specific CD4-positive helper T-lymphocyte- and cytotoxic T-lymphocyte (CTL)-mediated immune response against RAS mutant-specific-expressing cancer cells, resulting in an inhibition of tumor cell proliferation and tumor cell death. The vaccine can be given in combination with Balstilimab and QS-21 for patients with pancreatic cancer to increase efficacy. ",,,6356,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6356,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C200465,NCT: https://clinicaltrials.gov/study/NCT05638698,Hayleigh Kahn|Jie Zheng,,,, -821,VO:0007731,SCIB1 DNA vaccine,,melanoma vaccine,VO:0000422,,Gene name: TRP-2,1638,Clinical trial,DNA vaccine role,,,therapeutic cancer vaccine,melanoma,Homo sapiens,,intramuscular route,"A cancer vaccine that encodes a melanoma antigen tyrosinase-related protein 2 (TRP2) cytotoxic T-lymphocyte (CTL) epitope and a modified monoclonal antibody, a chimera of human IgG1/murine IgG2a with T cell mimotopes expressed within the complementarity-determining regions (CDR) of the antibodies, with potential immunostimulating and antineoplastic activities. The melanoma TRP2 CTL epitope vaccine SCIB1 expresses the modified antibody. Subsequently, the Fc component of the engineered antibody targets and binds to the CD64 receptor on the dendritic cells (DCs); upon processing by DCs, the cellular immune system may be activated to induce helper T-cell and CTL immune responses against tumor cells expressing the TRP2 antigen. SCIB1 can be used in combination with either nivolumab (Opdivo) with ipilimumab (Yervoy) or pembrolizumab (Keytruda), standard treatments approved for patients with advanced melanoma.",,,6349,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6349,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C91380,NCT: https://clinicaltrials.gov/study/NCT04079166,Hayleigh Kahn|Jie Zheng,,,, -822,VO:0007732,secPD-L1 vaccine,,cancer vaccine,VO:0000177,,Gene name: PD-L1,29126,Clinical trial,subunit vaccine role,,,therapeutic cancer vaccine,cancer,Homo sapiens,,,"A cancer vaccine made with secPD-L1, a splice variant of PD-L1 (programmed death ligand-1, an immune checkpoint pathway) that does not splice into the transmembrane domain, but instead produces a secreted form of PD-L1 that has a unique 18 amino acid tail containing a cysteine that allows it to homodimerize and more effectively inhibit lymphocyte function than monomeric soluble PD-L1. Recombinant secPD-L1 can dimerize and inhibit T-cell proliferation and IFN-gamma production in vitro. SecPD-L1 may function as a paracrine negative immune regulator within the tumor, since secPD-L1 does not require a cell-to-cell interaction to mediate its inhibitory effect. This could lead to improved survival for patients with numerous types of cancers, including lung cancer, melanoma, renal cell carcinoma, and Hodgkin lymphoma.",PubMed:30564891,,6376,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6376,,,,Hayleigh Kahn|Jie Zheng,,,, -823,VO:0007733,sialyl lewis-keyhole limpet hemocyanin conjugate vaccine,,cancer vaccine,VO:0000177,,,,Clinical trial,conjugate vaccine role,,,therapeutic cancer vaccine,cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine that consists of the oligosaccharide antigen sialyl Lewis (CA19-9) conjugated to the nonspecific immunomodulator keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. The sialyl Lewis-keyhole limpet hemocyanin conjugate vaccine may induce production of IgG and IgM antibodies as well as trigger an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing the sialyl Lewis antigen. The vaccine therapy together with QS21 may cause a stronger immune response and kill more tumor cells. ",,,6350,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6350,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C69000,NCT: https://clinicaltrials.gov/study/NCT00470574,Hayleigh Kahn|Jie Zheng,,,, -824,VO:0007734,tetanus peptide melanoma vaccine,,melanoma vaccine,VO:0000422,,,,Clinical trial,peptide vaccine role,,,therapeutic cancer vaccine,melanoma,Homo sapiens,,subcutaneous route|intradermal route,"A cancer vaccine consisting of peptides derived from melanoma-associated antigens and a modified T-cell epitope derived from tetanus toxoid. Vaccination with this agent may stimulate a host cytotoxic and helper T-cell response against tumor cells expressing melanoma-associated antigens, resulting in decreased tumor growth. This vaccine is compromised of multi-epitope melanoma peptide vaccine (12MP) and 1 tetanus peptide melanoma vaccine emulsified with GM-CSF and ISA-51 (incomplete Freund's adjuvant).",,,6355,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6355,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C2468,NCT: https://clinicaltrials.gov/study/NCT00071981,Hayleigh Kahn|Jie Zheng,,,, -825,VO:0007735,TGFβ2 antisense-GMCSF gene modified autologous tumor cell vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,cancer,Homo sapiens,,intradermal route,"A cancer vaccine made with GMCSF transgene that directly stimulates increased expression of tumor antigen(s) and enhances dendritic cell migration to the vaccination site. TGFβ2 blockade following intracellular TGFβ2 antisense gene expression reduces production of immune inhibiting activity at the vaccine site. This vaccine integrates enhancement of an anticancer immune response concurrently with a reduction in cancer-induced immune suppression. Autologous cancer cells are harvested from patients with advanced refractory cancer, and a TGFβ2 antisense / GMCSF expression vector plasmid is constructed. The autologous cancer tissue is irradiated and electrocorporated with the vector. ",,,6357,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6357,,,NCT: https://clinicaltrials.gov/study/NCT00684294,Hayleigh Kahn|Jie Zheng,,,, -826,VO:0007736,total tumor RNA-loaded dendritic cell vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,cancer,Homo sapiens,,intradermal route,"A cancer vaccine containing autologous dendritic cells (DCs) that are loaded with total tumor RNA (TTRNA) from a specific tumor, with potential immunostimulatory and antineoplastic activities. The vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against the tumor-associated antigens (TAAs) encoded by the TTRNA. The vaccine can be given in combination with Temozolomide (TMZ) and Autologous Hematopoietic Stem Cells (HSC).",,,6360,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6360,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C116913,NCT: https://clinicaltrials.gov/study/NCT03396575,Hayleigh Kahn|Jie Zheng,,,, -827,VO:0007737,transgenic lymphocyte immunization vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: telomerase,7015,Clinical trial,,,,therapeutic cancer vaccine,cancer,Homo sapiens,,,A cancer vaccine made as patient's lymphocytes are rendered transgenic for a gene coding for selected portion of telomerase an enzyme expressed in the vast majority of cancer cells. Transgenic cells are then returned to the patient to produce an immune response targeted at cancer cells expressing telomerase. The transgenic cells serve as antigen- presenting cells (APCs) with the dual function of antigen synthesis and presentation. Vaccination produces an immune response targeting cancer cells expressing telomerase.,PubMed:12653092,,6358,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6358,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C38720,NCT: https://clinicaltrials.gov/study/NCT00061035,Hayleigh Kahn|Jie Zheng,,,, -828,VO:0007738,TriAd cancer vaccine,,cancer vaccine,VO:0000177,,Gene name: CEA|Gene name: brachyury|Gene name: MUC1,1048|6862|4582,Clinical trial,recombinant vector vaccine role,,,therapeutic cancer vaccine,cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine of 3 adenoviral vaccines (ETBX-011, ETBX-051 & ETBX-061). ETBX-011 uses a replication-defective, E1- and E2b-deleted oncolytic adenoviral serotype 5 (Ad5) encoding an epitope of human carcinoembryonic antigen (CEA). ETBX-051 is composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human transcription factor brachyury encoded. ETBX-061 composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human glycoprotein mucin 1 (MUC1) encoded. The three of these vaccines act against tumor associated antigens and have potential immunostimulating and antineoplastic activities. The TriAd vaccine can be used in combination with Anti-PD-L1/TGF-beta trap (M7824) and Anktiva (N-803) to shrink previously untreated head and neck tumors before surgery or stop the tumors from coming back after all treatment.",,,6359,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6359,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C143034|NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C143035|NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91373,NCT: https://clinicaltrials.gov/study/NCT04247282,Hayleigh Kahn|Jie Zheng,,,, -829,VO:0007739,tumor antigen-sensitized DC vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine that can be used in combination with Neo-antigen DC vaccine and their sensitized T cells for the treatment of esophageal cancer, advanced malignant melanoma, bladder cancer and colorectal cancer.",,,6361,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6361,,,NCT: https://clinicaltrials.gov/study/NCT05023928|NCT: https://clinicaltrials.gov/study/NCT05235607,Hayleigh Kahn|Jie Zheng,,,, -830,VO:0007740,tumor lysate-pulsed dendritic cell vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,cancer,Homo sapiens,,,"A cancer vaccine that is composed of dendritic cells pulsed with tumor cells lysates that stimulate a potent and specific cell mediated anti-tumor immune response. It can be used in combination with high-dose chemotherapy and hematopoietic stem cell transplantation (HSCT). The combination may increase overall survival and progression-free survival for patients with high-risk pediatric and young adult tumors (localized solid tumors such as, sarcoma, neuroblastoma, and Wilms' tumor). ",,,6366,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6366,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1988,NCT: https://clinicaltrials.gov/study/NCT00405327,Hayleigh Kahn|Jie Zheng,,,, -831,VO:0007741,tumor lysate/KLH pulsed dendritic cell vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,sarcoma,Homo sapiens,,intradermal route,"A cancer vaccine made from proteins from the patient's tumor cells may boost the body's immune response against the tumor. The effects of chemotherapy on the immune system can potentially make immunotherapy more effective if administered soon after completion of chemotherapy. The addition of recombinant human IL-7 (interleukin 7) (rhIL-7 (recombinant human interleukin 7)) may make the immunotherapy more effective. Alpha cluster of differentiation 25 (CD25) and 8H9 depleted autologous lymphocytes plus tumor lysate/keyhole limpet hemocyanin (KLH) pulsed dendritic cell vaccines plus or minus r-hIL7 (CYT107) may induce immune responses to tumor lysate in patients (with Ewing's sarcoma, rhabdomyosarcoma or neuroblastoma).",,,6365,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6365,,,NCT: https://clinicaltrials.gov/study/NCT00923351,Hayleigh Kahn|Jie Zheng,,,, -832,VO:0007742,TVI-Brain-1 vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,cancer,Homo sapiens,,,"A cancer vaccine made as the patient's cancer will be surgically removed to provide cells for the vaccine, then the patient will be vaccinated twice with those cells and GM-CSF. After, the patient's blood will be filtered for white cells which will then be cultured and stimulated to reach a higher (killer) activity level. Next, the activated white blood cells will be infused into the patient's bloodstream so that they will be able to attack the cancer. Lastly, the entire process starting with vaccination will be repeated, for a total of two rounds of therapy. The autologous vaccine-enhanced ex vivo activated cancer neoantigens-specific T-cells TVI-Brain-1 recognize and bind to tumor cells expressing the cancer neoantigens, resulting in a cytotoxic T-lymphocyte (CTL)-mediated immune response against the patient's tumor cells.",,,6373,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6373,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C199632,NCT: https://clinicaltrials.gov/study/NCT01081223,Hayleigh Kahn|Jie Zheng,,,, -833,VO:0007743,whole tumor cell-based leukemia vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic cancer vaccine,leukemia,Homo sapiens,,subcutaneous route,"A cancer vaccine administered within the first 2 to 3 months after allogeneic stem cell transplantation may enhance graft-vs.-leukemia responses. Irradiated autologous cancer cells provide a source of tumor antigens at the vaccination site. Granulocyte macrophage colony-stimulating factor (GM-CSF) secreted by irradiated bystander cells stimulates the recruitment, maturation and immunostimulatory activity of dendritic cells (DCs) at the vaccination site. Autologous whole tumor cell-based vaccination may tip the balance between leukemia-specific and alloreactive T cell responses in favor of a graft-vs.-leukemia (GvL) effect.",PubMed:24482749,,6388,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6388,,,,Hayleigh Kahn|Jie Zheng,,,, \ No newline at end of file +772,VO:0007682,KLH and tumor lysate pulsed DC vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,cancer,Homo sapiens,,intradermal route,A cancer vaccine made with dendritic cells pulsed with KLH and tumor lysate for patients with neuroblastoma.,,,6303,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6303,,,NCT: https://clinicaltrials.gov/study/NCT02745756,Hayleigh Kahn|Jie Zheng,,,, +773,VO:0007683,KLH-id vaccine,,cancer vaccine,VO:0000177,,,,Clinical trial,subunit vaccine role,,,therapeutic vaccine function,cancer,Homo sapiens,,intramuscular route,A cancer vaccine made of tumor protein taken from a cancer patient's plasma (liquid part of the blood) and KLH (a protein designed to increase the immune response of the vaccine).,,,6259,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6259,,,NCT: https://clinicaltrials.gov/study/NCT01174082,Hayleigh Kahn|Jie Zheng,,,, +774,VO:0007684,KLH-pulsed autologous dendritic cell vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,cancer,Homo sapiens,,intratumoral route,"A cancer vaccine made with autologous dendritic cells pulsed with KLH for this vaccination, combined with radiation or a gene therapy agent, TNFerade. TNFerade or radiation serves to generate cell death stimulating the immune response. The dendritic cell vaccine may direct a distant and lasting effective anti-tumor immune response to achieve a local and systemic clinical benefit.",,,6304,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6304,,,NCT: https://clinicaltrials.gov/study/NCT00868114,Hayleigh Kahn|Jie Zheng,,,, +775,VO:0007685,KRAS-targeted mRNA vaccine,,cancer vaccine,VO:0000177,,Gene name: KRAS,3845,Clinical trial,RNA vaccine role,,,therapeutic vaccine function,cancer,Homo sapiens,,intramuscular route,"A cancer vaccine used alone or in combination with PD-1 inhibitor in patients with advanced solid tumors with KRAS mutation (G12C, G12D, or G12V) and HLA type HLA-A11:01 or HLA C08:02. The vaccine is a lipid nanoparticle (LNP)-formulated mRNA-based cancer vaccine that targets the most commonly occurring KRAS mutations (G12D, G12V, and G12C). The mRNA-derived KRAS-targeted vaccine V941 (mRNA-5671) is taken up and translated by antigen presenting cells (APCs). Following translation, the epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy tumor cells harboring these specific KRAS mutations.",,,6348,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6348,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C162186,NCT: https://clinicaltrials.gov/study/NCT05202561,Hayleigh Kahn|Jie Zheng,,,, +776,VO:0007686,LMP2A-loaded conventional DC vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: EBV|Gene name: LMP2,10376|5698,Clinical trial,,,,therapeutic vaccine function,lymphoma,Homo sapiens,,intravenous route,"A cancer vaccine made with Epstein Barr Virus (EBV)-derived tumor antigen, Latent Membrane Protein-2 (LMP2)-loaded dendritic cell (DC) vaccines are administered alone or co-administered with the TLR9 ligand, DUK-CPG-001, in patients with EBV+ lymphoma in the setting of autologous stem cell transplant with infusion of mature T cells. It may induce EBV derived tumor antigen specific CD8+ T cell response in patients with EBV+ lymphoma in the setting of autologous stem cell transplant.",,,6305,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6305,,,NCT: https://clinicaltrials.gov/study/NCT02115126,Hayleigh Kahn|Jie Zheng,,,, +777,VO:0007687,"MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine",,ovarian cancer vaccine,VO:0005493,,Gene name: MAGE-A1|Gene name: HER2-neu|Gene name: FBP,4100|2064|2348,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,ovarian cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine comprised of multiple peptides derived from MAGE-1A, Her-2/neu, and folate binding protein (FBP), with potential immunostimulating and antineoplastic properties. The MAGE-A1, Her-2/neu, FBP peptides cancer vaccine includes the peptides MAGE-A1:161-169, FBP:191-199, Her-2/neu:369-377, MAGE-A1:96-104, and Her-2/neu:754-762. Vaccination with this cancer vaccine may activate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing the corresponding antigens, resulting in tumor cell lysis. The vaccine compromises synthetic ovarian cancer-associated peptides administered with a synthetic tetanus toxoid helper peptide emulsified in Montanide ISA-51 before or after paclitaxel and carboplatin in patients with stage III-IV ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer undergoing optimal cytoreductive surgery. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving vaccine therapy and chemotherapy after surgery may kill any tumor cells that remain after surgery.",,,6306,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6306,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C62775,NCT: https://clinicaltrials.gov/study/NCT00373217,Hayleigh Kahn|Jie Zheng,,,, +778,VO:0007688,"MART-1, tyrosinase and MAGE-A6 autologous DC vaccine",,whole cell cancer vaccine,VO:0007658,,Gene name: MART-1|Gene name: tyrosinase|Gene name: MAGE-A6,2315|7299|4105,Clinical trial,,,,therapeutic vaccine function,melanoma,Homo sapiens,,intradermal route,"A cancer vaccine made with autologous dendritic cells (DC) are transduced with the MART-1, tyrosinase and MAGE-A6 (melanoma associated antigens, MAA) genes for melanoma patients. Some patients also receive interferon-alfa 2b (IFN) intravenously.",,,6280,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6280,,,NCT: https://clinicaltrials.gov/study/NCT01622933,Hayleigh Kahn|Jie Zheng,,,, +779,VO:0007689,mature dendritic cell melanoma vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,melanoma,Homo sapiens,,,A cancer vaccine that may elicit a cytotoxic T-cell (CTL) response against cancer cells. Autologous dendritic cells are pulsed with melanoma tumor-specific peptides. The mature dendritic cell (mDC3/8) vaccine (primer and booster) in patients with stage III and stage IV melanoma is followed by treatment with pembrolizumab (anti-PD-1 therapy). Using dendritic cells (a kind of white blood cell) as a vaccine could stimulate your own immune system to react to your melanoma cells.,,,6307,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6307,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C162250,NCT: https://clinicaltrials.gov/study/NCT03092453,Hayleigh Kahn|Jie Zheng,,,, +780,VO:0007690,MDX-1379 (gp100) melanoma peptide vaccine,,melanoma vaccine,VO:0000422,,Gene name: gp100,6490,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,melanoma,Homo sapiens,,subcutaneous route,"A cancer vaccine made up of two peptides that are pieces of a bigger melanoma protein (gp100). These peptides bind to HLA-A2 which is then recognized by T cells. It could be given in combination with MDX-010 (ipilimumab, BMS-734016). MDX-010 (anti-CTLA4) antibodies are designed to keep the immune system running by blocking CTLA-4 from down-regulating T cell activation.",,,6309,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6309,,,NCT: https://clinicaltrials.gov/study/NCT00094653,Hayleigh Kahn|Jie Zheng,,,, +781,VO:0007691,MDX-CTLA4 antibody/tyrosinase/gp100/MART-1 melanoma vaccine,,melanoma vaccine,VO:0000422,,Gene name: tyrosinase|Gene name: gp100|Gene name: MART-1,7299|6490|2315,Clinical trial,,,cocktail vaccine role,therapeutic vaccine function,melanoma,Homo sapiens,,intravenous route,"A cancer vaccine composed of CTLA-4 antibody; tyrosinase, gp100, and MART-1 peptides; and incomplete Freund's adjuvant (IFA) with or without interleukin-12 in patients with resected stage III or IV melanoma.",,,6310,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6310,,,NCT: https://clinicaltrials.gov/study/NCT00028431,Hayleigh Kahn|Jie Zheng,,,, +782,VO:0007692,melanoma helper peptide vaccine,,melanoma vaccine,VO:0000422,,,,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,melanoma,Homo sapiens,,subcutaneous route|intradermal route,"A cancer vaccine consisting of peptides derived from melanoma-associated antigens and an adjuvant peptide derived from tetanus toxoid. Vaccination with this agent may stimulate a host cytotoxic T-cell response against tumor cells expressing melanoma-associated antigens, resulting in tumor cell lysis. Vaccines made from peptides may make the body build an immune response to kill tumor cells. Vaccines using melanoma peptides from cytotoxic T cells and helper T cells could work in treating patients with metastatic melanoma. This vaccine contains 12 melanoma peptides restricted by Human Leukocyte Antigen (HLA)-A1, -A2, or -A3 and 6 melanoma helper peptides restricted by HLA-DR molecules emulsified with sargramostim (Granulocyte-macrophage colony-stimulating factor, GM-CSF) and Montanide ISA-51 or Montanide ISA-51 VG (ISA-51).",,,6311,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6311,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C38700,NCT: https://clinicaltrials.gov/ct2/show/NCT00071981,Hayleigh Kahn|Jie Zheng,,,, +783,VO:0007693,mixed bacterial cancer vaccine,,cancer vaccine,VO:0000177,,,,Clinical trial,,vaccine organism inactivated,,therapeutic vaccine function,cancer,Homo sapiens,,subcutaneous route|intralesional route,"A cancer vaccine containing a mixture of killed bacteria with potential immunostimulatory and antineoplastic activities. Mixed bacteria vaccine (MBV or Coley's toxins) consists of a pyrogenic bacterial lysate derived from Serratia marcescens and Streptococcus pyogenes; the active components in the lysate may be lipopolysaccharide (LPS), a component of the Gram-negative bacterial cell wall of Serratia, and streptokinase, an enzyme produced by Streptococcus pyogenes. LPS has been shown to stimulate the host humoral immune response and induce the release of various antitumor cytokines such as tumor necrosis factor (TNF) and interleukin-12 (IL-12). The mixed bacteria vaccine (MBV) is administered at a starting dose of 250 EU (1 µL) and escalated in each patient to a dose inducing the desired pyrogenic effect, defined as a body temperature of 38°C to 39.5°C. It is given to patients with malignant tumors that expressed the NY-ESO-1 antigen. It is designed to induce immunological effects and tumor response following vaccination. ",,,6314,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6314,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C74063,NCT: https://clinicaltrials.gov/study/NCT00623831,Hayleigh Kahn|Jie Zheng,,,, +784,VO:0007694,mRNA neoantigen tumor vaccine,,cancer vaccine,VO:0000177,,,,Clinical trial,RNA vaccine role,,,therapeutic vaccine function,cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine with or without PD-1/L1 may help treat patients with advanced gastric cancer. A personalized mRNA tumor vaccine encoding neoantigen may also help treat patients with advanced esophageal squamous carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma and colorectal adenocarcinoma. The vaccine can also be used in combination with PD-1 for the treatment of advanced solid tumors.",,,6328,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6328,,,NCT: https://clinicaltrials.gov/study/NCT05359354|NCT: https://clinicaltrials.gov/study/NCT05227378|NCT: https://clinicaltrials.gov/study/NCT03468244,Hayleigh Kahn|Jie Zheng,,,, +785,VO:0007695,mRNA tumor antigen DC vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,brain cancer,Homo sapiens,,,A cancer vaccine made with dendritic cells (DCs) pulsed with mRNA encoded tumor antigens. These personalized cell vaccines may lead to antitumor specific T cell responses. ,,,6339,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6339,,,NCT: https://clinicaltrials.gov/study/NCT02808416,Hayleigh Kahn|Jie Zheng,,,, +786,VO:0007696,mRNA-based personalized cancer vaccine NCI-4650,,cancer vaccine,VO:0000177,,,,Clinical trial,RNA vaccine role,,,therapeutic vaccine function,cancer,Homo sapiens,,intramuscular route,"A cancer vaccine targeting up to fifteen tumor-associated antigens (TAAs) that are specifically expressed by a patient's cancer cells, with potential immunostimulatory and antineoplastic activities. Up to fifteen neoantigen epitopes are incorporated in a proprietary formulation designed to maximize mRNA delivery and minimize mRNA-triggered immune responses. The mRNA-based PCV NCI-4650 is taken up and the mRNAs are translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This induces both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy the patient's cancer cells that express these neoantigens. Exome sequencing can identify certain gene mutations in a person's tumor. This can then be used to create cancer treatments. This mRNA vaccine might cause certain tumors to shrink. Immunogenic neoantigens and can predict for neoantigens binding the patient human leukocyte antigen (HLA) molecules from melanoma or epithelial cancer patients and use these epitopes for a personalized therapeutic messenger ribonucleic acid (mRNA) vaccine.",,,6324,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6324,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148239,NCT: https://clinicaltrials.gov/study/NCT03480152,Hayleigh Kahn|Jie Zheng,,,, +787,VO:0007697,MT-201-GBM monocyte vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,cancer,Homo sapiens,,intravenous route,"A cancer vaccine consisting of autologous monocytes loaded with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) as a fusion protein with the lysosome-associated membrane protein (LAMP), with potential immunostimulatory and antineoplastic activities. The autologous CMV-pp65-LAMP mRNA loaded monocyte vaccine MT-201-GBM exposes the immune system to the CMV pp65 peptide, which may elicit a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells. The incorporation of LAMP may route CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC class II antigen presentation, thereby promoting CD4-positive T-cell responses. MT-201-GBM (pp65CMV antigen monocytes) are administered to patients newly diagnosed with a type of brain tumor called glioblastoma (GBM) that has an unmethylated MGMT (O[6]-methylguanine-DNA methyltransferase) (MGMT) gene promoter. The vaccine is made from a type of immune cell called monocytes, which have been engineered to express a cytomegalovirus (CMV) protein. Patients also receive standard radiation therapy combined with temozolomide.",,,6315,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6315,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C179670,NCT: https://clinicaltrials.gov/study/NCT04741984,Hayleigh Kahn|Jie Zheng,,,, +788,VO:0007698,MUC1 peptide-poly-ICLC vaccine,,cancer vaccine,VO:0000177,,Gene name: MUC-1,4582,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine containing mucus 1 (MUC1) peptide and the adjuvant poly-ICLC with potential immunostimulatory and antineoplastic activities. MUC1 peptide-poly-ICLC adjuvant vaccine may induce the host immune system to mount a cytotoxic T cell response against MUC1-expressing tumor cells. MUC1 peptide-poly-ICLC adjuvant vaccine in boosting systemic immunity to MUC1 in women with stage I-III 'triple-negative' [i.e., ER(-) PR(-) HER2/neu(-)] breast cancer. MUC1 peptide-Poly-ICLC vaccine could also work in preventing lung cancer in current and former smokers at high risk for lung cancer. Vaccines made from peptides may help the body build an effective immune response to kill cells. MUC1 peptide-Poly-ICLC vaccine may stimulate the body's immune system and slow or stop the changes from normal to pre-cancer to cancer.",,,6316,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6316,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C82417,NCT: https://clinicaltrials.gov/study/NCT00986609|NCT: https://clinicaltrials.gov/study/NCT03300817,Hayleigh Kahn|Jie Zheng,,,, +789,VO:0007699,multi-epitope HER2 peptide vaccine TPIV100,,breast cancer vaccine,VO:0005484,,Gene name: HER2,2064,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,breast cancer,Homo sapiens,,intradermal route,"A cancer vaccine comprised of four peptides derived from the tumor-associated antigen (TAA) HER-2/neu (ErbB-2), with potential immunomodulating and antineoplastic activities. The four peptides may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing the HER-2/neu antigen, which may result in the inhibition of proliferation in Her-2/neu-expressing tumor cells. TPIV100 is a type of vaccine made from HER2 peptide that may help the body build an effective immune response to kill tumor cells that express HER2. Sargramostim increases the number of white blood cells in the body following chemotherapy for certain types of cancer and is used to alert the immune system. TPIV100 and sargramostim could work in treating patients with HER2 positive, stage II-III breast cancer.",,,6317,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6317,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C173525,NCT: https://clinicaltrials.gov/study/NCT04197687,Hayleigh Kahn|Jie Zheng,,,, +790,VO:0007700,multi-epitope melanoma peptide vaccine,,melanoma vaccine,VO:0000422,,Gene name: tyrosinase|Gene name: gp100|Gene name: MAGE-A3|Gene name: HLA-A|Gene name: HLA-B,7299|6490|4102|3105|3106,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,melanoma,Homo sapiens,,subcutaneous route,"A cancer vaccine consisting of a combination of peptides derived form several melanoma epitopes. Vaccination with multi-epitope melanoma peptide vaccine stimulates the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the corresponding antigens, resulting in tumor cell lysis. This vaccine may stimulate a broader CTL response compared to single-antigen vaccines. Vaccines made from melanoma peptides or antigens may help the body build an effective immune response to kill tumor cells in patients with stage IIC-IV melanoma. This vaccine is a tyrosinase/gp100/MAGE-3 class I peptide vaccine combined with Montanide ISA 51 or ISA 51 VG with CpG adjuvant 7909 in human leukocyte antigen (HLA) class I A1, A3 or A11 and B44 matched patients with surgically resected stages IIC, III and IV melanoma.",,,6318,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6318,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C38695,NCT: https://clinicaltrials.gov/study/NCT00085189,Hayleigh Kahn|Jie Zheng,,,, +791,VO:0007701,multiantigen liposome loaded dendritic cell vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,kidney cancer,Homo sapiens,,intradermal route,A cancer vaccine for which Advanced Renal Cell Carcinoma patients undergo total nephrectomy to harvest primary tumor for vaccine preparation. Dendritic cells are then pulsed with multiantigens or tumor cells. Some patients also receive vaccination with irradiated autologous tumor lysate. The vaccine may make the body build an immune response to kill tumor cells.,,,6284,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6284,,,NCT: https://clinicaltrials.gov/study/NCT00004880,Hayleigh Kahn|Jie Zheng,,,, +792,VO:0007702,multipeptide XS15 vaccine,,leukemia cancer vaccine,VO:0005487,,Gene name: TLR1|Gene name: TLR2,7096|7097,Clinical trial,,,cocktail vaccine role,therapeutic vaccine function,leukemia,Homo sapiens,,,"A cancer vaccine adjuvant and synthetic Toll-like receptor (TLR) type 1 and 2 ligand composed of a lipopeptide containing a water-soluble derivative of Pam3-Cys, the biologically active component of the mycobacterial 19 kDa lipoprotein of mycobacteria, that is covalently linked to a synthetic peptide (GDPKHPKSF), with potential immunostimulating activity. TLR1/2 agonist Pam3Cys-GDPKHPKSF targets, binds to and activates TLR1/2, which induces CD8- and T-helper 1 CD4-positive T-cell responses. This may enhance T-cell-mediated immune responses when administered together with peptide vaccine. A multi-peptide vaccine can be used in combination with the TLR1/2 ligand XS15 in CLL patients undergoing ibrutinib-based regimes. Applying several CLL-associated antigens simultaneously increases the likelihood that a multi-clonal, broad and at the same time highly specific T-cell response is mounted, thereby preventing potential tumor escape mechanisms. The novel TLR1/2 ligand (XS15, developed in Tübingen) that (i) is water-soluble and (ii) GMP-amenable, (iii) non-toxic and (iv) effective in inducing T cells specific for peptides in vivo. A personalized multi-peptide vaccination can also be used in combination with the TLR1/2 ligand XS15 for individual patients with advanced solid and hematological malignancies without any approved treatment options. ",,,6319,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6319,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C179595,NCT: https://clinicaltrials.gov/study/NCT04688385|NCT: https://clinicaltrials.gov/study/NCT05014607,Hayleigh Kahn|Jie Zheng,,,, +793,VO:0007703,multiple signals loaded dendritic cells vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,hepatocellular carcinoma,Homo sapiens,,intravenous route,A cancer vaccine that can efficiently present T cells with antigens of HCC sensitize their antitumor properties meanwhile low dose cyclophosphamide (CY) can effectively improve the microenvironment of immunity. Multiple signals loaded dendritic cells vaccine combined low dose of cyclophosphamide combining with radical surgery or TACE or targeted agents for patients with hepatocellular carcinoma coul prolong their survival time.,,,6320,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6320,,,NCT: https://clinicaltrials.gov/study/NCT04317248,Hayleigh Kahn|Jie Zheng,,,, +794,VO:0007704,mutated neopeptide vaccine,,brain cancer vaccine,VO:0005428,,Gene name: HLA,3123,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,brain cancer,Homo sapiens,,,"A cancer vaccine with neopeptides designed with single amino acid mutations to enhance their immunogenicity and bind to HLA class I and II molecules. Exome and RNA sequencing as well as in silico HLA-binding predictions to autologous HLA molecules were used to identify candidate neopeptides. Subsequently, in silico HLA-anchor placements were used to deduce putative T-cell receptor (TCR) contacts of peptides. Single amino acids of TCR contacting residues were then mutated by amino acid replacements. TIL-derived CD4+ T-cell clones showed strong responses and tumor cell lysis not only against the designed neopeptide but also against the unmutated natural peptides of the tumor. Turning tumor self-peptides into foreign antigens by introduction of designed mutations is a promising strategy to induce strong intratumoral CD4+ T-cell responses in a cold tumor like glioblastoma.",PubMed:36228153,,6383,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6383,,,,Hayleigh Kahn|Jie Zheng,,,, +795,VO:0007705,MVA-BN-CV301 vaccine,,cancer vaccine,VO:0000177,,Gene name: MUC1|Gene name: CEA|Gene name: B7.1|Gene name: ICAM-1|Gene name: LFA-3,4582|1048|941|3383|965,Clinical trial,recombinant vector vaccine role,,,therapeutic vaccine function,cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine consisting of a proprietary version of the recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding both the two human tumor-associated antigens (TAAs) carcinoembryonic antigen (CEA) and mucin-1 (MUC-1), and TRICOM, which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. MVA-BN-CV301, followed by multiple boosting doses of the fowlpox virus (FPV) vaccine CV301 may lead to a cytotoxic T-lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells is activated. In addition, the CV301-dependent anti-tumor CTL response upregulates the expression of programmed cell death ligand 1 (PD-L1); therefore, when CV301 is combined with a programmed cell death 1 (PD-1) immune checkpoint inhibitor, the antitumor effect may be increased. CV301 is a poxviral-based vaccine comprised of recombinant Modified vaccinia Ankara (MVA-BN-CV301, prime) and recombinant fowlpox (FPV-CV301, boost). CV301 contains transgenes encoding two (2) tumor-associated antigens (TAA), mucin 1 (MUC1) and carcinoembryonic antigen (CEA), as well as three costimulatory molecules (B7.1, intercellular adhesion molecule 1 (ICAM-1) and lymphocyte function-associated antigen 3 (LFA-3), designated TRICOM). It is given in combination with SX-682 and M7824 for patients with Triple Negative Breast Cancer (TNBC) and Human papilloma virus (HPV) negative head and neck squamous cell carcinoma (HNSCC).",,,6321,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6321,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C143059,NCT: https://clinicaltrials.gov/study/NCT04574583,Hayleigh Kahn|Jie Zheng,,,, +796,VO:0007706,MVF-HER-2(628-647)-CRL 1005 vaccine,,cancer vaccine,VO:0000177,,Gene name: HER2,2064,Clinical trial,,,,therapeutic vaccine function,cancer,Homo sapiens,,intramuscular route,"A cancer vaccine of a chimeric peptide immunogen of human epidermal growth factor-2 (HER-2) with antineoplastic property. MVF-HER-2(628-647)-CRL 1005 vaccine, coated with poloxamer CRL-1005 to form microparticles, consists of a mutated HER-2 B-cell epitope, HER-2(628-647), and a promiscuous T cell epitope (amino acid sequence 288-302) of the measles virus fusion protein (MVF). The vaccine may stimulate the host immune response to mount a cytotoxic T-lymphocyte response against tumor cells that overexpress the HER2 protein, resulting in tumor cell lysis. MVF-HER-2(628-647)-CRL 1005 vaccine may induce anti-HER-2 antibody in patients with metastatic or recurrent cancer (Breast, Ovarian, Non-small cell lung cancer, Gastric adenocarcinoma).",,,6322,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6322,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C2637,NCT: https://clinicaltrials.gov/study/NCT00017537,Hayleigh Kahn|Jie Zheng,,,, +797,VO:0007707,NEO-PV-01 vaccine,,lung cancer vaccine,VO:0005486,,,,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,lung cancer,Homo sapiens,,,"A cancer vaccine consisting of patient-specific mutated peptide epitopes, which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. The neoantigen-based anti-cancer vaccine NEO-PV-01 stimulates the host immune system to mount a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. Both metastatic squamous non-small cell lung cancer (NSCLC) and extensive stage small cell lung cancer (SCLC) are incurable with current therapies, but due to mutations induced by cigarette smoke, typically express a large number of altered proteins that can be recognized as foreign by the immune system. Targeting the immune system against tumor specific antigens using a peptide vaccine could lead to improved response rate and prolonged overall survival with no additional toxicity when combined with Pembrolizumab (monoclonal antibodies that block PD-1/PD-L1 interactions) and standard of care chemotherapy.",,,6325,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6325,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C129935,NCT: https://clinicaltrials.gov/study/NCT03166254,Hayleigh Kahn|Jie Zheng,,,, +798,VO:0007708,neoantigen DNA vaccine,,renal cancer vaccine,VO:0005494,,,,Clinical trial,DNA vaccine role,,,therapeutic vaccine function,kidney cancer,Homo sapiens,,intramuscular route,A cancer vaccine that may enhance anti-tumor immune response in Renal Cell Carcinoma in combination with checkpoint inhibitors ipilimumab (anti-CTLA-4 antibody) and nivolumab (anti-PD-1 antibody).,,,6326,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6326,,,NCT: https://clinicaltrials.gov/study/NCT03598816,Hayleigh Kahn|Jie Zheng,,,, +799,VO:0007709,neoantigen peptide vaccine,,cancer vaccine,VO:0000177,,,,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,cancer,Homo sapiens,,intramuscular route,"A cancer vaccine consisting of patient-specific antigens, which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. The neoantigen peptide vaccine, the peptides stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. Personalized neo-antigen peptide vaccine is a product combines multiple patient specific neo-antigens. Given personalized neo-antigen peptide vaccine together with Th1 polarizing adjuvant poly ICLC may induce a polyclonal, poly-epitope, cytolytic T cell immunity against the patient's tumor. Patients also receive nivolumab.",,,6327,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6327,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C165508,NCT: https://clinicaltrials.gov/study/NCT05098210,Hayleigh Kahn|Jie Zheng,,,, +800,VO:0007710,neoantigen synthetic long peptide vaccine,,cancer vaccine,VO:0000177,,,,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,cancer,Homo sapiens,,intramuscular route,"A cancer vaccine consisting of synthetic long peptides (SLPs), ranging from 20-35 amino acids in size, that are derived from two or more of the patient's tumor-specific mutant antigens (TSMAs), with potential immunostimulatory and antitumor activities. SLP vaccine may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL)-mediated immune response against the TSMAs expressed by the tumor cells. This vaccine is a optimized neoantigen synthetic long peptide (SLP) vaccines for pancreatic cancer patients following neoadjuvant chemotherapy. The neoantigen SLP vaccines will incorporate prioritized neoantigens and will be co-administered with poly-ICLC. It can be used in combination with chemoradiation with temozolomide for patients with newly diagnosed glioblastoma.",,,6332,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6332,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C150471,NCT: https://clinicaltrials.gov/study/NCT02510950|NCT: https://clinicaltrials.gov/study/NCT05111353,Hayleigh Kahn|Jie Zheng,,,, +801,VO:0007711,neoantigen-loaded autologous dendritic cell vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine consisting of autologous DCs loaded with immunogenic peptides derived from autologous cancer cells, with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-loaded autologous DC vaccine stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. Neoantigens arising from the mutations of the tumor genome expressed specifically on the tumor cell instead of normal cells, suggesting that vaccines targeting neoantigens should generate a highly tumor-specific response with minimal off-target effects. Neoantigens are identified from tumor tissues from a gastric cancer, hepatocellular carcinoma, lung cancer or colorectal cancer patient. Dendritic cells are then primed with synthesized peptides. The vaccine can be combined with microwave ablation ti treat patients with Hepatocellular Carcinoma (HCC). It can also be combined with Anti-PD1 (Nivolumab) as for patients with resected Hepatocellular Carcinoma (HCC) and Liver Metastases From Colorectal Cancer (CRLM). ",,,6281,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6281,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C141422,NCT: https://clinicaltrials.gov/study/NCT03674073| NCT: https://clinicaltrials.gov/study/NCT03871205| NCT: https://clinicaltrials.gov/study/NCT04147078| NCT: https://clinicaltrials.gov/study/NCT04912765],Hayleigh Kahn|Jie Zheng,,,, +802,VO:0007712,"NY-ESO-1, MAGE-A1, and MAGE-A3 dendritic cell vaccine",,whole cell cancer vaccine,VO:0007658,,Gene name: NY-ESO-1|Gene name: MAGE-A1|Gene name: MAGE-A3,1485|4100|4102,Clinical trial,,,,therapeutic vaccine function,cancer,Homo sapiens,,intramuscular route,"A cancer vaccine that is made from the subject's blood cells and is designed to interact in the patient's body with cells that are programmed to fight specific tumor proteins NY-ESO-1, Melanoma Antigen Gene-A1 (MAGE-A1) and Melanoma Antigen Gene-A3 (MAGE-A3). The vaccine can be given in combination with decitabine which may increase the amount and activity of these cancer proteins on the surface of tumor cells to increase the possibility that the vaccine will stimulate cells to act against the tumor cells. The dendritic cells may stimulate CD4 and CD8 antigen specific T cells in patients with relapsed or refractory pediatric high grade gliomas, medulloblastomas, and central nervous system primitive neuroectodermal tumors (CNS PNETs).",,,6367,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6367,,,NCT: https://clinicaltrials.gov/study/NCT02332889,Hayleigh Kahn|Jie Zheng,,,, +803,VO:0007713,NY-ESO-1/PRAME/MAGE-A3/WT-1 peptide vaccine,,leukemia cancer vaccine,VO:0005487,,Gene name: NY-ESO-1|Gene name: PRAME|Gene name: MAGE-A3|Gene name: WT-1,1485|23532|4102|7490,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,leukemia,Homo sapiens,,,"A cancer vaccine comprised of synthetic peptides derived from the cancer-testis antigen NY-ESO-1, preferentially expressed antigen in melanoma (PRAME), human melanoma antigen A3 (MAGE-A3) and the human Wilms tumor protein-1 (WT-1), with potential immunostimulating and antineoplastic activities. NY-ESO-1/PRAME/MAGE-A3/WT-1 peptide vaccine may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing NY-ESO-1, PRAME, MAGE-A3 and WT-1, resulting in tumor cell lysis. As proteins are degraded in cells, peptides are presented on the surface of these cells as a complex with tissue type molecules (HLA molecules). T-cells may then recognize the peptide-HLA complexes, via its T-cell receptor, potentially resulting in tumor-cell killing, if sufficient priming takes place. Cancer testis antigens (CTA's) are known to be immunogenic and are only expressed at immunoprivileged sites, thus out of reach of immune responses, and on cancer cells, making them ideal targets for therapeutic cancer vaccination. The CTA's chosen were NY-ESO-1, MAGE-A3 and PRAME. WT-1 is additionally included as this protein has proven to be an important antigen in hematological malignancies. It is combined with azacitidine for treatment of patients with high-risk myelodysplastic syndrome or acute myeloid leukemia. ",,,6329,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6329,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C127125,NCT: https://clinicaltrials.gov/study/NCT02750995,Hayleigh Kahn|Jie Zheng,,,, +804,VO:0007714,OCDC and NeoDC vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,esophageal cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine made with autologous DCs that are pulsed with HOCl-oxidized autologous tumor lysate (OCDC) and administered in prime phase, along with a personal neoantigen-sensitized DC(NeoDC) vaccine administered in the boost phase for Esophageal Squamous Cell Carcinoma.",,,6331,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6331,,,NCT: https://clinicaltrials.gov/study/NCT05317325,Hayleigh Kahn|Jie Zheng,,,, +805,VO:0007715,oral cancer vaccine V3-OVA,,ovarian cancer vaccine,VO:0005493,,,,Clinical trial,,,,therapeutic vaccine function,ovarian cancer,Homo sapiens,,oral route,"A cancer vaccine composed of autologous ovarian cancer antigens obtained from hydrolyzed, inactivated blood and tumor tissue of patients with ovarian cancer, with potential immunostimulatory and antineoplastic activities. The ovarian cancer antigens stimulate the immune system and activate a cytotoxic T-lymphocyte (CTL) immune response against ovarian cancer cells. Ovarian cancer patients can be given one pill a day for three months. ",,,6354,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6354,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C159540,NCT: https://clinicaltrials.gov/study/NCT03556566,Hayleigh Kahn|Jie Zheng,,,, +806,VO:0007716,oral therapeutic vaccine V3-X,,cancer vaccine,VO:0000177,,,,Clinical trial,,,,therapeutic vaccine function,cancer,Homo sapiens,,oral route,"A cancer vaccine consisting of the tumor-associated antigen (TAA) oligosaccharide antigen sialyl Lewis A (CA19-9; sialylated Lewis A antigen; carbohydrate antigen 19-9; cancer antigen 19-9), with potential immunostimulating and antineoplastic activities. Oral therapeutic vaccine V3-X induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing CA19-9. Cholangiocarcinoma (CCA) is a malignant neoplasm originating from the epithelial cells lining the intra- or extrahepatic biliary ducts. This immunotherapeutic formulation is made from pooled heat- and chemically-inactivated blood from donors with CCA for a pill for cholangiocarcinoma patients.",,,6333,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6333,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148144,NCT: https://clinicaltrials.gov/study/NCT03042182,Hayleigh Kahn|Jie Zheng,,,, +807,VO:0007717,P30-linked EphA2/CMV pp65/survivin peptide vaccine P30-EPS,,brain cancer vaccine,VO:0005428,,Gene name: EphA2|Gene name: survivin,1969|332,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,brain cancer,Homo sapiens,,,"A cancer vaccine comprised of three immunogenic tetanus toxoid epitope P30-linked tumor-associated antigen (TAA) peptides, P30-linked Ephrin receptor A2 (EphA2), P30-linked cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) and P30-linked survivin, with potential immunostimulating and antineoplastic activities. The vaccine may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing EphA2, CMV pp65 and survivin. Hiltonol is used as an adjuvant to stimulate or enhance the activation of your immune system. The vaccine and adjuvant may help treat HLA-A*0201 positive patients with a newly diagnosed, unmethylated, and untreated World Health Organization (WHO) grade IV malignant glioma.",,,6362,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6362,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C187131,NCT: https://clinicaltrials.gov/study/NCT05283109,Hayleigh Kahn|Jie Zheng,,,, +808,VO:0007718,P501-AS15 vaccine,,prostate cancer vaccine,VO:0005425,,,,Clinical trial,subunit vaccine role,,,therapeutic vaccine function,prostate cancer,Homo sapiens,,,"A cancer vaccine made up of CPC-P501 protein formulated with the adjuvant AS15. Patients with hormone-sensitive prostate cancer and rising PSA, after primary tumor treatment, can be treated with the P501-AS15 vaccine. ",,,6335,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6335,,,NCT: https://clinicaltrials.gov/study/NCT00148928,Hayleigh Kahn|Jie Zheng,,,, +809,VO:0007719,pancreatic tumor personalized neoantigen vaccine,,pancreatic cancer vaccine,VO:0005430,,,,Clinical trial,subunit vaccine role,,,therapeutic vaccine function,pancreatic cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine based on next-generation sequencing and major histocompatibility complex affinity prediction algorithm, which may help treat patients with pancreatic ductal adenocarcinoma. This vaccine may elicit measurable neoantigen-specific immunologic responses in patients.",,,6341,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6341,,,NCT: https://clinicaltrials.gov/study/NCT03558945,Hayleigh Kahn|Jie Zheng,,,, +810,VO:0007720,PD-L1 peptide vaccine,,melanoma vaccine,VO:0000422,,Gene name: PD-L1,29126,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,melanoma,Homo sapiens,,subcutaneous route,"A cancer vaccine composed of a peptide derived from the tumor-associated antigen (TAA) and immune checkpoint molecule programmed cell death-1 ligand 1 (PD-L1) combined with the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Vaccination with PD-L1 peptide vaccine may activate the immune system to induce an immune response against PD-L1-expressing cells. This may increase and restore the proliferation and activation of various immune cells, including cytotoxic T-lymphocytes (CTLs), and may eradicate PD-L1-expressing tumor cells. The vaccines aims to stimulate PD-L1 specific T-cells, hence eliminating both PD-L1 positive tumor cells as well as PD-L1 positive immunosuppressive and antigen presenting cells in the tumor microenvironment. It has been used in clinical trials for patients with multiple melanoma.",,,6338,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6338,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148146,NCT: https://clinicaltrials.gov/study/NCT03042793,Hayleigh Kahn|Jie Zheng,,,, +811,VO:0007721,PD-L1/IDO peptide vaccine IO102-103,,melanoma vaccine,VO:0000422,,Gene name: PD-L1|Gene name: IDO,29126|3620,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,melanoma,Homo sapiens,,,"A cancer vaccine composed of IO103, a peptide derived from the tumor-associated antigen (TAA) programmed cell death-1 ligand 1 (PD-L1), IO102, the 21-mer peptide vaccine derived from the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO), and the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Both IDO and PD-L1 reactive CD8 T cells are cytotoxic and can kill cancer cells and immune regulatory cells in vitro. Thus boosting specific T cells that recognize immune regulatory proteins such as IDO and PD-L1 may directly modulate immune regulation. The the programmed death 1 (PD-1) regulatory antibody Nivolumab may further help treat patients with metastatic melanoma.",,,6337,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6337,,NCI: ttps://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148154,NCT: https://clinicaltrials.gov/study/NCT03047928,Hayleigh Kahn|Jie Zheng,,,, +812,VO:0007722,personal neoantigen cancer vaccine,,cancer vaccine,VO:0000177,,,,Research,subunit vaccine role,,,therapeutic vaccine function,cancer,Homo sapiens,,,"A cancer vaccine designed to target the unique immunogenic mutations arising in each patient's tumor. Peptide binding to MHC is a critical gateway to both the initiation of a T-cell immune response by the antigen presenting cell (APC), and to the detection and elimination of tumor cells presenting the particular peptide by the stimulated cytotoxic T lymphocyte (CTL). The attraction of neoantigens as cancer targets for the immune system results from the structural and geographical features of the mutation. Neoantigen peptides are only found in tumor cells, so CTLs should show exquisite specificity, reducing the opportunity for autoimmune disease.",PubMed:25101225,,6387,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6387,,,,Hayleigh Kahn|Jie Zheng,,,, +813,VO:0007723,personalized follicular lymphoma vaccine,,lymphoma vaccine,VO:0005427,,,,Clinical trial,subunit vaccine role,,,therapeutic vaccine function,lymphoma,Homo sapiens,,,"A cancer vaccine co-administered with poly-ICLC, nivolumab, and rituximab (or another monoclonal antibody against CD20) to treat Follicular Lymphoma. The peptides comprising the vaccine are reconstituted in up to 4 pools with 5 peptides per pool (A, B, C, and D).",,,6342,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6342,,,NCT: https://clinicaltrials.gov/study/NCT03121677,Hayleigh Kahn|Jie Zheng,,,, +814,VO:0007724,personalized mature dendritic cell vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,lung cancer,Homo sapiens,,,"A cancer vaccine that may stimulate the immune system to react to lung cancer cells, in combination with Cyclophosphamide.",,,6340,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6340,,,NCT: https://clinicaltrials.gov/study/NCT02419170,Hayleigh Kahn|Jie Zheng,,,, +815,VO:0007725,personalized neoantigen melanoma vaccine,,melanoma vaccine,VO:0000422,,,,Clinical trial,subunit vaccine role,,,therapeutic vaccine function,melanoma,Homo sapiens,,,"A cancer vaccine for melanoma. Melanomas have mutations (changes in genetic material) that are specific to an individual patient and tumor. These mutations can cause the tumor cells to produce proteins that appear very different from the body's own cells. These proteins used in a vaccine may induce strong immune responses, which may help the participant's body fight any tumor cells that could cause the melanoma to come back in the future. NeoVax is a long-peptide vaccine targeting up to 20 personal neoantigens per patient for patients with surgically resected stage IIIB/C or IVM1a/b melanoma. There was long-term persistence of neoantigen-specific T cell responses following vaccination, with ex vivo detection of neoantigen-specific T cells exhibiting a memory phenotype, as well as diversification of neoantigen-specific T cell clones over time, with emergence of multiple T cell receptor clonotypes exhibiting distinct functional avidities. There was also tumor infiltration by neoantigen-specific T cell clones after vaccination and epitope spreading, suggesting on-target vaccine-induced tumor cell killing. Personal neoantigen peptide vaccines thus induce T cell responses that persist over years and broaden the spectrum of tumor-specific cytotoxicity in patients with melanoma. ",PubMed:33479501,,6375,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6375,,,NCT: https://clinicaltrials.gov/study/NCT01970358,Hayleigh Kahn|Jie Zheng,,,, +816,VO:0007726,PolyPEPI1018 CRC vaccine,,colorectal cancer vaccine,VO:0005426,,Gene name: CTAG1B,1485,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,colorectal cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine that contains 6 synthetic peptides mixed with the adjuvant Montanide™. The peptides were selected to induce T cell responses against 12 dominant epitopes from 7 cancer testis antigens (CTAs), which are the most frequently expressed CTAs in colorectal cancer. The 6 peptides were optimized to induce long lasting CRC specific T cell responses. Colorectal cancer peptide vaccine PolyPEPI1018 potentially elicits a cytotoxic T-lymphocyte response against colorectal tumors expressing the CTAs associated with the vaccine, which may result in a reduction in tumor cell proliferation. ",,,6343,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6343,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C154278,NCT: https://clinicaltrials.gov/study/NCT03391232,Hayleigh Kahn|Jie Zheng,,,, +817,VO:0007727,polyvalent melanoma vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,melanoma,Homo sapiens,,intradermal route,"A cancer vaccine consisting of whole irradiated heterologous melanoma cells which express multiple melanoma-related antigens. Polyvalent melanoma vaccine may stimulate an antitumoral cytotoxic T-cell immune response in the host, resulting in inhibition of tumor cell proliferation and tumor cell death. Vaccines may make the body build an immune response and kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Interferon alfa-2b may interfere with the growth of tumor cells. Treatment with this combination may help treat melanoma. ",,,6344,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6344,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1633,NCT: https://clinicaltrials.gov/study/NCT00004104,Hayleigh Kahn|Jie Zheng,,,, +818,VO:0007728,prodencel,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,prostate cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine made with autologous dendritic cells targeting prostate cancer (PC)-specific antigen(s), with potential immunostimulatory and antineoplastic activities. Upon administration of prodencel, the DCs stimulate a specific cytotoxic T-lymphocyte (CTL)-mediated immune response against PC cells expressing the antigen(s), resulting in tumor cell lysis. (NCIT_C192174) The vaccine could help treat patients with metastatic castration-resistant prostate cancer (mCRPC) after novel androgen-deprived therapy and docetaxel chemotherapy failure.",,,6345,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6345,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C192174,NCT: https://clinicaltrials.gov/study/NCT05533203,Hayleigh Kahn|Jie Zheng,,,, +819,VO:0007729,pUMVC3-IGFBP2-HER2-IGF1R plasmid DNA vaccine,,breast cancer vaccine,VO:0005484,,Gene name: IGFBP2|Gene name: HER2|Gene name: IGF1R,3485|2064|3480,Clinical trial,DNA vaccine role,,,therapeutic vaccine function,breast cancer,Homo sapiens,,intradermal route,"A cancer vaccine containing the mammalian expression vector pUMVC3 encoding epitopes derived from three tumor-associated antigens (TAAs): human insulin-like growth factor-binding protein 2 (IGFBP2), human epidermal growth factor receptor 2 (HER2; ERBB2) and insulin-like growth factor 1 receptor (IGF1R), with potential immunostimulating and antineoplastic activities. The vaccine This activates the immune system to mount a combined response from specific T helper type 1 (Th1) cells, memory T-cells and cytotoxic T-lymphocytes (CTL) against IGFBP2-, HER2-, and IGF1R-expressing tumor cells. This vaccine may prevent cancer from coming back in patients with non-metastatic, node positive, human epidermal growth factor receptor (HER)2 negative breast cancer in which all signs and symptoms have disappeared. Vaccines made from deoxyribonucleic acid (DNA) may help the body build an effective immune response to kill tumor cells. It is given in combination with sargramostim.",,,6346,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6346,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C127910,NCT: https://clinicaltrials.gov/study/NCT02780401,Hayleigh Kahn|Jie Zheng,,,, +820,VO:0007730,RAS peptide cancer vaccine TG01,,pancreatic cancer vaccine,VO:0005430,,,,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,pancreatic cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine containing seven 17 amino acids long synthetic RAS oncogene-encoded peptides representing the most common codon 12 and 13 oncogenic mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS), with potential immunomodulating and antineoplastic activities. The vaccine may stimulate a specific CD4-positive helper T-lymphocyte- and cytotoxic T-lymphocyte (CTL)-mediated immune response against RAS mutant-specific-expressing cancer cells, resulting in an inhibition of tumor cell proliferation and tumor cell death. The vaccine can be given in combination with Balstilimab and QS-21 for patients with pancreatic cancer to increase efficacy. ",,,6356,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6356,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C200465,NCT: https://clinicaltrials.gov/study/NCT05638698,Hayleigh Kahn|Jie Zheng,,,, +821,VO:0007731,SCIB1 DNA vaccine,,melanoma vaccine,VO:0000422,,Gene name: TRP-2,1638,Clinical trial,DNA vaccine role,,,therapeutic vaccine function,melanoma,Homo sapiens,,intramuscular route,"A cancer vaccine that encodes a melanoma antigen tyrosinase-related protein 2 (TRP2) cytotoxic T-lymphocyte (CTL) epitope and a modified monoclonal antibody, a chimera of human IgG1/murine IgG2a with T cell mimotopes expressed within the complementarity-determining regions (CDR) of the antibodies, with potential immunostimulating and antineoplastic activities. The melanoma TRP2 CTL epitope vaccine SCIB1 expresses the modified antibody. Subsequently, the Fc component of the engineered antibody targets and binds to the CD64 receptor on the dendritic cells (DCs); upon processing by DCs, the cellular immune system may be activated to induce helper T-cell and CTL immune responses against tumor cells expressing the TRP2 antigen. SCIB1 can be used in combination with either nivolumab (Opdivo) with ipilimumab (Yervoy) or pembrolizumab (Keytruda), standard treatments approved for patients with advanced melanoma.",,,6349,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6349,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C91380,NCT: https://clinicaltrials.gov/study/NCT04079166,Hayleigh Kahn|Jie Zheng,,,, +822,VO:0007732,secPD-L1 vaccine,,cancer vaccine,VO:0000177,,Gene name: PD-L1,29126,Clinical trial,subunit vaccine role,,,therapeutic vaccine function,cancer,Homo sapiens,,,"A cancer vaccine made with secPD-L1, a splice variant of PD-L1 (programmed death ligand-1, an immune checkpoint pathway) that does not splice into the transmembrane domain, but instead produces a secreted form of PD-L1 that has a unique 18 amino acid tail containing a cysteine that allows it to homodimerize and more effectively inhibit lymphocyte function than monomeric soluble PD-L1. Recombinant secPD-L1 can dimerize and inhibit T-cell proliferation and IFN-gamma production in vitro. SecPD-L1 may function as a paracrine negative immune regulator within the tumor, since secPD-L1 does not require a cell-to-cell interaction to mediate its inhibitory effect. This could lead to improved survival for patients with numerous types of cancers, including lung cancer, melanoma, renal cell carcinoma, and Hodgkin lymphoma.",PubMed:30564891,,6376,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6376,,,,Hayleigh Kahn|Jie Zheng,,,, +823,VO:0007733,sialyl lewis-keyhole limpet hemocyanin conjugate vaccine,,cancer vaccine,VO:0000177,,,,Clinical trial,conjugate vaccine role,,,therapeutic vaccine function,cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine that consists of the oligosaccharide antigen sialyl Lewis (CA19-9) conjugated to the nonspecific immunomodulator keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. The sialyl Lewis-keyhole limpet hemocyanin conjugate vaccine may induce production of IgG and IgM antibodies as well as trigger an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing the sialyl Lewis antigen. The vaccine therapy together with QS21 may cause a stronger immune response and kill more tumor cells. ",,,6350,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6350,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C69000,NCT: https://clinicaltrials.gov/study/NCT00470574,Hayleigh Kahn|Jie Zheng,,,, +824,VO:0007734,tetanus peptide melanoma vaccine,,melanoma vaccine,VO:0000422,,,,Clinical trial,peptide vaccine role,,,therapeutic vaccine function,melanoma,Homo sapiens,,subcutaneous route|intradermal route,"A cancer vaccine consisting of peptides derived from melanoma-associated antigens and a modified T-cell epitope derived from tetanus toxoid. Vaccination with this agent may stimulate a host cytotoxic and helper T-cell response against tumor cells expressing melanoma-associated antigens, resulting in decreased tumor growth. This vaccine is compromised of multi-epitope melanoma peptide vaccine (12MP) and 1 tetanus peptide melanoma vaccine emulsified with GM-CSF and ISA-51 (incomplete Freund's adjuvant).",,,6355,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6355,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C2468,NCT: https://clinicaltrials.gov/study/NCT00071981,Hayleigh Kahn|Jie Zheng,,,, +825,VO:0007735,TGFβ2 antisense-GMCSF gene modified autologous tumor cell vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,cancer,Homo sapiens,,intradermal route,"A cancer vaccine made with GMCSF transgene that directly stimulates increased expression of tumor antigen(s) and enhances dendritic cell migration to the vaccination site. TGFβ2 blockade following intracellular TGFβ2 antisense gene expression reduces production of immune inhibiting activity at the vaccine site. This vaccine integrates enhancement of an anticancer immune response concurrently with a reduction in cancer-induced immune suppression. Autologous cancer cells are harvested from patients with advanced refractory cancer, and a TGFβ2 antisense / GMCSF expression vector plasmid is constructed. The autologous cancer tissue is irradiated and electrocorporated with the vector. ",,,6357,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6357,,,NCT: https://clinicaltrials.gov/study/NCT00684294,Hayleigh Kahn|Jie Zheng,,,, +826,VO:0007736,total tumor RNA-loaded dendritic cell vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,cancer,Homo sapiens,,intradermal route,"A cancer vaccine containing autologous dendritic cells (DCs) that are loaded with total tumor RNA (TTRNA) from a specific tumor, with potential immunostimulatory and antineoplastic activities. The vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against the tumor-associated antigens (TAAs) encoded by the TTRNA. The vaccine can be given in combination with Temozolomide (TMZ) and Autologous Hematopoietic Stem Cells (HSC).",,,6360,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6360,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C116913,NCT: https://clinicaltrials.gov/study/NCT03396575,Hayleigh Kahn|Jie Zheng,,,, +827,VO:0007737,transgenic lymphocyte immunization vaccine,,whole cell cancer vaccine,VO:0007658,,Gene name: telomerase,7015,Clinical trial,,,,therapeutic vaccine function,cancer,Homo sapiens,,,A cancer vaccine made as patient's lymphocytes are rendered transgenic for a gene coding for selected portion of telomerase an enzyme expressed in the vast majority of cancer cells. Transgenic cells are then returned to the patient to produce an immune response targeted at cancer cells expressing telomerase. The transgenic cells serve as antigen- presenting cells (APCs) with the dual function of antigen synthesis and presentation. Vaccination produces an immune response targeting cancer cells expressing telomerase.,PubMed:12653092,,6358,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6358,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C38720,NCT: https://clinicaltrials.gov/study/NCT00061035,Hayleigh Kahn|Jie Zheng,,,, +828,VO:0007738,TriAd cancer vaccine,,cancer vaccine,VO:0000177,,Gene name: CEA|Gene name: brachyury|Gene name: MUC1,1048|6862|4582,Clinical trial,recombinant vector vaccine role,,,therapeutic vaccine function,cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine of 3 adenoviral vaccines (ETBX-011, ETBX-051 & ETBX-061). ETBX-011 uses a replication-defective, E1- and E2b-deleted oncolytic adenoviral serotype 5 (Ad5) encoding an epitope of human carcinoembryonic antigen (CEA). ETBX-051 is composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human transcription factor brachyury encoded. ETBX-061 composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human glycoprotein mucin 1 (MUC1) encoded. The three of these vaccines act against tumor associated antigens and have potential immunostimulating and antineoplastic activities. The TriAd vaccine can be used in combination with Anti-PD-L1/TGF-beta trap (M7824) and Anktiva (N-803) to shrink previously untreated head and neck tumors before surgery or stop the tumors from coming back after all treatment.",,,6359,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6359,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C143034|NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C143035|NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91373,NCT: https://clinicaltrials.gov/study/NCT04247282,Hayleigh Kahn|Jie Zheng,,,, +829,VO:0007739,tumor antigen-sensitized DC vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,cancer,Homo sapiens,,subcutaneous route,"A cancer vaccine that can be used in combination with Neo-antigen DC vaccine and their sensitized T cells for the treatment of esophageal cancer, advanced malignant melanoma, bladder cancer and colorectal cancer.",,,6361,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6361,,,NCT: https://clinicaltrials.gov/study/NCT05023928|NCT: https://clinicaltrials.gov/study/NCT05235607,Hayleigh Kahn|Jie Zheng,,,, +830,VO:0007740,tumor lysate-pulsed dendritic cell vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,cancer,Homo sapiens,,,"A cancer vaccine that is composed of dendritic cells pulsed with tumor cells lysates that stimulate a potent and specific cell mediated anti-tumor immune response. It can be used in combination with high-dose chemotherapy and hematopoietic stem cell transplantation (HSCT). The combination may increase overall survival and progression-free survival for patients with high-risk pediatric and young adult tumors (localized solid tumors such as, sarcoma, neuroblastoma, and Wilms' tumor). ",,,6366,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6366,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1988,NCT: https://clinicaltrials.gov/study/NCT00405327,Hayleigh Kahn|Jie Zheng,,,, +831,VO:0007741,tumor lysate/KLH pulsed dendritic cell vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,sarcoma,Homo sapiens,,intradermal route,"A cancer vaccine made from proteins from the patient's tumor cells may boost the body's immune response against the tumor. The effects of chemotherapy on the immune system can potentially make immunotherapy more effective if administered soon after completion of chemotherapy. The addition of recombinant human IL-7 (interleukin 7) (rhIL-7 (recombinant human interleukin 7)) may make the immunotherapy more effective. Alpha cluster of differentiation 25 (CD25) and 8H9 depleted autologous lymphocytes plus tumor lysate/keyhole limpet hemocyanin (KLH) pulsed dendritic cell vaccines plus or minus r-hIL7 (CYT107) may induce immune responses to tumor lysate in patients (with Ewing's sarcoma, rhabdomyosarcoma or neuroblastoma).",,,6365,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6365,,,NCT: https://clinicaltrials.gov/study/NCT00923351,Hayleigh Kahn|Jie Zheng,,,, +832,VO:0007742,TVI-Brain-1 vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,cancer,Homo sapiens,,,"A cancer vaccine made as the patient's cancer will be surgically removed to provide cells for the vaccine, then the patient will be vaccinated twice with those cells and GM-CSF. After, the patient's blood will be filtered for white cells which will then be cultured and stimulated to reach a higher (killer) activity level. Next, the activated white blood cells will be infused into the patient's bloodstream so that they will be able to attack the cancer. Lastly, the entire process starting with vaccination will be repeated, for a total of two rounds of therapy. The autologous vaccine-enhanced ex vivo activated cancer neoantigens-specific T-cells TVI-Brain-1 recognize and bind to tumor cells expressing the cancer neoantigens, resulting in a cytotoxic T-lymphocyte (CTL)-mediated immune response against the patient's tumor cells.",,,6373,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6373,,NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C199632,NCT: https://clinicaltrials.gov/study/NCT01081223,Hayleigh Kahn|Jie Zheng,,,, +833,VO:0007743,whole tumor cell-based leukemia vaccine,,whole cell cancer vaccine,VO:0007658,,,,Clinical trial,,,,therapeutic vaccine function,leukemia,Homo sapiens,,subcutaneous route,"A cancer vaccine administered within the first 2 to 3 months after allogeneic stem cell transplantation may enhance graft-vs.-leukemia responses. Irradiated autologous cancer cells provide a source of tumor antigens at the vaccination site. Granulocyte macrophage colony-stimulating factor (GM-CSF) secreted by irradiated bystander cells stimulates the recruitment, maturation and immunostimulatory activity of dendritic cells (DCs) at the vaccination site. Autologous whole tumor cell-based vaccination may tip the balance between leukemia-specific and alloreactive T cell responses in favor of a graft-vs.-leukemia (GvL) effect.",PubMed:24482749,,6388,VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6388,,,,Hayleigh Kahn|Jie Zheng,,,, \ No newline at end of file diff --git a/vo.owl b/vo.owl index 104d9b4..43edf03 100644 --- a/vo.owl +++ b/vo.owl @@ -19,7 +19,7 @@ xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:ncbitaxon="http://purl.obolibrary.org/obo/ncbitaxon#"> - + en Chris mungall Erica Marcos @@ -36,6 +36,7 @@ Barry Smith Bjoern Peters Edison Ong + Ellen Zhang Hong Yu Jason Hu Jie Zheng @@ -52,21 +53,20 @@ Rohit Goru Ronak Sutariya Samantha G. Sayers (SGS) + Taiyu Lin Thomas Todd + Xingxian Li Yongqun "Oliver" He (YH) Yu Lin (YL) Yuanyi (Penny) Pan - Zuoshuang "Allen" Xiang - Ellen Zhang - Taiyu Lin - Xingxian Li Yuping Zheng + Zuoshuang "Allen" Xiang The Vaccine Ontology (VO) is a community-based biomedical ontology in the domain of vaccine and vaccination. VO aims to standardize vaccine types and annotations, integrate various vaccine data, and support computer-assisted reasoning. The VO supports basic vaccine R&D and clincal vaccine usage. VO is being developed as a community-based ontology with support and collaborations from the vaccine and bio-ontology communities. OWL-DL An ontology in the domain of vaccine and vaccination Vaccine Ontology - 2024-06-26 + 2024-07-13 @@ -258,7 +258,6 @@ We also have the outstanding issue of how to aim different definitions to differ Consider re-defing to: An alternative name for a class or property which can mean the same thing as the preferred name (semantically equivalent, narrow, broad or related). alternative label - alternative term @@ -3427,7 +3426,7 @@ is_specified_output_of some - A shortcut relation that equals to: + A shortcut relation that is equivalent to: 'processed material' and (is_specified_output_of some 'vaccine preparation') and ('has function' some ('vaccine function' and ('is realized by' only ('vaccine immunization' and (realizes some ('vaccine host role' and (role_of some 'organism' and has_disposition some disease)))))))). The domain of this relation is a vaccine. The range of this relation is a disease. @@ -3454,16 +3453,32 @@ The range of this relation is a disease. - - A shortcut relation that equals to: -'processed material' and (is_specified_output_of some 'vaccine preparation') and ('has function' some ('vaccine function' and ('is realized by' only ('vaccine immunization' and (realizes some ('vaccine host role' and (role_of some 'organism')))))))). + + + + + + + + + + + + A shortcut relation that is equivalent to: +'processed material' and (is_specified_output_of some 'vaccine preparation') and ('has function' some ('vaccine function' and ('is realized by' only ('vaccine immunization' and (realizes some ('vaccine recipient role' and (role_of some 'organism')))))))). The domain of this relation is a vaccine. The range of this relation is a organism. + Anna Maria Masci Asiyah Yu Lin + Barry Smith + Jie Zheng Oliver He immunization for host + immunization for recipient + immunizes host vaccine immunization for host - immunizes host + vaccine immunization for recipient + immunizes recipient @@ -3505,7 +3520,7 @@ The range of this relation is a organism. - A shortcut relation that equals to: + A shortcut relation that is equivalent to: processed material and (is_specified_output_of some vaccine preparation) and (has function some (vaccine function and (is realized by only (vaccine immunization and (realizes some ('immunization target role' and (role_of some 'pathogen')))))))) The domain of this relation is a vaccine. @@ -4307,6 +4322,12 @@ Ranges: organism and 'has role' some 'pathogen role' quality + + + + (forall (x) (if (exists (t) (and (existsAt x t) (Quality x))) (forall (t_1) (if (existsAt x t_1) (Quality x))))) // axiom label in BFO2 CLIF: [105-001] + + @@ -4325,12 +4346,6 @@ Ranges: organism and 'has role' some 'pathogen role'(forall (x) (if (Quality x) (SpecificallyDependentContinuant x))) // axiom label in BFO2 CLIF: [055-001] - - - - (forall (x) (if (exists (t) (and (existsAt x t) (Quality x))) (forall (t_1) (if (existsAt x t_1) (Quality x))))) // axiom label in BFO2 CLIF: [105-001] - - @@ -27787,13 +27802,19 @@ https://sourceforge.net/p/obi/obi-terms/738/ - - + + + + + + + + @@ -27810,15 +27831,12 @@ https://sourceforge.net/p/obi/obi-terms/738/ - - - - - - - A vaccine is a processed material with the function that when administered, it prevents or ameliorates a disorder in a target organism by inducing or modifying adaptive immune responses specific to the antigens in the vaccine. + Material entity that is manufactured to realize the vaccine function. Many vaccines are developed to protect against infectious pathogens that causes infectious diseases. Many vaccines are also being developed against other diseases such as cancer, allergy, and autoimmune diseases. - YH, BP, BS, MC, LC, XZ, RS + Anna Maria Masci + Barry Smith + Jie Zheng + YH, BP, MC, LC, XZ, RS vaccine vaccine MeSH: D014612 @@ -27919,7 +27937,10 @@ https://sourceforge.net/p/obi/obi-terms/738/ - a process of administering substance in vivo that involves in adding a vaccine into a host (e.g., human) in vivo with the intent to invoke a protective or therapeutic adaptive immune response. + A process of administering a vaccine in vivo to a recipient (e.g., human) with the intent to invoke a protective or therapeutic adaptive immune response. + Anna Maria Masci + Barry Smith + Jie Zheng YH, BP vaccine administration process @@ -29134,7 +29155,7 @@ Reference: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=157& - A vaccine for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b. MENHIBRIX is approved for use in children 6 weeks of age through 18 months of age. + A vaccine for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b. MENHIBRIX is approved for use in children 6 weeks of age through 18 months of age. Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1437912 https://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm308566.htm @@ -32119,8 +32140,8 @@ https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm112854.h Adenovirus types 4 and 7 vaccine Adenovirus Type 4 and Type 7 Vaccine, Live, Oral - UMLS_CUI: C0695130 SNOMEDCT: 442561000 + UMLS_CUI: C0695130 @@ -33369,8 +33390,7 @@ https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm112854.h a vaccine component role that inheres in a recombinant vaccine vector as a vaccine component. The combination of a recombinant vaccine vector and a heterogenous protective antigen(s) inserted inside the vector for a recombinant vector vaccine. - YH - YL + YH,YL role recombinant vaccine vector role @@ -33438,8 +33458,7 @@ An adjuvant is a substance that helps and enhances the pharmacological effect of an organismal quality that indicates an organism (e.g., human) is immunized against a disease. To assign the state of 'immunized', we will need to do some assay to measure indicators of immunity, e.g., antibody titers in serum samples. - YL - YH + YH, YL quality immunized @@ -33893,7 +33912,10 @@ MUTATION: An isogenic sodC mutant constructed from B abortus 2308 by gene replac - A vaccine that prevents or treats cancer. It is produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced. + Vaccine that prevents or treats cancer. + Anna Maria Masci + Barry Smith + Jie Zheng Oliver He neoplasm vaccine tumor vaccine @@ -34873,8 +34895,7 @@ MUTATION: An isogenic sodC mutant constructed from B abortus 2308 by gene replac to be eaten. Melanie has submitted this term and its two subclasses to obo: http://sourceforge.net/tracker/?func=detail&aid=2873643&group_id=76834&atid=595654 - MC - YH + YH, MC quality edibility @@ -35331,12 +35352,12 @@ Ref: Hadler TC, et al. Immunization in developing countries. In: Vaccines. Edito - vaccine function is a function that inheres in a vaccine that induces protective immune response against a disease. It is realized in the immunization process in the host. + To induce or modify protective or therapeutic immune response against a disease. PERSPN: Oliver He: There has been hot discussion about whether we use 'vaccine function' or 'vaccine role'. Vaccine role may not be the good term to use. Vaccine is designed to be 'vaccine', so it should be vaccine function. One special case is cowpox virus. The cowpox virus can be mixed with some liquid like water and used as a smallpox vaccine. In this case, people often say: the cowpox virus has a 'vaccine role'. However, the cowpox virus vaccine is a processed material of a mix of the virus with water. The virus is a virus, it is not a vaccine per se. Therefore, vaccine role may not be an accurate term. - MC - XZ - and AR - YH + Anna Maria Masci + Barry Smith + Jie Zheng + YH, MC, XZ, and AR disposition vaccine function @@ -35873,9 +35894,9 @@ Ref: Hadler TC, et al. Immunization in developing countries. In: Vaccines. Edito a vaccine additive that stabilizes the vaccine emulsification manufacturing process and makes emulsion of the vaccine easier. YH, YL - WEB: http://www.ncbi.nlm.nih.gov/pubmed/16337664 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/16337664 vaccine component - Emulsifiers help bind ingredients together and keep them from separating, most commonly with oil and water. An emulsifier is also a surfactant that reduces the surface tension of a liquid and results in an easier, smoother spread. Reference: http://www.wisegeek.org/what-is-polysorbate-80.htm + Emulsifiers help bind ingredients together and keep them from separating, most commonly with oil and water. An emulsifier is also a surfactant that reduces the surface tension of a liquid and results in an easier, smoother spread. Reference: http://www.wisegeek.org/what-is-polysorbate-80.htm vaccine emulsifier @@ -36249,8 +36270,7 @@ Ref: Hadler TC, et al. Immunization in developing countries. In: Vaccines. Edito A quality of edibility that inheres in a bearer by virtue of the bearer being not suitable for oral ingestion. - MC - YH + YH, MC quality inedible @@ -37421,9 +37441,7 @@ Ref: Hadler TC, et al. Immunization in developing countries. In: Vaccines. Edito - YL - ZX - YH + YH, YL, ZX a vaccine organism that is inactived/killed killed vaccine organism organism @@ -37817,8 +37835,7 @@ Ref: Hadler TC, et al. Immunization in developing countries. In: Vaccines. Edito A role inheres in a material entity, that has been added into a vaccine's formulation by the manufacture for a specific purpose. For example: adjuvant to enhance the effect of immunogen, perservatives, stablizers and those materials added for affecting PH and isotonicity. - YH - YL + YL,YH Page 73, Chapter 6, Vaccine, 5th Edition. EXPERT CONSULT by Plotkin SA., et. al. 2008 role vaccine additive role @@ -38136,8 +38153,7 @@ Ref: Hadler TC, et al. Immunization in developing countries. In: Vaccines. Edito period of persistence of vaccine induced immune response is a temporal interval during which a vaccine-induced immune response continuously exists. This term is related to the process 'persistence of vaccine induced immune response'. - MC - YH + YH, MC temporal region period of persistence of vaccine induced immune response @@ -38412,8 +38428,7 @@ Ref: Hadler TC, et al. Immunization in developing countries. In: Vaccines. Edito vaccine candidate role is the role of a material entity in an investigation, which has not been experimentally or clinically verified to induce a protection or treatment in vivo in a host organism. This role should be a subclass of 'test substance role', which will be mireoted from OBI by OntoFox. - YH - BP + BP, YH role vaccine candidate role @@ -38593,7 +38608,8 @@ VE = (p-c)/p(1-c) x 100%. - preventive vaccine function is a vaccine function realized by the process of vaccination and leading to induction of an adaptive immune response to the antigens in a vaccine, which protects against a specific disorder. + A vaccine function realized by the process of vaccination and leading to induction of an adaptive immune response to prevent a specific disorder. + Jie Zheng YH prophylactic vaccine function disposition @@ -39257,7 +39273,10 @@ VE = (p-c)/p(1-c) x 100%. - immunization is a processual entity that primes or modifies an adaptivie immune response to some antigens. + A process that results in an adaptive immune response to one or more antigens. + Anna Maria Masci + Barry Smith + Jie Zheng YH, XZ, BP WEB: http://en.wikipedia.org/wiki/Immunization process @@ -39270,8 +39289,12 @@ VE = (p-c)/p(1-c) x 100%. - Active immunization is an immunization process that entails the introduction of a foreign molecule into the body, which causes the body itself to generate adaptive immunity against the target. - YH, XZ + An immunization that involves the introduction of foreign molecules into a recipient body, in a way which causes the recipient to actively induce adaptive immunity against the immunization target. + Anna Maria Masci + Barry Smith + Jie Zheng + Oliver He + XZ WEB: http://en.wikipedia.org/wiki/Immunization process active immunization @@ -39289,9 +39312,13 @@ VE = (p-c)/p(1-c) x 100%. - Passive immunization is an immunization process where pre-synthesized elements of the immune system are transferred to an organism so that the body does not need to produce these elements itself. + An immunization where pre-synthesized elements of the immune system are transferred to an organism so that the body does not need to produce these elements itself. Currently, antibodies can be used for passive immunization. This method of immunization works very quickly. However, it is short lasting. The antibodies are naturally broken down. If there are no B cells to produce more antibodies, they will disappear. YH, XZ + Anna Maria Masci + Barry Smith + Jie Zheng + Oliver He WEB: http://en.wikipedia.org/wiki/Immunization process passive immunization @@ -39344,7 +39371,10 @@ VE = (p-c)/p(1-c) x 100%. - artificial active immunization is an active immunization that occurs when a person or animal is vaccinated with a specific vaccine. + An immunization that is induced by a vaccine via vaccination process. + Anna Maria Masci + Barry Smith + Jie Zheng YH, XZ artificial active immunization WEB: http://en.wikipedia.org/wiki/Immunization @@ -39406,8 +39436,7 @@ VE = (p-c)/p(1-c) x 100%. - XZ - YH + YH, XZ disposition preventive infectious disease vaccine function @@ -39773,7 +39802,7 @@ VE = (p-c)/p(1-c) x 100%. YH protein human ACPP - GenBank: AC020633; Protein RefSeq: NP_001090 + GenBank: AC020633; Protein RefSeq: NP_001090 @@ -40016,8 +40045,7 @@ VE = (p-c)/p(1-c) x 100%. time of survival of live vaccine inside host is a temporal interval during which a live vaccine survives inside a host organism. This entity is related to the process survival of live vaccine inside host. - MC - YH + YH, MC temporal region time of survival of live vaccine inside host @@ -40388,7 +40416,8 @@ Toxins can be small molecules, peptides, or proteins that are capable of causing - The therapeutic vaccine function is a function realized by the process of vaccination and leading to induction of an adaptive immune response to the antigens in a vaccine, which ameliorates a specific disorder. + A vaccine function realized the process of vaccination and leading to induction of an adaptive immune response to treat an existing specific disorder. + Jie Zheng YH disposition therapeutic vaccine function @@ -40630,12 +40659,7 @@ Toxins can be small molecules, peptides, or proteins that are capable of causing vaccine candidate is a processed material that is designed to prevent or ameliorate a disorder in a target organism by modulating adaptive immune responses in that organism by administrating the vaccine. During our call, we decided not to say vaccine candidate is an output of vaccine preparation, which may be reserved for vaccine alone. -- Aug 4, 2009. - AR - BP - LC - MC - and ZX - YH + YH, AR, BP, LC, MC, and ZX material entity vaccine candidate @@ -40828,8 +40852,7 @@ Toxins can be small molecules, peptides, or proteins that are capable of causing immunization objective is the specification of an objective to achieve immunization. - XZ - YH + YH, XZ WEB: http://en.wikipedia.org/wiki/Immunization information content entity immunization objective @@ -42387,7 +42410,7 @@ However, even this may not be comprehensive. - A live attenuated Shigella flexneri 2a vaccine that carries deletions of the plasmid-borne virulence gene icsA (mediating intra- and intercellular spread) and the chromosomal locus iuc (encoding aerobactin). + A live attenuated Shigella flexneri 2a vaccine that carries deletions of the plasmid-borne virulence gene icsA (mediating intra- and intercellular spread) and the chromosomal locus iuc (encoding aerobactin). YH PMID:10377124 vaccine @@ -46659,8 +46682,7 @@ Ref: Finn TM and Egan W, in Vaccines fifth edition, 2008. Page 73. a role inhers in a vaccine component that when added into a vccine formmulation, it can prevent the growth of bacteria or fungi that inadvertently may be introduced into the vaccine during administrating process or the manufacturing process. - YH - YL + YH,YL P73 Chapter 6, Vaccine 5th edition by Plotkin, S. et al. role The CFR requires that, with certain defined exceptions, preservatives must be added to mulitdose vials of vaccine. (P73 Chapter 6, Vaccine 5th edition by Plotkin, S. et al.) @@ -46948,8 +46970,7 @@ Ref: Finn TM and Egan W, in Vaccines fifth edition, 2008. Page 73. vaccine allergen is a material entity that is capable of stimulating a type-I hypersensitivity reaction in atopic individuals who has been vaccinated with a vaccine. - ZX - YH + YH, ZX WEB: http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf material entity vaccine allergen @@ -46977,9 +46998,7 @@ Ref: Finn TM and Egan W, in Vaccines fifth edition, 2008. Page 73.chicken egg protein allergen is a vaccine allergen that is composed of chicken egg protein. Egg protein may come from NCIS thesaurus egg - poultry, combination of minimal anatomy terminology and NCBI taxonomy... Eventually, this term chicken egg protein allergen may become a cross product of sevreal ontology terms. - MC - ZX - YH + YH, ZX, MC material entity chicken egg protein allergen @@ -46990,8 +47009,7 @@ of minimal anatomy terminology and NCBI taxonomy... Eventually, this term chicke - ZX - YH + YH, ZX material entity latex vaccine allergen @@ -47002,8 +47020,7 @@ of minimal anatomy terminology and NCBI taxonomy... Eventually, this term chicke - ZX - YH + YH, ZX material entity gelatin vaccine allergen @@ -47014,8 +47031,7 @@ of minimal anatomy terminology and NCBI taxonomy... Eventually, this term chicke - ZX - YH + YH, ZX material entity protamine sulfate vaccine allergen @@ -47026,8 +47042,7 @@ of minimal anatomy terminology and NCBI taxonomy... Eventually, this term chicke - ZX - YH + YH, ZX material entity polymyxin B vaccine allergen @@ -47298,9 +47313,9 @@ of minimal anatomy terminology and NCBI taxonomy... Eventually, this term chicke a vaccine emulsifier that uses polysorbate 80, also known as polyoxyethylene sorbitan monooleate or Tween(TM) 80. YH,YL Tween 80 vaccine emulsifier - WEB: http://www.wisegeek.org/what-is-polysorbate-80.htm + WEB: http://www.wisegeek.org/what-is-polysorbate-80.htm vaccine component - Tween 80 is an amber-colored, viscous liquid with a slightly bitter taste. The product is a derivative of sorbitol and oleic acid. + Tween 80 is an amber-colored, viscous liquid with a slightly bitter taste. The product is a derivative of sorbitol and oleic acid. polysorbate 80 vaccine emulsifier @@ -48766,7 +48781,7 @@ marker vaccine - A DNA vaccine plasmid vector that has the plasmid label phCMV1. This plasmid is 4200 base pairs long, has a CMV promoter, contains kanamycin and neomycin antibiotics resistance genes, and is manufactured by Genlantis. + A DNA vaccine plasmid vector that has the plasmid label phCMV1. This plasmid is 4200 base pairs long, has a CMV promoter, contains kanamycin and neomycin antibiotics resistance genes, and is manufactured by Genlantis. Rebecca Racz, Yongqun He WEB: http://www.genlantis.com/faq-phcmv.html vaccine component @@ -49344,7 +49359,7 @@ marker vaccine WEB: http://www.ncbi.nlm.nih.gov/pubmed/21907709 - a bacterial vaccine vector using a live attenuated Salmonella enterica strain SL3261. + a bacterial vaccine vector using a live attenuated Salmonella enterica strain SL3261. Yongqun He, Carly Mantin vaccine component Salmonella typhimurium SL3261 vaccine vector @@ -49462,7 +49477,7 @@ marker vaccine WEB: http://www.ncbi.nlm.nih.gov/pubmed/9767712 - a bacterial vaccine vector using the HS93Tox- mutant of the serovar 7 strain of Actinobacillus pleuropneumoniae. This mutant lacks the genes encoding the toxin ApxA and the post-translational activating protein ApxC, but still has genes required for secretion, making it a good vector. + a bacterial vaccine vector using the HS93Tox- mutant of the serovar 7 strain of Actinobacillus pleuropneumoniae. This mutant lacks the genes encoding the toxin ApxA and the post-translational activating protein ApxC, but still has genes required for secretion, making it a good vector. Yongqun He, Carly Mantin vaccine component Actinobacillus pleuropneumoniae HS93Tox vaccine vector @@ -49488,10 +49503,9 @@ marker vaccine - A Listeria monocytogenes vaccine vector that uses the highly attenuated LM1-2 strain - + A Listeria monocytogenes vaccine vector that uses the highly attenuated LM1-2 strain YH - PMID: 23027427 + PMID: 23027427 vaccine component L. monocytogenes LM1-2 vaccine vector @@ -49921,7 +49935,7 @@ marker vaccine - A Herpes simplex virus vaccine vector that uses a virus type 1 strain + A Herpes simplex virus vaccine vector that uses a virus type 1 strain Yongqun He, Shunzhou Deng HSV-1 vaccine vector PMID: 19428888 @@ -50121,7 +50135,7 @@ marker vaccine - an adenovirus vaccine vector that contains a deletion of the gp64 gene. As a result of the deletion, this vector is unable to propagate infection from cell to cell, and this defect results from both a severe reduction in the production of budded virions and the absence of GP64 on virions. + an adenovirus vaccine vector that contains a deletion of the gp64 gene. As a result of the deletion, this vector is unable to propagate infection from cell to cell, and this defect results from both a severe reduction in the production of budded virions and the absence of GP64 on virions. Yongqun He PMID: 17989172 vaccine component @@ -50238,8 +50252,7 @@ marker vaccine - XZ - YH + YH, XZ WEB: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0821a1.htm information content entity CDC recommendation of the use of Influenza A (h1N1) 2009 vaccine @@ -50252,8 +50265,7 @@ marker vaccine A population group that have priority for vaccination when a vaccine is first available. - XZ - YH + YH, XZ vaccination target group material entity vaccinee priority group @@ -50304,8 +50316,7 @@ marker vaccine - XZ - XY + XY, XZ WEB: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0821a1.htm material entity pregnant women @@ -50392,8 +50403,7 @@ marker vaccine - XZ - XY + XY, XZ WEB: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0821a1.htm material entity persons living with or providing care for infants aged <6 months @@ -50405,8 +50415,7 @@ marker vaccine - XZ - XY + XY, XZ WEB: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0821a1.htm material entity health-care and emergency medical services personnel @@ -50418,8 +50427,7 @@ marker vaccine - XZ - XY + XY, XZ WEB: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0821a1.htm material entity persons aged 6 months--24 years @@ -50431,8 +50439,7 @@ marker vaccine - XZ - XY + XY, XZ WEB: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0821a1.htm material entity persons aged 25--64 years with medical conditions at higher risk for influenza-related complications @@ -51137,8 +51144,7 @@ marker vaccine vaccine viability is a viability of a vaccine organism. - ZX - YH + YH, ZX quality vaccine organism viability @@ -51241,8 +51247,7 @@ marker vaccine vaccine being viable is a vaccine viability that indicates a vaccine uses live organism. - ZX - YH + YH, ZX quality vaccine organism live @@ -51279,8 +51284,7 @@ marker vaccine - ZX - YH + YH, ZX quality no vaccine protection @@ -51291,8 +51295,7 @@ marker vaccine - ZX - YH + YH, ZX quality significant vaccine protection @@ -51303,8 +51306,7 @@ marker vaccine - ZX - YH + YH, ZX quality enhanced significant protection @@ -51492,8 +51494,7 @@ marker vaccine - ZX - YH + YH, ZX information content entity vaccination dose specification @@ -51510,8 +51511,7 @@ marker vaccine - ZX - YH + YH, ZX information content entity challenge dose specification @@ -51523,8 +51523,7 @@ marker vaccine specification of time interval after vaccination for challenge is a plan specification that specifies the time interval after vacciation for challenge - ZX - YH + YH, ZX information content entity specification of vaccination-challenge interval @@ -51536,8 +51535,7 @@ marker vaccine pathogen challenge protocol is a protocol that is used for a pathogen challenge process. - ZX - YH + YH, ZX information content entity pathogen challenge protocol @@ -52974,8 +52972,7 @@ However, running the reasoner takes time. As a way to reducing the time, I have - ZX - YH + YH, ZX material entity protective antigen @@ -53310,7 +53307,7 @@ However, running the reasoner takes time. As a way to reducing the time, I have - SYNFLORIX is indicated for active immunization of infants and children from 6 weeks up to 5 years of age against Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and invasive disease caused by these serotypes (including sepsis, meningitis, bacteraemic pneumonia, pleural empyema and bacteraemia). + SYNFLORIX is indicated for active immunization of infants and children from 6 weeks up to 5 years of age against Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and invasive disease caused by these serotypes (including sepsis, meningitis, bacteraemic pneumonia, pleural empyema and bacteraemia). ZX WEB: http://www.gsk.ca/english/docs-pdf/product-monographs/Synflorix.pdf vaccine @@ -53797,7 +53794,7 @@ However, running the reasoner takes time. As a way to reducing the time, I have - + @@ -53810,13 +53807,15 @@ However, running the reasoner takes time. As a way to reducing the time, I have - A role that inheres in an organism that is the target of a vaccination. - Jie Zheng - ZX - YH + Role that inheres in an organism that is the target of a vaccine administration (vaccination process). + Allen Xiang + Anna Maria Masci + Barry Smith + Jie Zheng + Oliver He https://github.com/vaccineontology/VO/issues/677 role - vaccine host role + vaccine recipient role @@ -53826,8 +53825,7 @@ However, running the reasoner takes time. As a way to reducing the time, I have A role that represents a target (i.e., some disorder) of immunization. - ZX - YH + YH, ZX role immunization target role @@ -53892,8 +53890,7 @@ However, running the reasoner takes time. As a way to reducing the time, I have - ZX - YH + YH, ZX role immunization target role of bacterial pathogen @@ -53904,8 +53901,7 @@ However, running the reasoner takes time. As a way to reducing the time, I have - ZX - YH + YH, ZX role immunization target role of viral pathogen @@ -53916,8 +53912,7 @@ However, running the reasoner takes time. As a way to reducing the time, I have - ZX - YH + YH, ZX role immunization target role of parasite pathogen @@ -53928,8 +53923,7 @@ However, running the reasoner takes time. As a way to reducing the time, I have - ZX - YH + YH, ZX role immunization target role of fungal pathogen @@ -55017,8 +55011,7 @@ However, running the reasoner takes time. As a way to reducing the time, I have a role that is inherenced in a gene that can be mutated in a virulent pathogen, leading to an attenuated strain serving as a live attenuated vaccine strain. - YL - YH + YH, YL role virmugen role @@ -55213,9 +55206,7 @@ However, running the reasoner takes time. As a way to reducing the time, I have an organism that is vaccinated with a vaccine - MC - YL - YH + YH, YL, MC vaccinated organism organism vaccinee @@ -55354,9 +55345,7 @@ However, running the reasoner takes time. As a way to reducing the time, I have an organism that is immunized for a disease - MC - YL - YH + YH, YL, MC organism immunized organism @@ -55397,9 +55386,7 @@ However, running the reasoner takes time. As a way to reducing the time, I have an organism that is unvaccinated with a vaccine - MC - YL - YH + YH, YL, MC organism unvaccinated organism @@ -98678,7 +98665,7 @@ http://www.medicines.org.uk/guides/priorix/Vaccinations%20%28all%29/ - a polysorbate 20 vaccine stabilizer that is Alkest TW20. + a polysorbate 20 vaccine stabilizer that is Alkest TW20. YH, YL vaccine component Alkest TW 20 vaccine stabilizer @@ -98690,7 +98677,7 @@ http://www.medicines.org.uk/guides/priorix/Vaccinations%20%28all%29/ - a polysorbate 20 vaccine stabilizer that is Tween 20. + a polysorbate 20 vaccine stabilizer that is Tween 20. YH, YL vaccine component Tween 20 vaccine stabilizer @@ -104191,13 +104178,20 @@ over. - + + + + + + + + Jie Zheng Khadeejah Khan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1657332 + Xingxian Li 1657332 influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML 46276184 - vaccine component + vaccine influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML @@ -104982,13 +104976,20 @@ over. - + + + + + + + + Jie Zheng Khadeejah Khan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1658708 + Xingxian Li 1658708 influenza A virus A/California/7/2009 (H1N1) antigen 0.12 MG/ML 46275391 - vaccine component + vaccine influenza A virus A/California/7/2009 (H1N1) antigen 0.12 MG/ML @@ -107823,13 +107824,20 @@ over. - + + + + + + + + Jie Zheng Khadeejah Khan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1601398 + Xingxian Li 1601398 Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen 0.1 MG/ML 45892092 - vaccine component + vaccine Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen 0.1 MG/ML @@ -107850,13 +107858,20 @@ over. - + + + + + + + + Jie Zheng Khadeejah Khan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1601399 + Xingxian Li 1601399 Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen 0.1 MG/ML 45892093 - vaccine component + vaccine Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen 0.1 MG/ML @@ -107881,6 +107896,7 @@ over. Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1601236 + 1601236 Outer Membrane Vesicles (Neisseria Meningitidis Group B Nz98/254 Strain) 44012722 OMOP1131632 @@ -107932,13 +107948,20 @@ over. - + + + + + + + + Jie Zheng Khadeejah Khan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1593129 + Xingxian Li 1593129 Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen 0.12 MG/ML 45775637 - vaccine component + vaccine Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen 0.12 MG/ML @@ -110314,13 +110337,20 @@ over. - + + + + + + + + Jie Zheng Khadeejah Khan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1660921 + Xingxian Li 1660921 influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML 46276011 - vaccine component + vaccine influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML @@ -110365,13 +110395,20 @@ over. - + + + + + + + + Jie Zheng Khadeejah Khan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1724009 + Xingxian Li 1724009 influenza A virus A/California/7/2009 (H1N1) antigen 0.015 MG/ML 35606413 - vaccine component + vaccine influenza A virus A/California/7/2009 (H1N1) antigen 0.015 MG/ML @@ -110888,13 +110925,20 @@ over. - + + + + + + + + Jie Zheng Khadeejah Khan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1657223 + Xingxian Li 1657223 influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML 46276097 - vaccine component + vaccine influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML @@ -110915,13 +110959,20 @@ over. - + + + + + + + + Jie Zheng Khadeejah Khan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1658709 + Xingxian Li 1658709 influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.12 MG/ML 46275392 - vaccine component + vaccine influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.12 MG/ML @@ -110930,13 +110981,20 @@ over. - + + + + + + + + Jie Zheng Khadeejah Khan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1657225 + Xingxian Li 1657225 influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML 46276099 - vaccine component + vaccine influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML @@ -110945,13 +111003,20 @@ over. - + + + + + + + + Jie Zheng Khadeejah Khan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1723999 + Xingxian Li 1723999 influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.015 MG/ML 35606409 - vaccine component + vaccine influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.015 MG/ML @@ -110960,13 +111025,20 @@ over. - + + + + + + + + Jie Zheng Khadeejah Khan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1664468 + Xingxian Li 1664468 influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 50000000 MG/ML 46287742 - vaccine component + vaccine influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 50000000 MG/ML @@ -110987,13 +111059,20 @@ over. - + + + + + + + + Jie Zheng Khadeejah Khan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1657132 + Xingxian Li 1657132 influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML 46275997 - vaccine component + vaccine influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML @@ -111014,12 +111093,20 @@ over. - + + + + + + + + Jie Zheng Khadeejah Khan, Oliver He + Xingxian Li 1657129 influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML 46275994 - vaccine component + vaccine influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML @@ -111041,13 +111128,20 @@ over. - + + + + + + + + Jie Zheng Khadeejah Khan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1657227 + Xingxian Li 1657227 influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML 46276101 - vaccine component + vaccine influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML @@ -111056,13 +111150,20 @@ over. - + + + + + + + + Jie Zheng Khadeejah Khan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1664469 + Xingxian Li 1664469 influenza B virus B/Brisbane/60/2008 antigen 50000000 MG/ML 46287743 - vaccine component + vaccine influenza B virus B/Brisbane/60/2008 antigen 50000000 MG/ML @@ -111071,13 +111172,20 @@ over. - + + + + + + + + Jie Zheng Khadeejah Khan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1661110 + Xingxian Li 1661110 influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML 46276042 - vaccine component + vaccine influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML @@ -111086,13 +111194,20 @@ over. - + + + + + + + + Jie Zheng Khadeejah Khan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1801177 + Xingxian Li 1801177 influenza B virus B/Brisbane/60/2008 antigen 0.12 MG/ML 36249504 - vaccine component + vaccine influenza B virus B/Brisbane/60/2008 antigen 0.12 MG/ML @@ -111131,13 +111246,20 @@ over. - + + + + + + + + Jie Zheng Khadeejah Khan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1946982 + Xingxian Li 1946982 influenza B virus B/Brisbane/60/2008 antigen 158000000 UNT/ML 792418 - vaccine component + vaccine influenza B virus B/Brisbane/60/2008 antigen 158000000 UNT/ML @@ -111158,13 +111280,20 @@ over. - + + + + + + + + Jie Zheng Khadeejah Khan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1657135 + Xingxian Li 1657135 influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML 46276000 - vaccine component + vaccine influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML @@ -111185,13 +111314,20 @@ over. - + + + + + + + + Jie Zheng Khadeejah Khan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1657229 + Xingxian Li 1657229 influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML 46276103 - vaccine component + vaccine influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML @@ -111200,13 +111336,20 @@ over. - + + + + + + + + Jie Zheng Khadeejah Khan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1660923 + Xingxian Li 1660923 influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML 46276013 - vaccine component + vaccine influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML @@ -111215,13 +111358,20 @@ over. - + + + + + + + + Jie Zheng Khadeejah Khan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1658710 + Xingxian Li 1658710 influenza B virus B/Phuket/3073/2013 antigen 0.12 MG/ML 46275393 - vaccine component + vaccine influenza B virus B/Phuket/3073/2013 antigen 0.12 MG/ML @@ -111230,13 +111380,20 @@ over. - + + + + + + + + Jie Zheng Khadeejah Khan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1946983 + Xingxian Li 1946983 influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML 792419 - vaccine component + vaccine influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML @@ -111245,13 +111402,20 @@ over. - + + + + + + + + Jie Zheng Khadeejah Khan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1664470 + Xingxian Li 1664470 influenza B virus B/Phuket/3073/2013 antigen 50000000 MG/ML 46287744 - vaccine component + vaccine influenza B virus B/Phuket/3073/2013 antigen 50000000 MG/ML @@ -115458,17 +115622,20 @@ over. - + + + + + + + + Jie Zheng Kallan Roan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/2050417 + Xingxian Li 2050417 influenza B virus B/Maryland/15/2016 antigen 0.12 MG/ML 35200031 - vaccine component - CUI: C4719040 - RXAUI: 10289778 - RXN STRENGTH: 0.12 MG/ML - TUI: T200 + vaccine influenza B virus B/Maryland/15/2016 antigen 0.12 MG/ML @@ -115477,17 +115644,20 @@ over. - + + + + + + + + Jie Zheng Kallan Roan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1928338 + Xingxian Li 1928338 influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.12 MG/ML 1593351 - vaccine component - CUI: C4490425 - RXAUI: 9198822 - RXN STRENGTH: 0.12 MG/ML - TUI: T200 + vaccine influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.12 MG/ML @@ -115496,17 +115666,20 @@ over. - + + + + + + + + Jie Zheng Kallan Roan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/2050416 + Xingxian Li 2050416 influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.12 MG/ML 35200030 - vaccine component - CUI: C4719039 - RXAUI: 10289777 - RXN STRENGTH: 0.12 MG/ML - TUI: T200 + vaccine influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.12 MG/ML @@ -115515,17 +115688,20 @@ over. - + + + + + + + + Jie Zheng Kallan Roan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1801176 + Xingxian Li 1801176 influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.12 MG/ML 36249503 - vaccine component - CUI: C4271783 - RXAUI: 8237152 - RXN STRENGTH: 0.12 MG/ML - TUI: T200 + vaccine influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.12 MG/ML @@ -118595,16 +118771,20 @@ over. - + + + + + + + + Jie Zheng Kallan Roan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1660922 + Xingxian Li 1660922 influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.09 MG/ML 46276012 - vaccine component - CUI: C4047148 - RXAUI: 7258095 - TUI: T200 + vaccine influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.09 MG/ML @@ -118613,16 +118793,20 @@ over. - + + + + + + + + Jie Zheng Kallan Roan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1794431 + Xingxian Li 1794431 influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML 36249494 - vaccine component - CUI: C4257282 - RXAUI: 8222590 - TUI: T200 + vaccine influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML @@ -118631,16 +118815,20 @@ over. - + + + + + + + + Jie Zheng Kallan Roan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1801069 + Xingxian Li 1801069 influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML 36249398 - vaccine component - CUI: C4271787 - RXAUI: 8236905 - TUI: T200 + vaccine influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML @@ -118649,16 +118837,20 @@ over. - + + + + + + + + Jie Zheng Kallan Roan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1928310 + Xingxian Li 1928310 influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML 1593193 - vaccine component - CUI: C4490406 - RXAUI: 9198778 - TUI: T200 + vaccine influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML @@ -118667,16 +118859,20 @@ over. - + + + + + + + + Jie Zheng Kallan Roan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1928291 + Xingxian Li 1928291 influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML 1593183 - vaccine component - CUI: C4490396 - RXAUI: 9198757 - TUI: T200 + vaccine influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML @@ -118685,16 +118881,20 @@ over. - + + + + + + + + Jie Zheng Kallan Roan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/2048958 + Xingxian Li 2048958 influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML 1559888 - vaccine component - CUI: C4704185 - RXAUI: 10279935 - TUI: T200 + vaccine influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML @@ -118703,16 +118903,20 @@ over. - + + + + + + + + Jie Zheng Kallan Roan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/2048959 + Xingxian Li 2048959 influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML 1559889 - vaccine component - CUI: C4704186 - RXAUI: 10279936 - TUI: T200 + vaccine influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML @@ -121318,16 +121522,20 @@ over. - + + + + + + + + Jie Zheng Kallan Roan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1928300 + Xingxian Li 1928300 influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML 1593184 - vaccine component - CUI: C4490397 - RXAUI: 9198766 - TUI: T200 + vaccine influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML @@ -125669,16 +125877,20 @@ over. - + + + + + + + + Jie Zheng Kallan Roan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1801604 + Xingxian Li 1801604 influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML 40220715 - vaccine component - CUI: C4276333 - RXAUI: 8238450 - TUI: T200 + vaccine influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML @@ -126218,15 +126430,18 @@ over. - - http://purl.bioontology.org/ontology/RXNORM/1986822 + + + + + + + + OHDSI Vaccine WG 1986822 varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML 792778 - protein - CUI: C4530096 - RXAUI: 9698277 - TUI: T200 + vaccine Varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML @@ -126249,15 +126464,19 @@ over. - - http://purl.bioontology.org/ontology/RXNORM/1664467 + + + + + + + + Jie Zheng + Xingxian Li 1664467 influenza A virus A/Bolivia/559/2013 (H1N1) antigen 50000000 MG/ML 46287741 - vaccine component - CUI: C4050818 - RXAUI: 7266777 - TUI: T200 + vaccine influenza A virus A/Bolivia/559/2013 (H1N1) antigen 50000000 MG/ML @@ -126617,16 +126836,20 @@ over. - + + + + + + + + Jie Zheng Kallan Roan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1801822 + Xingxian Li 1801822 influenza A virus A/New Caledonia/71/2014 (H3N2) antigen 50000000 MG/ML 40220742 - vaccine component - CUI: C4276331 - RXAUI: 8238992 - TUI: T200 + vaccine influenza A virus A/New Caledonia/71/2014 (H3N2) antigen 50000000 MG/ML @@ -126905,16 +127128,20 @@ over. - + + + + + + + + Jie Zheng Kallan Roan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1946980 + Xingxian Li 1946980 influenza A virus A/New Caledonia/71/2014 (H3N2) antigen 158000000 UNT/ML 792416 - vaccine component - CUI: C4529654 - RXAUI: 9278643 - TUI: T200 + vaccine influenza A virus A/New Caledonia/71/2014 (H3N2) antigen 158000000 UNT/ML @@ -126938,16 +127165,20 @@ over. - + + + + + + + + Jie Zheng Kallan Roan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1946981 + Xingxian Li 1946981 influenza A virus A/Slovenia/2903/2015 (H1N1) antigen 158000000 UNT/ML 792417 - vaccine component - CUI: C4529655 - RXAUI: 9278644 - TUI: T200 + vaccine influenza A virus A/Slovenia/2903/2015 (H1N1) antigen 158000000 UNT/ML @@ -127039,16 +127270,20 @@ over. - + + + + + + + + Jie Zheng Kallan Roan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/2054271 + Xingxian Li 2054271 influenza B virus B/Colorado/06/2017 antigen 158000000 UNT/ML 35200282 - vaccine component - CUI: C4719748 - RXAUI: 10329902 - TUI: T200 + vaccine influenza B virus B/Colorado/06/2017 antigen 158000000 UNT/ML @@ -127190,16 +127425,20 @@ over. - + + + + + + + + Jie Zheng Kallan Roan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/2054270 + Xingxian Li 2054270 influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 158000000 UNT/ML 35200281 - vaccine component - CUI: C4719747 - RXAUI: 10329901 - TUI: T200 + vaccine influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 158000000 UNT/ML @@ -130991,15 +131230,19 @@ over. - - http://purl.bioontology.org/ontology/RXNORM/2050374 + + + + + + + + Jie Zheng + Xingxian Li 2050374 influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.09 MG/ML 35200021 - vaccine component - CUI: C4719019 - RXAUI: 10289671 - TUI: T200 + vaccine influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.09 MG/ML @@ -131008,15 +131251,19 @@ over. - - http://purl.bioontology.org/ontology/RXNORM/2050375 + + + + + + + + Jie Zheng + Xingxian Li 2050375 influenza B virus B/Maryland/15/2016 antigen 0.09 MG/ML 35200022 - vaccine component - CUI: C4719020 - RXAUI: 10289672 - TUI: T200 + vaccine influenza B virus B/Maryland/15/2016 antigen 0.09 MG/ML @@ -131292,16 +131539,20 @@ over. - + + + + + + + + Jie Zheng Kallan Roan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1724000 + Xingxian Li 1724000 influenza B virus B/Brisbane/9/2014 antigen 0.015 MG/ML 35606410 - vaccine component - CUI: C4060367 - RXAUI: 7710861 - TUI: T200 + vaccine influenza B virus B/Brisbane/9/2014 antigen 0.015 MG/ML @@ -133095,13 +133346,17 @@ over. - + + + + + + + + Jie Zheng Kallan Roan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1812935 - vaccine component - CUI: C4291328 - RXAUI: 8262960 - TUI: T200 + Xingxian Li + vaccine vibrio cholerae CVD 103-HGR strain live antigen 12000000 UNT/ML @@ -139484,13 +139739,17 @@ over. - + + + + + + + + Jie Zheng Kallan Roan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1799961 - vaccine component - CUI: C4271790 - RXAUI: 8235199 - TUI: T200 + Xingxian Li + vaccine BACILLUS ANTHRACIS STRAIN V770-NP1-R ANTIGENS 0.1 MG/ML @@ -153695,16 +153954,20 @@ over. - + + + + + + + + Jie Zheng Kallan Roan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/1437844 + Xingxian Li 1437844 meningococcal group C polysaccharide 0.01 MG/ML 43560725 - vaccine component - C3666861 - RXAUI: 5495920 - TUI: T200 + vaccine meningococcal group C polysaccharide 0.01 MG/ML @@ -153713,16 +153976,20 @@ over. - + + + + + + + + Jie Zheng Kallan Roan, Oliver He - http://purl.bioontology.org/ontology/RXNORM/350967 + Xingxian Li 350967 meningococcal group C polysaccharide 0.1 MG/ML 19097997 - vaccine component - CUI: C1167603 - RXAUI: 1545436 - TUI: T200 + vaccine meningococcal group C polysaccharide 0.1 MG/ML @@ -154640,15 +154907,19 @@ over. - - http://purl.bioontology.org/ontology/RXNORM/328467 + + + + + + + + Jie Zheng + Xingxian Li 328467 meningococcal group A polysaccharide 0.1 MG/ML 509080 - vaccine component - CUI: C1123385 - RXAUI: 1505209 - TUI: T200 + vaccine meningococcal group A polysaccharide 0.1 MG/ML @@ -155105,8 +155376,7 @@ over. A vaccine role that inheres in a vaccine using virus-like particles (VLPs), multiprotein structures that mimic the organization and conformation of authentic native viruses but lack the viral genome, potentially yielding safer and cheaper vaccines. - Oliver He - Anthony Huffman + Anthony Huffman, Oliver He virus like particle vaccine role https://pubmed.ncbi.nlm.nih.gov/20923267/ role @@ -155224,9 +155494,7 @@ over. - Anthony Huffman - Oliver He - Anna Maria Masci + Anna Maria Masci, Anthony Huffman, Oliver He quality The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855. human age @@ -155238,9 +155506,7 @@ over. - Anthony Huffman - Oliver He - Anna Maria Masci + Anna Maria Masci, Anthony Huffman, Oliver He quality The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855. child age @@ -155252,9 +155518,7 @@ over. - Anthony Huffman - Oliver He - Anna Maria Masci + Anna Maria Masci, Anthony Huffman, Oliver He quality The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855. adolescence age @@ -155266,9 +155530,7 @@ over. - Anthony Huffman - Oliver He - Anna Maria Masci + Anna Maria Masci, Anthony Huffman, Oliver He quality The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855. adult age @@ -155280,9 +155542,7 @@ over. - Anthony Huffman - Oliver He - Anna Maria Masci + Anna Maria Masci, Anthony Huffman, Oliver He quality The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855. senior age @@ -162306,8 +162566,7 @@ Point of Contact: Dennis Carson, UCSD A role of a material entity that binds to TLR4 and activates the receptor for pathogen recognition and activation of innate immunity. TLR4 agonist role - Amogh Madireddi - Oliver He + Oliver He, Amogh Madireddi Toll-like receptor 4 agonist role https://en.wikipedia.org/wiki/TLR4 role @@ -162322,8 +162581,7 @@ Point of Contact: Dennis Carson, UCSD A role of a material entity that binds to TLR3 and activates the receptor for pathogen recognition and activation of innate immunity. TLR3 agonist role - Amogh Madireddi - Oliver He + Oliver He, Amogh Madireddi Toll-like receptor 3 agonist role https://en.wikipedia.org/wiki/TLR3 role @@ -162338,8 +162596,7 @@ Point of Contact: Dennis Carson, UCSD A role of a material entity that binds to TLR8 and activates the receptor for pathogen recognition and activation of innate immunity. TLR8 agonist role - Amogh Madireddi - Oliver He + Oliver He, Amogh Madireddi Toll-like receptor 8 agonist role https://en.wikipedia.org/wiki/TLR8 role @@ -162354,8 +162611,7 @@ Point of Contact: Dennis Carson, UCSD A role of a material entity that binds to TLR2 and activates the receptor for pathogen recognition and activation of innate immunity. TLR2 agonist role - Amogh Madireddi - Oliver He + Oliver He, Amogh Madireddi Toll-like receptor 2 agonist role https://en.wikipedia.org/wiki/TLR2 role @@ -167555,9 +167811,8 @@ https://clinicaltrials.gov/ct2/show/NCT03926728 - A gene expressing a protein, either partially or entirely, serving as the antigen within a specific cancer vaccine. - Anna Maria Masci - Yongqun He + Gene expressing a protein which serves, either in whole or in part, as an antigen within a cancer vaccine. + Yongqun He|Anna Maria Masci|Barry Smith|Jie Zheng https://github.com/vaccineontology/VO/issues/677 gene canvaxgen @@ -174243,7 +174498,7 @@ none - A synthetic vaccine used for cancer immunotherapy also known as Ras(val 12)-Vaccinia Vaccine,‚Äö√†√∂‚àö¬ßRASVAC-C‚Äö√†√∂‚àö¬ßis based on a mutant peptide epitope of the Ras oncoprotein at codon 12 (valine instead of glycine) that induces recognition and induction of tumor-specific, cell-mediated immune responses. Ras is an intracellular GTP-binding protein involved in signal transduction and regulation of proliferation and differentiation.‚Äö√†√∂‚àö¬ß + A synthetic vaccine used for cancer immunotherapy also known as Ras(val 12)-Vaccinia Vaccine, RASVAC-V is based on a mutant peptide epitope of the Ras oncoprotein at codon 12 (valine instead of glycine) that induces recognition and induction of tumor-specific, cell-mediated immune responses. Ras is an intracellular GTP-binding protein involved in signal transduction and regulation of proliferation and differentiation. Jie Zheng Jimmy Guo Oliver He @@ -177302,7 +177557,7 @@ none - A cancer vaccine containing immunogenic, HLA-A2-specific epitopes derived from X-box‚Äö√†√∂‚àö‚Ñ¢binding protein 1-unspliced (XBP1-US), XBP1-spliced (SP), syndecan-1 (CD138), and CS1 (CD2 subset 1, CRACC, SLAMF7, CD319) with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, XBP1-US/XBP1-SP/CD138/CS1 multipeptide vaccine PVX-410 may stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens. The tumor associated antigens (TAAs) XBP1-US, XBP1-SP, CD138 and CS1, are overexpressed on the surface of multiple myeloma (MM) cells. + A cancer vaccine containing immunogenic, HLA-A2-specific epitopes derived from X-box-binding protein 1-unspliced (XBP1-US), XBP1-spliced (SP), syndecan-1 (CD138), and CS1 (CD2 subset 1, CRACC, SLAMF7, CD319) with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, XBP1-US/XBP1-SP/CD138/CS1 multipeptide vaccine PVX-410 may stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens. The tumor associated antigens (TAAs) XBP1-US, XBP1-SP, CD138 and CS1, are overexpressed on the surface of multiple myeloma (MM) cells. Jie Zheng Jimmy Guo Oliver He @@ -180020,7 +180275,7 @@ none - A recombinant retroviral virus derived from SR-A strain of Rous sarcoma virus carrying a constitutively active form of the‚Äö√†√∂‚àö¬ßAKT‚Äö√†√∂‚àö¬ßGene. The viral vector‚Äö√†√∂‚àö¬ßRCAS‚Äö√†√∂‚àö¬ßharbors a Replication Competent ALV Splice acceptor. This recombinant virus was use in animal model to study gliomagenesis. + A recombinant retroviral virus derived from SR-A strain of Rous sarcoma virus carrying a constitutively active form of the AKT Gene. The viral vector RCAS harbors a Replication Competent ALV Splice acceptor. This recombinant virus was use in animal model to study gliomagenesis. Jie Zheng Jimmy Guo Oliver He @@ -180066,7 +180321,7 @@ none - A recombinant retroviral virus derived from SR-A strain of Rous sarcoma virus carrying a human gene encoding the G12D mutant form of K-Ras. The viral vector,‚Äö√†√∂‚àö¬ßRCAS‚Äö√†√∂‚àö¬ßharbors a Replication Competent ALV Splice acceptor. This recombinant virus was use in animal model to study gliomagenesis. + A recombinant retroviral virus derived from SR-A strain of Rous sarcoma virus carrying a human gene encoding the G12D mutant form of K-Ras. The viral vector, RCAS harbors a Replication Competent ALV Splice acceptor. This recombinant virus was use in animal model to study gliomagenesis. Jie Zheng Jimmy Guo Oliver He @@ -180136,6 +180391,64 @@ none + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine that may stimulate an immune response against 4 different melanoma associated antigens. This may lead to a reduction in tumor cell proliferation of cancer cells expressing these antigens. The vaccine may contain 4 class I MHC-restricted synthetic melanoma peptides (1 each restricted by HLA-A1, -A3, and two restricted by HLA-A2) and a helper tetanus peptide. The peptides may include Melan-A, gp100, MAGE-3, and NA17. The vaccine can be used in combination Ontak, which may produce an immune response in patients with metastatic melanoma, and the Ontak may improve these immune responses and lead to tumor shrinkage. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C91722 + NCT: https://clinicaltrials.gov/study/NCT00515528 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6370 + 2315 + 4102 + 6490 + 6370 + Clinical trial + Gene name: Melan-A|Gene name: gp100|Gene name: MAGE-3|Gene name: NA17 + 4-peptide melanoma vaccine + + + + @@ -180300,7 +180613,7 @@ none - 2 class major histocompatibility complex‚Äö√†√∂‚àö‚Ñ¢restricted melanoma peptides + 2 class major histocompatibility complex-restricted melanoma peptides. Eliyas Asfaw Ibrahim Seleznev Jie Zheng @@ -183004,6 +183317,50 @@ none + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine used to treat patients with malignant melanoma. It is made of a compatible melanoma cell line that has been engineered to express a molecule termed 4-1BBL, which enhances the chances of the cell line to be recognized by the patient's immune system, and to induce its stimulation, with an immune response to residual tumor in the body. It will be used in combination with intravenous low dose cyclophosphamide, 300 mg/m2. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT01898039 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6260 + 8744 + 6260 + Clinical trial + Gene name: 4-1BBL + a2/4-1bbl melanoma vaccine + + + + @@ -184071,6 +184428,50 @@ none + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine that uses adenovirus MUC1 and Survivin transfected autologous dendritic cells combined with cytokine-induced killer cells in cancer patients with Extensive-Stage Small- Cell Lung Cancer. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT01174082 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6261 + 332 + 4582 + 6261 + Clinical trial + Gene name: MUC1|Gene name: Survivin + adenovirus-transfected autologous dc vaccine plus cik cells + + + + @@ -186013,6 +186414,51 @@ none + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine composed of autologous, mature dendritic cells (DCs) are electroporated with in vitro transcribed (IVT) RNAs encoding for a synthetic form of T-cell protein CD40 ligand (CD40L) and IVT RNA encoding for autologous tumor-associated antigens (TAAs) derived from patient-specific bladder cell carcinoma (BCC) cells, with potential immunostimulatory and antineoplastic activities. The RNA is translated and processed, and BCC-specific antigenic peptides are subsequently presented via major histocompatibility complex (MHC) Class I molecules on the DCs surface. The MHC-presented peptides interact with and activate CD8-positive T-cells, which elicits a highly specific cytotoxic T-cell (CTL) response against tumor cells expressing the patient-specific BCC TAAs. The signal cascade initiated by expression of the co-stimulatory molecule CD40L results in the secretion of the inflammatory cytokine IL-12, which further stimulates CTLs. The vaccine can be used in combination with gemcitabine hydrochloride and cisplatin which stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading, while the vaccine helps the body build an effective immune response to kill tumor cells. In combination, they may make the tumor smaller and reduce the amount of tissue that needs to be removed by surgery in patients with bladder cancer. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C129522 + NCT: https://clinicaltrials.gov/study/NCT02944357 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6363 + 959 + 6363 + Clinical trial + Gene name: CD40LG + ags-003-bld vaccine + + + + @@ -186247,10 +186693,10 @@ none - + - - + + @@ -186260,14 +186706,14 @@ none - - + + - + @@ -186276,35 +186722,40 @@ none - Eliyas Asfaw - Ibrahim Seleznev + A cancer vaccine that restored priming of Anaplastic lymphoma kinase (ALK)-specific CD8+ T cells, eradicated lung tumors in combination with ALK tyrosine kinase inhibitors (TKIs) and prevented metastatic dissemination of tumors to the brain. Human ALK peptides are displayed by HLA-A*02:01 and HLA-B*07:02 molecules. The peptides are immunogenic and recognized by CD8+ T cells from individuals with non-small cell lung cancer (NSCLC). + Hayleigh Kahn Jie Zheng - Oliver He - PubMed:21036724 - VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5230 - https://github.com/vaccineontology/VO/issues/296 - 5230 - Clinical trial - BCG, Cell Wall Skeleton Vaccine + PubMed:37430060 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6382 + 6382 + Research + alk peptide vaccine - + - - + + + + + + + + + - + @@ -186313,46 +186764,36 @@ none - A vaccine consisting of replication-defective recombinant adenovirus that encodes for Bcl-Xs with potential antineoplastic activity. Vaccination with Bcl-Xs adenovirus vaccine induces apoptosis in Bcl-2 and Bcl-XL positive cancer cells, resulting in decreased tumor growth while leaving normal cells unaffected. Bcl-Xs block the function of the protooncogenes Bcl-2 and Bcl-XL which are overexpressed in a variety of solid tumors and promote cancer cell survival by inhibiting apoptosis. (NCI04)A vaccine consisting of replication-defective recombinant adenovirus that encodes for Bcl-Xs with potential antineoplastic activity. Vaccination with Bcl-Xs adenovirus vaccine induces apoptosis in Bcl-2 and Bcl-XL positive cancer cells, resulting in decreased tumor growth while leaving normal cells unaffected. Bcl-Xs block the function of the protooncogenes Bcl-2 and Bcl-XL which are overexpressed in a variety of solid tumors and promote cancer cell survival by inhibiting apoptosis. - Eliyas Asfaw - Ibrahim Seleznev + A cancer vaccine made of allogeneic pancreatic tumor cells are transfected with a GM-CSF gene to treat ocally advanced, unresectable or metastatic pancreatic adenocarcinoma. It may be in combination with Ipilimumab (an antibody that blocks negative signals to T cells). + Hayleigh Kahn Jie Zheng - Oliver He - PubMed:7479929 - VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5399 - https://github.com/vaccineontology/VO/issues/297 - 598 - 7306 - 5399 + NCT: https://clinicaltrials.gov/study/NCT00836407 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6336 + 12981 + 6336 Clinical trial - VO:0007589 - Gene name: BCL2L1|Gene name: TYRP1 - Bcl-Xs Adenovirus Vaccine + Gene name: GM-CSF + allogeneic GM-CSF-secreting lethally irradiated pancreatic tumor cell vaccine - + - - + + + - - - - - - - + @@ -186361,27 +186802,27 @@ none - A transforming growth factor beta2 (TGF-beta2) antisense gene-modified allogeneic tumor cell vaccine with potential immunostimulatory and antineoplastic activities. Belagenpumatucel-L is prepared by transfecting allogeneic non-small cell lung cancer (NSCLC) cells with a plasmid containing a TGF-beta2 antisense transgene, expanding the cells, and then irradiating and freezing them. Upon administration, this agent may elicit a cytotoxic T lymphocyte (CTL) response against host NSCLC cells, resulting in decreased tumor cell proliferation; vaccine immunogenicity may be potentiated by suppression of tumor TGF-beta2 production by antisense RNA expressed by the vaccine plasmid TGF-beta2 antisense transgene. Elevated levels of TGF-beta2 are frequently linked to immunosuppression in cancer patients and may be inversely correlated with prognosis in patients with NSCLC. - Eliyas Asfaw - Ibrahim Seleznev + A cancer vaccine that consists of an allogeneic cell line that has a high expression level of melanoma molecules (HLA A2/4-1BB Ligand), and has been genetically modified to induce a strong immune response. Stimulation of the immune response against the tumor can help destroy residual tumor in melanoma patients with very high risk for disease recurrence and in patients with relatively low tumor burden who already got first line treatment for their disease. + Hayleigh Kahn Jie Zheng - Oliver He - PubMed:26211534 - VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5374 - https://github.com/vaccineontology/VO/issues/298 - 7042 - 5374 + NCT: https://clinicaltrials.gov/study/NCT01861938 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6313 + 3105 + 8744 + 6313 Clinical trial - Gene name: TGFB2 - Belagenpumatucel-L Vaccine + Gene name: HLA-A|Gene name: 4-1BBL + allogeneic HLA-A2/4-1BB ligand-expressing melanoma vaccine - + - + + + @@ -186390,14 +186831,14 @@ none - - + + - + @@ -186406,27 +186847,25 @@ none - A synthetic vaccine combining the peptide antigens of two proteins, ras oncoprotein and tumor suppressor p53 - Eliyas Asfaw - Ibrahim Seleznev + A cancer vaccine that uses anti-HER2/HER3 dendritic cells in combination with Pembrolizumab in patients with Asymptomatic Brain Metastasis From Triple Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC). The dendritic cells boost the immune system, and the Pembrolizumab enhances cancer immune responses, in combination they may shrink the cancer. + Hayleigh Kahn Jie Zheng - Oliver He - PubMed:15983396 - VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4992 - https://github.com/vaccineontology/VO/issues/299 - 7157 - 4992 + NCT: https://clinicaltrials.gov/study/NCT04348747 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6263 + 2064 + 2065 + 6263 Clinical trial - Gene name: TP53 (P53) - Berzofsky Ras/P53 Peptide Vaccine + Gene name: HER2|Gene name:HER3 + anti-HER2/HER3 dendritic cell vaccine - + - - + + @@ -186443,47 +186882,7 @@ none - - - - - - - - - - A cancer vaccine composed of a replication-deficient, attenuated derivative of the vaccinia virus strain Ankara expressing both a CD8+ T-cell epitope from the brachyury protein and a triad of T-cell co-stimulatory molecules (MVA Brachyury-TRICOM), with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration of the brachyury-expressing modified vaccinia Ankara (MVA)-TRICOM vaccine, the expressed brachyury protein induces specific CD8+ and CD4+ T-cell responses against brachyury-expressing tumor cells. This causes both tumor cell lysis and a decrease in the growth of brachyury-expressing tumor cells. Brachyury, a member of the T-box family of transcription factors that is overexpressed in numerous cancer cell types, is correlated with increased epithelial-mesenchymal transition (EMT), cancer resistance and cancer progression. TRICOM, a triad of three human T-cell co-stimulatory molecules, B7.1, ICAM-1 and LFA-3, enhances antigen-specific T-cell activation. - Eliyas Asfaw - Ibrahim Seleznev - Jie Zheng - Oliver He - VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5439 - https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2022-05711&r=1 - https://github.com/vaccineontology/VO/issues/310 - 925 - 5439 - Clinical trial - Gene name: CD8A - Brachyury-expressing Modified Vaccinia Ankara-TRICOM Vaccine - - - - - - - - - - - - - - - - - - - + @@ -186492,28 +186891,24 @@ none - A cell-based cancer vaccine comprised of brain tumor initiating cells (BTICs), with potential immunostimulating and antineoplastic activity. BITCs are from the glioblastoma multiforme (GBM) cell line GBM-6 and contain glioma stem-like cell-associated antigens. Upon administration, the BITC vaccine may stimulate a specific anti-tumoral cytotoxic T-lymphocyte (CTL) response against brain tumor cancer cells and brain tumor stem like cells, resulting in tumor cell lysis. BITC have unique antigenicity and have the ability to self-renew; vaccination against BITC antigens may kill these cells and may prevent tumor recurrences. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He - VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5210 - https://github.com/vaccineontology/VO/issues/311 - 3383 - 941 - 965 - 5210 + PubMed:21036724 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5230 + https://github.com/vaccineontology/VO/issues/296 + 5230 Clinical trial - Gene name: CD58|Gene name: ICAM1|Gene name: CD80 - Brain Tumor Initiating Cell Vaccine + BCG, Cell Wall Skeleton Vaccine - + - - + + @@ -186524,7 +186919,7 @@ none - + @@ -186533,25 +186928,29 @@ none - A cancer vaccine consisting of recombinant modified vaccinia Ankara (rMVA) encoding the prostate specific antigen (PSA), the prostate-specific membrane antigen (PSMA) and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM). Vaccination with PSA/PSMA in combination with TRICOM may enhance antigen presentation, resulting in the augmentation of a cytotoxic T cell (CTL) immune response against tumor cells over-expressing PSA or PSMA. + A vaccine consisting of replication-defective recombinant adenovirus that encodes for Bcl-Xs with potential antineoplastic activity. Vaccination with Bcl-Xs adenovirus vaccine induces apoptosis in Bcl-2 and Bcl-XL positive cancer cells, resulting in decreased tumor growth while leaving normal cells unaffected. Bcl-Xs block the function of the protooncogenes Bcl-2 and Bcl-XL which are overexpressed in a variety of solid tumors and promote cancer cell survival by inhibiting apoptosis. (NCI04)A vaccine consisting of replication-defective recombinant adenovirus that encodes for Bcl-Xs with potential antineoplastic activity. Vaccination with Bcl-Xs adenovirus vaccine induces apoptosis in Bcl-2 and Bcl-XL positive cancer cells, resulting in decreased tumor growth while leaving normal cells unaffected. Bcl-Xs block the function of the protooncogenes Bcl-2 and Bcl-XL which are overexpressed in a variety of solid tumors and promote cancer cell survival by inhibiting apoptosis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He - NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29561 - VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5309 - https://github.com/vaccineontology/VO/issues/312 - 5309 + PubMed:7479929 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5399 + https://github.com/vaccineontology/VO/issues/297 + 598 + 7306 + 5399 Clinical trial - rMVA-PSA/PSMA/TRICOM vaccine + VO:0007589 + Gene name: BCL2L1|Gene name: TYRP1 + Bcl-Xs Adenovirus Vaccine - + - - + + @@ -186568,7 +186967,7 @@ none - + @@ -186577,25 +186976,854 @@ none - A vaccine consisting of a replication-defective recombinant canarypox virus (ALVAC) that encodes the gene for human interleukin-12 (hIL-12). Produced mainly by B-cells, IL-12 is an endogenous cytokine that activates natural killer (NK) cells, promotes cytotoxic T lymphocyte (CTL) responses, induces the release of interferon-gamma (IFN-gamma), and may exhibit antitumor and anti-angiogenic effects. Vaccination with canarypox-hIL-12 melanoma vaccine may stimulate the host immune system to mount an immune response against tumor cells, thereby inhibiting tumor growth and/or metastasis. + A transforming growth factor beta2 (TGF-beta2) antisense gene-modified allogeneic tumor cell vaccine with potential immunostimulatory and antineoplastic activities. Belagenpumatucel-L is prepared by transfecting allogeneic non-small cell lung cancer (NSCLC) cells with a plasmid containing a TGF-beta2 antisense transgene, expanding the cells, and then irradiating and freezing them. Upon administration, this agent may elicit a cytotoxic T lymphocyte (CTL) response against host NSCLC cells, resulting in decreased tumor cell proliferation; vaccine immunogenicity may be potentiated by suppression of tumor TGF-beta2 production by antisense RNA expressed by the vaccine plasmid TGF-beta2 antisense transgene. Elevated levels of TGF-beta2 are frequently linked to immunosuppression in cancer patients and may be inversely correlated with prognosis in patients with NSCLC. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He - VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5544 - https://github.com/vaccineontology/VO/issues/313 - 2521 - 5544 + PubMed:26211534 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5374 + https://github.com/vaccineontology/VO/issues/298 + 7042 + 5374 Clinical trial - Gene name: FUS - Canarypox-hIL-12 Melanoma Vaccine + Gene name: TGFB2 + Belagenpumatucel-L Vaccine - + - + + + + + + + + + + + + + + + + + + + + + + + + + + + A synthetic vaccine combining the peptide antigens of two proteins, ras oncoprotein and tumor suppressor p53 + Eliyas Asfaw + Ibrahim Seleznev + Jie Zheng + Oliver He + PubMed:15983396 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4992 + https://github.com/vaccineontology/VO/issues/299 + 7157 + 4992 + Clinical trial + Gene name: TP53 (P53) + Berzofsky Ras/P53 Peptide Vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine composed of a replication-deficient, attenuated derivative of the vaccinia virus strain Ankara expressing both a CD8+ T-cell epitope from the brachyury protein and a triad of T-cell co-stimulatory molecules (MVA Brachyury-TRICOM), with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration of the brachyury-expressing modified vaccinia Ankara (MVA)-TRICOM vaccine, the expressed brachyury protein induces specific CD8+ and CD4+ T-cell responses against brachyury-expressing tumor cells. This causes both tumor cell lysis and a decrease in the growth of brachyury-expressing tumor cells. Brachyury, a member of the T-box family of transcription factors that is overexpressed in numerous cancer cell types, is correlated with increased epithelial-mesenchymal transition (EMT), cancer resistance and cancer progression. TRICOM, a triad of three human T-cell co-stimulatory molecules, B7.1, ICAM-1 and LFA-3, enhances antigen-specific T-cell activation. + Eliyas Asfaw + Ibrahim Seleznev + Jie Zheng + Oliver He + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5439 + https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2022-05711&r=1 + https://github.com/vaccineontology/VO/issues/310 + 925 + 5439 + Clinical trial + Gene name: CD8A + Brachyury-expressing Modified Vaccinia Ankara-TRICOM Vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cell-based cancer vaccine comprised of brain tumor initiating cells (BTICs), with potential immunostimulating and antineoplastic activity. BITCs are from the glioblastoma multiforme (GBM) cell line GBM-6 and contain glioma stem-like cell-associated antigens. Upon administration, the BITC vaccine may stimulate a specific anti-tumoral cytotoxic T-lymphocyte (CTL) response against brain tumor cancer cells and brain tumor stem like cells, resulting in tumor cell lysis. BITC have unique antigenicity and have the ability to self-renew; vaccination against BITC antigens may kill these cells and may prevent tumor recurrences. + Eliyas Asfaw + Ibrahim Seleznev + Jie Zheng + Oliver He + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5210 + https://github.com/vaccineontology/VO/issues/311 + 3383 + 941 + 965 + 5210 + Clinical trial + Gene name: CD58|Gene name: ICAM1|Gene name: CD80 + Brain Tumor Initiating Cell Vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine consisting of recombinant modified vaccinia Ankara (rMVA) encoding the prostate specific antigen (PSA), the prostate-specific membrane antigen (PSMA) and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM). Vaccination with PSA/PSMA in combination with TRICOM may enhance antigen presentation, resulting in the augmentation of a cytotoxic T cell (CTL) immune response against tumor cells over-expressing PSA or PSMA. + Eliyas Asfaw + Ibrahim Seleznev + Jie Zheng + Oliver He + NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29561 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5309 + https://github.com/vaccineontology/VO/issues/312 + 5309 + Clinical trial + rMVA-PSA/PSMA/TRICOM vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A vaccine consisting of a replication-defective recombinant canarypox virus (ALVAC) that encodes the gene for human interleukin-12 (hIL-12). Produced mainly by B-cells, IL-12 is an endogenous cytokine that activates natural killer (NK) cells, promotes cytotoxic T lymphocyte (CTL) responses, induces the release of interferon-gamma (IFN-gamma), and may exhibit antitumor and anti-angiogenic effects. Vaccination with canarypox-hIL-12 melanoma vaccine may stimulate the host immune system to mount an immune response against tumor cells, thereby inhibiting tumor growth and/or metastasis. + Eliyas Asfaw + Ibrahim Seleznev + Jie Zheng + Oliver He + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5544 + https://github.com/vaccineontology/VO/issues/313 + 2521 + 5544 + Clinical trial + Gene name: FUS + Canarypox-hIL-12 Melanoma Vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine that uses dendritic cells pulsed with autologous tumor homogenate in combination With High Dose-IL2 and immunomodulating radiotherapy for patients with Metastatic RCC. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT03226236 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6266 + 6266 + Clinical trial + autolgous DC vaccine pulsed with autologous tumor homogenate for metastatic rcc + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine that consists of of irradiated autologous tumor cells admixed with GM-CSF-secreting bystander cells. The CD8+ T cells can react against CLL-associated antigens. Autologous tumor cell vaccination is an effective strategy to advance long-term leukemia control following allogeneic hematopoietic stem cell transplantation (allo-HSCT). + Hayleigh Kahn + Jie Zheng + PubMed:23912587 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6379 + 6379 + Clinical trial + autologous CLL tumor cell vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine that uses autologous cancer testis (CT) antigen specific dendritic cell (DC) preceded by decitabine as a demethylating chemotherapy for patients with high-risk neuroblastoma, Ewings sarcoma, osteogenic sarcoma, rhabdomyosarcoma or synovial sarcoma. The mature DC is pulsed with overlapping peptides mixes derived from full-length NY-ESO-1, MAGE-A1, and MAGE-A3. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT01241162 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6268 + 1485 + 4100 + 4102 + 6268 + Clinical trial + Gene name: NY-ESO-1|Gene name: MAGE-A1|Gene name: MAGE-A3 + autologous cancer testis antigen specific dendritic cell vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine consisting of autologous dendritic cells (DCs) loaded with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) as a fusion protein with the full-length lysosome-associated membrane protein (flLAMP), with potential immunostimulatory and antineoplastic activities. The vaccine exposes the immune system to the CMV pp65 peptide, which may elicit a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells. The incorporation of flLAMP may route CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC class II antigen presentation, thereby promoting CD4-positive T-cell responses. Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) is a powerful adjuvant capable of stimulating macrophage function, inducing proliferation and maturation of DCs, and is able to enhance T-lymphocyte stimulatory function. The vaccine can be used in combination with monoclonal antibodies, such as basiliximab, that can block tumor growth in different ways, as well as temozolomide, and radiation therpay. The combination of treatments may kill more tumor cells. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C156067 + NCT: https://clinicaltrials.gov/study/NCT00626483 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6347 + 27074 + 6347 + Clinical trial + Gene name: LAMP + autologous CMV-pp65-flLAMP mRNA loaded dendritic cell vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made of dendritic cells (DCs) loaded with personalized peptides (PEP) given in combination with low-dose cyclophosphamide for patients with advanced or recurrent metastatic NSCLC. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT05195619 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6267 + 6267 + Clinical trial + autologous dendritic cell vaccine loaded with personalized peptide vaccine (pep-dc vaccine) + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine that encodes macrophage inflammatory protein 3 alpha (MIP3a)-fused lymphoma idiotype in single chain format for patients with atients with Asymptomatic Phase Lymphoplasmacytic Lymphoma. + Hayleigh Kahn + Jie Zheng + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6264 + 6364 + 6264 + Clinical trial + Gene name: MIP3a + autologous lymphoma immunoglobulin-derived scFv-chemokine DNA vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine that uses autologous neuroblastoma cells, irradiated and genetically modified by adenoviral vectors to secrete interleukin-2 (IL-2) for patients with high-risk neuroblastoma. The adenoviral vector are used to transduce the cells ex-vivo, patients are not treated with the viral vector. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT00048386 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6269 + 3558 + 6269 + Clinical trial + Gene name: IL-2 + autologous neuroblastoma cell vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine that is composed of oxidized ovarian tumor cell lysate, with potential immunostimulatory and antineoplastic activities. The autologous oxidized ovarian tumor cell lysate vaccine exposes the immune system to an undefined amount of tumor-associated antigens (TAAs), which may result in the induction of both anti-tumor cytotoxic T-lymphocytes (CTLs) and antibody-dependent responses against TAA-expressing cells, leading to tumor cell lysis. Compared to non-oxidized tumor cell lysate vaccines, oxidized tumor cell lysate vaccines induce necrotic cell death, increase the immunogenicity of the TAAs and may enhance the anti-tumor immune response. Cyclophosphamide/Fludarabine Lymphodepletion and an immunomodulatory combination of Interferon-alpha Bevacizumab and Aspirin followed by adoptive transfer of vaccine-primed ex vivo CD3/CD28-costimulated peripheral blood autologous T cells and vaccination with whole tumor vaccine administered intradermally in combination with Bevacizumab in patients with recurrent ovarian cancer fallopian tube or primary peritoneal cancer may help treat their tumors. Patients will receive 5-10 million cells intradermally. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C122402 + NCT: [https://clinicaltrials.gov/study/NCT01312376 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6330 + 6330 + Clinical trial + autologous oxidized ovarian tumor cell lysate vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine consisting of total tumor RNA (TTRNA) derived and amplified from autologous tumor cells and mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) as a fusion protein with the full-length lysosome-associated membrane protein (flLAMP), formulated in DOTAP lipid particles, with potential immunostimulatory and antineoplastic activities. he autologous total tumor mRNA and CMV-pp65-flLAMP mRNA loaded liposome vaccine, the mRNA is taken up, translated and presented by antigen presenting cells (APCs). This leads to an induction of both cytotoxic T-lymphocyte and memory T-cell dependent immune responses that specifically target and destroy the patient's cancer cells that express these tumor antigens. The incorporation of flLAMP may route CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC class II antigen presentation, thereby promoting CD4-positive T-cell responses. Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine is used to treat patients with Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM). The vaccine is also used for for the treatment of early melanoma recurrence following adjuvant Anti-PD-1 antibody therapy. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C178432 + NCT: https://clinicaltrials.gov/study/NCT04573140 + NCT: https://clinicaltrials.gov/study/NCT05264974 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6270 + 27074 + 6270 + Clinical trial + Gene name: LAMP + autologous total tumor mrna and CMV-pp65-flLAMP mRNA loaded liposome vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made from the patient's cancer cells that may make the body build an immune response and kill their tumor cells. The autologous tumor cell vaccine will be given together with adjuvant interferon gamma or sargramostim (GM-CSF) in patients with advanced cancer (breast, lung, prostate, colorectal, sarcoma, renal, melanoma). The vaccine uses irradiated autologous tumor cells and tumor lysate. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT00002505 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6364 + 6364 + Clinical trial + autologous tumor cell lysate vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made from the patient's own tumor tissue may stimulate an immune response against the patient's tumor cells. O-Vax nay induce a DTH response to autologous, DNP-modified ovarian cancer cells. The vaccine includes DNP-modified autologous ovarian tumor cells followed by cyclophosphamide then weekly doses of DNP-modified autologous ovarian tumor cells mixed with Bacillus of Calmette and Guérin (BCG). + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT00660101 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6334 + 6334 + Clinical trial + autologous, dnp-modified ovarian cancer vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine containing human acute myeloid leukemic (AML) blasts that have been genetically engineered to express a B7.1/IIL-2 fusion protein. It uses B7.1 (CD80)/IL-2 immune gene therapy for high risk MDS RAEB-2 and acute myeloid leukaemia (AML) patients who are unsuitable for an allogeneic haematological stem cell transplant. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT02493829 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6265 + 941 + 6265 + Clinical trial + Gene name: B7.1 + B7.1/​IL-2 leukaemia cell vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made with BC-819 (also known as DTA-H19), which is a double-stranded DNA plasmid, 4,560 base pairs (bp) in length, carrying the gene for the Diphtheria toxin A (DT-A) chain under the regulation of the H19 promoter. The DT-A chain expression is triggered by the presence of H19 transcription factors that are only up-regulated in tumor cells. The selective initiation of toxin expression results in selective tumor cell destruction via inhibition of protein synthesis selectively in the tumor cell, enabling highly targeted cancer treatment. It is used in combination with intravenously administered gemcitabine for patients with Locally Advanced Pancreatic Adenocarcinoma. The activation of the H19 gene promoter-containing plasmids and DTA expression are limited to tumor cells, as high levels of H19 expression are only found in tumor cells. DTA disrupts protein synthesis. Tumor-cell selective expression of this toxin leads to the selective destruction of the tumor while sparing healthy, normal cells. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C107685 + NCT: https://clinicaltrials.gov/study/NCT01413087 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6273 + 6273 + Clinical trial + BC-819 vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made up of Bcl-xl_42 and the adjuvant CAF09b for patients with hormone-sensitive Prostate Cancer (PC) and lymph node metastases. B-cell lymphoma extra large protein (Bcl-xl) protein plays a vital role in the cancer cell's ability to avoid programmed cell death (apoptosis) and is upregulated in a variety of cancerous diseases, Bcl-xl_42 is a peptide fragment of the full protein and can lead to the death of cancer cells. CAF09b improves the activation of the immune system. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT03412786 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6272 + 6272 + Clinical trial + Bcl-Xl_42-CAF09b vaccine + + + + + + + @@ -186860,6 +188088,56 @@ none + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine consisting of the bcr-abl b2a2 fusion oncoprotein, frequently expressed in chronic myelogenous leukemia (CML), with potential antineoplastic activity. Vaccination with the bcr-abl (b2a2)-derived peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl b2a2 fusion protein. (NCIT_C61309) The vaccine is made from made from the proteins that cause leukemia cells in CML to behave abnormally. Imatinib mesylate is the standard therapy for CML and blocks the function of this protein. In combination, these may decrease or eliminate all evidence of disease in patients who have CML that is in remission after treatment with imatinib mesylate, but who still have small amounts of detectable disease. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C61309 + NCT: https://clinicaltrials.gov/study/NCT00267085 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6353 + 25 + 6354 + Clinical trial + Gene name: bcr-abl + Bcr-Abl (b2a2)-derived peptide vaccine + + + + @@ -187224,6 +188502,56 @@ none + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine consisting of the bcr-abl b2a2 fusion oncoprotein, frequently expressed in chronic myelogenous leukemia (CML), with potential antineoplastic activity. Vaccination with the bcr-abl (b2a2)-derived peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl b2a2 fusion protein. The vaccine is made from made from the proteins that cause leukemia cells in CML to behave abnormally. Imatinib mesylate is the standard therapy for CML and blocks the function of this protein. In combination, these may decrease or eliminate all evidence of disease in patients who have CML that is in remission after treatment with imatinib mesylate, but who still have small amounts of detectable disease. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C61310 + NCT: https://clinicaltrials.gov/study/NCT00466726 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6274 + 25 + 6274 + Clinical trial + Gene name: bcr-abl + Bcr-Abl (b3a2)-derived peptide vaccine + + + + @@ -188777,6 +190105,57 @@ none + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine consisting of the bcr-abl b3a2 fusion oncoprotein, frequently expressed in chronic myelogenous leukemia (CML), with potential antineoplastic activity. Vaccination with the bcr-abl (b3a2)-derived peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl b3a2 fusion protein. The bcr-abl p210-b3a2 breakpoint-derived pentapeptide vaccine is used in combination with GM-CSF. The peptides may help the body build an effective immune response to kill cancer cells, and the GM-CSF may increase the number of immune cells found in bone marrow or peripheral blood. This combination is used to treat patients with Philadelphia chromosome-positive chronic myelogenous leukemia. It can also be used in combination with imatinib mesylate to decrease or eliminate all evidence of disease in patients who have CML that is in remission after treatment with imatinib mesylate, but who still have small amounts of detectable disease + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C2205 + NCT: https://clinicaltrials.gov/study/NCT00004052 + NCT: https://clinicaltrials.gov/study/NCT00455221 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6372 + 25 + 6372 + Clinical trial + Gene name: bcr-abl + Bcr-Abl peptide vaccine + + + + @@ -191323,6 +192702,52 @@ none + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine that is a bivalent vaccine with the antigens GD2L and GD3L for patients with High-Risk Neuroblastoma. The antigens are linked to KLH and mixed with OPT-821. It is given in combination with oral β-glucan, which can help white blood cells kill cancer. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT00911560 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6262 + 6262 + Clinical trial + bivalent neuroblastoma vaccine with adjuvant OPT-821 + + + + @@ -192088,6 +193513,48 @@ none + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made of peripheral blood and tumor specimen harvested from patients with metastatic adenocarcinoma of the pancreas to generate cancer stem cell (CSC)-loaded denritic cell (DC) vaccines. CSC-primed antibodies and T cells are capable of selective targeting CSCs and conferring antitumor immunity. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT02074046 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6276 + 6276 + Clinical trial + cancer stem cell-loaded dc vaccine + + + + @@ -192910,6 +194377,43 @@ Immunization Route: Intramuscular injection (i.m.) + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made with chimeric antigen receptor (CAR) T cells that can be used to treat solid tumors. These CAR-T cells are engineered to target carbonic anhydrase IX (CAIX) to secrete anti-PD-L1 monoclonal antibody (mAb), termed immune-restoring (IR) CAR G36-PDL1. The T cells can be used to treat clear cell renal cell carcinoma (ccRCC) with reconstituted human leukocyte antigen (HLA) partially matched human leukocytes derived from fetal CD34+ hematopoietic stem cells (HSCs) and bearing human ccRCC skrc-59 cells under the kidney capsule. The cells can restore active antitumor immunity by promoting tumor-killing cytotoxicity, reducing immunosuppressive cell components such as M2 macrophages and exhausted CD8+ T cells, and enhancing T follicular helper (Tfh)-B cell crosstalk. + Hayleigh Kahn + Jie Zheng + PubMed:38327771 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6380 + 3105 + 6380 + Research + Gene name: HLA + CAR G36-PDL1 vaccine + + + + @@ -193228,12 +194732,11 @@ Immunization Route: Intramuscular injection (i.m.) - + - - + + - @@ -193243,31 +194746,40 @@ Immunization Route: Intramuscular injection (i.m.) - + - + + + + + + + + A cancer vaccine for bladder cancer designed to generate an immune response against a protein called human chorionic gonadotropin-beta (hCG-β). hCG-β is made by several types of cancers, including bladder cancer, and has been shown to be associated with shorter times to development of metastases and reduced survival in bladder cancer. Administering the CDX-1307 vaccine will cause the body's immune system to attack bladder cancer cells in order to kill them or otherwise keep them from spreading or coming back. The human monoclonal antibody (B11) directed against the mannose receptor and linked to the beta-subunit of human chorionic gonadotropin (hCG beta) with potential immunostimulating and antineoplastic activities. The monoclonal antibody moiety of human monoclonal antibody B11-hCG beta fusion protein CDX-1307 binds to mannose receptors on antigen presenting cells (APCs), including human dendritic cells (DCs) and macrophages. APCs present the processed hCG beta antigen on their cell surfaces, which may initiate an antibody-dependent cell-mediated cytotoxicity (ADCC) response against hCG beta-expressing tumor cells. + Hayleigh Kahn Jie Zheng - Justin Song - Oliver He - Penny Pan - https://github.com/vaccineontology/VO/issues/517 - 7299 - Gene name: Tyrosinase - Melanoma DNA vaccine TA2M(TM) encoding tyrosinase peptides + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C77858 + NCT: https://clinicaltrials.gov/study/NCT01094496 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6277 + 1082 + 6277 + Clinical trial + Gene name: hCG-β + CDX-1307 vaccine - + - - + + @@ -193275,62 +194787,84 @@ Immunization Route: Intramuscular injection (i.m.) + + + + + + - + - A synthetic allogeneic cancer vaccine. Melanoma theraccine typically consists of lysed melanoma cells obtained from several melanoma cell lines combined with an adjuvant (such as DETOX or RIBI). This agent may be combined with immunomodulatory cytokines such as interferon alpha. Melanoma theraccine may induce a rise in the level of cytotoxic T-lymphocyte precursors. + + + + + + + A cancer vaccine prepared as tumor cells are isolated from the lesion site of patients with recurrent or metastatic bladder cancer, and dendritic cells or macrophages are isolated from peripheral blood. The vaccine activates an immune response and the microenvironment of bladder cancer lesions, and improves the anti-recurrence treatment effect of bladder cancer. + Hayleigh Kahn Jie Zheng - Justin Song - Oliver He - Penny Pan - VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4989 - https://github.com/vaccineontology/VO/issues/522 - 282617 - 4989 - Gene name: IFNL3 - Melanoma Theraccine + NCT: https://clinicaltrials.gov/study/NCT05559177 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6278 + 6278 + Clinical trial + chimeric exosomal tumor vaccine - + - - + + + + + + + + + - + - A therapeutic melanoma vaccine consisting of autologous dendritic cells (DCs) pulsed with antigens from lethally irradiated autologous tumor cells derived from a patient-specific, continuously proliferating and melanoma-initiating cell line and suspended in a solution containing the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration, melapuldencel-T may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against the patient's repertoire of melanoma-associated antigens, particularly tumor stem cell antigens, found in the irradiated autologous cancer cells. As an immunostimulant, GM-CSF enhances the activation of dendritic cells (DCs) and promotes antigen presentation to both B- and T-lymphocytes. + + + + + + + A cancer vaccine that treats patients with Binet Stage A Chronic Lymphocytic Leukemia (CLL) by using a fragment of Deoxyribonucleic acid (DNA) containing the sequence of their own immunoglobulin gene. The vaccine is designed to generate an immune response and shrink or slow the CLL. + Hayleigh Kahn Jie Zheng - Justin Song - Oliver He - Penny Pan - VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5014 - https://github.com/vaccineontology/VO/issues/523 - 5014 - Melapuldencel-T Vaccine + NCT: https://clinicaltrials.gov/study/NCT00038415 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6279 + 6279 + Clinical trial + CLL idiotypic DNA vaccine - + - - + + + @@ -193339,37 +194873,44 @@ Immunization Route: Intramuscular injection (i.m.) - - + + - + - A multipeptide cancer vaccine comprised of 12 melanoma peptides restricted by Class I MHC (12MP), plus a tetanus helper peptide + + + + + + + A cancer vaccine for patients with Locally Advanced, Triple-Negative Breast Cancer or ER-Positive, Her2-Negative Breast Cancer to receive ex vivo-generated tumor antigen-loaded dendritic cells (DCs), which can prime lymphocytes and regulate and maintain immune responses. The vaccine may boost T cell immunity targeted against breast cancer, enhance chemotherapy effectiveness and decrease tumor metastagenicity, and decrease the recurrence rates of LA TNBC and ER+/HER2- BC. + Hayleigh Kahn Jie Zheng - Justin Song - Oliver He - Penny Pan - VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5261 - https://github.com/vaccineontology/VO/issues/524 - 22178 - 6490 - 5261 - Gene name: gp100|Gene name: TRP-1 - MELITAC 12.1 Peptide Vaccine + NCT: https://clinicaltrials.gov/study/NCT02018458 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6288 + 2064 + 7490 + 931 + 6288 + Clinical trial + Gene name: cyclin B1|Gene name: WT-1|Gene name: CEF + cyclin B1/WT-1/CEF-loaded DC vaccine - + - - + + + @@ -193379,30 +194920,35 @@ Immunization Route: Intramuscular injection (i.m.) - + - A humanized anti-idiotypic (anti-Id) monoclonal antibody (MoAb) that mimics the disialoganglioside GD2 with potential immunostimulating and antineoplastic activities. Upon administration, monoclonal antibody 4B5 anti-idiotype vaccine may elicit both cellular and humoral immune responses against GD2- expressing tumor cells. GD2 is a glycosphingolipid (ceramide and oligosaccharide) that may be highly expressed by melanomas and other neuroectodermal tumors, while only minimally expressed by normal tissues. + + + + + + + A cancer vaccine consisting of autologous dendritic cells (DCs) fused with autologous acute myeloid leukemia (AML) cells, with potential immunostimulatory and antineoplastic activities. It is generated in vitro by mixing DCs and irradiated AML cells harvested from individual patients, in the presence of polyethylene glycol (PEG), to produce hybrid DC-leukemia fusion cells. The vaccine may elicit a cytotoxic T-lymphocyte (CTL)-mediated antitumor immune response against a broad array of AML-associated antigens, which may lead to AML cell lysis. When dendritic cells and tumor cells are brought together, the dendritic cells can stimulate immune responses against the tumor and, in some cases, cause the tumor to shrink. GM-CSF is a drug that stimulates white blood cells and is given with the DC AML Vaccine in an effort to enhance the effect of the vaccine. + Hayleigh Kahn Jie Zheng - Justin Song - Oliver He - Penny Pan - VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5039 - https://github.com/vaccineontology/VO/issues/535 - 2064 - 5039 - Gene name: ERBB2 - Monoclonal Antibody 4B5 Anti-Idiotype Vaccine + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148214 + NCT: https://clinicaltrials.gov/study/NCT01096602 + NCT: https://clinicaltrials.gov/study/NCT03059485 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6374 + 6374 + Clinical trial + DC/AML fusion vaccine - + - - + + - + @@ -193411,63 +194957,618 @@ Immunization Route: Intramuscular injection (i.m.) - - + + - + - A vaccine consisting of a plasmid DNA encoding the murine melanoma-associated antigen gp100. Upon administration, expressed gp100 antigen may stimulate a cytotoxic T cell HLA-A2.1-restricted immune response against tumor cells that express the gp100 antigen, resulting in tumor cell lysis. + + + + + + + A cancer vaccine made using the participant's own blood cells. The vaccine will contain a virus called an adenovirus, similar the virus that causes the common cold. The dendritic cells contain survivin+, CD11c+, Human Leukocyte Antigen - antigen D Related (HLA-DR)+ by flow-cytometry. The vaccine is given in combination with G-CSF, T cells, and the CD34 progenitor cells. + Hayleigh Kahn Jie Zheng - Justin Song - Oliver He - Penny Pan - VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5386 - https://github.com/vaccineontology/VO/issues/539 - 20431 - 5386 - Gene name: Pmel17 - Mouse gp100 Plasmid DNA Vaccine + NCT: https://clinicaltrials.gov/study/NCT02851056 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6351 + 3123 + 332 + 3684 + 6351 + Clinical trial + Gene name: survivin|Gene name: CD11|Gene name: HLA-DR + dendritic cell survivin vaccine - + - - + + + + + + + + + - + + + + + + + + A cancer vaccine composed of dendritic cells pulsed with peptide epitopes that stimulate cytotoxic T lymphocyte anti-tumor activity. This vaccine is used to treat diffuse hemispheric glioma with a H3 G34 mutation that has come back (recurrent) and/or is growing, spreading, or getting worse (progressive). It is made with the patient's own white blood cells and peptide-pulsed dendritic cells, which may help the body build an effective immune response to kill tumor cells. It is combined with immunotherapy monoclonal antibodies, such as nivolumab and ipilimumab, which also may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. + Hayleigh Kahn Jie Zheng - Justin Song - Oliver He - Penny Pan - https://github.com/vaccineontology/VO/issues/543 - 768 - Gene name: CA9 - mRNA-Electroporated Dendritic Cells Vaccine + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1987 + NCT: https://clinicaltrials.gov/study/NCT05457959 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6282 + 6282 + Clinical trial + dendritic cell tumor peptide vaccine - + - + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine onsisting of autologous dendritic cells (DCs) fused with patient-derived plasma cell (multiple) myeloma cells with potential immunostimulatory and antineoplastic activities. Autologous DC/multiple myeloma fusions stimulate both helper and cytotoxic T-lymphocyte (CTL) responses through the presentation of internalized and newly synthesized tumor associated antigens (TAAs). This may promote cellular and humoral antitumor immune responses in patients with plasma cell myeloma. This vaccine uses Dendritic cell/myeloma fusions with granulocyte macrophage colony-stimulating factor (GM-CSF) adjuvant plus lenalidomide maintenance therapy. The dendritic cell myeloma vaccine may improve response in patients with multiple myeloma after autologous Hematopoietic Cell Transplant (HCT). + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C158480 + NCT: https://clinicaltrials.gov/study/NCT02728102 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6323 + 6323 + Clinical trial + dendritic cell/​myeloma fusion vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Jie Zheng + Justin Song + Oliver He + Penny Pan + https://github.com/vaccineontology/VO/issues/517 + 7299 + Gene name: Tyrosinase + Melanoma DNA vaccine TA2M(TM) encoding tyrosinase peptides + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made of tumor cells and tumor stem cells that are isolated from a sample from a patient with glioblastoma multiforme. Dendritic cells are isolated from peripheral blood mononuclear cells and cultured. The tumor sample provides tumor specific antigens to prepare the dendritic vaccine. Cytotoxic lymphocytes are obtained from peripheral blood after dendritic vaccine administrations. Hematopoietic stem cells are harvested from closely related donor after granulocyte-colony-stimulating factor (G-CSF) administration. Allogeneic haploidentical hematopoietic stem cells are administered intrathecally, dendritic cells are administered subcutaneously, and cytotoxic lymphocytes are adminstered intrathecally. The combination of these treatments may control tumor cell quantity and target regulation of effector functions of tumor stem cells. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT01759810 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6285 + 6285 + Clinical trial + dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine from tumor cells and tumor stem cells that are isolated from a sample from a patient with glioblastoma multiforme. Dendritic cells are isolated from peripheral blood mononuclear cells and cultured. The tumor sample provides tumor specific antigens to prepare the dendritic vaccine. Cytotoxic lymphocytes are obtained from peripheral blood after dendritic vaccine administrations. Hematopoietic stem cells are harvested from closely related donor after granulocyte-colony-stimulating factor (G-CSF) administration. Autologous haploidentical hematopoietic stem cells are administered intrathecally, dendritic cells are administered subcutaneously, and cytotoxic lymphocytes are adminstered intrathecally. The combination of these treatments may control tumor cell quantity and target regulation of effector functions of tumor stem cells. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT01759810 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6286 + 6286 + Clinical trial + dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine based on ex vivo genetic modifications in combination with known tumor-specific antigens may substantially enhance the activation potential of tumor-specific T cells with improved benefit to patients. This DC vaccine is based on autologous DCs pulsed with genetically modified tumor cells or related antigens such as neoantigens to induce a strong anti-tumor immunity. The patient will receive intravenous cyclophosphamide (200 mg/m2) or oral (cytoxan) before the vaccine, followed by DC vaccine and intravenous bevacizumab (15 mg/kg). + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT03914768 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6301 + 6301 + Clinical trial + DIPG and GMB Immunomodulatory DC vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made with PEG fusions generated from allogeneic dendritic cells and autologous tumor-derived cells with GM-CSF and Il-4. The vaccine is irradiated, frozen, and thawed before being administered to patients with AJCC Stage IV Renal Cell Carcinoma. The vaccine could have and effect on the immune system and cancer. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT00625755 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6287 + 6287 + Clinical trial + electrofusion DC vaccine + + + + + + + + + + + + + + + + + + + + + + A synthetic allogeneic cancer vaccine. Melanoma theraccine typically consists of lysed melanoma cells obtained from several melanoma cell lines combined with an adjuvant (such as DETOX or RIBI). This agent may be combined with immunomodulatory cytokines such as interferon alpha. Melanoma theraccine may induce a rise in the level of cytotoxic T-lymphocyte precursors. + Jie Zheng + Justin Song + Oliver He + Penny Pan + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4989 + https://github.com/vaccineontology/VO/issues/522 + 282617 + 4989 + Gene name: IFNL3 + Melanoma Theraccine + + + + + + + + + + + + + + + + + + + + + + A therapeutic melanoma vaccine consisting of autologous dendritic cells (DCs) pulsed with antigens from lethally irradiated autologous tumor cells derived from a patient-specific, continuously proliferating and melanoma-initiating cell line and suspended in a solution containing the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration, melapuldencel-T may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against the patient's repertoire of melanoma-associated antigens, particularly tumor stem cell antigens, found in the irradiated autologous cancer cells. As an immunostimulant, GM-CSF enhances the activation of dendritic cells (DCs) and promotes antigen presentation to both B- and T-lymphocytes. + Jie Zheng + Justin Song + Oliver He + Penny Pan + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5014 + https://github.com/vaccineontology/VO/issues/523 + 5014 + Melapuldencel-T Vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + A multipeptide cancer vaccine comprised of 12 melanoma peptides restricted by Class I MHC (12MP), plus a tetanus helper peptide + Jie Zheng + Justin Song + Oliver He + Penny Pan + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5261 + https://github.com/vaccineontology/VO/issues/524 + 22178 + 6490 + 5261 + Gene name: gp100|Gene name: TRP-1 + MELITAC 12.1 Peptide Vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine comprised of estrogen receptor alpha (ERa; estrogen receptor 1; ESR1) mutant peptides, combined with the immunoadjuvants granulocyte-macrophage colony-stimulating factor (GM-CSF) and montanide ISA, with potential immunomodulating and antineoplastic activities. ESR1 mutant peptides in the ESR1 peptides/GM-CSF/montanide ISA vaccine may activate the immune system to induce an immune response against tumor cells expressing these ESR1 mutations. Cancer peptides used in this vaccine are derived from the estrogen receptor and are combined with the adjuvant Montanide ISA and GM-CSF to enhance their immune response. The vaccine may improve outcomes of patients with endocrine resistant breast cancer. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C175590 + NCT: https://clinicaltrials.gov/study/NCT04270149 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6289 + 2099 + 6289 + Clinical trial + Gene name: ESR1 + ESR1 peptide vaccine + + + + + + + + + + + + + + + + + + + + + + A humanized anti-idiotypic (anti-Id) monoclonal antibody (MoAb) that mimics the disialoganglioside GD2 with potential immunostimulating and antineoplastic activities. Upon administration, monoclonal antibody 4B5 anti-idiotype vaccine may elicit both cellular and humoral immune responses against GD2- expressing tumor cells. GD2 is a glycosphingolipid (ceramide and oligosaccharide) that may be highly expressed by melanomas and other neuroectodermal tumors, while only minimally expressed by normal tissues. + Jie Zheng + Justin Song + Oliver He + Penny Pan + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5039 + https://github.com/vaccineontology/VO/issues/535 + 2064 + 5039 + Gene name: ERBB2 + Monoclonal Antibody 4B5 Anti-Idiotype Vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A vaccine consisting of a plasmid DNA encoding the murine melanoma-associated antigen gp100. Upon administration, expressed gp100 antigen may stimulate a cytotoxic T cell HLA-A2.1-restricted immune response against tumor cells that express the gp100 antigen, resulting in tumor cell lysis. + Jie Zheng + Justin Song + Oliver He + Penny Pan + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5386 + https://github.com/vaccineontology/VO/issues/539 + 20431 + 5386 + Gene name: Pmel17 + Mouse gp100 Plasmid DNA Vaccine + + + + + + + + + + + + + + + + + + + + + + Jie Zheng + Justin Song + Oliver He + Penny Pan + https://github.com/vaccineontology/VO/issues/543 + 768 + Gene name: CA9 + mRNA-Electroporated Dendritic Cells Vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine directed against the soluble protein idiotype of an individual follicular lymphoma with potential antineoplastic activity. The vaccine may induce an idiotype-specific cytotoxic T-lymphocyte (CTL) response against follicular lymphoma cells expressing the idiotype, resulting in tumor cell lysis. Idiotypic vaccinations have the capacity of inducing an idiotype- and tumor-specific immune response, inducing specific immune responses able to kill in vivo follicular lymphoma cells, and prolonging survival of responding patients. This vaccine may contribute to preventing relapse indefinitely in responding patients. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C71036 + NCT: https://clinicaltrials.gov/study/NCT00530140 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6290 + 6290 + Clinical trial + follicular lymphoma, patient-specific, soluble protein idiotype vaccine + + + + + + + @@ -194017,6 +196118,53 @@ Immunization Route: Intramuscular injection (i.m.) + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made from tumor-specific neopeptides resulting from frameshift mutations in tumor cells, so-called Frames, present potentially potent targets for the immune system and can be utilized in therapeutic anti-cancer vaccination with the intention to synergize in their effect with immune checkpoint inhibitors. The personalized vaccine FRAME-001 based on a patient's Framome and selection of Frame peptides in advanced NSCLC cancer patients after standard first line treatment consisting of immune checkpoint inhibitor pembrolizumab as monotherapy or combined with chemotherapy (carboplatin/cisplatin and pemetrexed/paclitaxel) could help treat patients with non-small cell lung cancer. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT04998474 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6291 + 6291 + Clinical trial + FRAME-001 personalized vaccine + + + + @@ -197444,9 +199592,7 @@ Immunization Route: Intramuscular injection (i.m.) A cancer that is caused by human papillomavirus (HPV) infection. HPV infection can lead to six types of cancer including anal, cervical, oropharyngeal, penile, vaginal, and vulvar cancer. placeholder, will send new term requst to DOID - Anna Maria Masci - Xingxian Li - Jie Zheng + Jie Zheng, Xingxian Li, Anna Maria Masci https://github.com/vaccineontology/VO/issues/677 disposition HPV associated cancer @@ -197470,10 +199616,20 @@ Immunization Route: Intramuscular injection (i.m.) + + + + + + + + - An antigen expressed by the tumor cells, which may be exclusively present on tumor cells or overexpressed on them. - Anna Maria Masci + Either a tumor-specific or a tumor-associated antigen. + Anna Maria Masci + Barry Smith Jie Zheng + Oliver He https://github.com/vaccineontology/VO/issues/677 material entity tumor antigen @@ -197496,8 +199652,9 @@ Immunization Route: Intramuscular injection (i.m.) - A cancer vaccine that prevents cancer development associated with viral infections. + Cancer vaccine that prevents cancer formation and development. Anna Maria Masci + Barry Smith Jie Zheng Oliver He https://github.com/vaccineontology/VO/issues/677 @@ -197522,8 +199679,9 @@ Immunization Route: Intramuscular injection (i.m.) - A cancer vaccine that aims to eliminate or control tumor cells by recognizing the tumor cells and stimulating the immune system via tumor antigens. + Cancer vaccine that aims to eliminate or control tumor cells. Anna Maria Masci + Barry Smith Jie Zheng Oliver He https://github.com/vaccineontology/VO/issues/677 @@ -197587,6 +199745,3749 @@ Immunization Route: Intramuscular injection (i.m.) + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made with T cells genetically engineered to express anti-GD2 Chimeric Antigen Receptor to treat patients with children and young adults with GD2+ solid tumors, including neuroblastoma. The T cells may have an antitumor effect. They can be used in combination with AP1903 and Cyclophosphamide. (NCT02107963) There are increased CXCR3- classical monocytes in patients as CAR-T numbers waned. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT02107963 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6381 + pubmed:38134936 + 6381 + Clinical trial + GD2-CAR vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine used to treat patients with small cell lung cancer by using several components (small cell lung cancer targets) that have been tested individually in patients with small cell lung cancer or other cancers (GD2, GD3, Globo H, Fucosyl GM1 and N-propionylated polysialic acid) so that the body will make antibodies to the vaccine which will also react against the cancer. Two other substances (KLH and OPT-821) are added which boost the immune system. Vaccination with the pentavalent KLH conjugate vaccine may induce production of IgG and IgM antibodies as well as an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumors expressing any of these antigens. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C97034 + NCT: https://clinicaltrials.gov/study/NCT01349647 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6275 + 2524 + 2583 + 6489 + 8705 + 6275 + Clinical trial + Gene name: GD 2|Gene name: GD3|Gene name: Globo H|Gene name: fucosyl GM1 + GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid KLH conjugate vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made with HLA class I-matched allogeneic human prostate carcinoma cells that are genetically engineered to secrete interleukin-2 and interferon gamma for patients with prostate carcinoma. Interleukin-2 may stimulate a person's white blood cells including natural killer cells to kill prostate cancer cells. Interferon gamma may interfere with the growth of the cancer cells. Combining interferon gamma with interleukin-2 may be a more effective treatment for prostate cancer. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT00002637 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6292 + 3458 + 3558 + 6292 + Clinical trial + Gene name: IL2|Gene name: Interferon gamma + genetically engineered allogeneic prostate carinoma cells secreting interleukin-2 and interferon gamma + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine comprised of K562 cells transfected with the granulocyte macrophage-colony stimulating factor (GM-CSF) gene with potential immunopotentiating properties. This vaccine may stimulate the host immune system to produce an antitumoral T-lymphocyte response, thereby inhibiting tumor growth. A cultured cell line is genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from a patient. Vaccines made from gene-modified cancer cells may help the body build an effective immune response to kill cancer cells. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving vaccine therapy together with imatinib mesylate may be an effective treatment for chronic myelogenous leukemia. The vaccine can also be combined with stem cell transplantation. The vaccine may induce an immune response to common myeloid antigens (e.g., Wilms' tumor-1 [WT-1], survivin, or proteinase-3) in patients with Myelodysplastic Syndrome. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C52190 + NCT: https://clinicaltrials.gov/study/NCT00301093 + NCT: https://clinicaltrials.gov/study/NCT00361296 + NCT: https://clinicaltrials.gov/study/NCT00442130 + NCT: https://clinicaltrials.gov/study/NCT00809250 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6293 + 1437 + 6293 + Clinical trial + Gene name: GM-CSF + GM-K562 cell vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine composed of irradiated tumor cells transduced with granulocyte-macrophage colony-stimulating factor (GM-CSF) and CD40-ligand (CD40L) genes. The vaccine may stimulate an anti-tumoral dendritic cell-mediated host immune response. Universal GM-CSF-producing and CD40L-expressing bystander cell line is used to form an autologous tumor cell-based vaccine for patients with mantle cell lymphoma in order to make the body build an effective immune response to kill cancer cells. It can be used in combination with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Dexamethasone, and IL-2. The vaccine can be done with bystander and autologous tumor cells for patients with malignant melanoma. It can also be combined with lenalidomide for patients with myelodysplastic syndrome (MDS). + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT00840931 + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C48391 + NCT: https://clinicaltrials.gov/study/NCT00101101 + NCT: https://clinicaltrials.gov/study/NCT00101166 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6271 + 959 + 6271 + Clinical trial + Gene name: CD40LG + GM.CD40L cell vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine using dendritic cells (a kind of white blood cell) as a vaccine could stimulate your own immune system to react to your melanoma cells. Autologous dendritic cells are pulsed with 2 gp100 melanoma peptides (G209-2M and G280-9V) plus up to an additional 10 unique melanoma tumor-specific peptides. Patients also receive cyclophosphamide 300mg/m2 IV in order to deplete regulatory T cells. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT00683670 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6308 + 6490 + 6308 + Clinical trial + Gene name: gp100 + gp100 mature dendritic cell vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine that uses irradiated, adenovirus transduced autologous myeloblasts to secrete granulocyte-macrophage colony-stimulating factor (GVAX) early after allogeneic hematopoietic stem cell transplantation (HSCT) to induce potent immune responses. The vaccine may prevent advanced myelodysplastic syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), or acute myeloid leukemia (AML) from relapsing after stem cell transplant. The patients own cancer cells are engineered to produce a protein called GM-CSF, which can be effective in stimulating a powerful immune response specific to that cancer. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT01773395 + PubMed:34807983 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6385 + 1437 + 6385 + Clinical trial + Gene name: GM-CSF + GVAX leukemia vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine composed of a peptide derived from histone H3.3 containing the amino acid substitution mutation lysine (Lys) 27-to-methionine (H3.3K27M), with potential immunoactivating and antineoplastic activities. Following the administration of the vaccine, the immune system may exert a cytotoxic T-lymphocyte (CTL)-mediated immune response against H3.3K27M-expressing tumor cells. A lysine 27-to-methionine (K27M) somatic mutation at histone H3 variant (H3.3) is a feature mutation in diffuse intrinsic pontine gliomas (DIPGs). This vaccine contains an H3.3-K27M targeted neoantigen peptide that can be taken up by antigen-presenting cells (APCs). APCs can present the peptide with the major histocompatibility complex (MHC) molecules on cell surface, thereby activating neoantigen-specific T cells and triggering corresponding cytotoxic T cell immune responses to eliminate H3.3-K27M-expressing DIPG cells. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C132684 + NCT: https://clinicaltrials.gov/study/NCT04749641 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6295 + 6295 + Clinical trial + H3.3K27M-specific peptide vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine comprised of HER-2-neu and carcinoembryonic antigen synthetic (CEA) peptides, combined with the adjuvants granulocyte-macrophage colony stimulating factor (GM-CSF), and Montanide ISA-51 with potential antineoplastic activity. The vaccine may stimulate a cytotoxic T-cell response against HER-2-neu- and CEA-expressing tumor cells. Vaccines made from peptides may make the body build an immune response to kill tumor cells. This vaccine is compromised of HER-2-neu and carcinoembryonic antigen synthetic peptides, sargramostim (GM-CSF), and Montanide ISA-51, and aims to cause an immune response in patients with stage IIB, III, or IV colorectal cancer. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C48392 + NCT: https://clinicaltrials.gov/study/NCT00091286 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6294 + 1048 + 2064 + 6294 + Clinical trial + Gene name: carcinoembryonic antigen|Gene name: HER-2-neu + HER-2-neu, CEA peptides, GM-CSF, montanide ISA-51 vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made from peptides that may help the body build an effective immune response to kill tumor cells. Patients with HER2 positive locally advanced breast cancer can be vaccinated with a HER2 Intracellular Domain (ICD) peptide-based vaccine administered concurrently with trastuzumab. The vaccine may lead to an immune response (HER2 specific T cell immunity and/or the development of intramolecular epitope spreading). + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT00343109 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6352 + 2064 + 6352 + Clinical trial + Gene name: HER-2/neu + HER2 ICD peptide vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine for vaccination with neoantigens that can both expand pre-existing neoantigen-specific T-cell populations and induce a broader repertoire of new T-cell specificities in cancer patients, tipping the intra-tumoural balance in favour of enhanced tumour control. The vaccine targets up to 20 predicted personal tumour neoantigens. The vaccine induced CD4+ and CD8+ T cells responses. These T cells discriminated mutated from wild-type antigens, and in some cases directly recognized autologous tumour. + Hayleigh Kahn + Jie Zheng + PubMed:28678778 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6377 + 3123 + 6377 + Clinical trial + Gene name: HLA + HLA neoantigen vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made from a person's white blood cells mixed with tumor proteins (HLA-A1- and HLA-A2.1-restricted peptides derived from melanoma-associated tumor antigens) and CD40-ligand, and may make the body build an immune response to kill tumor cells. This is combined with denileukin diftitox, which + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT00056134 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6283 + 3105 + 959 + 6283 + Clinical trial + Gene name: HLA-A|Gene name: CD40L + HLA-A1, HLA-A2, and CD40-ligand pulsed dendritic cell vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine consisting of Hodgkin lymphoma cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene with potential antineoplastic activity. Hodgkin antigens-GM-CSF-expressing cell vaccine may stimulate a cytotoxic T-lymphocyte (CTL) immune response against Hodgkin lymphoma-associated antigens, which may result in the lysis of tumor cells expressing these antigens. Also, transfected Hodgkin lymphoma cells secrete GM-CSF, which may potentiate the CTL response against Hodgkin lymphoma-associated antigens. Vaccines made from a tumor antigen may help the body build an effective immune response to kill tumor cells. This vaccine contains cells expressing Hodgkin's antigens and GM-CSF, and could cause an immunological response in Hodgkin's lymphoma patients. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C61592 + NCT: https://clinicaltrials.gov/study/NCT00478062 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6296 + 6296 + Clinical trial + hodgkin's antigens-GM-CSF-expressing cell vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine consisting of a recombinant, attenuated, replication-incompetent form of the Semliki Forest Virus (SFV) vector encoding the viral oncoproteins E6 and E7 derived from the human papillomavirus (HPV), with potential immunomodulating and antineoplastic activities. The vaccine induces expression of the E6/E7 proteins and stimulates both the innate and the adaptive immune system, resulting in a potent cytotoxic T-lymphocyte (CTL) response against and lysis of tumor cells expressing HPV E6 and E7. The vaccine may help to treat patients with a history of (pre) malignant cervical lesions. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148539 + NCT: https://clinicaltrials.gov/study/NCT03141463 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6369 + 1489078 + 1489079 + 6369 + Clinical trial + Gene name: E6|Gene name: E7 + HPV E6/E7-encoding semliki forest virus vaccine Vvax001 + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine composed of irradiated allogeneic breast cancer cell lines (HAB-1 and HAB-2) that have been transduced with a recombinant Moloney murine leukemia virus (MoMLV)-based retroviral vector expressing the murine alpha (1,3) GT gene. The immune response to the foreign substance could stimulate the immune system to attack the patient's own cancer cells that have similar proteins without this sugar pattern, causing the tumor to remain stable or shrink. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT00090480 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6297 + 14594 + 6297 + Clinical trial + Gene name: Ggta1 + hyperacute - breast cancer vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine composed of irradiated allogeneic melanoma cell lines (HAM-1, HAM-2 and HAM-3). These cell lines have been transduced with a recombinant Moloney murine leukemia virus (MoMLV)-based retroviral vector expressing the murine alpha(1,3)GT gene, a mouse gene that causes the production of a foreign pattern of protein-sugars on the cell surface. The immune response to the foreign substance could stimulate the immune system to attack the patient's own cancer cells that have similar proteins without this sugar pattern, causing the tumor to remain stable or shrink. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT00300612 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6298 + 14594 + 6298 + Clinical trial + Gene name: Ggta1 + hyperacute-melanoma vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine composed of irradiated allogeneic prostate cancer cell lines (HAP-1 and HAP-2) that have been transduced with a recombinant Moloney murine leukemia virus (MoMLV)-based retroviral vector expressing the murine alpha (1,3) GT gene, a mouse gene that causes the production of a foreign pattern of protein-sugars on the cell surface. It is hoped that the immune response to the foreign substance will stimulate the immune system to attack the patient's own cancer cells that have similar proteins without this sugar pattern, causing the tumor to remain stable or shrink.. The expression of the murine alpha (1,3) galactosyltransferase [alpha (1,3) GT] gene results in the cell surface expression of alpha (1,3) galactosyl-epitopes (alpha-gal) on membrane glycoproteins and glycolipids. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT00105053 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6299 + 14594 + 6299 + Clinical trial + Gene name: Ggta1 + hyperacute-prostate cancer vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine derived from the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) with potential immunomodulating and antineoplastic activities. It may activate the immune system to induce an immune response against IDO-expressing tumor cells, which may restore the proliferation and activation of various immune cells including cytotoxic T-lymphocytes (CTLs), natural killer cells (NKs), and dendritic cells (DCs), and may eradicate IDO-expressing tumor cells through a CTL-mediated response. This vaccine, using a small fragment of IDO, can be used in combination with either Ipilimumab or Vemurafenib to treat malignant melanoma that has metastasized. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C159498 + NCT: https://clinicaltrials.gov/study/NCT02077114 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6368 + 3620 + 6368 + Clinical trial + Gene name: IDO + IDO peptide vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine compromised of melanoma peptides plus GM-CSF-in-adjuvant. It is combined with low-dose IL-2 therapy, which could significantly enhance the immunologic efficacy. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT00928902 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6312 + 6312 + Clinical trial + IL-2 peptide and GM-CSF-in-adjuvant melanoma vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made with autologous dendritic cells that are manufactured with GM-CSF, IL15 and loaded with melanoma/HIV peptides and KLH; then activated with LPS and CD40 Ligand.IL15 is a T cell growth factor that could have a very important role in cancer immunotherapy. IL15 DCs are particularly efficient at priming functional melanoma specific CD8+ T cells. The use of IL15 in the manufacture of the DC vaccine could result in an improved immunotherapy product for melanoma patients. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT01189383 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6300 + 3600 + 6300 + Clinical trial + Gene name: IL15 + IL15-DC vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine that could teach T-cells to detect and kill cancer cells better. Intracel KLH is given without adjuvant subcutaneously and with Tetanus Toxoid 0.5 ml intramuscularly. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT00000105 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6302 + 6302 + Clinical trial + intracel KLH vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made with dendritic cells pulsed with KLH and tumor lysate for patients with neuroblastoma. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT02745756 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6303 + 6303 + Clinical trial + KLH and tumor lysate pulsed DC vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made of tumor protein taken from a cancer patient's plasma (liquid part of the blood) and KLH (a protein designed to increase the immune response of the vaccine). + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT01174082 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6259 + 6259 + Clinical trial + KLH-id vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made with autologous dendritic cells pulsed with KLH for this vaccination, combined with radiation or a gene therapy agent, TNFerade. TNFerade or radiation serves to generate cell death stimulating the immune response. The dendritic cell vaccine may direct a distant and lasting effective anti-tumor immune response to achieve a local and systemic clinical benefit. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT00868114 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6304 + 6304 + Clinical trial + KLH-pulsed autologous dendritic cell vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine used alone or in combination with PD-1 inhibitor in patients with advanced solid tumors with KRAS mutation (G12C, G12D, or G12V) and HLA type HLA-A11:01 or HLA C08:02. The vaccine is a lipid nanoparticle (LNP)-formulated mRNA-based cancer vaccine that targets the most commonly occurring KRAS mutations (G12D, G12V, and G12C). The mRNA-derived KRAS-targeted vaccine V941 (mRNA-5671) is taken up and translated by antigen presenting cells (APCs). Following translation, the epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy tumor cells harboring these specific KRAS mutations. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C162186 + NCT: https://clinicaltrials.gov/study/NCT05202561 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6348 + 3845 + 6348 + Clinical trial + Gene name: KRAS + KRAS-targeted mRNA vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made with Epstein Barr Virus (EBV)-derived tumor antigen, Latent Membrane Protein-2 (LMP2)-loaded dendritic cell (DC) vaccines are administered alone or co-administered with the TLR9 ligand, DUK-CPG-001, in patients with EBV+ lymphoma in the setting of autologous stem cell transplant with infusion of mature T cells. It may induce EBV derived tumor antigen specific CD8+ T cell response in patients with EBV+ lymphoma in the setting of autologous stem cell transplant. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT02115126 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6305 + 10376 + 5698 + 6305 + Clinical trial + Gene name: EBV|Gene name: LMP2 + LMP2A-loaded conventional DC vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine comprised of multiple peptides derived from MAGE-1A, Her-2/neu, and folate binding protein (FBP), with potential immunostimulating and antineoplastic properties. The MAGE-A1, Her-2/neu, FBP peptides cancer vaccine includes the peptides MAGE-A1:161-169, FBP:191-199, Her-2/neu:369-377, MAGE-A1:96-104, and Her-2/neu:754-762. Vaccination with this cancer vaccine may activate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing the corresponding antigens, resulting in tumor cell lysis. The vaccine compromises synthetic ovarian cancer-associated peptides administered with a synthetic tetanus toxoid helper peptide emulsified in Montanide ISA-51 before or after paclitaxel and carboplatin in patients with stage III-IV ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer undergoing optimal cytoreductive surgery. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving vaccine therapy and chemotherapy after surgery may kill any tumor cells that remain after surgery. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C62775 + NCT: https://clinicaltrials.gov/study/NCT00373217 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6306 + 2064 + 2348 + 4100 + 6306 + Clinical trial + Gene name: MAGE-A1|Gene name: HER2-neu|Gene name: FBP + MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made with autologous dendritic cells (DC) are transduced with the MART-1, tyrosinase and MAGE-A6 (melanoma associated antigens, MAA) genes for melanoma patients. Some patients also receive interferon-alfa 2b (IFN) intravenously. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT01622933 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6280 + 2315 + 4105 + 7299 + 6280 + Clinical trial + Gene name: MART-1|Gene name: tyrosinase|Gene name: MAGE-A6 + MART-1, tyrosinase and MAGE-A6 autologous DC vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine that may elicit a cytotoxic T-cell (CTL) response against cancer cells. Autologous dendritic cells are pulsed with melanoma tumor-specific peptides. The mature dendritic cell (mDC3/8) vaccine (primer and booster) in patients with stage III and stage IV melanoma is followed by treatment with pembrolizumab (anti-PD-1 therapy). Using dendritic cells (a kind of white blood cell) as a vaccine could stimulate your own immune system to react to your melanoma cells. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C162250 + NCT: https://clinicaltrials.gov/study/NCT03092453 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6307 + 6307 + Clinical trial + mature dendritic cell melanoma vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made up of two peptides that are pieces of a bigger melanoma protein (gp100). These peptides bind to HLA-A2 which is then recognized by T cells. It could be given in combination with MDX-010 (ipilimumab, BMS-734016). MDX-010 (anti-CTLA4) antibodies are designed to keep the immune system running by blocking CTLA-4 from down-regulating T cell activation. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT00094653 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6309 + 6490 + 6309 + Clinical trial + Gene name: gp100 + MDX-1379 (gp100) melanoma peptide vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine composed of CTLA-4 antibody; tyrosinase, gp100, and MART-1 peptides; and incomplete Freund's adjuvant (IFA) with or without interleukin-12 in patients with resected stage III or IV melanoma. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT00028431 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6310 + 2315 + 6490 + 7299 + 6310 + Clinical trial + Gene name: tyrosinase|Gene name: gp100|Gene name: MART-1 + MDX-CTLA4 antibody/tyrosinase/gp100/MART-1 melanoma vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine consisting of peptides derived from melanoma-associated antigens and an adjuvant peptide derived from tetanus toxoid. Vaccination with this agent may stimulate a host cytotoxic T-cell response against tumor cells expressing melanoma-associated antigens, resulting in tumor cell lysis. Vaccines made from peptides may make the body build an immune response to kill tumor cells. Vaccines using melanoma peptides from cytotoxic T cells and helper T cells could work in treating patients with metastatic melanoma. This vaccine contains 12 melanoma peptides restricted by Human Leukocyte Antigen (HLA)-A1, -A2, or -A3 and 6 melanoma helper peptides restricted by HLA-DR molecules emulsified with sargramostim (Granulocyte-macrophage colony-stimulating factor, GM-CSF) and Montanide ISA-51 or Montanide ISA-51 VG (ISA-51). + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C38700 + NCT: https://clinicaltrials.gov/ct2/show/NCT00071981 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6311 + 6311 + Clinical trial + melanoma helper peptide vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine containing a mixture of killed bacteria with potential immunostimulatory and antineoplastic activities. Mixed bacteria vaccine (MBV or Coley's toxins) consists of a pyrogenic bacterial lysate derived from Serratia marcescens and Streptococcus pyogenes; the active components in the lysate may be lipopolysaccharide (LPS), a component of the Gram-negative bacterial cell wall of Serratia, and streptokinase, an enzyme produced by Streptococcus pyogenes. LPS has been shown to stimulate the host humoral immune response and induce the release of various antitumor cytokines such as tumor necrosis factor (TNF) and interleukin-12 (IL-12). The mixed bacteria vaccine (MBV) is administered at a starting dose of 250 EU (1 µL) and escalated in each patient to a dose inducing the desired pyrogenic effect, defined as a body temperature of 38°C to 39.5°C. It is given to patients with malignant tumors that expressed the NY-ESO-1 antigen. It is designed to induce immunological effects and tumor response following vaccination. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C74063 + NCT: https://clinicaltrials.gov/study/NCT00623831 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6314 + 6314 + Clinical trial + mixed bacterial cancer vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine with or without PD-1/L1 may help treat patients with advanced gastric cancer. A personalized mRNA tumor vaccine encoding neoantigen may also help treat patients with advanced esophageal squamous carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma and colorectal adenocarcinoma. The vaccine can also be used in combination with PD-1 for the treatment of advanced solid tumors. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT03468244 + NCT: https://clinicaltrials.gov/study/NCT05227378 + NCT: https://clinicaltrials.gov/study/NCT05359354 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6328 + 6328 + Clinical trial + mRNA neoantigen tumor vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made with dendritic cells (DCs) pulsed with mRNA encoded tumor antigens. These personalized cell vaccines may lead to antitumor specific T cell responses. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT02808416 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6339 + 6339 + Clinical trial + mRNA tumor antigen DC vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine targeting up to fifteen tumor-associated antigens (TAAs) that are specifically expressed by a patient's cancer cells, with potential immunostimulatory and antineoplastic activities. Up to fifteen neoantigen epitopes are incorporated in a proprietary formulation designed to maximize mRNA delivery and minimize mRNA-triggered immune responses. The mRNA-based PCV NCI-4650 is taken up and the mRNAs are translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This induces both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy the patient's cancer cells that express these neoantigens. Exome sequencing can identify certain gene mutations in a person's tumor. This can then be used to create cancer treatments. This mRNA vaccine might cause certain tumors to shrink. Immunogenic neoantigens and can predict for neoantigens binding the patient human leukocyte antigen (HLA) molecules from melanoma or epithelial cancer patients and use these epitopes for a personalized therapeutic messenger ribonucleic acid (mRNA) vaccine. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148239 + NCT: https://clinicaltrials.gov/study/NCT03480152 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6324 + 6324 + Clinical trial + mRNA-based personalized cancer vaccine NCI-4650 + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine consisting of autologous monocytes loaded with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) as a fusion protein with the lysosome-associated membrane protein (LAMP), with potential immunostimulatory and antineoplastic activities. The autologous CMV-pp65-LAMP mRNA loaded monocyte vaccine MT-201-GBM exposes the immune system to the CMV pp65 peptide, which may elicit a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells. The incorporation of LAMP may route CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC class II antigen presentation, thereby promoting CD4-positive T-cell responses. MT-201-GBM (pp65CMV antigen monocytes) are administered to patients newly diagnosed with a type of brain tumor called glioblastoma (GBM) that has an unmethylated MGMT (O[6]-methylguanine-DNA methyltransferase) (MGMT) gene promoter. The vaccine is made from a type of immune cell called monocytes, which have been engineered to express a cytomegalovirus (CMV) protein. Patients also receive standard radiation therapy combined with temozolomide. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C179670 + NCT: https://clinicaltrials.gov/study/NCT04741984 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6315 + 6315 + Clinical trial + MT-201-GBM monocyte vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine containing mucus 1 (MUC1) peptide and the adjuvant poly-ICLC with potential immunostimulatory and antineoplastic activities. MUC1 peptide-poly-ICLC adjuvant vaccine may induce the host immune system to mount a cytotoxic T cell response against MUC1-expressing tumor cells. MUC1 peptide-poly-ICLC adjuvant vaccine in boosting systemic immunity to MUC1 in women with stage I-III 'triple-negative' [i.e., ER(-) PR(-) HER2/neu(-)] breast cancer. MUC1 peptide-Poly-ICLC vaccine could also work in preventing lung cancer in current and former smokers at high risk for lung cancer. Vaccines made from peptides may help the body build an effective immune response to kill cells. MUC1 peptide-Poly-ICLC vaccine may stimulate the body's immune system and slow or stop the changes from normal to pre-cancer to cancer. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C82417 + NCT: https://clinicaltrials.gov/study/NCT00986609 + NCT: https://clinicaltrials.gov/study/NCT03300817 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6316 + 4582 + 6316 + Clinical trial + Gene name: MUC-1 + MUC1 peptide-poly-ICLC vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine comprised of four peptides derived from the tumor-associated antigen (TAA) HER-2/neu (ErbB-2), with potential immunomodulating and antineoplastic activities. The four peptides may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing the HER-2/neu antigen, which may result in the inhibition of proliferation in Her-2/neu-expressing tumor cells. TPIV100 is a type of vaccine made from HER2 peptide that may help the body build an effective immune response to kill tumor cells that express HER2. Sargramostim increases the number of white blood cells in the body following chemotherapy for certain types of cancer and is used to alert the immune system. TPIV100 and sargramostim could work in treating patients with HER2 positive, stage II-III breast cancer. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C173525 + NCT: https://clinicaltrials.gov/study/NCT04197687 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6317 + 2064 + 6317 + Clinical trial + Gene name: HER2 + multi-epitope HER2 peptide vaccine TPIV100 + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine consisting of a combination of peptides derived form several melanoma epitopes. Vaccination with multi-epitope melanoma peptide vaccine stimulates the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the corresponding antigens, resulting in tumor cell lysis. This vaccine may stimulate a broader CTL response compared to single-antigen vaccines. Vaccines made from melanoma peptides or antigens may help the body build an effective immune response to kill tumor cells in patients with stage IIC-IV melanoma. This vaccine is a tyrosinase/gp100/MAGE-3 class I peptide vaccine combined with Montanide ISA 51 or ISA 51 VG with CpG adjuvant 7909 in human leukocyte antigen (HLA) class I A1, A3 or A11 and B44 matched patients with surgically resected stages IIC, III and IV melanoma. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C38695 + NCT: https://clinicaltrials.gov/study/NCT00085189 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6318 + 3105 + 3106 + 4102 + 6490 + 7299 + 6318 + Clinical trial + Gene name: tyrosinase|Gene name: gp100|Gene name: MAGE-A3|Gene name: HLA-A|Gene name: HLA-B + multi-epitope melanoma peptide vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine for which Advanced Renal Cell Carcinoma patients undergo total nephrectomy to harvest primary tumor for vaccine preparation. Dendritic cells are then pulsed with multiantigens or tumor cells. Some patients also receive vaccination with irradiated autologous tumor lysate. The vaccine may make the body build an immune response to kill tumor cells. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT00004880 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6284 + 6284 + Clinical trial + multiantigen liposome loaded dendritic cell vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine adjuvant and synthetic Toll-like receptor (TLR) type 1 and 2 ligand composed of a lipopeptide containing a water-soluble derivative of Pam3-Cys, the biologically active component of the mycobacterial 19 kDa lipoprotein of mycobacteria, that is covalently linked to a synthetic peptide (GDPKHPKSF), with potential immunostimulating activity. TLR1/2 agonist Pam3Cys-GDPKHPKSF targets, binds to and activates TLR1/2, which induces CD8- and T-helper 1 CD4-positive T-cell responses. This may enhance T-cell-mediated immune responses when administered together with peptide vaccine. A multi-peptide vaccine can be used in combination with the TLR1/2 ligand XS15 in CLL patients undergoing ibrutinib-based regimes. Applying several CLL-associated antigens simultaneously increases the likelihood that a multi-clonal, broad and at the same time highly specific T-cell response is mounted, thereby preventing potential tumor escape mechanisms. The novel TLR1/2 ligand (XS15, developed in Tübingen) that (i) is water-soluble and (ii) GMP-amenable, (iii) non-toxic and (iv) effective in inducing T cells specific for peptides in vivo. A personalized multi-peptide vaccination can also be used in combination with the TLR1/2 ligand XS15 for individual patients with advanced solid and hematological malignancies without any approved treatment options. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C179595 + NCT: https://clinicaltrials.gov/study/NCT04688385 + NCT: https://clinicaltrials.gov/study/NCT05014607 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6319 + 7096 + 7097 + 6319 + Clinical trial + Gene name: TLR1|Gene name: TLR2 + multipeptide XS15 vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine that can efficiently present T cells with antigens of HCC sensitize their antitumor properties meanwhile low dose cyclophosphamide (CY) can effectively improve the microenvironment of immunity. Multiple signals loaded dendritic cells vaccine combined low dose of cyclophosphamide combining with radical surgery or TACE or targeted agents for patients with hepatocellular carcinoma coul prolong their survival time. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT04317248 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6320 + 6320 + Clinical trial + multiple signals loaded dendritic cells vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine with neopeptides designed with single amino acid mutations to enhance their immunogenicity and bind to HLA class I and II molecules. Exome and RNA sequencing as well as in silico HLA-binding predictions to autologous HLA molecules were used to identify candidate neopeptides. Subsequently, in silico HLA-anchor placements were used to deduce putative T-cell receptor (TCR) contacts of peptides. Single amino acids of TCR contacting residues were then mutated by amino acid replacements. TIL-derived CD4+ T-cell clones showed strong responses and tumor cell lysis not only against the designed neopeptide but also against the unmutated natural peptides of the tumor. Turning tumor self-peptides into foreign antigens by introduction of designed mutations is a promising strategy to induce strong intratumoral CD4+ T-cell responses in a cold tumor like glioblastoma. + Hayleigh Kahn + Jie Zheng + PubMed:36228153 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6383 + 3123 + 6383 + Clinical trial + Gene name: HLA + mutated neopeptide vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine consisting of a proprietary version of the recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding both the two human tumor-associated antigens (TAAs) carcinoembryonic antigen (CEA) and mucin-1 (MUC-1), and TRICOM, which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. MVA-BN-CV301, followed by multiple boosting doses of the fowlpox virus (FPV) vaccine CV301 may lead to a cytotoxic T-lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells is activated. In addition, the CV301-dependent anti-tumor CTL response upregulates the expression of programmed cell death ligand 1 (PD-L1); therefore, when CV301 is combined with a programmed cell death 1 (PD-1) immune checkpoint inhibitor, the antitumor effect may be increased. CV301 is a poxviral-based vaccine comprised of recombinant Modified vaccinia Ankara (MVA-BN-CV301, prime) and recombinant fowlpox (FPV-CV301, boost). CV301 contains transgenes encoding two (2) tumor-associated antigens (TAA), mucin 1 (MUC1) and carcinoembryonic antigen (CEA), as well as three costimulatory molecules (B7.1, intercellular adhesion molecule 1 (ICAM-1) and lymphocyte function-associated antigen 3 (LFA-3), designated TRICOM). It is given in combination with SX-682 and M7824 for patients with Triple Negative Breast Cancer (TNBC) and Human papilloma virus (HPV) negative head and neck squamous cell carcinoma (HNSCC). + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C143059 + NCT: https://clinicaltrials.gov/study/NCT04574583 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6321 + 1048 + 3383 + 4582 + 941 + 965 + 6321 + Clinical trial + Gene name: MUC1|Gene name: CEA|Gene name: B7.1|Gene name: ICAM-1|Gene name: LFA-3 + MVA-BN-CV301 vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine of a chimeric peptide immunogen of human epidermal growth factor-2 (HER-2) with antineoplastic property. MVF-HER-2(628-647)-CRL 1005 vaccine, coated with poloxamer CRL-1005 to form microparticles, consists of a mutated HER-2 B-cell epitope, HER-2(628-647), and a promiscuous T cell epitope (amino acid sequence 288-302) of the measles virus fusion protein (MVF). The vaccine may stimulate the host immune response to mount a cytotoxic T-lymphocyte response against tumor cells that overexpress the HER2 protein, resulting in tumor cell lysis. MVF-HER-2(628-647)-CRL 1005 vaccine may induce anti-HER-2 antibody in patients with metastatic or recurrent cancer (Breast, Ovarian, Non-small cell lung cancer, Gastric adenocarcinoma). + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C2637 + NCT: https://clinicaltrials.gov/study/NCT00017537 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6322 + 2064 + 6322 + Clinical trial + Gene name: HER2 + MVF-HER-2(628-647)-CRL 1005 vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine consisting of patient-specific mutated peptide epitopes, which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. The neoantigen-based anti-cancer vaccine NEO-PV-01 stimulates the host immune system to mount a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. Both metastatic squamous non-small cell lung cancer (NSCLC) and extensive stage small cell lung cancer (SCLC) are incurable with current therapies, but due to mutations induced by cigarette smoke, typically express a large number of altered proteins that can be recognized as foreign by the immune system. Targeting the immune system against tumor specific antigens using a peptide vaccine could lead to improved response rate and prolonged overall survival with no additional toxicity when combined with Pembrolizumab (monoclonal antibodies that block PD-1/PD-L1 interactions) and standard of care chemotherapy. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C129935 + NCT: https://clinicaltrials.gov/study/NCT03166254 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6325 + 6325 + Clinical trial + NEO-PV-01 vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine that may enhance anti-tumor immune response in Renal Cell Carcinoma in combination with checkpoint inhibitors ipilimumab (anti-CTLA-4 antibody) and nivolumab (anti-PD-1 antibody). + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT03598816 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6326 + 6326 + Clinical trial + neoantigen DNA vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine consisting of patient-specific antigens, which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. The neoantigen peptide vaccine, the peptides stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. Personalized neo-antigen peptide vaccine is a product combines multiple patient specific neo-antigens. Given personalized neo-antigen peptide vaccine together with Th1 polarizing adjuvant poly ICLC may induce a polyclonal, poly-epitope, cytolytic T cell immunity against the patient's tumor. Patients also receive nivolumab. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C165508 + NCT: https://clinicaltrials.gov/study/NCT05098210 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6327 + 6327 + Clinical trial + neoantigen peptide vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine consisting of synthetic long peptides (SLPs), ranging from 20-35 amino acids in size, that are derived from two or more of the patient's tumor-specific mutant antigens (TSMAs), with potential immunostimulatory and antitumor activities. SLP vaccine may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL)-mediated immune response against the TSMAs expressed by the tumor cells. This vaccine is a optimized neoantigen synthetic long peptide (SLP) vaccines for pancreatic cancer patients following neoadjuvant chemotherapy. The neoantigen SLP vaccines will incorporate prioritized neoantigens and will be co-administered with poly-ICLC. It can be used in combination with chemoradiation with temozolomide for patients with newly diagnosed glioblastoma. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C150471 + NCT: https://clinicaltrials.gov/study/NCT02510950 + NCT: https://clinicaltrials.gov/study/NCT05111353 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6332 + 6332 + Clinical trial + neoantigen synthetic long peptide vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine consisting of autologous DCs loaded with immunogenic peptides derived from autologous cancer cells, with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-loaded autologous DC vaccine stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. Neoantigens arising from the mutations of the tumor genome expressed specifically on the tumor cell instead of normal cells, suggesting that vaccines targeting neoantigens should generate a highly tumor-specific response with minimal off-target effects. Neoantigens are identified from tumor tissues from a gastric cancer, hepatocellular carcinoma, lung cancer or colorectal cancer patient. Dendritic cells are then primed with synthesized peptides. The vaccine can be combined with microwave ablation ti treat patients with Hepatocellular Carcinoma (HCC). It can also be combined with Anti-PD1 (Nivolumab) as for patients with resected Hepatocellular Carcinoma (HCC) and Liver Metastases From Colorectal Cancer (CRLM). + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT03871205 + NCT: https://clinicaltrials.gov/study/NCT04147078 + NCT: https://clinicaltrials.gov/study/NCT04912765] + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C141422 + NCT: https://clinicaltrials.gov/study/NCT03674073 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6281 + 6281 + Clinical trial + neoantigen-loaded autologous dendritic cell vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine that is made from the subject's blood cells and is designed to interact in the patient's body with cells that are programmed to fight specific tumor proteins NY-ESO-1, Melanoma Antigen Gene-A1 (MAGE-A1) and Melanoma Antigen Gene-A3 (MAGE-A3). The vaccine can be given in combination with decitabine which may increase the amount and activity of these cancer proteins on the surface of tumor cells to increase the possibility that the vaccine will stimulate cells to act against the tumor cells. The dendritic cells may stimulate CD4 and CD8 antigen specific T cells in patients with relapsed or refractory pediatric high grade gliomas, medulloblastomas, and central nervous system primitive neuroectodermal tumors (CNS PNETs). + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT02332889 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6367 + 1485 + 4100 + 4102 + 6367 + Clinical trial + Gene name: NY-ESO-1|Gene name: MAGE-A1|Gene name: MAGE-A3 + NY-ESO-1, MAGE-A1, and MAGE-A3 dendritic cell vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine comprised of synthetic peptides derived from the cancer-testis antigen NY-ESO-1, preferentially expressed antigen in melanoma (PRAME), human melanoma antigen A3 (MAGE-A3) and the human Wilms tumor protein-1 (WT-1), with potential immunostimulating and antineoplastic activities. NY-ESO-1/PRAME/MAGE-A3/WT-1 peptide vaccine may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing NY-ESO-1, PRAME, MAGE-A3 and WT-1, resulting in tumor cell lysis. As proteins are degraded in cells, peptides are presented on the surface of these cells as a complex with tissue type molecules (HLA molecules). T-cells may then recognize the peptide-HLA complexes, via its T-cell receptor, potentially resulting in tumor-cell killing, if sufficient priming takes place. Cancer testis antigens (CTA's) are known to be immunogenic and are only expressed at immunoprivileged sites, thus out of reach of immune responses, and on cancer cells, making them ideal targets for therapeutic cancer vaccination. The CTA's chosen were NY-ESO-1, MAGE-A3 and PRAME. WT-1 is additionally included as this protein has proven to be an important antigen in hematological malignancies. It is combined with azacitidine for treatment of patients with high-risk myelodysplastic syndrome or acute myeloid leukemia. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C127125 + NCT: https://clinicaltrials.gov/study/NCT02750995 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6329 + 1485 + 23532 + 4102 + 7490 + 6329 + Clinical trial + Gene name: NY-ESO-1|Gene name: PRAME|Gene name: MAGE-A3|Gene name: WT-1 + NY-ESO-1/PRAME/MAGE-A3/WT-1 peptide vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made with autologous DCs that are pulsed with HOCl-oxidized autologous tumor lysate (OCDC) and administered in prime phase, along with a personal neoantigen-sensitized DC(NeoDC) vaccine administered in the boost phase for Esophageal Squamous Cell Carcinoma. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT05317325 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6331 + 6331 + Clinical trial + OCDC and NeoDC vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine composed of autologous ovarian cancer antigens obtained from hydrolyzed, inactivated blood and tumor tissue of patients with ovarian cancer, with potential immunostimulatory and antineoplastic activities. The ovarian cancer antigens stimulate the immune system and activate a cytotoxic T-lymphocyte (CTL) immune response against ovarian cancer cells. Ovarian cancer patients can be given one pill a day for three months. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C159540 + NCT: https://clinicaltrials.gov/study/NCT03556566 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6354 + 6354 + Clinical trial + oral cancer vaccine V3-OVA + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine consisting of the tumor-associated antigen (TAA) oligosaccharide antigen sialyl Lewis A (CA19-9; sialylated Lewis A antigen; carbohydrate antigen 19-9; cancer antigen 19-9), with potential immunostimulating and antineoplastic activities. Oral therapeutic vaccine V3-X induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing CA19-9. Cholangiocarcinoma (CCA) is a malignant neoplasm originating from the epithelial cells lining the intra- or extrahepatic biliary ducts. This immunotherapeutic formulation is made from pooled heat- and chemically-inactivated blood from donors with CCA for a pill for cholangiocarcinoma patients. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148144 + NCT: https://clinicaltrials.gov/study/NCT03042182 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6333 + 6333 + Clinical trial + oral therapeutic vaccine V3-X + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine comprised of three immunogenic tetanus toxoid epitope P30-linked tumor-associated antigen (TAA) peptides, P30-linked Ephrin receptor A2 (EphA2), P30-linked cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) and P30-linked survivin, with potential immunostimulating and antineoplastic activities. The vaccine may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing EphA2, CMV pp65 and survivin. Hiltonol is used as an adjuvant to stimulate or enhance the activation of your immune system. The vaccine and adjuvant may help treat HLA-A*0201 positive patients with a newly diagnosed, unmethylated, and untreated World Health Organization (WHO) grade IV malignant glioma. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C187131 + NCT: https://clinicaltrials.gov/study/NCT05283109 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6362 + 1969 + 332 + 6362 + Clinical trial + Gene name: EphA2|Gene name: survivin + P30-linked EphA2/CMV pp65/survivin peptide vaccine P30-EPS + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made up of CPC-P501 protein formulated with the adjuvant AS15. Patients with hormone-sensitive prostate cancer and rising PSA, after primary tumor treatment, can be treated with the P501-AS15 vaccine. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT00148928 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6335 + 6335 + Clinical trial + P501-AS15 vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine based on next-generation sequencing and major histocompatibility complex affinity prediction algorithm, which may help treat patients with pancreatic ductal adenocarcinoma. This vaccine may elicit measurable neoantigen-specific immunologic responses in patients. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT03558945 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6341 + 6341 + Clinical trial + pancreatic tumor personalized neoantigen vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine composed of a peptide derived from the tumor-associated antigen (TAA) and immune checkpoint molecule programmed cell death-1 ligand 1 (PD-L1) combined with the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Vaccination with PD-L1 peptide vaccine may activate the immune system to induce an immune response against PD-L1-expressing cells. This may increase and restore the proliferation and activation of various immune cells, including cytotoxic T-lymphocytes (CTLs), and may eradicate PD-L1-expressing tumor cells. The vaccines aims to stimulate PD-L1 specific T-cells, hence eliminating both PD-L1 positive tumor cells as well as PD-L1 positive immunosuppressive and antigen presenting cells in the tumor microenvironment. It has been used in clinical trials for patients with multiple melanoma. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148146 + NCT: https://clinicaltrials.gov/study/NCT03042793 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6338 + 29126 + 6338 + Clinical trial + Gene name: PD-L1 + PD-L1 peptide vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine composed of IO103, a peptide derived from the tumor-associated antigen (TAA) programmed cell death-1 ligand 1 (PD-L1), IO102, the 21-mer peptide vaccine derived from the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO), and the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Both IDO and PD-L1 reactive CD8 T cells are cytotoxic and can kill cancer cells and immune regulatory cells in vitro. Thus boosting specific T cells that recognize immune regulatory proteins such as IDO and PD-L1 may directly modulate immune regulation. The the programmed death 1 (PD-1) regulatory antibody Nivolumab may further help treat patients with metastatic melanoma. + Hayleigh Kahn + Jie Zheng + NCI: ttps://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148154 + NCT: https://clinicaltrials.gov/study/NCT03047928 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6337 + 29126 + 3620 + 6337 + Clinical trial + Gene name: PD-L1|Gene name: IDO + PD-L1/IDO peptide vaccine IO102-103 + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine designed to target the unique immunogenic mutations arising in each patient's tumor. Peptide binding to MHC is a critical gateway to both the initiation of a T-cell immune response by the antigen presenting cell (APC), and to the detection and elimination of tumor cells presenting the particular peptide by the stimulated cytotoxic T lymphocyte (CTL). The attraction of neoantigens as cancer targets for the immune system results from the structural and geographical features of the mutation. Neoantigen peptides are only found in tumor cells, so CTLs should show exquisite specificity, reducing the opportunity for autoimmune disease. + Hayleigh Kahn + Jie Zheng + PubMed:25101225 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6387 + 6387 + Research + personal neoantigen cancer vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine co-administered with poly-ICLC, nivolumab, and rituximab (or another monoclonal antibody against CD20) to treat Follicular Lymphoma. The peptides comprising the vaccine are reconstituted in up to 4 pools with 5 peptides per pool (A, B, C, and D). + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT03121677 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6342 + 6342 + Clinical trial + personalized follicular lymphoma vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine that may stimulate the immune system to react to lung cancer cells, in combination with Cyclophosphamide. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT02419170 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6340 + 6340 + Clinical trial + personalized mature dendritic cell vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine for melanoma. Melanomas have mutations (changes in genetic material) that are specific to an individual patient and tumor. These mutations can cause the tumor cells to produce proteins that appear very different from the body's own cells. These proteins used in a vaccine may induce strong immune responses, which may help the participant's body fight any tumor cells that could cause the melanoma to come back in the future. NeoVax is a long-peptide vaccine targeting up to 20 personal neoantigens per patient for patients with surgically resected stage IIIB/C or IVM1a/b melanoma. There was long-term persistence of neoantigen-specific T cell responses following vaccination, with ex vivo detection of neoantigen-specific T cells exhibiting a memory phenotype, as well as diversification of neoantigen-specific T cell clones over time, with emergence of multiple T cell receptor clonotypes exhibiting distinct functional avidities. There was also tumor infiltration by neoantigen-specific T cell clones after vaccination and epitope spreading, suggesting on-target vaccine-induced tumor cell killing. Personal neoantigen peptide vaccines thus induce T cell responses that persist over years and broaden the spectrum of tumor-specific cytotoxicity in patients with melanoma. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT01970358 + PubMed:33479501 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6375 + 6375 + Clinical trial + personalized neoantigen melanoma vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine that contains 6 synthetic peptides mixed with the adjuvant Montanide™. The peptides were selected to induce T cell responses against 12 dominant epitopes from 7 cancer testis antigens (CTAs), which are the most frequently expressed CTAs in colorectal cancer. The 6 peptides were optimized to induce long lasting CRC specific T cell responses. Colorectal cancer peptide vaccine PolyPEPI1018 potentially elicits a cytotoxic T-lymphocyte response against colorectal tumors expressing the CTAs associated with the vaccine, which may result in a reduction in tumor cell proliferation. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C154278 + NCT: https://clinicaltrials.gov/study/NCT03391232 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6343 + 1485 + 6343 + Clinical trial + Gene name: CTAG1B + PolyPEPI1018 CRC vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine consisting of whole irradiated heterologous melanoma cells which express multiple melanoma-related antigens. Polyvalent melanoma vaccine may stimulate an antitumoral cytotoxic T-cell immune response in the host, resulting in inhibition of tumor cell proliferation and tumor cell death. Vaccines may make the body build an immune response and kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Interferon alfa-2b may interfere with the growth of tumor cells. Treatment with this combination may help treat melanoma. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1633 + NCT: https://clinicaltrials.gov/study/NCT00004104 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6344 + 6344 + Clinical trial + polyvalent melanoma vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made with autologous dendritic cells targeting prostate cancer (PC)-specific antigen(s), with potential immunostimulatory and antineoplastic activities. Upon administration of prodencel, the DCs stimulate a specific cytotoxic T-lymphocyte (CTL)-mediated immune response against PC cells expressing the antigen(s), resulting in tumor cell lysis. (NCIT_C192174) The vaccine could help treat patients with metastatic castration-resistant prostate cancer (mCRPC) after novel androgen-deprived therapy and docetaxel chemotherapy failure. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C192174 + NCT: https://clinicaltrials.gov/study/NCT05533203 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6345 + 6345 + Clinical trial + prodencel + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine containing the mammalian expression vector pUMVC3 encoding epitopes derived from three tumor-associated antigens (TAAs): human insulin-like growth factor-binding protein 2 (IGFBP2), human epidermal growth factor receptor 2 (HER2; ERBB2) and insulin-like growth factor 1 receptor (IGF1R), with potential immunostimulating and antineoplastic activities. The vaccine This activates the immune system to mount a combined response from specific T helper type 1 (Th1) cells, memory T-cells and cytotoxic T-lymphocytes (CTL) against IGFBP2-, HER2-, and IGF1R-expressing tumor cells. This vaccine may prevent cancer from coming back in patients with non-metastatic, node positive, human epidermal growth factor receptor (HER)2 negative breast cancer in which all signs and symptoms have disappeared. Vaccines made from deoxyribonucleic acid (DNA) may help the body build an effective immune response to kill tumor cells. It is given in combination with sargramostim. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C127910 + NCT: https://clinicaltrials.gov/study/NCT02780401 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6346 + 2064 + 3480 + 3485 + 6346 + Clinical trial + Gene name: IGFBP2|Gene name: HER2|Gene name: IGF1R + pUMVC3-IGFBP2-HER2-IGF1R plasmid DNA vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine containing seven 17 amino acids long synthetic RAS oncogene-encoded peptides representing the most common codon 12 and 13 oncogenic mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS), with potential immunomodulating and antineoplastic activities. The vaccine may stimulate a specific CD4-positive helper T-lymphocyte- and cytotoxic T-lymphocyte (CTL)-mediated immune response against RAS mutant-specific-expressing cancer cells, resulting in an inhibition of tumor cell proliferation and tumor cell death. The vaccine can be given in combination with Balstilimab and QS-21 for patients with pancreatic cancer to increase efficacy. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C200465 + NCT: https://clinicaltrials.gov/study/NCT05638698 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6356 + 6356 + Clinical trial + RAS peptide cancer vaccine TG01 + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine that encodes a melanoma antigen tyrosinase-related protein 2 (TRP2) cytotoxic T-lymphocyte (CTL) epitope and a modified monoclonal antibody, a chimera of human IgG1/murine IgG2a with T cell mimotopes expressed within the complementarity-determining regions (CDR) of the antibodies, with potential immunostimulating and antineoplastic activities. The melanoma TRP2 CTL epitope vaccine SCIB1 expresses the modified antibody. Subsequently, the Fc component of the engineered antibody targets and binds to the CD64 receptor on the dendritic cells (DCs); upon processing by DCs, the cellular immune system may be activated to induce helper T-cell and CTL immune responses against tumor cells expressing the TRP2 antigen. SCIB1 can be used in combination with either nivolumab (Opdivo) with ipilimumab (Yervoy) or pembrolizumab (Keytruda), standard treatments approved for patients with advanced melanoma. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C91380 + NCT: https://clinicaltrials.gov/study/NCT04079166 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6349 + 1638 + 6349 + Clinical trial + Gene name: TRP-2 + SCIB1 DNA vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made with secPD-L1, a splice variant of PD-L1 (programmed death ligand-1, an immune checkpoint pathway) that does not splice into the transmembrane domain, but instead produces a secreted form of PD-L1 that has a unique 18 amino acid tail containing a cysteine that allows it to homodimerize and more effectively inhibit lymphocyte function than monomeric soluble PD-L1. Recombinant secPD-L1 can dimerize and inhibit T-cell proliferation and IFN-gamma production in vitro. SecPD-L1 may function as a paracrine negative immune regulator within the tumor, since secPD-L1 does not require a cell-to-cell interaction to mediate its inhibitory effect. This could lead to improved survival for patients with numerous types of cancers, including lung cancer, melanoma, renal cell carcinoma, and Hodgkin lymphoma. + Hayleigh Kahn + Jie Zheng + PubMed:30564891 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6376 + 29126 + 6376 + Clinical trial + Gene name: PD-L1 + secPD-L1 vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine that consists of the oligosaccharide antigen sialyl Lewis (CA19-9) conjugated to the nonspecific immunomodulator keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. The sialyl Lewis-keyhole limpet hemocyanin conjugate vaccine may induce production of IgG and IgM antibodies as well as trigger an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing the sialyl Lewis antigen. The vaccine therapy together with QS21 may cause a stronger immune response and kill more tumor cells. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C69000 + NCT: https://clinicaltrials.gov/study/NCT00470574 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6350 + 6350 + Clinical trial + sialyl lewis-keyhole limpet hemocyanin conjugate vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine consisting of peptides derived from melanoma-associated antigens and a modified T-cell epitope derived from tetanus toxoid. Vaccination with this agent may stimulate a host cytotoxic and helper T-cell response against tumor cells expressing melanoma-associated antigens, resulting in decreased tumor growth. This vaccine is compromised of multi-epitope melanoma peptide vaccine (12MP) and 1 tetanus peptide melanoma vaccine emulsified with GM-CSF and ISA-51 (incomplete Freund's adjuvant). + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C2468 + NCT: https://clinicaltrials.gov/study/NCT00071981 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6355 + 6355 + Clinical trial + tetanus peptide melanoma vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made with GMCSF transgene that directly stimulates increased expression of tumor antigen(s) and enhances dendritic cell migration to the vaccination site. TGFβ2 blockade following intracellular TGFβ2 antisense gene expression reduces production of immune inhibiting activity at the vaccine site. This vaccine integrates enhancement of an anticancer immune response concurrently with a reduction in cancer-induced immune suppression. Autologous cancer cells are harvested from patients with advanced refractory cancer, and a TGFβ2 antisense / GMCSF expression vector plasmid is constructed. The autologous cancer tissue is irradiated and electrocorporated with the vector. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT00684294 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6357 + 6357 + Clinical trial + TGFβ2 antisense-GMCSF gene modified autologous tumor cell vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine containing autologous dendritic cells (DCs) that are loaded with total tumor RNA (TTRNA) from a specific tumor, with potential immunostimulatory and antineoplastic activities. The vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against the tumor-associated antigens (TAAs) encoded by the TTRNA. The vaccine can be given in combination with Temozolomide (TMZ) and Autologous Hematopoietic Stem Cells (HSC). + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C116913 + NCT: https://clinicaltrials.gov/study/NCT03396575 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6360 + 6360 + Clinical trial + total tumor RNA-loaded dendritic cell vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made as patient's lymphocytes are rendered transgenic for a gene coding for selected portion of telomerase an enzyme expressed in the vast majority of cancer cells. Transgenic cells are then returned to the patient to produce an immune response targeted at cancer cells expressing telomerase. The transgenic cells serve as antigen- presenting cells (APCs) with the dual function of antigen synthesis and presentation. Vaccination produces an immune response targeting cancer cells expressing telomerase. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C38720 + NCT: https://clinicaltrials.gov/study/NCT00061035 + PubMed:12653092 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6358 + 7015 + 6358 + Clinical trial + Gene name: telomerase + transgenic lymphocyte immunization vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine of 3 adenoviral vaccines (ETBX-011, ETBX-051 & ETBX-061). ETBX-011 uses a replication-defective, E1- and E2b-deleted oncolytic adenoviral serotype 5 (Ad5) encoding an epitope of human carcinoembryonic antigen (CEA). ETBX-051 is composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human transcription factor brachyury encoded. ETBX-061 composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human glycoprotein mucin 1 (MUC1) encoded. The three of these vaccines act against tumor associated antigens and have potential immunostimulating and antineoplastic activities. The TriAd vaccine can be used in combination with Anti-PD-L1/TGF-beta trap (M7824) and Anktiva (N-803) to shrink previously untreated head and neck tumors before surgery or stop the tumors from coming back after all treatment. + Hayleigh Kahn + Jie Zheng + NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91373 + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C143034 + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C143035 + NCT: https://clinicaltrials.gov/study/NCT04247282 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6359 + 1048 + 4582 + 6862 + 6359 + Clinical trial + Gene name: CEA|Gene name: brachyury|Gene name: MUC1 + TriAd cancer vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine that can be used in combination with Neo-antigen DC vaccine and their sensitized T cells for the treatment of esophageal cancer, advanced malignant melanoma, bladder cancer and colorectal cancer. + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT05023928 + NCT: https://clinicaltrials.gov/study/NCT05235607 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6361 + 6361 + Clinical trial + tumor antigen-sensitized DC vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine that is composed of dendritic cells pulsed with tumor cells lysates that stimulate a potent and specific cell mediated anti-tumor immune response. It can be used in combination with high-dose chemotherapy and hematopoietic stem cell transplantation (HSCT). The combination may increase overall survival and progression-free survival for patients with high-risk pediatric and young adult tumors (localized solid tumors such as, sarcoma, neuroblastoma, and Wilms' tumor). + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1988 + NCT: https://clinicaltrials.gov/study/NCT00405327 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6366 + 6366 + Clinical trial + tumor lysate-pulsed dendritic cell vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made from proteins from the patient's tumor cells may boost the body's immune response against the tumor. The effects of chemotherapy on the immune system can potentially make immunotherapy more effective if administered soon after completion of chemotherapy. The addition of recombinant human IL-7 (interleukin 7) (rhIL-7 (recombinant human interleukin 7)) may make the immunotherapy more effective. Alpha cluster of differentiation 25 (CD25) and 8H9 depleted autologous lymphocytes plus tumor lysate/keyhole limpet hemocyanin (KLH) pulsed dendritic cell vaccines plus or minus r-hIL7 (CYT107) may induce immune responses to tumor lysate in patients (with Ewing's sarcoma, rhabdomyosarcoma or neuroblastoma). + Hayleigh Kahn + Jie Zheng + NCT: https://clinicaltrials.gov/study/NCT00923351 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6365 + 6365 + Clinical trial + tumor lysate/KLH pulsed dendritic cell vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine made as the patient's cancer will be surgically removed to provide cells for the vaccine, then the patient will be vaccinated twice with those cells and GM-CSF. After, the patient's blood will be filtered for white cells which will then be cultured and stimulated to reach a higher (killer) activity level. Next, the activated white blood cells will be infused into the patient's bloodstream so that they will be able to attack the cancer. Lastly, the entire process starting with vaccination will be repeated, for a total of two rounds of therapy. The autologous vaccine-enhanced ex vivo activated cancer neoantigens-specific T-cells TVI-Brain-1 recognize and bind to tumor cells expressing the cancer neoantigens, resulting in a cytotoxic T-lymphocyte (CTL)-mediated immune response against the patient's tumor cells. + Hayleigh Kahn + Jie Zheng + NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C199632 + NCT: https://clinicaltrials.gov/study/NCT01081223 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6373 + 6373 + Clinical trial + TVI-Brain-1 vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cancer vaccine administered within the first 2 to 3 months after allogeneic stem cell transplantation may enhance graft-vs.-leukemia responses. Irradiated autologous cancer cells provide a source of tumor antigens at the vaccination site. Granulocyte macrophage colony-stimulating factor (GM-CSF) secreted by irradiated bystander cells stimulates the recruitment, maturation and immunostimulatory activity of dendritic cells (DCs) at the vaccination site. Autologous whole tumor cell-based vaccination may tip the balance between leukemia-specific and alloreactive T cell responses in favor of a graft-vs.-leukemia (GvL) effect. + Hayleigh Kahn + Jie Zheng + PubMed:24482749 + VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6388 + 6388 + Clinical trial + whole tumor cell-based leukemia vaccine + + + + @@ -202282,410 +208183,1661 @@ Immunization Route: Intramuscular injection (i.m.) - + + + + + A variable representing the vaccine antigen (SARS-CoV-2 protein, whole organism) etc. + Anthony Huffman + PMID:24259431 + information content entity + vaccine antigen variable + + + + + + + + + A variable representing the vaccine adjuvant (silver) etc. + Anthony Huffman + PMID:24259431 + information content entity + vaccine adjuvant variable + + + + + + + + + A variable representing the vaccine vector (DNA plasmid, viral vector) etc. + Anthony Huffman + PMID:24259431 + information content entity + vaccine vector variable + + + + + + + + + A variable representing the vaccine preservative + Anthony Huffman + PMID:24259431 + information content entity + vaccine preservative variable + + + + + + + + + A study design variable that is used in a vaccine study. + Anthony Huffman + information content entity + vaccine study design variable + + + + + + + + + A study design that is about a vaccine study. + Anthony Huffman + information content entity + vaccine study design + + + + + + + + + A vaccine study design that is about the host response to a vaccine. + Anthony Huffman + information content entity + host response to vaccine study design + + + + + + + + + A vaccine study design that is about the vaccine challenge to a host. + Anthony Huffman + information content entity + vaccine challenge study design + + + + + + + + + A measurement datum that records the presence of a disease process in a host during the implementation of a vaccine study. + Anthony Huffman + data item + host disease state datum + + + + + + + + + A biological sex datum that records the biological sex of the target of a vaccine. + Anthony Huffman + data item + host sex datum + + + + + + + + + A measurment datum that records the age of thost. + Anthony Huffman + data item + host age datum + + + + + + + + + A measurement datum that records to involvement of the host of the pregnancy process. + Anthony Huffman + data item + host pregnancy datum + + + + + + + + + A measurment datum that records the quality of the host to have a comorbidity. + Anthony Huffman + data item + host comorbidity datum + + + + + + + + + A measurment datum that records the presence of a prior infection or immune memory to a pathogen. + Anthony Huffman + data item + host pathogen exposure datum + + + + + + + + + A measurment datum that records the interval between the vaccine challenge and the sacrifice of the organism during a vaccine challenge. + Anthony Huffman + data item + challenge-killing interval datum + + + + + + + + + A measurment datum that records the route of a pathogen challenge occurs in. + Anthony Huffman + data item + challenge admistration route datum + + + + + + + + + A measurment datum that records the method of sacrifice (i.e. killing). + Anthony Huffman + data item + sacrifice process datum + + + + + + + + + A measurment datum that records the presence or abasence of adverse event in a host in response of some vaccine. + Anthony Huffman + data item + host adverse event to vaccine datum + + + + + + + + + A measurment datum that records the measurement of an assay. + Anthony Huffman + data item + assay mesurement datum + + + + + + + + + A measurment datum that records the time point between the start of a first intervention in a planned process and the measurment of a sample. + Anthony Huffman + data item + assay measurement sample interval + + + + + + + + + A measurment datum that records the type of assay used. + Anthony Huffman + data item + assay type datum + + + + + + + + + A measurment datum that records the version of an analysis tool (software) used for an assay. + Anthony Huffman + data item + assay analysis tool version datum + + + + + + + + + A measurment datum that records the type of platform used for an assay. + Anthony Huffman + data item + assay platform datum + + + + + + + + + A measurment datum that records the utilization of an attenaution process on a pathogen. + Anthony Huffman + data item + pathogen attenuation datum + + + + + + + + + A measurment datum that records the number of occurences the host was vaccinated as part of the vaccination process. + Anthony Huffman + data item + vaccination frequency datum + + + + + + + + + A measurment datum that records the interval between vaccinations of a host. + Anthony Huffman + data item + vaccination interval datum + + + + + + + + + A measurment datum that records the intended target of a vaccine. + Anthony Huffman + data item + vaccine target datum + + + + + + + + + A measurment datum that records the vaccine vector of a vaccine. + Anthony Huffman + data item + vaccine vector datum + + + + + + + + + A measurment datum that records the vaccine preservative of a vaccine. + Anthony Huffman + data item + vaccine preservative datum + + + + + + + + + An assay that measures the survival rate of organisms exposed to a pathogen. + Anthony Huffman + assay + vaccine challenge survival assay + + + + + + + + + An assay that measures the gut adhesion of a pathogen within an organism. + Anthony Huffman + assay + pathogen gut adhesion assay + + + + + + + + + An assay that measures the titer of antibodies that neturalize a pathogen within an organism. + Anthony Huffman + assay + viral neutralization titer assay + + + + + + + + + + + + + + + + + A directive information entity that is part of a study design. It can be eithor independent variables whose values are selected to determine its relationship to an observed phenomenon (the dependent variable) or dependent variables that are studied and expected to change when the independent variable varies. + Jie Zheng + information content entity + study design variable + + + + + + + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + meningococcal group A polysaccharide vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + meningococcal group C polysaccharide vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + Bacillus anthracis strain V770-NP1-R antigen vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + Neisseria meningitidis serogroup B recombinant NADA fusion protein antigen vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + influenza A virus A/Brisbane/10/2010 (H1N1) antigen vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + Influenza A virus (H1N1) antigen vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + influenza A virus A/South Australia/55/2014 (H3N2) antigen vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + influenza A virus (H3N2) antigen vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + influenza B virus B/Utah/9/2014 antigen vaccine + + + + + - - - A variable representing the vaccine antigen (SARS-CoV-2 protein, whole organism) etc. - Anthony Huffman - PMID:24259431 - information content entity - vaccine antigen variable + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + influenza B virus antigen vaccine - + - - - A variable representing the vaccine adjuvant (silver) etc. - Anthony Huffman - PMID:24259431 - information content entity - vaccine adjuvant variable + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + influenza A virus A/Christchurch/16/2010 (H1N1) antigen vaccine - + - - - A variable representing the vaccine vector (DNA plasmid, viral vector) etc. - Anthony Huffman - PMID:24259431 - information content entity - vaccine vector variable + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen vaccine - + - - - A variable representing the vaccine preservative - Anthony Huffman - PMID:24259431 - information content entity - vaccine preservative variable + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + influenza B virus B/Brisbane/60/2008 antigen vaccine - + - - - A study design variable that is used in a vaccine study. - Anthony Huffman - information content entity - vaccine study design variable + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + influenza B virus B/Phuket/3073/2013 antigen vaccine - + - - - A study design that is about a vaccine study. - Anthony Huffman - information content entity - vaccine study design + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + influenza A virus A/California/7/2009 (H1N1) antigen vaccine - + - - - A vaccine study design that is about the host response to a vaccine. - Anthony Huffman - information content entity - host response to vaccine study design + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + influenza A virus A/Bolivia/559/2013 (H1N1) antigen vaccine - + - - - A vaccine study design that is about the vaccine challenge to a host. - Anthony Huffman - information content entity - vaccine challenge study design + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + influenza B virus B/Brisbane/9/2014 antigen vaccine - + - - - A measurement datum that records the presence of a disease process in a host during the implementation of a vaccine study. - Anthony Huffman - data item - host disease state datum + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen vaccine - + - - - A biological sex datum that records the biological sex of the target of a vaccine. - Anthony Huffman - data item - host sex datum + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + influenza B virus B/Hong Kong/259/2010 antigen vaccine - + - - - A measurment datum that records the age of thost. - Anthony Huffman - data item - host age datum + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + influenza A virus A/New Caledonia/71/2014 (H3N2) antigen vaccine - + - - - A measurement datum that records to involvement of the host of the pregnancy process. - Anthony Huffman - data item - host pregnancy datum + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + vibrio cholerae CVD 103-HGR strain live antigen vaccine - + - - - A measurment datum that records the quality of the host to have a comorbidity. - Anthony Huffman - data item - host comorbidity datum + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + influenza A virus A/Michigan/45/2015 (H1N1) antigen vaccine - + - - - A measurment datum that records the presence of a prior infection or immune memory to a pathogen. - Anthony Huffman - data item - host pathogen exposure datum + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen vaccine - + - - - A measurment datum that records the interval between the vaccine challenge and the sacrifice of the organism during a vaccine challenge. - Anthony Huffman - data item - challenge-killing interval datum + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + influenza A virus A/Slovenia/2903/2015 (H1N1) antigen vaccine - + - - - A measurment datum that records the route of a pathogen challenge occurs in. - Anthony Huffman - data item - challenge admistration route datum + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + influenza B virus B/Maryland/15/2016 antigen vaccine - + - - - A measurment datum that records the method of sacrifice (i.e. killing). - Anthony Huffman - data item - sacrifice process datum + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen vaccine - + - - - A measurment datum that records the presence or abasence of adverse event in a host in response of some vaccine. - Anthony Huffman - data item - host adverse event to vaccine datum + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + influenza B virus B/Colorado/06/2017 antigen vaccine - + - - - A measurment datum that records the measurement of an assay. - Anthony Huffman - data item - assay mesurement datum + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + Neisseria meningitidis Group B Membrane vesicles External Omv vaccine - + - - - A measurment datum that records the time point between the start of a first intervention in a planned process and the measurment of a sample. - Anthony Huffman - data item - assay measurement sample interval + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + Neisseria meningitidis Recombinant Fusion Protein Fhbp Group B vaccine - + - - - A measurment datum that records the type of assay used. - Anthony Huffman - data item - assay type datum + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + Bordetella Pertussis Filamentous Haemagglutinin Antigen vaccine - + - - - A measurment datum that records the version of an analysis tool (software) used for an assay. - Anthony Huffman - data item - assay analysis tool version datum + + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + Bordetella Pertussis Fimbriae Serotype 2 And 3 Antigen vaccine - + - - - A measurment datum that records the type of platform used for an assay. - Anthony Huffman - data item - assay platform datum + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + Haemophilus capsular oligosaccharide vaccine - + - - - A measurment datum that records the utilization of an attenaution process on a pathogen. - Anthony Huffman - data item - pathogen attenuation datum + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + influenza A virus (H5N1) antigen vaccine - + - - - A measurment datum that records the number of occurences the host was vaccinated as part of the vaccination process. - Anthony Huffman - data item - vaccination frequency datum + + + + + + + + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + hepatitis A virus strain CR 326F antigen, inactivated vaccine - + - - - A measurment datum that records the interval between vaccinations of a host. - Anthony Huffman - data item - vaccination interval datum + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + Varicella zoster virus glycoprotein E vaccine - + - - - A measurment datum that records the intended target of a vaccine. - Anthony Huffman - data item - vaccine target datum + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + hepatitis B virus subtype ADW2 HBsAg surface protein antigen vaccine - + - - - A measurment datum that records the vaccine vector of a vaccine. - Anthony Huffman - data item - vaccine vector datum + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + Varicella zoster virus glycoprotein E, recombinant vaccine - + - - - A measurment datum that records the vaccine preservative of a vaccine. - Anthony Huffman - data item - vaccine preservative datum + + + + + + + + + + + + + + + + + + + + Jie Zheng + Xingxian Li + vaccine + influenza A virus A/Victoria/361/2011 (H3N2) antigen vaccine - + - - - An assay that measures the survival rate of organisms exposed to a pathogen. - Anthony Huffman - assay - vaccine challenge survival assay + + + A route of administration that inject the material (such as vaccines, allergens) directly into a tumor. + Jie Zheng + site + intratumoral route - + - - - An assay that measures the gut adhesion of a pathogen within an organism. - Anthony Huffman - assay - pathogen gut adhesion assay + + + A route of administration that inject the material (such as vaccines, allergens) directly into a lesion or into the skin. + Jie Zheng + site + intralesional route - + - - - An assay that measures the titer of antibodies that neturalize a pathogen within an organism. - Anthony Huffman - assay - viral neutralization titer assay + + + Antigen that is only expressed by tumor cells. + Anna Maria Masci + Barry Smith + Jie Zheng + Oliver He + material entity + tumor-specific antigen - + - - - - - - - - - - - A directive information entity that is part of a study design. It can be eithor independent variables whose values are selected to determine its relationship to an observed phenomenon (the dependent variable) or dependent variables that are studied and expected to change when the independent variable varies. + + + Antigen that is overexpressed by tumor cells. + Anna Maria Masci + Barry Smith Jie Zheng - information content entity - study design variable + Oliver He + material entity + tumor-associated antigen @@ -216199,7 +223351,7 @@ Note: The 6K protein is part of the 6K-E1 structural protein YH, ZX protein The GEL1 mRNA of C. posadasii was detected at the highest level during the endosporulation stage of the parasitic cycle, and the mature protein was immunolocalized to the surface of endospores. BALB/c or C57BL/6 mice were immunized subcutaneously with the bacterium-expressed recombinant protein (rGel1p) to evaluate its protective efficacy against a lethal challenge of C. posadasii by either the intraperitoneal or intranasal route. In both cases, rGel1p-immune mice infected with the pathogen showed a significant reduction in fungal burden and increased survival compared to nonimmune mice [PubMed: 12761077]. - GEL1 + GEL1.00 Protegen ID: 799; NCBI Protein GI: 14582416; NCBITaxon: 199306 @@ -225394,11 +232546,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Merck 0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Merck - OMOP3073781 44197058 - 44197058 OMOP3073781 vaccine 0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Merck @@ -226952,11 +234101,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1 by European 0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1 by European - OMOP3073746 44197023 - 44197023 OMOP3073746 vaccine 0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1 by European @@ -228107,11 +235253,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 1 by Merck 0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 1 by Merck - OMOP3073874 44197151 - 44197151 OMOP3073874 vaccine 0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 1 by Merck @@ -228471,11 +235614,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Merck 0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Merck - OMOP3073820 44197097 - 44197097 OMOP3073820 vaccine 0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Merck @@ -228665,11 +235805,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis A Vaccine, Inactivated 320 UNT/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution 0.5 ML Hepatitis A Vaccine, Inactivated 320 UNT/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution - OMOP1127375 44132744 - 44132744 OMOP1127375 vaccine 0.5 ML Hepatitis A Vaccine, Inactivated 320 UNT/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution @@ -228804,11 +235941,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis A Vaccine, Inactivated 320 UNT/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution [Vivaxim] by Sanofi 0.5 ML Hepatitis A Vaccine, Inactivated 320 UNT/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution [Vivaxim] by Sanofi - OMOP1127399 44132768 - 44132768 OMOP1127399 vaccine 0.5 ML Hepatitis A Vaccine, Inactivated 320 UNT/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution [Vivaxim] by Sanofi @@ -229287,11 +236421,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by European 1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by European - OMOP3066671 44189948 - 44189948 OMOP3066671 vaccine 1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by European @@ -232588,11 +239719,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 1 by Merck 1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 1 by Merck - OMOP3066785 44190062 - 44190062 OMOP3066785 vaccine 1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 1 by Merck @@ -232778,11 +239906,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 10 by Merck 1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 10 by Merck - OMOP3066564 44189841 - 44189841 OMOP3066564 vaccine 1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 10 by Merck @@ -233395,11 +240520,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Merck 1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Merck - OMOP3066479 44189756 - 44189756 OMOP3066479 vaccine 1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Merck @@ -233585,11 +240707,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 10 by Merck 1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 10 by Merck - OMOP3066087 44189364 - 44189364 OMOP3066087 vaccine 1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 10 by Merck @@ -240721,13 +247840,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2588234 2588234 hepatitis B surface antigen (isoform L), recombinant 0.01 MG/ML 1758555 - protein + vaccine hepatitis B surface antigen (isoform L), recombinant 0.01 MG/ML @@ -241253,11 +248377,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - Hepatitis B Surface Antigen Vaccine 0.02 MG/ML [Hepasorbat] Hepatitis B Surface Antigen Vaccine 0.02 MG/ML [Hepasorbat] - OMOP3044904 44168181 - 44168181 OMOP3044904 vaccine Hepatitis B Surface Antigen Vaccine 0.02 MG/ML [Hepasorbat] @@ -244205,11 +251326,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] - OMOP3049622 44172899 - 44172899 OMOP3049622 vaccine Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] @@ -247444,11 +254562,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] 1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] - OMOP3066237 44189514 - 44189514 OMOP3066237 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] @@ -251880,11 +258995,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 1 Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 1 - OMOP3049621 44172898 - 44172898 OMOP3049621 vaccine Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 1 @@ -251939,11 +259051,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 10 Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 10 - OMOP3057074 44180351 - 44180351 OMOP3057074 vaccine Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 10 @@ -251998,11 +259107,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 3 Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 3 - OMOP3038271 44161548 - 44161548 OMOP3038271 vaccine Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 3 @@ -257191,11 +264297,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] by Glaxosmithkline 0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] by Glaxosmithkline - OMOP1127449 44132818 - 44132818 OMOP1127449 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] by Glaxosmithkline @@ -264002,11 +271105,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 1 1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 1 - OMOP3066449 44189726 - 44189726 OMOP3066449 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 1 @@ -264061,11 +271161,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 10 1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 10 - OMOP3066147 44189424 - 44189424 OMOP3066147 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 10 @@ -264120,11 +271217,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 3 1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 3 - OMOP3066236 44189513 - 44189513 OMOP3066236 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 3 @@ -271271,11 +278365,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Aca Mueller 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Aca Mueller - OMOP3073853 44197130 - 44197130 OMOP3073853 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Aca Mueller @@ -271324,11 +278415,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Axicorp 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Axicorp - OMOP3073901 44197178 - 44197178 OMOP3073901 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Axicorp @@ -271377,11 +278465,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Cc 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Cc - OMOP3073872 44197149 - 44197149 OMOP3073872 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Cc @@ -271430,11 +278515,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Emra-Med 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Emra-Med - OMOP3073777 44197054 - 44197054 OMOP3073777 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Emra-Med @@ -271483,11 +278565,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Eurim-Pharm 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Eurim-Pharm - OMOP3073818 44197095 - 44197095 OMOP3073818 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Eurim-Pharm @@ -271536,11 +278615,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Gerke 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Gerke - OMOP3073819 44197096 - 44197096 OMOP3073819 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Gerke @@ -271589,11 +278665,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Merck 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Merck - OMOP3073780 44197057 - 44197057 OMOP3073780 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Merck @@ -271642,11 +278715,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Mtk 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Mtk - OMOP3073779 44197056 - 44197056 OMOP3073779 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Mtk @@ -271695,11 +278765,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Aca Mueller 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Aca Mueller - OMOP3073776 44197053 - 44197053 OMOP3073776 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Aca Mueller @@ -271748,11 +278815,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Cc 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Cc - OMOP3073850 44197127 - 44197127 OMOP3073850 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Cc @@ -271801,11 +278865,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Emra-Med 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Emra-Med - OMOP3073930 44197207 - 44197207 OMOP3073930 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Emra-Med @@ -271854,11 +278915,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Eurim-Pharm 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Eurim-Pharm - OMOP3073900 44197177 - 44197177 OMOP3073900 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Eurim-Pharm @@ -271907,11 +278965,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Merck 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Merck - OMOP3073852 44197129 - 44197129 OMOP3073852 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Merck @@ -271960,11 +279015,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Mtk 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Mtk - OMOP3073740 44197017 - 44197017 OMOP3073740 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Mtk @@ -272013,11 +279065,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Emra-Med 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Emra-Med - OMOP3073897 44197174 - 44197174 OMOP3073897 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Emra-Med @@ -272066,11 +279115,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Eurim-Pharm 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Eurim-Pharm - OMOP3073817 44197094 - 44197094 OMOP3073817 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Eurim-Pharm @@ -272119,11 +279165,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Merck 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Merck - OMOP3073814 44197091 - 44197091 OMOP3073814 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Merck @@ -272172,11 +279215,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Mtk 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Mtk - OMOP3073869 44197146 - 44197146 OMOP3073869 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Mtk @@ -272225,11 +279265,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 50 by Merck 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 50 by Merck - OMOP3073954 44197231 - 44197231 OMOP3073954 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 50 by Merck @@ -274742,11 +281779,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Aca Mueller 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Aca Mueller - OMOP3073741 44197018 - 44197018 OMOP3073741 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Aca Mueller @@ -274795,11 +281829,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Axicorp 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Axicorp - OMOP3073932 44197209 - 44197209 OMOP3073932 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Axicorp @@ -274848,11 +281879,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Cc 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Cc - OMOP3073902 44197179 - 44197179 OMOP3073902 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Cc @@ -274901,11 +281929,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Emra-Med 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Emra-Med - OMOP3073778 44197055 - 44197055 OMOP3073778 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Emra-Med @@ -274954,11 +281979,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Eurim-Pharm 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Eurim-Pharm - OMOP3073816 44197093 - 44197093 OMOP3073816 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Eurim-Pharm @@ -275007,11 +282029,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Europharma 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Europharma - OMOP3073745 44197022 - 44197022 OMOP3073745 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Europharma @@ -275060,11 +282079,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Gerke 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Gerke - OMOP3073744 44197021 - 44197021 OMOP3073744 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Gerke @@ -275113,11 +282129,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Kohlpharma 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Kohlpharma - OMOP3073854 44197131 - 44197131 OMOP3073854 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Kohlpharma @@ -275166,11 +282179,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Merck 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Merck - OMOP3073871 44197148 - 44197148 OMOP3073871 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Merck @@ -275219,11 +282229,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Orifarm Leverkus 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Orifarm Leverkus - OMOP3073815 44197092 - 44197092 OMOP3073815 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Orifarm Leverkus @@ -275272,11 +282279,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Cc 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Cc - OMOP3073870 44197147 - 44197147 OMOP3073870 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Cc @@ -275325,11 +282329,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Emra-Med 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Emra-Med - OMOP3073851 44197128 - 44197128 OMOP3073851 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Emra-Med @@ -275378,11 +282379,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Eurim-Pharm 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Eurim-Pharm - OMOP3073899 44197176 - 44197176 OMOP3073899 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Eurim-Pharm @@ -275431,11 +282429,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Europharma 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Europharma - OMOP3073743 44197020 - 44197020 OMOP3073743 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Europharma @@ -275484,11 +282479,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Kohlpharma 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Kohlpharma - OMOP3073933 44197210 - 44197210 OMOP3073933 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Kohlpharma @@ -275537,11 +282529,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Merck 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Merck - OMOP3073931 44197208 - 44197208 OMOP3073931 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Merck @@ -275590,11 +282579,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 20 by Kohlpharma 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 20 by Kohlpharma - OMOP3073742 44197019 - 44197019 OMOP3073742 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 20 by Kohlpharma @@ -275643,11 +282629,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 20 by Merck 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 20 by Merck - OMOP3073898 44197175 - 44197175 OMOP3073898 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 20 by Merck @@ -279448,11 +286431,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 1 by European 0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 1 by European - OMOP3073873 44197150 - 44197150 OMOP3073873 vaccine 0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 1 by European @@ -280061,11 +287041,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution Box of 1 by Orifarm Leverkus 1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution Box of 1 by Orifarm Leverkus - OMOP3066360 44189637 - 44189637 OMOP3066360 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution Box of 1 by Orifarm Leverkus @@ -280114,11 +287091,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution Box of 10 by Orifarm Leverkus 1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution Box of 10 by Orifarm Leverkus - OMOP3066478 44189755 - 44189755 OMOP3066478 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution Box of 10 by Orifarm Leverkus @@ -282015,11 +288989,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Aca Mueller 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Aca Mueller - OMOP3066259 44189536 - 44189536 OMOP3066259 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Aca Mueller @@ -282068,11 +289039,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Axicorp 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Axicorp - OMOP3066085 44189362 - 44189362 OMOP3066085 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Axicorp @@ -282121,11 +289089,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Cc 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Cc - OMOP3066670 44189947 - 44189947 OMOP3066670 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Cc @@ -282174,11 +289139,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Emra-Med 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Emra-Med - OMOP3066357 44189634 - 44189634 OMOP3066357 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Emra-Med @@ -282227,11 +289189,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Eurim-Pharm 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Eurim-Pharm - OMOP3066082 44189359 - 44189359 OMOP3066082 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Eurim-Pharm @@ -282280,11 +289239,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Merck 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Merck - OMOP3066081 44189358 - 44189358 OMOP3066081 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Merck @@ -282333,11 +289289,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Mtk 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Mtk - OMOP3066667 44189944 - 44189944 OMOP3066667 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Mtk @@ -282386,11 +289339,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Orifarm Leverkus 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Orifarm Leverkus - OMOP3066669 44189946 - 44189946 OMOP3066669 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Orifarm Leverkus @@ -282439,11 +289389,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Veron 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Veron - OMOP3066080 44189357 - 44189357 OMOP3066080 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Veron @@ -282492,11 +289439,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Aca Mueller 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Aca Mueller - OMOP3066782 44190059 - 44190059 OMOP3066782 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Aca Mueller @@ -282545,11 +289489,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Emra-Med 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Emra-Med - OMOP3066084 44189361 - 44189361 OMOP3066084 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Emra-Med @@ -282598,11 +289539,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Eurim-Pharm 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Eurim-Pharm - OMOP3066666 44189943 - 44189943 OMOP3066666 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Eurim-Pharm @@ -282651,11 +289589,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Merck 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Merck - OMOP3066781 44190058 - 44190058 OMOP3066781 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Merck @@ -282704,11 +289639,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Mtk 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Mtk - OMOP3066554 44189831 - 44189831 OMOP3066554 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Mtk @@ -282757,11 +289689,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Orifarm Leverkus 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Orifarm Leverkus - OMOP3066476 44189753 - 44189753 OMOP3066476 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Orifarm Leverkus @@ -282810,11 +289739,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Veron 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Veron - OMOP3066470 44189747 - 44189747 OMOP3066470 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Veron @@ -282863,11 +289789,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Merck 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Merck - OMOP3066258 44189535 - 44189535 OMOP3066258 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Merck @@ -282916,11 +289839,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Veron 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Veron - OMOP3066665 44189942 - 44189942 OMOP3066665 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Veron @@ -285713,11 +292633,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Aca Mueller 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Aca Mueller - OMOP3066263 44189540 - 44189540 OMOP3066263 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Aca Mueller @@ -285766,11 +292683,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Axicorp 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Axicorp - OMOP3066557 44189834 - 44189834 OMOP3066557 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Axicorp @@ -285819,11 +292733,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Cc 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Cc - OMOP3066086 44189363 - 44189363 OMOP3066086 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Cc @@ -285872,11 +292783,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Emra-Med 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Emra-Med - OMOP3066474 44189751 - 44189751 OMOP3066474 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Emra-Med @@ -285925,11 +292833,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Eurim-Pharm 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Eurim-Pharm - OMOP3066262 44189539 - 44189539 OMOP3066262 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Eurim-Pharm @@ -285978,11 +292883,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Europharma 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Europharma - OMOP3066359 44189636 - 44189636 OMOP3066359 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Europharma @@ -286031,11 +292933,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Gerke 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Gerke - OMOP3066266 44189543 - 44189543 OMOP3066266 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Gerke @@ -286084,11 +292983,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Kohlpharma 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Kohlpharma - OMOP3066358 44189635 - 44189635 OMOP3066358 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Kohlpharma @@ -286137,11 +293033,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Merck 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Merck - OMOP3066783 44190060 - 44190060 OMOP3066783 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Merck @@ -286190,11 +293083,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Orifarm Leverkus 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Orifarm Leverkus - OMOP3066473 44189750 - 44189750 OMOP3066473 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Orifarm Leverkus @@ -286243,11 +293133,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Veron 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Veron - OMOP3066472 44189749 - 44189749 OMOP3066472 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Veron @@ -286296,11 +293183,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Aca Mueller 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Aca Mueller - OMOP3066556 44189833 - 44189833 OMOP3066556 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Aca Mueller @@ -286349,11 +293233,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Axicorp 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Axicorp - OMOP3066555 44189832 - 44189832 OMOP3066555 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Axicorp @@ -286402,11 +293283,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Cc 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Cc - OMOP3066668 44189945 - 44189945 OMOP3066668 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Cc @@ -286455,11 +293333,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Emra-Med 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Emra-Med - OMOP3066013 44189290 - 44189290 OMOP3066013 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Emra-Med @@ -286508,11 +293383,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Eurim-Pharm 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Eurim-Pharm - OMOP3066261 44189538 - 44189538 OMOP3066261 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Eurim-Pharm @@ -286561,11 +293433,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Europharma 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Europharma - OMOP3066477 44189754 - 44189754 OMOP3066477 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Europharma @@ -286614,11 +293483,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Gerke 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Gerke - OMOP3066265 44189542 - 44189542 OMOP3066265 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Gerke @@ -286667,11 +293533,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Kohlpharma 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Kohlpharma - OMOP3066171 44189448 - 44189448 OMOP3066171 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Kohlpharma @@ -286720,11 +293583,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Merck 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Merck - OMOP3066354 44189631 - 44189631 OMOP3066354 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Merck @@ -286773,11 +293633,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Orifarm Leverkus 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Orifarm Leverkus - OMOP3066353 44189630 - 44189630 OMOP3066353 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Orifarm Leverkus @@ -286826,11 +293683,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 20 by Merck 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 20 by Merck - OMOP3066471 44189748 - 44189748 OMOP3066471 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 20 by Merck @@ -286879,11 +293733,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 20 by Veron 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 20 by Veron - OMOP3066260 44189537 - 44189537 OMOP3066260 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 20 by Veron @@ -287834,11 +294685,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 1 by Glaxosmithkline 1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 1 by Glaxosmithkline - OMOP3066362 44189639 - 44189639 OMOP3066362 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 1 by Glaxosmithkline @@ -287893,11 +294741,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 3 by Glaxosmithkline 1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 3 by Glaxosmithkline - OMOP3066361 44189638 - 44189638 OMOP3066361 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 3 by Glaxosmithkline @@ -294554,12 +301399,9 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 1 by European 1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 1 by European - OMOP3066562 41334010 44189839 - 44189839 OMOP2531972 OMOP3066562 vaccine @@ -294609,11 +301451,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 3 by European 1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 3 by European - OMOP3066561 44189838 - 44189838 OMOP3066561 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 3 by European @@ -295558,11 +302397,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Aca Mueller 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Aca Mueller - OMOP3066559 44189836 - 44189836 OMOP3066559 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Aca Mueller @@ -295611,11 +302447,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Axicorp 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Axicorp - OMOP3066170 44189447 - 44189447 OMOP3066170 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Axicorp @@ -295664,11 +302497,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Cc 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Cc - OMOP3066560 44189837 - 44189837 OMOP3066560 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Cc @@ -295717,11 +302547,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Emra-Med 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Emra-Med - OMOP3066264 44189541 - 44189541 OMOP3066264 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Emra-Med @@ -295770,11 +302597,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Eurim-Pharm 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Eurim-Pharm - OMOP3066784 44190061 - 44190061 OMOP3066784 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Eurim-Pharm @@ -295823,11 +302647,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Europharma 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Europharma - OMOP3066083 44189360 - 44189360 OMOP3066083 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Europharma @@ -295876,11 +302697,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Gerke 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Gerke - OMOP3066169 44189446 - 44189446 OMOP3066169 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Gerke @@ -295929,11 +302747,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by HVD 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by HVD - OMOP3066553 44189830 - 44189830 OMOP3066553 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by HVD @@ -295982,11 +302797,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Kohlpharma 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Kohlpharma - OMOP3066475 44189752 - 44189752 OMOP3066475 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Kohlpharma @@ -296035,11 +302847,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Merck 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Merck - OMOP3066355 44189632 - 44189632 OMOP3066355 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Merck @@ -296088,11 +302897,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Mtk 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Mtk - OMOP3066558 44189835 - 44189835 OMOP3066558 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Mtk @@ -296141,11 +302947,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Orifarm Leverkus 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Orifarm Leverkus - OMOP3066019 44189296 - 44189296 OMOP3066019 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Orifarm Leverkus @@ -296194,11 +302997,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Veron 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Veron - OMOP3066356 44189633 - 44189633 OMOP3066356 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Veron @@ -296863,11 +303663,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 10 ML Hepatitis B Surface Antigen Vaccine 0.001 MG/ML Prefilled Syringe Box of 1 by Orifarm Leverkus 10 ML Hepatitis B Surface Antigen Vaccine 0.001 MG/ML Prefilled Syringe Box of 1 by Orifarm Leverkus - OMOP3069421 44192698 - 44192698 OMOP3069421 vaccine 10 ML Hepatitis B Surface Antigen Vaccine 0.001 MG/ML Prefilled Syringe Box of 1 by Orifarm Leverkus @@ -303559,12 +310356,9 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10 by Abacus Medicine 1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10 by Abacus Medicine - OMOP3066563 41334016 44189840 - 44189840 OMOP2531978 OMOP3066563 vaccine @@ -317369,11 +324163,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.05 MG/ML Injectable Solution by Aventis 0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.05 MG/ML Injectable Solution by Aventis - OMOP1127403 44132772 - 44132772 OMOP1127403 vaccine 0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.05 MG/ML Injectable Solution by Aventis @@ -318025,11 +324816,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML diphtheria toxoid vaccine, inactivated 25 LFU/ML / Pertussis Vaccine 8 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution 0.5 ML diphtheria toxoid vaccine, inactivated 25 LFU/ML / Pertussis Vaccine 8 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution - OMOP1127416 44132785 - 44132785 OMOP1127416 vaccine 0.5 ML diphtheria toxoid vaccine, inactivated 25 LFU/ML / Pertussis Vaccine 8 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution @@ -318152,11 +324940,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML diphtheria toxoid vaccine, inactivated 25 LFU/ML / Pertussis Vaccine 8 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution [Tri-Immunol Im] by Lederle Products 0.5 ML diphtheria toxoid vaccine, inactivated 25 LFU/ML / Pertussis Vaccine 8 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution [Tri-Immunol Im] by Lederle Products - OMOP1127457 44132826 - 44132826 OMOP1127457 vaccine 0.5 ML diphtheria toxoid vaccine, inactivated 25 LFU/ML / Pertussis Vaccine 8 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution [Tri-Immunol Im] by Lederle Products @@ -318419,11 +325204,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension by Iaf Biovac 0.5 ML diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension by Iaf Biovac - OMOP1127402 44132771 - 44132771 OMOP1127402 vaccine 0.5 ML diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension by Iaf Biovac @@ -318962,11 +325744,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / Pertussis Vaccine 0.021 MG/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension 0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / Pertussis Vaccine 0.021 MG/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension - OMOP1127333 44132702 - 44132702 OMOP1127333 vaccine 0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / Pertussis Vaccine 0.021 MG/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension @@ -319948,11 +326727,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML diphtheria toxoid vaccine, inactivated 50 LFU/ML / Pertussis Vaccine 24 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution by Aventis 0.5 ML diphtheria toxoid vaccine, inactivated 50 LFU/ML / Pertussis Vaccine 24 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution by Aventis - OMOP1127364 44132733 - 44132733 OMOP1127364 vaccine 0.5 ML diphtheria toxoid vaccine, inactivated 50 LFU/ML / Pertussis Vaccine 24 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution by Aventis @@ -320002,11 +326778,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML diphtheria toxoid vaccine, inactivated 50 LFU/ML / tetanus toxin 10 LFU/ML Injectable Solution 0.5 ML diphtheria toxoid vaccine, inactivated 50 LFU/ML / tetanus toxin 10 LFU/ML Injectable Solution - OMOP1127378 44132747 - 44132747 OMOP1127378 vaccine 0.5 ML diphtheria toxoid vaccine, inactivated 50 LFU/ML / tetanus toxin 10 LFU/ML Injectable Solution @@ -320055,11 +326828,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML diphtheria toxoid vaccine, inactivated 50 LFU/ML / tetanus toxin 10 LFU/ML Injectable Solution by Aventis 0.5 ML diphtheria toxoid vaccine, inactivated 50 LFU/ML / tetanus toxin 10 LFU/ML Injectable Solution by Aventis - OMOP1127515 44132884 - 44132884 OMOP1127515 vaccine 0.5 ML diphtheria toxoid vaccine, inactivated 50 LFU/ML / tetanus toxin 10 LFU/ML Injectable Solution by Aventis @@ -320108,11 +326878,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.02 MG/ML Injectable Solution 0.5 ML Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.02 MG/ML Injectable Solution - OMOP1127475 44132844 - 44132844 OMOP1127475 vaccine 0.5 ML Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.02 MG/ML Injectable Solution @@ -320325,11 +327092,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.08 MG/ML Injectable Solution 0.5 ML Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.08 MG/ML Injectable Solution - OMOP1127411 44132780 - 44132780 OMOP1127411 vaccine 0.5 ML Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.08 MG/ML Injectable Solution @@ -320435,11 +327199,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.08 MG/ML Injection [ActHIB] 0.5 ML Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.08 MG/ML Injection [ActHIB] - OMOP1127388 44132757 - 44132757 OMOP1127388 vaccine 0.5 ML Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.08 MG/ML Injection [ActHIB] @@ -320488,11 +327249,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML meningococcal group C polysaccharide 0.02 MG/ML / tetanus toxoid vaccine, inactivated 0.04 MG/ML Injectable Suspension 0.5 ML meningococcal group C polysaccharide 0.02 MG/ML / tetanus toxoid vaccine, inactivated 0.04 MG/ML Injectable Suspension - OMOP1127469 44132838 - 44132838 OMOP1127469 vaccine 0.5 ML meningococcal group C polysaccharide 0.02 MG/ML / tetanus toxoid vaccine, inactivated 0.04 MG/ML Injectable Suspension @@ -320733,11 +327491,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 160 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution [T Polio Adsorbed] 0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 160 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution [T Polio Adsorbed] - OMOP1127383 44132752 - 44132752 OMOP1127383 vaccine 0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 160 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution [T Polio Adsorbed] @@ -320804,11 +327559,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 160 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution [T Polio Adsorbed] by Aventis 0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 160 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution [T Polio Adsorbed] by Aventis - OMOP1127355 44132724 - 44132724 OMOP1127355 vaccine 0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 160 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution [T Polio Adsorbed] by Aventis @@ -358008,13 +364760,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2588235 2588235 hepatitis B surface antigen (isoform M), recombinant 0.01 MG/ML 1758556 - protein + vaccine hepatitis B surface antigen (isoform M), recombinant 0.01 MG/ML @@ -358081,13 +364838,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2588236 2588236 hepatitis B surface antigen (isoform S), recombinant 0.01 MG/ML 1758557 - protein + vaccine hepatitis B surface antigen (isoform S), recombinant 0.01 MG/ML @@ -360545,11 +367307,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Pertussis Vaccine 600 UNT/ML Injectable Suspension 0.5 ML Pertussis Vaccine 600 UNT/ML Injectable Suspension - OMOP1127338 44132707 - 44132707 OMOP1127338 vaccine 0.5 ML Pertussis Vaccine 600 UNT/ML Injectable Suspension @@ -360592,11 +367351,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Pertussis Vaccine 600 UNT/ML Injectable Suspension [Acel-P] 0.5 ML Pertussis Vaccine 600 UNT/ML Injectable Suspension [Acel-P] - OMOP1127441 44132810 - 44132810 OMOP1127441 vaccine 0.5 ML Pertussis Vaccine 600 UNT/ML Injectable Suspension [Acel-P] @@ -364016,13 +370772,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/331446 331446 Neisseria meningitidis 0.5 MG/ML 19087335 - vaccine component + vaccine Neisseria meningitidis 0.5 MG/ML @@ -364448,13 +371209,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/343255 343255 Haemophilus capsular oligosaccharide 0.015 MG/ML 586322 - vaccine component + vaccine Haemophilus capsular oligosaccharide 0.015 MG/ML @@ -365711,9 +372477,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - + @@ -365745,9 +372510,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - + @@ -365779,9 +372543,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - + @@ -365845,9 +372608,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - + @@ -365879,9 +372641,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - + @@ -365913,9 +372674,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - + @@ -370553,11 +377313,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML diphtheria toxoid vaccine, inactivated 0.03 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Meningitec] 0.5 ML diphtheria toxoid vaccine, inactivated 0.03 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Meningitec] - OMOP1127495 44132864 - 44132864 OMOP1127495 vaccine 0.5 ML diphtheria toxoid vaccine, inactivated 0.03 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Meningitec] @@ -370607,11 +377364,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Menjugate] 0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Menjugate] - OMOP1127438 44132807 - 44132807 OMOP1127438 vaccine 0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Menjugate] @@ -370880,11 +377634,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML diphtheria toxoid vaccine, inactivated 0.03 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension 0.5 ML diphtheria toxoid vaccine, inactivated 0.03 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension - OMOP1127335 44132704 - 44132704 OMOP1127335 vaccine 0.5 ML diphtheria toxoid vaccine, inactivated 0.03 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension @@ -371016,11 +377767,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML diphtheria toxoid vaccine, inactivated 0.03 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Meningitec] by Nuron Biotech 0.5 ML diphtheria toxoid vaccine, inactivated 0.03 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Meningitec] by Nuron Biotech - OMOP1127516 44132885 - 44132885 OMOP1127516 vaccine 0.5 ML diphtheria toxoid vaccine, inactivated 0.03 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Meningitec] by Nuron Biotech @@ -371069,11 +377817,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Menjugate] by Glaxosmithkline 0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Menjugate] by Glaxosmithkline - OMOP1127369 44132738 - 44132738 OMOP1127369 vaccine 0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Menjugate] by Glaxosmithkline @@ -372191,11 +378936,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Solution 0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Solution - OMOP1127374 44132743 - 44132743 OMOP1127374 vaccine 0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Solution @@ -372256,11 +378998,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Solution Box of 5 0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Solution Box of 5 - OMOP1127473 44132842 - 44132842 OMOP1127473 vaccine 0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Solution Box of 5 @@ -377972,11 +384711,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution 0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution - OMOP1127409 44132778 - 44132778 OMOP1127409 vaccine 0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution @@ -378037,11 +384773,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution Box of 10 0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution Box of 10 - OMOP1127325 44132694 - 44132694 OMOP1127325 vaccine 0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution Box of 10 @@ -378102,11 +384835,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution Box of 10 by Merck 0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution Box of 10 by Merck - OMOP1127398 44132767 - 44132767 OMOP1127398 vaccine 0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution Box of 10 by Merck @@ -378161,11 +384891,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 20000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution 0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 20000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution - OMOP1127471 44132840 - 44132840 OMOP1127471 vaccine 0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 20000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution @@ -378227,11 +384954,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 20000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution [Priorix] 0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 20000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution [Priorix] - OMOP1127427 44132796 - 44132796 OMOP1127427 vaccine 0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 20000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution [Priorix] @@ -378781,11 +385505,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - Measles Vaccine / Mumps Vaccine / Rubella virus vaccine / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Solution [ProQuad] Measles Vaccine / Mumps Vaccine / Rubella virus vaccine / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Solution [ProQuad] - OMOP3041268 44164545 - 44164545 OMOP3041268 vaccine Measles Vaccine / Mumps Vaccine / Rubella virus vaccine / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Solution [ProQuad] @@ -392664,11 +399385,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML Injectable Solution [Pnu-Imune] 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML Injectable Solution [Pnu-Imune] - OMOP1127484 44132853 - 44132853 OMOP1127484 vaccine 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML Injectable Solution [Pnu-Imune] @@ -393549,11 +400267,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML Injectable Solution [Pnu-Imune] by Lederle Products 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML Injectable Solution [Pnu-Imune] by Lederle Products - OMOP1127442 44132811 - 44132811 OMOP1127442 vaccine 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML Injectable Solution [Pnu-Imune] by Lederle Products @@ -394476,12 +401191,9 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 10 by Abacus Medicine 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 10 by Abacus Medicine - OMOP3073953 41407309 44197230 - 44197230 OMOP2605271 OMOP3073953 vaccine @@ -394877,11 +401589,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 1 by Merck 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 1 by Merck - OMOP3073812 44197089 - 44197089 OMOP3073812 vaccine 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 1 by Merck @@ -395100,11 +401809,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 10 by Merck 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 10 by Merck - OMOP3073775 44197052 - 44197052 OMOP3073775 vaccine 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 10 by Merck @@ -395367,11 +402073,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 20 by Merck 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 20 by Merck - OMOP3073866 44197143 - 44197143 OMOP3073866 vaccine 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 20 by Merck @@ -395502,11 +402205,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 1 by Merck 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 1 by Merck - OMOP3073929 44197206 - 44197206 OMOP3073929 vaccine 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 1 by Merck @@ -395593,11 +402293,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 10 by Merck 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 10 by Merck - OMOP3073739 44197016 - 44197016 OMOP3073739 vaccine 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 10 by Merck @@ -395684,11 +402381,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 20 by Merck 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 20 by Merck - OMOP3073868 44197145 - 44197145 OMOP3073868 vaccine 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 20 by Merck @@ -396131,12 +402825,9 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 1 by European 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 1 by European - OMOP3073813 41409432 44197090 - 44197090 OMOP2607394 OMOP3073813 vaccine @@ -396212,12 +402903,9 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 10 by European 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 10 by European - OMOP3073867 41409257 44197144 - 44197144 OMOP2607219 OMOP3073867 vaccine @@ -396255,11 +402943,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 20 by Emra-Med 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 20 by Emra-Med - OMOP3073896 44197173 - 44197173 OMOP3073896 vaccine 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 20 by Emra-Med @@ -396296,12 +402981,9 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 20 by European 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 20 by European - OMOP3073928 41408115 44197205 - 44197205 OMOP2606077 OMOP3073928 vaccine @@ -396999,11 +403681,10 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injectable Suspension [Ixiaro] by Valneva - OMOP4986340 + 0.5 ML Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injectable Suspension [Ixiaro] by Valneva rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain 1000 MG [Rotarix] 36074314 - 44132817 + 44132817 OMOP4986340 vaccine 0.5 ML Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injectable Suspension [Ixiaro] by Valneva @@ -397874,11 +404555,10 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML Injectable Solution [Mumpsvax] + 0.5 ML Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML Injectable Solution [Mumpsvax] L1 protein, Human papillomavirus type 16 Vaccine / L1 protein, Human papillomavirus type 18 Vaccine Injection [Cervarix] - OMOP995487 36882767 - 44132795 + 44132795 OMOP995487 vaccine 0.5 ML Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML Injectable Solution [Mumpsvax] @@ -397921,11 +404601,10 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML Injectable Solution [Mumpsvax] by Merck - OMOP505435 + 0.5 ML Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML Injectable Solution [Mumpsvax] by Merck Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain Powder for Oral Suspension [Rotarix] 43185349 - 44132874 + 44132874 OMOP505435 vaccine 0.5 ML Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML Injectable Solution [Mumpsvax] by Merck @@ -407544,13 +414223,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/358497 358497 Haemophilus capsular oligosaccharide 0.03 MG/ML 19099054 - vaccine component + vaccine Haemophilus capsular oligosaccharide 0.03 MG/ML @@ -407559,13 +414243,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/384561 384561 Neisseria meningitidis 0.25 MG/ML 515692 - vaccine component + vaccine Neisseria meningitidis 0.25 MG/ML @@ -408263,13 +414952,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/1869639 1869639 influenza A virus A/Indonesia/05/2005 (H5N1) antigen 0.0075 MG/ML 1594218 - vaccine component + vaccine influenza A virus A/Indonesia/05/2005 (H5N1) antigen 0.0075 MG/ML @@ -408278,13 +414972,24 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/1876707 1876707 yellow fever virus strain 17D-204 live antigen 2000 UNT/ML [Stamaril] 1593655 - vaccine component + vaccine yellow fever virus strain 17D-204 live antigen 2000 UNT/ML [Stamaril] @@ -408293,13 +414998,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/1928530 1928530 influenza A virus A/Singapore/GP2050/2015 (H3N2) antigen 0.03 MG/ML 1593541 - vaccine component + vaccine influenza A virus A/Singapore/GP2050/2015 (H3N2) antigen 0.03 MG/ML @@ -408308,13 +415018,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/1942126 1942126 influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML 793950 - vaccine component + vaccine influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML @@ -408323,13 +415038,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2050799 2050799 influenza B virus antigen 0.03 MG/ML 35200075 - vaccine component + vaccine influenza B virus antigen 0.03 MG/ML @@ -408338,13 +415058,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2056522 2056522 influenza A virus A/North Carolina/04/2016 (H3N2) antigen 0.03 MG/ML 35200566 - vaccine component + vaccine influenza A virus A/North Carolina/04/2016 (H3N2) antigen 0.03 MG/ML @@ -408353,13 +415078,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2056524 2056524 influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML 35200568 - vaccine component + vaccine influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML @@ -408368,13 +415098,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2056526 2056526 influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML 35200570 - vaccine component + vaccine influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML @@ -408383,13 +415118,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2177390 2177390 influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML 1361075 - vaccine component + vaccine influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML @@ -408398,13 +415138,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2177391 2177391 influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML 1361076 - vaccine component + vaccine influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML @@ -408413,13 +415158,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2177690 2177690 influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.12 MG/ML 1361095 - vaccine component + vaccine influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.12 MG/ML @@ -408428,13 +415178,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2177691 2177691 influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.12 MG/ML 1361096 - vaccine component + vaccine influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.12 MG/ML @@ -408443,13 +415198,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2178089 2178089 influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.09 MG/ML 1361151 - vaccine component + vaccine influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.09 MG/ML @@ -408458,13 +415218,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2178090 2178090 influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.09 MG/ML 1361152 - vaccine component + vaccine influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.09 MG/ML @@ -408473,13 +415238,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2180398 2180398 influenza A virus A/Idaho/07/2018 (H1N1) antigen 0.03 MG/ML 1361315 - vaccine component + vaccine influenza A virus A/Idaho/07/2018 (H1N1) antigen 0.03 MG/ML @@ -408488,13 +415258,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2180399 2180399 influenza A virus A/Indiana/08/2018 (H3N2) antigen 0.03 MG/ML 1361316 - vaccine component + vaccine influenza A virus A/Indiana/08/2018 (H3N2) antigen 0.03 MG/ML @@ -408503,13 +415278,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2198897 2198897 influenza A virus A/Kansas/14/2017 (H3N2) antigen 158000000 UNT/ML 37496498 - vaccine component + vaccine influenza A virus A/Kansas/14/2017 (H3N2) antigen 158000000 UNT/ML @@ -408518,13 +415298,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2198898 2198898 influenza A virus A/Switzerland/3330/2017 (H1N1) antigen 158000000 UNT/ML 37496499 - vaccine component + vaccine influenza A virus A/Switzerland/3330/2017 (H1N1) antigen 158000000 UNT/ML @@ -408548,13 +415333,24 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2275271 2275271 hepatitis A virus strain CR 326F antigen, inactivated 50 UNT/ML 37498652 - vaccine component + vaccine hepatitis A virus strain CR 326F antigen, inactivated 50 UNT/ML @@ -408563,13 +415359,31 @@ Note: The 6K protein is part of the 6K-E1 structural protein + + + + + + + + + + + + + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2275275 2275275 hepatitis A virus strain CR 326F antigen, inactivated 50 UNT/ML [Vaqta] 37498655 - vaccine component + vaccine hepatitis A virus strain CR 326F antigen, inactivated 50 UNT/ML [Vaqta] @@ -408578,13 +415392,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2280739 2280739 influenza A virus A/South Australia/34/2019 (H3N2) antigen 0.03 MG/ML 37498843 - vaccine component + vaccine influenza A virus A/South Australia/34/2019 (H3N2) antigen 0.03 MG/ML @@ -408593,13 +415412,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2280740 2280740 influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML 37498844 - vaccine component + vaccine influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML @@ -408608,13 +415432,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2280748 2280748 influenza A virus (H3N2) antigen 0.03 MG/ML 37498851 - vaccine component + vaccine influenza A virus (H3N2) antigen 0.03 MG/ML @@ -408623,13 +415452,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2379630 2379630 influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML 1146353 - vaccine component + vaccine influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML @@ -408638,13 +415472,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2379631 2379631 influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML 1146354 - vaccine component + vaccine influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML @@ -408653,13 +415492,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2380592 2380592 influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML 1146456 - vaccine component + vaccine influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML @@ -408668,13 +415512,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2380593 2380593 influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML 1146457 - vaccine component + vaccine influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML @@ -408683,13 +415532,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2380839 2380839 influenza A virus A/Delaware/39/2019 (H3N2) antigen 0.03 MG/ML 1146488 - vaccine component + vaccine influenza A virus A/Delaware/39/2019 (H3N2) antigen 0.03 MG/ML @@ -408698,13 +415552,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2380840 2380840 influenza A virus A/Nebraska/14/2019 (H1N1) antigen 0.03 MG/ML 1146489 - vaccine component + vaccine influenza A virus A/Nebraska/14/2019 (H1N1) antigen 0.03 MG/ML @@ -408713,13 +415572,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2380841 2380841 influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML 1146490 - vaccine component + vaccine influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML @@ -408728,13 +415592,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2380854 2380854 influenza A virus A/Hawaii/70/2019 (H1N1) antigen 0.09 MG/ML 1146500 - vaccine component + vaccine influenza A virus A/Hawaii/70/2019 (H1N1) antigen 0.09 MG/ML @@ -408743,13 +415612,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2380855 2380855 influenza A virus A/Minnesota/41/2019 (H3N2) antigen 0.09 MG/ML 1146501 - vaccine component + vaccine influenza A virus A/Minnesota/41/2019 (H3N2) antigen 0.09 MG/ML @@ -408758,13 +415632,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2380856 2380856 influenza B virus B/Washington/02/2019 antigen 0.09 MG/ML 1146502 - vaccine component + vaccine influenza B virus B/Washington/02/2019 antigen 0.09 MG/ML @@ -408773,13 +415652,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2383542 2383542 influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.0857 MG/ML 1146552 - vaccine component + vaccine influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.0857 MG/ML @@ -408788,13 +415672,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2383543 2383543 influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.0857 MG/ML 1146553 - vaccine component + vaccine influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.0857 MG/ML @@ -408803,13 +415692,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2383544 2383544 influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML 1146606 - vaccine component + vaccine influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML @@ -408818,13 +415712,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2383545 2383545 influenza B virus B/Washington/02/2019 antigen 0.0857 MG/ML 1146607 - vaccine component + vaccine influenza B virus B/Washington/02/2019 antigen 0.0857 MG/ML @@ -408833,13 +415732,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2388149 2388149 influenza A virus A/Hawaii/66/2019 (H1N1) antigen 158000000 UNT/ML 37002437 - vaccine component + vaccine influenza A virus A/Hawaii/66/2019 (H1N1) antigen 158000000 UNT/ML @@ -408848,13 +415752,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2388150 2388150 influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 158000000 UNT/ML 37002438 - vaccine component + vaccine influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 158000000 UNT/ML @@ -408863,13 +415772,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2388151 2388151 influenza B virus B/Washington/02/2019 antigen 158000000 UNT/ML 37002439 - vaccine component + vaccine influenza B virus B/Washington/02/2019 antigen 158000000 UNT/ML @@ -408878,13 +415792,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2479042 2479042 influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML 739848 - vaccine component + vaccine influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML @@ -408893,13 +415812,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2561272 2561272 influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML 1537382 - vaccine component + vaccine influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML @@ -408908,13 +415832,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2562993 2562993 influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.0857 MG/ML 1537469 - vaccine component + vaccine influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.0857 MG/ML @@ -408923,13 +415852,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2563001 2563001 influenza A virus A/Washington/19/2020 (H1N1) antigen 0.03 MG/ML 1537474 - vaccine component + vaccine influenza A virus A/Washington/19/2020 (H1N1) antigen 0.03 MG/ML @@ -408938,13 +415872,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2563010 2563010 influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.0857 MG/ML 1537480 - vaccine component + vaccine influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.0857 MG/ML @@ -408953,13 +415892,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2563011 2563011 influenza A virus A/Wisconsin/588/2019 (H1N1) antigen 0.09 MG/ML 1537481 - vaccine component + vaccine influenza A virus A/Wisconsin/588/2019 (H1N1) antigen 0.09 MG/ML @@ -408968,13 +415912,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2563023 2563023 influenza A virus A/Cambodia/e0826360/2020 (H3N2) antigen 0.03 MG/ML 1537492 - vaccine component + vaccine influenza A virus A/Cambodia/e0826360/2020 (H3N2) antigen 0.03 MG/ML @@ -408983,13 +415932,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2563036 2563036 influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.09 MG/ML 1537503 - vaccine component + vaccine influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.09 MG/ML @@ -408998,13 +415952,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2564394 2564394 influenza A virus A/Tasmania/503/2020 (H3N2) antigen 158000000 UNT/ML 701447 - vaccine component + vaccine influenza A virus A/Tasmania/503/2020 (H3N2) antigen 158000000 UNT/ML @@ -409013,13 +415972,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2564396 2564396 influenza A virus A/Victoria/1/2020 (H1N1) antigen 158000000 UNT/ML 701449 - vaccine component + vaccine influenza A virus A/Victoria/1/2020 (H1N1) antigen 158000000 UNT/ML @@ -409028,13 +415992,24 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2588239 2588239 hepatitis B surface antigen (isoform L), recombinant 0.01 MG/ML / hepatitis B surface antigen (isoform M), recombinant 0.01 MG/ML / hepatitis B surface antigen (isoform S), recombinant 0.01 MG/ML [Prehevbrio] 1758559 - vaccine component + vaccine hepatitis B surface antigen (isoform L), recombinant 0.01 MG/ML / hepatitis B surface antigen (isoform M), recombinant 0.01 MG/ML / hepatitis B surface antigen (isoform S), recombinant 0.01 MG/ML [Prehevbrio] @@ -409043,13 +416018,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2593855 2593855 influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML 1759211 - vaccine component + vaccine influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML @@ -409058,13 +416038,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2593856 2593856 influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML 1759212 - vaccine component + vaccine influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML @@ -409073,13 +416058,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2605044 2605044 influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML 780052 - vaccine component + vaccine influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML @@ -409088,13 +416078,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2605089 2605089 influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML 780067 - vaccine component + vaccine influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML @@ -409103,13 +416098,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2605098 2605098 influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.0857 MG/ML 780074 - vaccine component + vaccine influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.0857 MG/ML @@ -409118,13 +416118,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2605099 2605099 influenza B virus B/Michigan/01/2021 antigen 0.0857 MG/ML 780075 - vaccine component + vaccine influenza B virus B/Michigan/01/2021 antigen 0.0857 MG/ML @@ -409133,13 +416138,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2605562 2605562 influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.09 MG/ML 780103 - vaccine component + vaccine influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.09 MG/ML @@ -409148,13 +416158,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2605563 2605563 influenza B virus B/Austria/1359417/2021 antigen 0.09 MG/ML 780104 - vaccine component + vaccine influenza B virus B/Austria/1359417/2021 antigen 0.09 MG/ML @@ -409163,13 +416178,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2605726 2605726 influenza A virus A/Darwin/11/2021 (H3N2) antigen 0.03 MG/ML 780122 - vaccine component + vaccine influenza A virus A/Darwin/11/2021 (H3N2) antigen 0.03 MG/ML @@ -409178,13 +416198,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2605727 2605727 influenza A virus A/Delaware/55/2019 (H1N1) antigen 0.03 MG/ML 780123 - vaccine component + vaccine influenza A virus A/Delaware/55/2019 (H1N1) antigen 0.03 MG/ML @@ -409193,13 +416218,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2605728 2605728 influenza B virus B/Singapore/WUH4618/2021 antigen 0.03 MG/ML 780124 - vaccine component + vaccine influenza B virus B/Singapore/WUH4618/2021 antigen 0.03 MG/ML @@ -409208,13 +416238,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2607742 2607742 influenza A virus A/Norway/16606/2021 (H3N2) antigen 158000000 UNT/ML 1525409 - vaccine component + vaccine influenza A virus A/Norway/16606/2021 (H3N2) antigen 158000000 UNT/ML @@ -409223,13 +416258,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2607743 2607743 influenza B virus B/Austria/1359417/2021 antigen 158000000 UNT/ML 1525410 - vaccine component + vaccine influenza B virus B/Austria/1359417/2021 antigen 158000000 UNT/ML @@ -409238,13 +416278,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2630222 2630222 influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.0857 MG/ML 1301743 - vaccine component + vaccine influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.0857 MG/ML @@ -409253,13 +416298,18 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + + + + + + + OHDSI Vaccine WG - http://purl.bioontology.org/ontology/RXNORM/2630656 2630656 influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.03 MG/ML 1301766 - vaccine component + vaccine influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.03 MG/ML @@ -413240,7 +420290,6 @@ Note: The 6K protein is part of the 6K-E1 structural protein - @@ -421670,7 +428719,6 @@ Note: The 6K protein is part of the 6K-E1 structural protein - @@ -424477,7 +431525,7 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + @@ -424503,7 +431551,7 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + @@ -424543,7 +431591,6 @@ Note: The 6K protein is part of the 6K-E1 structural protein - @@ -424583,8 +431630,7 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - + @@ -424622,6 +431668,7 @@ Note: The 6K protein is part of the 6K-E1 structural protein + @@ -428873,7 +435920,6 @@ Note: The 6K protein is part of the 6K-E1 structural protein - @@ -428959,7 +436005,6 @@ Note: The 6K protein is part of the 6K-E1 structural protein - @@ -429045,8 +436090,7 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - + @@ -429130,8 +436174,7 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - + @@ -443254,8 +450297,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - + + @@ -458207,9 +465250,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - + @@ -464285,7 +471327,7 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + @@ -464488,7 +471530,7 @@ Note: The 6K protein is part of the 6K-E1 structural protein - + @@ -464514,6 +471556,7 @@ Note: The 6K protein is part of the 6K-E1 structural protein + @@ -464585,8 +471628,7 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - + @@ -464624,6 +471666,7 @@ Note: The 6K protein is part of the 6K-E1 structural protein + @@ -464668,8 +471711,7 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - + @@ -464701,7 +471743,6 @@ Note: The 6K protein is part of the 6K-E1 structural protein - @@ -464747,8 +471788,7 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - + @@ -464780,7 +471820,6 @@ Note: The 6K protein is part of the 6K-E1 structural protein - @@ -467337,11 +474376,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG OHDSI Vaccine WG - Typhoid Vaccine Live Ty21a Extended Release Oral Capsule [Vivotif] - OMOP3052539 Typhoid Vaccine Live Ty21a Extended Release Oral Capsule [Vivotif] 44175816 - 44175816 OMOP3052539 vaccine Typhoid Vaccine Live Ty21a Extended Release Oral Capsule [Vivotif] @@ -467687,11 +474723,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG OHDSI Vaccine WG - Typhoid Vaccine Live Ty21a Extended Release Oral Capsule - OMOP3044996 Typhoid Vaccine Live Ty21a Extended Release Oral Capsule 44168273 - 44168273 OMOP3044996 vaccine Typhoid Vaccine Live Ty21a Extended Release Oral Capsule @@ -468374,11 +475407,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG OHDSI Vaccine WG - 0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution 0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution - OMOP1127406 44132775 - 44132775 OMOP1127406 vaccine 0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution @@ -474530,11 +481560,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / influenza B virus antigen 0.02 MG/ML Injectable Solution [HibTITER] 0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / influenza B virus antigen 0.02 MG/ML Injectable Solution [HibTITER] - OMOP1127353 44132722 - 44132722 OMOP1127353 vaccine 0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / influenza B virus antigen 0.02 MG/ML Injectable Solution [HibTITER] @@ -474713,11 +481740,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / influenza B virus antigen 0.02 MG/ML Injectable Solution Box of 5 0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / influenza B virus antigen 0.02 MG/ML Injectable Solution Box of 5 - OMOP1127379 44132748 - 44132748 OMOP1127379 vaccine 0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / influenza B virus antigen 0.02 MG/ML Injectable Solution Box of 5 @@ -479198,11 +486222,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 PFU/ML Injectable Suspension 0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 PFU/ML Injectable Suspension - OMOP1130210 44135579 - 44135579 OMOP1130210 vaccine 0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 PFU/ML Injectable Suspension @@ -479245,11 +486266,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 PFU/ML Injectable Suspension [Zostavax] 0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 PFU/ML Injectable Suspension [Zostavax] - OMOP1130208 44135577 - 44135577 OMOP1130208 vaccine 0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 PFU/ML Injectable Suspension [Zostavax] @@ -479292,11 +486310,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 PFU/ML Injectable Suspension [Zostavax] by Merck 0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 PFU/ML Injectable Suspension [Zostavax] by Merck - OMOP1130209 44135578 - 44135578 OMOP1130209 vaccine 0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 PFU/ML Injectable Suspension [Zostavax] by Merck @@ -479477,11 +486492,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Prefilled Syringe [Zostavax] Box of 1 by Merck 0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Prefilled Syringe [Zostavax] Box of 1 by Merck - OMOP3077949 44201226 - 44201226 OMOP3077949 vaccine 0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Prefilled Syringe [Zostavax] Box of 1 by Merck @@ -479920,12 +486932,9 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - 1 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution [Varilrix] Box of 1 by European 1 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution [Varilrix] Box of 1 by European - OMOP3066079 41327980 44189356 - 44189356 OMOP2525942 OMOP3066079 vaccine @@ -481829,11 +488838,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - Aconitum napellus extract / ferrous cation / Gelsemium Sempervirens Preparation / Gentiana lutea root extract / Influenza A virus / Lactate / Luffa operculata whole extract / VERATRUM ALBUM Preparation Injectable Solution Aconitum napellus extract / ferrous cation / Gelsemium Sempervirens Preparation / Gentiana lutea root extract / Influenza A virus / Lactate / Luffa operculata whole extract / VERATRUM ALBUM Preparation Injectable Solution - OMOP3063768 44187045 - 44187045 OMOP3063768 vaccine Aconitum napellus extract / ferrous cation / Gelsemium Sempervirens Preparation / Gentiana lutea root extract / Influenza A virus / Lactate / Luffa operculata whole extract / VERATRUM ALBUM Preparation Injectable Solution @@ -481876,11 +488882,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - Aconitum napellus extract / ferrous cation / Gelsemium Sempervirens Preparation / Gentiana lutea root extract / Influenza A virus / Lactate / Luffa operculata whole extract / VERATRUM ALBUM Preparation Injectable Solution [Metavirulent] Aconitum napellus extract / ferrous cation / Gelsemium Sempervirens Preparation / Gentiana lutea root extract / Influenza A virus / Lactate / Luffa operculata whole extract / VERATRUM ALBUM Preparation Injectable Solution [Metavirulent] - OMOP3052722 44175999 - 44175999 OMOP3052722 vaccine Aconitum napellus extract / ferrous cation / Gelsemium Sempervirens Preparation / Gentiana lutea root extract / Influenza A virus / Lactate / Luffa operculata whole extract / VERATRUM ALBUM Preparation Injectable Solution [Metavirulent] @@ -481918,11 +488921,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - Aconitum napellus extract / ferrous cation / Gelsemium Sempervirens Preparation / Gentiana lutea root extract / Influenza A virus / Lactate / Luffa operculata whole extract / VERATRUM ALBUM Preparation Oral Solution Aconitum napellus extract / ferrous cation / Gelsemium Sempervirens Preparation / Gentiana lutea root extract / Influenza A virus / Lactate / Luffa operculata whole extract / VERATRUM ALBUM Preparation Oral Solution - OMOP3060023 44183300 - 44183300 OMOP3060023 vaccine Aconitum napellus extract / ferrous cation / Gelsemium Sempervirens Preparation / Gentiana lutea root extract / Influenza A virus / Lactate / Luffa operculata whole extract / VERATRUM ALBUM Preparation Oral Solution @@ -481965,11 +488965,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein OHDSI Vaccine WG - Aconitum napellus extract / ferrous cation / Gelsemium Sempervirens Preparation / Gentiana lutea root extract / Influenza A virus / Lactate / Luffa operculata whole extract / VERATRUM ALBUM Preparation Oral Solution [Metavirulent] Aconitum napellus extract / ferrous cation / Gelsemium Sempervirens Preparation / Gentiana lutea root extract / Influenza A virus / Lactate / Luffa operculata whole extract / VERATRUM ALBUM Preparation Oral Solution [Metavirulent] - OMOP3045281 44168558 - 44168558 OMOP3045281 vaccine Aconitum napellus extract / ferrous cation / Gelsemium Sempervirens Preparation / Gentiana lutea root extract / Influenza A virus / Lactate / Luffa operculata whole extract / VERATRUM ALBUM Preparation Oral Solution [Metavirulent] @@ -481980,9 +488977,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - - + + @@ -482046,9 +489042,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - - + + @@ -487893,9 +494888,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - - + + @@ -487933,9 +494927,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - - + + @@ -487973,9 +494966,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - - + + @@ -488013,9 +495005,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - - + + @@ -488053,9 +495044,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - - + + @@ -488093,9 +495083,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - - + + @@ -488133,9 +495122,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - - + + @@ -488173,9 +495161,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - - + + @@ -488213,9 +495200,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - - + + @@ -488253,9 +495239,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - - + + @@ -488293,9 +495278,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - - + + @@ -488333,9 +495317,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - - + + @@ -488373,9 +495356,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - - + + @@ -488413,9 +495395,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - - + + @@ -493264,9 +500245,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - - + + @@ -493298,9 +500278,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - - + + @@ -493786,9 +500765,9 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - - + + + @@ -493864,9 +500843,9 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - - + + + @@ -493942,9 +500921,9 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - - + + + @@ -494134,9 +501113,9 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - - + + + @@ -494212,9 +501191,9 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - - + + + @@ -494290,9 +501269,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - - + + @@ -494484,9 +501462,8 @@ Note: The 6K protein is part of the 6K-E1 structural protein - - - + + diff --git a/vo_terms.tsv b/vo_terms.tsv index 781c22f..0de5cb2 100644 --- a/vo_terms.tsv +++ b/vo_terms.tsv @@ -1241,7 +1241,7 @@ "VO_0001240" "aluminum potassium sulfate adjuvant" "Class" "VO_0001241" "Alhydrogel vaccine adjuvant" "Class" "VO_0001242" "cholera toxin B subunit vaccine adjuvant" "Class" -"VO_0001243" "immunizes host" "ObjectProperty" +"VO_0001243" "immunizes recipient" "ObjectProperty" "VO_0001244" "Prevnar 13 vaccine" "Class" "VO_0001245" "Synflorix vaccine" "Class" "VO_0001246" "Menveo vaccine" "Class" @@ -1272,7 +1272,7 @@ "VO_0001271" "Montanide vaccine adjuvant" "Class" "VO_0001272" "EtxB vaccine adjuvant" "Class" "VO_0001273" "Polygen vaccine adjuvant" "Class" -"VO_0001274" "vaccine host role" "Class" +"VO_0001274" "vaccine recipient role" "Class" "VO_0001275" "immunization target role" "Class" "VO_0001276" "bacterial vaccine immunization" "Class" "VO_0001277" "viral vaccine immunization" "Class" @@ -5823,6 +5823,7 @@ "VO_0007182" "RCAS-Akt Vaccine" "Class" "VO_0007183" "RCAS-Ras Vaccine" "Class" "VO_0007184" "Telomerase: 540-548 Peptide Vaccine" "Class" +"VO_0007185" "4-peptide melanoma vaccine" "Class" "VO_0007186" "1(SOCS1)-silenced dendritic cell (DC) Vaccine" "Class" "VO_0007187" "117-126:FGF-5 Peptide Vaccine" "Class" "VO_0007188" "12 Melanoma Peptide Vaccine" "Class" @@ -5885,6 +5886,7 @@ "VO_0007245" "ALVAC-ESO-1 Vaccine" "Class" "VO_0007246" "ALVAC-hB7.1 Vaccine" "Class" "VO_0007247" "ALVAC-MART-1 Vaccine" "Class" +"VO_0007248" "a2/4-1bbl melanoma vaccine" "Class" "VO_0007249" "ALVAC(2) Melanoma Multi-antigen Vaccine" "Class" "VO_0007250" "ALVAC(2)-NY-ESO-1 (M)/TRICOM Vaccine" "Class" "VO_0007251" "AML mRNA Positive Lysate Loaded Autologous Dendritic Cell Vaccine" "Class" @@ -5909,6 +5911,7 @@ "VO_0007270" "antigen-targeted Personalized Breast Cancer Vaccine" "Class" "VO_0007271" "APC8015F vaccine" "Class" "VO_0007272" "Apoptotic Autologous Tumor Cells-pulsed Alpha-type-1 Polarized Dendritic Cells Vaccine" "Class" +"VO_0007273" "adenovirus-transfected autologous dc vaccine plus cik cells" "Class" "VO_0007274" "AUT-OV-ALVAC-hB7.1 Vaccine" "Class" "VO_0007275" "Autologous Ad-CD154-Transduced CLL B Cells Vaccine" "Class" "VO_0007276" "Autologous Anti-gp100:154-162 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes Vaccine" "Class" @@ -5952,11 +5955,16 @@ "VO_0007314" "Autologous Renal Cell Carcinoma Tumor Lysate-Pulsed Dendritic Cell Vaccine" "Class" "VO_0007315" "Autologous Sarcoma Lysate-pulsed Dendritic Cell Vaccine" "Class" "VO_0007316" "Autologous TARP Peptide-Pulsed Dendritic Cell Vaccine" "Class" +"VO_0007317" "ags-003-bld vaccine" "Class" "VO_0007318" "Autologous Tumor Cell Proteoliposome Chronic Lymphocytic Leukemia Vaccine" "Class" "VO_0007319" "Autologous Tumor Cell Vaccine" "Class" "VO_0007320" "Autologous Tumor-associated Peptide Antigen-pulsed Dendritic Cell Vaccine" "Class" "VO_0007321" "Autologous-Cell Leukemia Vaccine" "Class" "VO_0007322" "Autologous-Cell Melanoma Vaccine" "Class" +"VO_0007323" "alk peptide vaccine" "Class" +"VO_0007324" "allogeneic GM-CSF-secreting lethally irradiated pancreatic tumor cell vaccine" "Class" +"VO_0007325" "allogeneic HLA-A2/4-1BB ligand-expressing melanoma vaccine" "Class" +"VO_0007326" "anti-HER2/HER3 dendritic cell vaccine" "Class" "VO_0007327" "BCG, Cell Wall Skeleton Vaccine" "Class" "VO_0007328" "Bcl-Xs Adenovirus Vaccine" "Class" "VO_0007329" "Belagenpumatucel-L Vaccine" "Class" @@ -5965,12 +5973,27 @@ "VO_0007332" "Brain Tumor Initiating Cell Vaccine" "Class" "VO_0007333" "rMVA-PSA/PSMA/TRICOM vaccine" "Class" "VO_0007334" "Canarypox-hIL-12 Melanoma Vaccine" "Class" +"VO_0007335" "autolgous DC vaccine pulsed with autologous tumor homogenate for metastatic rcc" "Class" +"VO_0007336" "autologous CLL tumor cell vaccine" "Class" +"VO_0007337" "autologous cancer testis antigen specific dendritic cell vaccine" "Class" +"VO_0007338" "autologous CMV-pp65-flLAMP mRNA loaded dendritic cell vaccine" "Class" +"VO_0007339" "autologous dendritic cell vaccine loaded with personalized peptide vaccine (pep-dc vaccine)" "Class" +"VO_0007340" "autologous lymphoma immunoglobulin-derived scFv-chemokine DNA vaccine" "Class" +"VO_0007341" "autologous neuroblastoma cell vaccine" "Class" +"VO_0007342" "autologous oxidized ovarian tumor cell lysate vaccine" "Class" +"VO_0007343" "autologous total tumor mrna and CMV-pp65-flLAMP mRNA loaded liposome vaccine" "Class" +"VO_0007344" "autologous tumor cell lysate vaccine" "Class" +"VO_0007345" "autologous, dnp-modified ovarian cancer vaccine" "Class" +"VO_0007346" "B7.1/​IL-2 leukaemia cell vaccine" "Class" +"VO_0007347" "BC-819 vaccine" "Class" +"VO_0007348" "Bcl-Xl_42-CAF09b vaccine" "Class" "VO_0007349" "CAP-2 (CEA Peptide 9-mer) Vaccine" "Class" "VO_0007350" "CAP-3 (CEA Peptide 9-mer) Vaccine" "Class" "VO_0007351" "Carcinoembryonic Antigen Peptide 1-6D Vaccine" "Class" "VO_0007352" "Carcinoembryonic Antigen Peptide 1-6D Virus-Like Replicon Particles Vaccine" "Class" "VO_0007353" "Carcinoembryonic Antigen Peptide-1 Vaccine" "Class" "VO_0007354" "Carcinoembryonic Antigen RNA-pulsed DC Cancer Vaccine" "Class" +"VO_0007355" "Bcr-Abl (b2a2)-derived peptide vaccine" "Class" "VO_0007356" "CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine" "Class" "VO_0007357" "CD133 Antigen Peptide-pulsed Autologous Dendritic Cell Vaccine" "Class" "VO_0007358" "CD80 Breast Cancer Vaccine" "Class" @@ -5979,6 +6002,7 @@ "VO_0007361" "Chimeric Ad11p/Ad3 Oncolytic Virus Vaccine" "Class" "VO_0007362" "CMV pp65 Peptide-pulsed Autologous Dendritic Cell Vaccine" "Class" "VO_0007363" "CMVpp65/gB Plasmid Vaccine ASP0113" "Class" +"VO_0007364" "Bcr-Abl (b3a2)-derived peptide vaccine" "Class" "VO_0007365" "CTP-37-DT Vaccine" "Class" "VO_0007366" "Cyclin B1 Peptide-pulsed Autologous Dendritic Cell Vaccine" "Class" "VO_0007367" "Cytokine-Induced Killer Cells Vaccine" "Class" @@ -6014,6 +6038,7 @@ "VO_0007397" "hTERT/Survivin/CMV Multipeptide Vaccine" "Class" "VO_0007398" "Mammaglobin-A DNA Vaccine" "Class" "VO_0007399" "Modified Vaccinia Ankara (Bavarian Nordic)-HER2 Vaccine" "Class" +"VO_0007400" "Bcr-Abl peptide vaccine" "Class" "VO_0007401" "E1M(184V) Peptide Vaccine" "Class" "VO_0007402" "hTERT mRNA/Survivin Peptide-double-loaded Autologous Dendritic Cell Vaccine" "Class" "VO_0007403" "hTERT Multipeptide/Montanide ISA-51 VG/Imiquimod Vaccine GX 301" "Class" @@ -6075,6 +6100,7 @@ "VO_0007459" "Leukemic Apoptotic Corpse-Pulsed Autologous Dendritic Cells Vaccine" "Class" "VO_0007460" "Multi-peptide CMV-Modified Vaccinia Ankara Vaccine" "Class" "VO_0007461" "GVAX Lung Cancer Vaccine" "Class" +"VO_0007462" "bivalent neuroblastoma vaccine with adjuvant OPT-821" "Class" "VO_0007463" "HLA-A*2402-Restricted VEGFR1 Peptide Vaccine" "Class" "VO_0007464" "HLA-A2402-Restricted VEGFR1/2 Multipeptide Vaccine" "Class" "VO_0007465" "IL-2/Lptn Gene-Modified Allogeneic Neuroblastoma Tumor Cell Vaccine" "Class" @@ -6092,6 +6118,7 @@ "VO_0007477" "GITRL RNA-transfected Autologous Dendritic Cell Vaccine" "Class" "VO_0007478" "GM-CSF, IL-12 and GM-CSF+IL-12 genetically modified tumor cell vaccine" "Class" "VO_0007479" "GM-CSF-encoding Oncolytic Adenovirus CGTG-102 vaccine" "Class" +"VO_0007480" "cancer stem cell-loaded dc vaccine" "Class" "VO_0007481" "gp100 + Mart-1 + Mart-3 vaccine" "Class" "VO_0007482" "gp100 Adenovirus Vaccine" "Class" "VO_0007483" "gp100 and GM-CSF DNA/Gold Vaccine" "Class" @@ -6111,6 +6138,7 @@ "VO_0007497" "hTERT/Survivin/Melanoma Tumor Cell-Derived mRNA-Transfected Dendritic Cell Vaccine" "Class" "VO_0007498" "Long Peptide Vaccine 7" "Class" "VO_0007499" "MAGE-3.A1 Peptide Vaccine" "Class" +"VO_0007500" "CAR G36-PDL1 vaccine" "Class" "VO_0007501" "MART-1 Vaccine" "Class" "VO_0007502" "MART-1 Adenovirus Vaccine" "Class" "VO_0007503" "MART-1 Fowlpox Vaccine" "Class" @@ -6120,13 +6148,27 @@ "VO_0007507" "MART-1:27-35 Peptide Vaccine" "Class" "VO_0007508" "Melan-A VLP Vaccine" "Class" "VO_0007509" "Melan-A/MAGE-3.DP4 Peptide Vaccine" "Class" +"VO_0007510" "CDX-1307 vaccine" "Class" +"VO_0007511" "chimeric exosomal tumor vaccine" "Class" +"VO_0007512" "CLL idiotypic DNA vaccine" "Class" +"VO_0007513" "cyclin B1/WT-1/CEF-loaded DC vaccine" "Class" +"VO_0007514" "DC/AML fusion vaccine" "Class" +"VO_0007515" "dendritic cell survivin vaccine" "Class" +"VO_0007516" "dendritic cell tumor peptide vaccine" "Class" +"VO_0007517" "dendritic cell/​myeloma fusion vaccine" "Class" "VO_0007518" "Melanoma DNA vaccine TA2M(TM) encoding tyrosinase peptides" "Class" +"VO_0007519" "dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes" "Class" +"VO_0007520" "dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes" "Class" +"VO_0007521" "DIPG and GMB Immunomodulatory DC vaccine" "Class" +"VO_0007522" "electrofusion DC vaccine" "Class" "VO_0007523" "Melanoma Theraccine" "Class" "VO_0007524" "Melapuldencel-T Vaccine" "Class" "VO_0007525" "MELITAC 12.1 Peptide Vaccine" "Class" +"VO_0007526" "ESR1 peptide vaccine" "Class" "VO_0007527" "Monoclonal Antibody 4B5 Anti-Idiotype Vaccine" "Class" "VO_0007528" "Mouse gp100 Plasmid DNA Vaccine" "Class" "VO_0007529" "mRNA-Electroporated Dendritic Cells Vaccine" "Class" +"VO_0007530" "follicular lymphoma, patient-specific, soluble protein idiotype vaccine" "Class" "VO_0007531" "Murine TYRP2 Plasmid DNA Vaccine" "Class" "VO_0007532" "hTERT-LAMP mRNA-loaded Autologous Dendritic Cell Vaccine GRNVAC1" "Class" "VO_0007533" "ESO-1 (161-180) Peptide Vaccine" "Class" @@ -6139,6 +6181,7 @@ "VO_0007540" "MAGE-A3-expressing Adenovirus Type 5 Vaccine" "Class" "VO_0007541" "hTERT I540/R572Y/D988Y Multipeptide Vaccine" "Class" "VO_0007542" "Idiotype-Pulsed Autologous Dendritic Cell Vaccine APC8020" "Class" +"VO_0007543" "FRAME-001 personalized vaccine" "Class" "VO_0007544" "MVA-PSA/PAP Prostate Cancer Vaccine" "Class" "VO_0007545" "MVA-EBNA1/LMP2 Vaccine" "Class" "VO_0007546" "LMP-2:340-349 Peptide Vaccine" "Class" @@ -6256,6 +6299,89 @@ "VO_0007658" "whole cell cancer vaccine" "Class" "VO_0007659" "whole tumor cell cancer vaccine" "Class" "VO_0007660" "DNA cancer vaccine" "Class" +"VO_0007661" "GD2-CAR vaccine" "Class" +"VO_0007662" "GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid KLH conjugate vaccine" "Class" +"VO_0007663" "genetically engineered allogeneic prostate carinoma cells secreting interleukin-2 and interferon gamma" "Class" +"VO_0007664" "GM-K562 cell vaccine" "Class" +"VO_0007665" "GM.CD40L cell vaccine" "Class" +"VO_0007666" "gp100 mature dendritic cell vaccine" "Class" +"VO_0007667" "GVAX leukemia vaccine" "Class" +"VO_0007668" "H3.3K27M-specific peptide vaccine" "Class" +"VO_0007669" "HER-2-neu, CEA peptides, GM-CSF, montanide ISA-51 vaccine" "Class" +"VO_0007670" "HER2 ICD peptide vaccine" "Class" +"VO_0007671" "HLA neoantigen vaccine" "Class" +"VO_0007672" "HLA-A1, HLA-A2, and CD40-ligand pulsed dendritic cell vaccine" "Class" +"VO_0007673" "hodgkin's antigens-GM-CSF-expressing cell vaccine" "Class" +"VO_0007674" "HPV E6/E7-encoding semliki forest virus vaccine Vvax001" "Class" +"VO_0007675" "hyperacute - breast cancer vaccine" "Class" +"VO_0007676" "hyperacute-melanoma vaccine" "Class" +"VO_0007677" "hyperacute-prostate cancer vaccine" "Class" +"VO_0007678" "IDO peptide vaccine" "Class" +"VO_0007679" "IL-2 peptide and GM-CSF-in-adjuvant melanoma vaccine" "Class" +"VO_0007680" "IL15-DC vaccine" "Class" +"VO_0007681" "intracel KLH vaccine" "Class" +"VO_0007682" "KLH and tumor lysate pulsed DC vaccine" "Class" +"VO_0007683" "KLH-id vaccine" "Class" +"VO_0007684" "KLH-pulsed autologous dendritic cell vaccine" "Class" +"VO_0007685" "KRAS-targeted mRNA vaccine" "Class" +"VO_0007686" "LMP2A-loaded conventional DC vaccine" "Class" +"VO_0007687" "MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine" "Class" +"VO_0007688" "MART-1, tyrosinase and MAGE-A6 autologous DC vaccine" "Class" +"VO_0007689" "mature dendritic cell melanoma vaccine" "Class" +"VO_0007690" "MDX-1379 (gp100) melanoma peptide vaccine" "Class" +"VO_0007691" "MDX-CTLA4 antibody/tyrosinase/gp100/MART-1 melanoma vaccine" "Class" +"VO_0007692" "melanoma helper peptide vaccine" "Class" +"VO_0007693" "mixed bacterial cancer vaccine" "Class" +"VO_0007694" "mRNA neoantigen tumor vaccine" "Class" +"VO_0007695" "mRNA tumor antigen DC vaccine" "Class" +"VO_0007696" "mRNA-based personalized cancer vaccine NCI-4650" "Class" +"VO_0007697" "MT-201-GBM monocyte vaccine" "Class" +"VO_0007698" "MUC1 peptide-poly-ICLC vaccine" "Class" +"VO_0007699" "multi-epitope HER2 peptide vaccine TPIV100" "Class" +"VO_0007700" "multi-epitope melanoma peptide vaccine" "Class" +"VO_0007701" "multiantigen liposome loaded dendritic cell vaccine" "Class" +"VO_0007702" "multipeptide XS15 vaccine" "Class" +"VO_0007703" "multiple signals loaded dendritic cells vaccine" "Class" +"VO_0007704" "mutated neopeptide vaccine" "Class" +"VO_0007705" "MVA-BN-CV301 vaccine" "Class" +"VO_0007706" "MVF-HER-2(628-647)-CRL 1005 vaccine" "Class" +"VO_0007707" "NEO-PV-01 vaccine" "Class" +"VO_0007708" "neoantigen DNA vaccine" "Class" +"VO_0007709" "neoantigen peptide vaccine" "Class" +"VO_0007710" "neoantigen synthetic long peptide vaccine" "Class" +"VO_0007711" "neoantigen-loaded autologous dendritic cell vaccine" "Class" +"VO_0007712" "NY-ESO-1, MAGE-A1, and MAGE-A3 dendritic cell vaccine" "Class" +"VO_0007713" "NY-ESO-1/PRAME/MAGE-A3/WT-1 peptide vaccine" "Class" +"VO_0007714" "OCDC and NeoDC vaccine" "Class" +"VO_0007715" "oral cancer vaccine V3-OVA" "Class" +"VO_0007716" "oral therapeutic vaccine V3-X" "Class" +"VO_0007717" "P30-linked EphA2/CMV pp65/survivin peptide vaccine P30-EPS" "Class" +"VO_0007718" "P501-AS15 vaccine" "Class" +"VO_0007719" "pancreatic tumor personalized neoantigen vaccine" "Class" +"VO_0007720" "PD-L1 peptide vaccine" "Class" +"VO_0007721" "PD-L1/IDO peptide vaccine IO102-103" "Class" +"VO_0007722" "personal neoantigen cancer vaccine" "Class" +"VO_0007723" "personalized follicular lymphoma vaccine" "Class" +"VO_0007724" "personalized mature dendritic cell vaccine" "Class" +"VO_0007725" "personalized neoantigen melanoma vaccine" "Class" +"VO_0007726" "PolyPEPI1018 CRC vaccine" "Class" +"VO_0007727" "polyvalent melanoma vaccine" "Class" +"VO_0007728" "prodencel" "Class" +"VO_0007729" "pUMVC3-IGFBP2-HER2-IGF1R plasmid DNA vaccine" "Class" +"VO_0007730" "RAS peptide cancer vaccine TG01" "Class" +"VO_0007731" "SCIB1 DNA vaccine" "Class" +"VO_0007732" "secPD-L1 vaccine" "Class" +"VO_0007733" "sialyl lewis-keyhole limpet hemocyanin conjugate vaccine" "Class" +"VO_0007734" "tetanus peptide melanoma vaccine" "Class" +"VO_0007735" "TGFβ2 antisense-GMCSF gene modified autologous tumor cell vaccine" "Class" +"VO_0007736" "total tumor RNA-loaded dendritic cell vaccine" "Class" +"VO_0007737" "transgenic lymphocyte immunization vaccine" "Class" +"VO_0007738" "TriAd cancer vaccine" "Class" +"VO_0007739" "tumor antigen-sensitized DC vaccine" "Class" +"VO_0007740" "tumor lysate-pulsed dendritic cell vaccine" "Class" +"VO_0007741" "tumor lysate/KLH pulsed dendritic cell vaccine" "Class" +"VO_0007742" "TVI-Brain-1 vaccine" "Class" +"VO_0007743" "whole tumor cell-based leukemia vaccine" "Class" "VO_0010000" "Crptosporidium parvum Cp12" "Class" "VO_0010001" "Crptosporidium parvum Cp21" "Class" "VO_0010002" "Crptosporidium parvum Cp15" "Class" @@ -6540,6 +6666,51 @@ "VO_0010286" "pathogen gut adhesion assay" "Class" "VO_0010287" "viral neutralization titer assay" "Class" "VO_0010288" "study design variable" "Class" +"VO_0010289" "meningococcal group A polysaccharide vaccine" "Class" +"VO_0010290" "meningococcal group C polysaccharide vaccine" "Class" +"VO_0010291" "Bacillus anthracis strain V770-NP1-R antigen vaccine" "Class" +"VO_0010292" "Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen vaccine" "Class" +"VO_0010293" "Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen vaccine" "Class" +"VO_0010294" "Neisseria meningitidis serogroup B recombinant NADA fusion protein antigen vaccine" "Class" +"VO_0010295" "Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen vaccine" "Class" +"VO_0010296" "influenza A virus A/Brisbane/10/2010 (H1N1) antigen vaccine" "Class" +"VO_0010297" "Influenza A virus (H1N1) antigen vaccine" "Class" +"VO_0010298" "influenza A virus A/South Australia/55/2014 (H3N2) antigen vaccine" "Class" +"VO_0010299" "influenza A virus (H3N2) antigen vaccine" "Class" +"VO_0010300" "influenza B virus B/Utah/9/2014 antigen vaccine" "Class" +"VO_0010301" "influenza B virus antigen vaccine" "Class" +"VO_0010302" "influenza A virus A/Christchurch/16/2010 (H1N1) antigen vaccine" "Class" +"VO_0010303" "influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen vaccine" "Class" +"VO_0010304" "influenza B virus B/Brisbane/60/2008 antigen vaccine" "Class" +"VO_0010305" "influenza B virus B/Phuket/3073/2013 antigen vaccine" "Class" +"VO_0010306" "influenza A virus A/California/7/2009 (H1N1) antigen vaccine" "Class" +"VO_0010307" "influenza A virus A/Bolivia/559/2013 (H1N1) antigen vaccine" "Class" +"VO_0010308" "influenza B virus B/Brisbane/9/2014 antigen vaccine" "Class" +"VO_0010309" "influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen vaccine" "Class" +"VO_0010310" "influenza B virus B/Hong Kong/259/2010 antigen vaccine" "Class" +"VO_0010311" "influenza A virus A/New Caledonia/71/2014 (H3N2) antigen vaccine" "Class" +"VO_0010312" "vibrio cholerae CVD 103-HGR strain live antigen vaccine" "Class" +"VO_0010313" "influenza A virus A/Michigan/45/2015 (H1N1) antigen vaccine" "Class" +"VO_0010314" "influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen vaccine" "Class" +"VO_0010315" "influenza A virus A/Slovenia/2903/2015 (H1N1) antigen vaccine" "Class" +"VO_0010316" "influenza B virus B/Maryland/15/2016 antigen vaccine" "Class" +"VO_0010317" "influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen vaccine" "Class" +"VO_0010318" "influenza B virus B/Colorado/06/2017 antigen vaccine" "Class" +"VO_0010319" "Neisseria meningitidis Group B Membrane vesicles External Omv vaccine" "Class" +"VO_0010320" "Neisseria meningitidis Recombinant Fusion Protein Fhbp Group B vaccine" "Class" +"VO_0010321" "Bordetella Pertussis Filamentous Haemagglutinin Antigen vaccine" "Class" +"VO_0010322" "Bordetella Pertussis Fimbriae Serotype 2 And 3 Antigen vaccine" "Class" +"VO_0010323" "Haemophilus capsular oligosaccharide vaccine" "Class" +"VO_0010324" "influenza A virus (H5N1) antigen vaccine" "Class" +"VO_0010325" "hepatitis A virus strain CR 326F antigen, inactivated vaccine" "Class" +"VO_0010326" "Varicella zoster virus glycoprotein E vaccine" "Class" +"VO_0010327" "hepatitis B virus subtype ADW2 HBsAg surface protein antigen vaccine" "Class" +"VO_0010328" "Varicella zoster virus glycoprotein E, recombinant vaccine" "Class" +"VO_0010329" "influenza A virus A/Victoria/361/2011 (H3N2) antigen vaccine" "Class" +"VO_0010330" "intratumoral route" "Class" +"VO_0010331" "intralesional route" "Class" +"VO_0010332" "tumor-specific antigen" "Class" +"VO_0010333" "tumor-associated antigen" "Class" "VO_0010632" "country" "Class" "VO_0010633" "USA" "Class" "VO_0010637" "Rubella virus vaccine" "Class" @@ -7166,7 +7337,7 @@ "VO_0011327" "PLB" "Class" "VO_0011328" "AMN1" "Class" "VO_0011329" "ELI-Ag1" "Class" -"VO_0011330" "GEL1" "Class" +"VO_0011330" "GEL1.00" "Class" "VO_0011331" "URE" "Class" "VO_0011332" "Pmp1" "Class" "VO_0011333" "Pra" "Class"